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1.1 Rationale  
Globally, the population is ageing with an estimated 33% of people predicted to be 
aged 60 years or over by 2050 (1). Ageing has been linked to a loss of muscle mass, 
strength and function as well as declines in cognitive function. These age-related 
losses, for a variety of reasons, place older adults at a higher risk for various chronic 
diseases, including dementia, which can markedly increase the risk of falls and 
fractures (2), thus increasing the burden on society as a whole and in particular, the 
healthcare system (3). Injuries due to falls resulting from a decline in physical 
function can also lead to a loss of independence which has been associated with 
deterioration in health-related quality of life (HR-QoL). This is important as a 
reduction in HR-QoL has been associated with an increased likelihood of developing 
depression and related disorders as well as cognitive impairment and dementia (4-6). 
However, this relationship is bi-directional with dementia and cognitive decline also 
being associated with declines in HR-QoL, due to a loss of independence, autonomy 
and self-efficacy (7, 8). 
 
Cognitive impairment is a broad term used to describe a range of impaired brain 
functions relating to the ability of a person to think, attend selectively, plan, problem 
solve, remember and formulate ideas. It is generally accepted that, with advancing 
age, cognitive ability steadily declines, although in some cases, normal age-related 
cognitive decline can progress into mild cognitive impairment (MCI) or dementia. It 
has been estimated that 10-20% of older adults aged over 65 years have MCI and in 
2011, it was estimated that 173 Australians progressed from having MCI to dementia 
everyday (9). In 2015, 342,800 Australians were estimated to have dementia (10) and 
this figure is expected to increase to 1.13 million by the year 2050 (11). This 
continuum of cognitive decline can severely interfere with common activities of 
daily living (12) such as bathing, dressing and eating, with more severe cognitive 
impairment and dementia associated with a marked increase in the risk of falls (2). 
Falls and injuries can lead to an increasing need for ongoing professional care as well 
as healthcare expenditure by the government (2). In 2009-10, it was estimated that a 
total expenditure of $4.9 billion on the Australian aged care system was related to 
dementia alone (9). As such, with the projected increase in the number of older 
adults aged over 65 years, dementia cases and related falls and injuries globally, the 
burden on the individual and the healthcare system through hospitalisations and the 
need for long-term care, threatens to increase in future years.  
    
3 
 
 
Currently there is no cure for MCI and dementia, but many factors have been 
suggested to increase the risk for these conditions. A range of genetic, 
environmental, cardiovascular, psychological and lifestyle factors have all been 
implicated, including physical activity and poor dietary habits, which suggests that 
lifestyle modification may assist in preventing cognitive decline and lessen the future 
burden of dementia (13). More recently, research has suggested that low muscle 
mass and strength and accelerated muscle loss may also be associated with an 
increased risk for cognitive decline (3, 14-16). For instance, a cross-sectional study 
in 353 men aged 65 years and over found that sarcopenia (age-related loss in muscle 
mass, strength and function) was independently associated with a three-fold 
increased risk for cognitive impairment (14). Conversely, there is some evidence that 
greater muscle strength is associated with reduced risk of cognitive related disorders 
(3, 15). For instance, one prospective study with a mean follow-up of 3.6 years in 
970 adults with a mean age of 80.3 years found that for each one unit increase in 
muscle strength, there was a 43% decrease in the risk of Alzheimer’s disease (AD) 
and a 34% decreased risk for MCI (15). While the relationship between muscle and 
cognitive function may partially be explained by a tendency for those who are 
cognitively impaired to do less physical activity leading to a loss of muscle mass (3, 
14), it has also been speculated that these findings may be explained in part by 
various circulating inflammatory markers (e.g. interleukin-6 [IL-6] and tumor 
necrosis factor [TNF]-α) and oxidative stress markers, which have been associated 
with sarcopenia and cognitive decline (3, 14). Collectively, these findings suggest 
that muscle and cognitive function are interrelated, and while it is difficult to 
determine the direction of the relationship and what aspects of muscle (mass, 
strength, function or the combination) are important, it is possible that strategies 
which optimise muscle health and function may also lead to improvements in 
cognitive function.  
 
There is compelling evidence demonstrating that progressive resistance training 
(PRT) can improve muscle mass, size and strength in older adults (17, 18) with 
emerging evidence also indicating that PRT may also improve cognitive function in 
both healthy and cognitively impaired adults (15, 16, 19, 20). Previous research has 
also established that aerobic fitness and aerobic exercise training are associated with 
beneficial effects for cognitive function and HR-QoL (21-35). Taken together, these 
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findings suggest that a multi-component exercise program which targets muscle 
mass, strength and function as well as aerobic fitness, is likely to be most effective 
for improving cognitive function in older adults compared to one modality alone. 
This is supported by the findings of a meta-analysis of 18 intervention studies which 
found that an exercise program with multiple modalities enhanced cognitive function 
more than just aerobic exercise alone (effect size [ES]= 0.59 versus ES=0.41) (36). A 
similar finding has been found in people with MCI and dementia (ES=0.57) (37). 
However, there is mixed evidence with regard to the combination of PRT and 
aerobic exercise on reducing falls risk. Alternatively, challenging balance and 
mobility exercises have been shown to be most effective for reducing falls risk in 
older adults (38). On this basis, a multi-component exercise program comprising 
PRT, aerobic training and challenging balance/mobility training, is likely to provide 
the greatest benefit in terms of improving muscle health and function as well as 
cognitive function and HR-QoL into old age.   
 
Extensive research has been conducted into the effects of diet and nutritional factors 
on cognitive function. Although the findings are still largely mixed, it is generally 
accepted that a Mediterranean diet characterised by a high intake of fruits, 
vegetables, legumes, nuts and fish, a high intake of unsaturated fatty acids, has been 
associated with a reduced risk of cognitive decline (39-41). In contrast, a Western-
style diet characterised by a high intake of animal and saturated fats, refined sugars 
and lower intakes of fruits and vegetables, has been associated with poorer cognitive 
function (42-44). More recently, there has been emerging evidence suggesting that 
dietary protein may be linked to cognitive function (45-55). While this an area which 
has not been extensively studied, previous research has focused on the effect of 
different types of protein including whey, dairy, soy and protein supplementation on 
cognitive function, although there is a lack of evidence with regard to the effect of 
animal protein on cognitive function.  
 
In Australia, the major source of protein in the diet is red meat but the effect of 
protein from lean red meat on cognitive function has received little attention. There 
is some research which has shown that an increased consumption of red meat is 
related to an increased risk of heart disease or type 2 diabetes, which has been 
suggested to be related to an increase in systemic inflammation associated with an 
increased intake of iron and saturated fat in some forms of red and processed meat 
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(56, 57). However, most people are unaware that lean red meat has a relatively low 
level of saturated fat and provides many important nutrients including omega-3 long-
chain fatty acids, iron, zinc, vitamins B12 and B6 and possibly vitamin D (58, 59), 
some of which have been associated with improved cognitive function and 
reductions in markers of chronic, low grade systemic inflammation. Further, red 
meat contains all the essential amino acids which may play an important role in 
regulating various growth factors (IGF-1) and neurotransmitters (e.g. serotonin and 
catecholamine) (60) related to cognitive function (61, 62). 
 
The current Australian dietary guidelines recommend that adults consume no more 
than 455g per week of trimmed red meat per week (or 3-4 serves) (63, 64). However, 
it has been reported that Australian adults aged over 60 years are consuming 34% 
less meat compared to those aged 25-44 years (65). This is important because protein 
plays an important role in building and maintaining muscle by promoting a positive 
net protein balance during muscle protein synthesis. However, there is evidence that 
this process becomes blunted with age (66, 67) and so older adults may require a 
higher dose of protein to maintain a positive balance. While the precise dose of 
protein for health benefits for older adults is unknown, there is emerging evidence 
which has suggested that a daily protein intake of >1.0 to 1.2 g/kg body weight or 
25-40g of high quality protein ingested following PRT is optimal to enhance muscle 
protein synthesis (MPS) (68, 69). This suggests that the combination of PRT with a 
protein-enriched diet may result in additive or synergistic effects for MPS, however, 
the evidence from human intervention trials in terms of the long-term effects on 
muscle mass and strength remains mixed (70, 71). This is likely due to a range of 
factors including discrepancies regarding the type, dose and distribution of protein 
between studies. Despite this, a previous 4-month randomised controlled trial (RCT) 
conducted in older Australian women found that a protein-enriched diet achieved 
through the consumption of lean red meat (~1.3g/kg daily) on six days a week in 
combination with PRT twice a week, was sufficient to induce greater gains in lean 
muscle mass and strength compared to PRT alone (72). However, this dose of lean 
red meat is well above the current recommendations and this study did not assess 
cognitive function. 
 
There have been limited studies which have investigated the effect of the 
combination of exercise and protein on cognitive function but there is a sound 
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rationale behind potential added benefits for cognitive function. This includes 
increased cerebral blood flow as well as changes to various neurobiological and 
inflammatory markers related to cognitive function (73, 74). Specifically, there is 
evidence which suggests that exercise can up regulate various anti-inflammatory 
cytokines, and decrease various pro-inflammatory cytokines which have been 
implicated with  cognitive decline (25, 26). PRT has been associated with increases 
in circulating IGF-1 levels which is well known to play an important role in muscle 
growth, but it has also been shown to have neuroprotective actions by promoting 
neuronal growth, survival and differentiation (23). There is currently mixed evidence 
for the effects of exercise on serum brain-derived neurotrophic factor (BDNF), which 
is a biomarker of brain plasticity. However, there is evidence that BDNF is linked to 
cognition, and can stimulate neurons (brain cells) to survive longer and branch and 
connect in new ways (synaptic plasticity) to promote memory and learning (75-77). 
Others have reported that BDNF may be linked with vascular endothelial growth 
factor (VEGF), which is important for the development of new blood vessels (78), 
although currently evidence is mixed with regard to its role in cognitive function. 
Protein has also been linked with increases in IGF-1 (72), although there is little 
evidence to support a beneficial effect of dietary protein on BDNF, VEGF and 
markers of inflammation.  
 
Given that both dietary protein and exercise may alter various neurobiological and 
inflammatory markers relevant to cognitive function, the combination of a multi-
component exercise program and a protein-enriched diet achieved through the 
consumption of lean red meat, may represent an effective approach to improve 
muscle and cognitive function as well as HR-QoL in older adults. There is currently 
very limited research in this area, however, evidence from the 4-month RCT 
conducted by Daly and colleagues mentioned above, showed that there was a 10% 
greater increase in IGF-1 and 16% reduction in serum IL-6 in those women receiving 
lean red meat in combination with PRT, compared to PRT alone (72). Additionally, 
no harmful effects of red meat were observed on other measures of health including 
kidney function and blood lipids despite the dose of red meat being above current 
guidelines. Therefore, the current study outlined in this thesis aims to determine 
whether a protein-enriched diet of 80g of cooked lean red meat twice a day on each 
of the three days that a multi-component exercise program was performed, is 
sufficient to improve muscle and cognitive function compared to PRT alone in older 
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adults, as well as various neurobiological, growth and inflammatory markers and 
HR-QoL. This thesis will be the first to evaluate whether adherence to Australian 
dietary recommendations with regard to lean red meat combined with a 24-week 
multi-component exercise program can improve the above measures in healthy 
community-dwelling older adults. It was hypothesised that this study will provide 
direct evidence that the current guidelines to consume three weekly serves of red 
meat is a safe, acceptable and an effective dose and source of protein that can have 
beneficial effects on improving multiple physical and cognitive health outcomes 
when combined with a novel multi-component exercise program in older adults.  
 
The findings from the study described in detail in this thesis will form the basis for 
more precise nutrition (and exercise) guidelines for the management and prevention 
of age-related changes in cognitive function and HR-QoL in older adults. This may 
provide the basis for future research to investigate the potential for these factors to be 
incorporated into treatment and prevention plans for cognitive decline and dementia, 
reducing the financial and healthcare burden in years to come. 
 
1.2 Aims of thesis  
The primary aim of this thesis was to investigate the effects of a multi-component 
exercise program comprising of aerobic and PRT with challenging balance/mobility 
training on three days a week, in combination with a protein-enriched diet with lean 
red meat consumed on the training days, on cognitive function and HR-QoL in older 
adults compared to exercise alone. The secondary aims of this thesis were to: 1) 
investigate the effect of the intervention on various growth, neurobiological and 
inflammatory markers and bioavailable zinc which has been related to cognitive 
function, and 2) conduct an exploratory analysis to evaluate whether baseline or 
changes in the various growth, neurobiological and inflammatory markers, and 
bioavailable zinc as well as muscle mass, strength and function, were associated with 
changes in cognitive function and HR-QoL. Data collected for this thesis was part of 
a 24-week RCT referred to as the Seniors Thinking, Exercise and Protein (STEPS) 
study that was designed to examined the effects of the intervention on muscle mass, 
size, strength and function. 
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The specific aims of this thesis were:  
(1) To investigate the effects of a multi-component exercise program in combination 
with a protein-enriched diet achieved by consuming lean red meat on each of the 
three training days, on cognitive function and HR-QoL in community-dwelling older 
adults, compared to multi-component exercise alone.  
 
(2) To investigate the effects of a multi-component exercise program in combination 
with a protein-enriched diet achieved by consuming lean red meat on each of the 
three training days on circulating neurobiological and inflammatory markers, IGF-1 
and bioavailable zinc, compared to multi-component exercise alone.  
 
(3) To investigate the cross-sectional association between muscle mass, size, strength 
and function with measures of cognitive function and HR-QoL. 
 
(4) To evaluate the association between baseline and changes in muscle mass, size, 
strength and function as well as various growth, neurobiological and inflammatory 
markers, and bioavailable zinc, with measures of cognitive function and HR-QoL. 
 
1.3 Hypotheses 
It was hypothesised that:  
(1) A protein-enriched diet combined with a multi-component exercise program will 
result in greater improvements in cognitive function and HR-QoL compared to multi-
component exercise alone in community-dwelling older adults.  
 
(2) A protein-enriched diet combined with a multi-component exercise program will 
result in greater reductions in inflammatory markers and increases in concentrations 
of neurobiological markers, IGF-1 and bioavailable zinc, compared to multi-
component exercise alone in community-dwelling older adults. 
 
(3) Higher levels/scores of muscle mass, strength and function at baseline will be 
associated with higher baseline scores for cognitive function.  
 
(4) Baseline levels as well as changes in muscle mass, size, strength and function as 
well as various growth, neurobiological and inflammatory markers, and bioavailable 
zinc, will be associated with changes in cognitive function and HR-QoL. 
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Part 1. Overview of Cognitive Changes Associated with Ageing 
The world’s population is ageing and it is predicted that 33% of the global 
population will be aged over 60 years by 2050 (1). It is well established that ageing is 
associated with deterioration in a wide range of psychological and cognitive abilities 
including memory, executive function, visuospatial abilities and attention, which can 
lead to mild cognitive impairment, dementia and other related diseases including 
Alzheimer’s disease (AD). In the past two decades there has been considerable 
interest in evaluating the changes that occur cognitively due to ageing. This is due to 
evidence suggesting that there may be a long prodromal period of up to 20 years 
before a diagnosis of dementia is made (79). Indeed, age-related cognitive decline 
has become a global public health concern with up to 50% of adults aged 64 years 
and over reporting memory difficulties (1). Difficulties with tasks associated with 
executive function have also been associated with age-related cognitive decline as 
well as difficulties with dividing attention (80). Although subtle changes in cognitive 
impairment may not significantly impact daily functioning (81), the risk for injury 
while executing daily activities may be increased even with minor cognitive 
impairment. It is therefore important to identify normal age-related and pathological 
changes, and possible avenues for prevention and ways to maintain quality of life 
(QoL) throughout ageing.   
 
The following section will briefly explore age-related changes in brain structure and 
function associated with normal ageing. The concept of cognitive impairment will 
then be introduced and the epidemiology and costs of cognitive impairment and 
dementia will be discussed. Finally, risk factors associated with cognitive 
impairment and dementia will be reviewed with a focus on those factors which may 
be amendable to change through modifying lifestyle factors.  
 
1.1 Cognitive ageing 
Cognitive function is a multi-faceted concept used to describe groups of abilities and 
processes controlled by the brain (82). Across the lifespan, cognitive function 
increases up until early adulthood after which there is a gradual decline (83). More 
specific details relating to the age-related changes in cognitive function will be 
discussed below. In general, cognitive function can be separated into crystallised and 
fluid intelligence. Crystallised intelligence refers to abilities that are developed and 
accumulated throughout life and refers to abilities such as verbal skills, general 
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knowledge and numerical skills (83). Fluid intelligence is comprised of different 
abilities that are innately determined (83). The core crystallised and fluid abilities, 
commonly referred to as ‘domains’, include memory, language, visuospatial abilities, 
attention, processing speed and executive function (82, 84). While it is generally 
accepted that these domains decline from mid adulthood into old age (83), there are 
mixed findings with regard to the age of onset in which each domain starts to 
decline. The section below will provide a brief overview of the age-related decline in 
each of the above cognitive domains.  
 
1.1.1 Age-related changes in specific cognitive domains 
The age at which cognitive decline becomes measureable in regards to performance 
in different cognitive domains is a subject of ongoing debate. A review of studies, 
which included the Seattle longitudinal study that involved 500 participants aged 
between 20 and 70 years who were followed since 1956, concluded that overall there 
is no cognitive decline before the age of 60 (85). Figure 2.1 shows cross-sectional 
and longitudinal estimates for declines in a range of cognitive abilities and domains 
from this study. A more recent prospective study using cognitive data from a large 10 
year study following adults aged between 45 and 70 years, found that cognitive 
decline was evident in from as early as 45 years of age (86). 
 
 
 
 
 
 
 
 
 
Figure 2.1: Cross-sectional and longitudinal estimates of age-related change in 
specific cognitive function domains from the Seattle Longitudinal study. Taken from 
Schaie et al. (87). 
 
Memory and attention are the cognitive domains that most commonly decline with 
age (80). Memory can be separated into four categories: episodic, semantic, 
procedural and working memory (88). Episodic memory refers to memories of 
Longitudinal Cross-sectional 
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specific events and is suggested to decline from middle age onwards and is a 
common feature of AD (88). Semantic memory relates to comprised factual 
information and has been reported to increase from middle age (35-40 years) until 
the beginning of old age (55-60 years), but then declines in the very elderly (88, 89). 
Procedural memory refers to the ability to perform motor skills and habits and is 
often unaffected by ageing or cognitive impairment (90). Lastly, working memory, 
which is commonly referred to as short-term memory, is the temporary storage of 
information before it enters long-term memory and is also typically affected by 
ageing (90). The changes in these aspects of memory have been explained by 
findings which show that asymmetrical activation (using one hemisphere of the brain 
more than the other), particularly in the frontal lobes, becomes more symmetrical 
with age (88). This has been suggested to be the brain’s way of compensating for 
loss of activation and decreases in frontal lobe volume (88).  
 
Attention can play a role in every cognitive domain and can therefore have a broad 
impact when affected by age-related decline (80). Divided attention in particular has 
been observed to be affected by age, whereas selective attention is noted to only be 
slightly slower than in younger people (80, 91). These changes have been proposed 
to be due to a phenomenon known as the speed-accuracy trade off where deficits in 
information processing speed cause older adults to perform tasks more slowly in 
order to maintain the same level as accuracy as a younger person (92). In fact, 
processing speed has been proposed to begin declining from the age of 30 years (91).  
 
Higher level functions such as language and executive function may also deteriorate 
with age as they often rely on more basic processes which may be more prone to age-
related deficit (80). However, for the most part, language is relatively unaffected (80, 
86). Executive function on the other hand, which includes planning, organisation, 
reasoning and problem-solving skills, has been observed to decline progressively 
with age (91). In particular, mental flexibility and reasoning with objects that are 
unfamiliar, have been identified as abilities that are most commonly affected (91). In 
contrast, visuospatial ability which includes object perception (recognising familiar 
objects or faces) and spatial perception (perceiving physical location of objects in 
relation to others) appears to remains intact with advancing age (91).  
 
In summary, there is an ongoing debate in regards to the age at which cognitive 
decline begins with some research stating that there is no change before the age of 60 
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years and others showing that decline begins earlier in middle age. While further 
research is needed in this area, there is evidence that a range of cognitive domains 
are affected by age to varying degrees, particularly memory and attention. Executive 
functions are also commonly observed to decline with age, although language, 
visuospatial skills (namely object and spatial perception) appear to remain relatively 
intact. 
 
1.1.2 Structural changes associated with age-related cognitive decline  
Cognitive ageing has previously been described as a progressive process which is 
determined by an accumulation of damage to the brain through oxidative stress and 
inflammation across the lifespan (83). As such, there are a number of physiological 
and structural changes that occur in the brain and these changes may explain (or at 
least contribute to) the decline observed in certain cognitive abilities. While several 
excellent reviews have discussed in depth the various physiological and structural 
brain changes that occur with age (for a review refer to Deary et al. (93) and Peters et 
al. (88)), the main variables associated with age-related decline include a reduction in 
brain volume, reduced cortical thickness, impaired myelin integrity, hippocampal 
atrophy, accumulation of neurofibrillary tangles and changes in neurotransmitters 
(94). Each of these will be briefly discussed below. 
 
It is well established that our brains shrink in volume as we age (95) which has been 
attributed to neuronal cell death (88), particularly in the prefrontal cortex (96). The 
deterioration and ‘thinning’ of the cortex due to ageing and loss of neurons is shown 
in Figure 2.2. This is mainly due to loss of grey matter which has been estimated to 
decline at a rate of 5% per decade after the age of 40 years, which increases even 
further after the age of 70 years (88). The prefrontal cortex plays a primary role in 
executive function which suggests that neuronal death in this region may impair such 
abilities. Deficits in executive function have also been suggested to be linked to 
declines in memory as the act of remembering can rely on controlled processes 
which guide retrieval (97).  
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Figure 2.2: Age-related changes in the brain cortex. An increase in the blue shaded 
regions (top from left to right) highlights that there is preferential cortical thinning. 
This can also been seen in the bottom axial image of the brain with an increase in 
white space from left to right.  Taken from Landau et al. (2013) (98). 
 
Age-related changes in various vascular risk factors (e.g. blood pressure), can also 
causes lesions to develop in the white matter of the brain (88). White matter in the 
brain is made up of the myelin surrounding and protecting the neurons and it has 
been suggested that the frontal lobes are also affected primarily by these lesions, 
even in normal ageing (88). The decline in white matter remains consistent in healthy 
adults until the age of 70 years after which a more rapid rate of loss has been 
observed (93). Damage to myelin or disruptions in connectivity has been linked to 
impaired information processing which may result in disorganised thinking, 
hallucinations and mood disorders, all of which are commonly observed in people 
with dementia (99). Furthermore, a review on memory and executive function in 
ageing found that there is a positive association between the severity of white matter 
lesions and declines in cognitive function including memory and executive function 
(97).  
 
There is some evidence which suggests that the hippocampus along with the 
prefrontal cortex experiences the greatest structural changes with advancing age (88). 
For instance, it has been estimated that hippocampus volume declines by 35% 
between the ages of 30 and 90 years (100). As the hippocampus is strongly linked to 
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memory, loss of volume or damage to this region is associated with memory 
difficulties, particularly in regards to episodic and spatial memory (101). 
 
Neurofibrillary tangles and beta amyloid plaques (Aβ) are often associated with 
dementia however they can also be observed in non-demented older adults (102, 
103). These tangles and plaques are created by an accumulation of abnormal proteins 
in the brain and can impact on functioning according to the region that they are 
invading. Inflammation, oxidative stress and neurovascular dysfunction across the 
lifespan are thought to contribute to the development of these tangles and plaques 
(13).  
 
1.1.3 Neurotransmitter and hormonal changes associated with age-related 
cognitive decline 
Changes in important neurotransmitters such as dopamine and serotonin have also 
been suggested to play a role in age-related cognitive decline (88). For instance, 
dopamine levels, which control the reward and pleasure centre and regulate 
movement and emotional responses (104), have been reported to decrease in the 
brain by 10% per decade following early adulthood (88). Serotonin, which plays a 
role in depression, pain and endocrinological functioning (hormone regulation) 
(105), also decreases with age and has been associated with neurogenesis and 
synaptic plasticity (88).  
 
Additionally, various hormonal factors including estrogen, testosterone and adrenal 
hormones are also thought to influence the brain and cognitive function through the 
ageing process (106). This is particularly evident through menopause with some 
findings indicating that estrogen therapy may be a protective factor against AD as it 
increases dopaminergic activity (88). Testosterone is thought to play a role in 
androgen supply to the hippocampus which is important for memory and learning 
(106). Additionally, low levels of an adrenal hormone known as 
dehydroepiandrosterone (DHEA) has been associated with cognitive decline, and 
supplementation has been shown to improve various measures of cognitive function 
(106). There are many other neurological mechanisms which may play a role in the 
ageing brain and these will be discussed in more detail below. 
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1.1.4 Neurobiological changes associated with age-related cognitive decline 
There are a number of growth factors and neurobiological markers, including IGF-1, 
vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor 
(BDNF), which may also play a role in maintaining cognitive function and 
preventing cognitive decline. These markers may also interact with other lifestyle 
risk factors associated with cognitive decline, particularly diet and exercise. The 
relationship between these markers and diet and exercise will be discussed in detail 
in subsequent sections (see sections 2.5 and 3). A brief description of the role of 
these markers on cognitive function and brain health and the effect of ageing on 
these markers is provided below. 
 
IGF-1 is a growth factor which is important for neurogenesis across the lifespan 
(107). IGF-1 also plays an important role in proliferation, anti-apoptotic functions 
and the transport of amino acids and protein synthesis (108). However, IGF-1 
naturally decreases with age and has also consistently been implicated in age-related 
cognitive decline (107, 109, 110). For instance, IGF-1 can been found in the 
hippocampus and the prefrontal cortex (111) and a reduction of IGF-1 in these areas 
could lead to a decline in memory, learning and decision making. Furthermore, a 
review on the effects of IGF-1 on cognitive function in adults found that IGF-1 levels 
are important for stimulating a number of different neuronal cells and for resistance 
to amyloid toxicity, preventing the onset of AD (111). A meta-analysis of 13 studies 
examining the effects of IGF-1 on cognitive function in healthy older adults also 
found a significant positive correlation between IGF-1 and the Mini Mental State 
Examination (MMSE) scores (effect size of 0.81) and a positive correlation between 
serum IGF-1 and all measures of cognitive function (effect size of 0.57) (109). 
However, it is important to interpret this finding with caution as the MMSE has 
limitations with regard to measuring cognitive function. This is discussed in further 
detail below. 
 
VEGF is one of the most important growth factors associated with angiogenesis (the 
development of new blood vessels) (78). Due to the role of VEGF in angiogenesis 
and its ability to cross the blood brain barrier (BBB), VEGF levels may be associated 
with improved cognitive function although the current evidence is mixed (112-114). 
A study examining the expression of VEGF in the hippocampus of AD patients at 
different stages of disease progression found that VEGF is found in abundance 
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around amyloid plaques in the brains of AD patients (112). This has been suggested 
to explain the observation that AD patients have lower levels of serum VEGF 
compared to healthy controls, as VEGF is accumulating in these plaques (112, 113). 
However, other findings suggest that levels of VEGF are higher in people with AD 
than healthy adults (114).  
 
Ageing is also associated with decreased levels of circulating BDNF (77). While 
BDNF is important for preventing neuronal death during stress (75, 76), it also acts 
at the neural synapse to enhance long-term potentiation (LTP) which strengthens 
synapses associated with memory and learning (77). There is some evidence to 
suggest that higher levels of BDNF in the hippocampus may be associated with 
improvements in spatial learning (in rats) (115), and may also contribute to reversing 
brain atrophy and reducing age-related cognitive decline (in primates) (116). In 
humans, reduced serum levels of BDNF have been found in individuals with MCI 
(116) and a positive correlation between BDNF and cognitive performance has also 
been observed (116). Like IGF-1 and VEGF, BDNF can cross the blood-brain barrier 
(BBB) and so it is possible that peripheral levels may have an effect on brain BDNF 
concentrations (76). One study which investigated the effects of peripheral BDNF 
concentrations on impairments in memory and learning in adults aged between 55 
and 74 years, found that lower levels of circulating BDNF were associated with 
global and specific cognitive impairment in older women, but not men (76). This was 
thought to be due to the use of sex hormones by some women although further 
analyses could not clarify this finding.  
 
In summary, various growth and neurobiological markers including IGF-1, VEGF 
and BDNF have been shown to play important roles in maintaining brain health and 
are all affected by ageing. While the evidence for IGF-1 and its role in memory and 
learning appears to be consistent, the evidence for VEGF and BDNF is less clear due 
to mixed findings and limitations in current studies. Further research for the roles of 
these markers in maintaining brain health and preventing cognitive decline is 
warranted. 
 
1.1.5 Measuring cognitive function 
Psychological tests are used to measure individual differences related to a 
psychological concept such as a cognitive domain, based on a sample of relevant 
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behaviour in a scientifically controlled situation (117). They can be used, in a general 
sense, to assess cognitive capabilities of humans (e.g. intelligence tests) or to assess 
more specific cognitive functions which are known to be related to a specific brain 
structure or pathway (e.g. neuropsychological tests). Further, structured cognitive 
assessment measures can be accurate and valuable in the early detection of dementia 
or MCI (118) which can make a difference to the treatment and prognosis for the 
individual.  
 
A plethora of cognitive tools are available to measure cognitive function. This can 
make the interpretation (and comparison) of studies investigating cognitive function 
difficult given the complexity of cognition itself, as well as inconsistencies in the 
cognitive tasks used across studies and the way that cognitive test data are analysed 
and reported (119). It is therefore important to select appropriate tools which are 
sensitive and specific with regard to what is being measured and for the population 
being assessed. Table 2.1 provides an overview of commonly used cognitive tools 
which have been found to be sensitive to cognitive change in trials assessing the 
effects of nutrition. 
 
Table 2.1. Commonly used cognitive tools which have been shown to be 
sensitive to change in response to a dietary intervention 
Tests Advantages Limitations 
7-Minute Screener - Little or no education 
bias 
- Validated in primary 
care 
- Difficult administration 
- Complex scoring 
Abbreviated 
mental test (AMT) 
- Easy administration 
- Verbal memory test 
- Education/culture bias 
- Does not test executive 
function of visuospatial 
ability 
Cambridge 
Cognitive 
Examination 
(CAMCOG) 
- Tests many domains - Difficult and long 
administration 
- Lacks standardisation for 
scoring and administration 
General 
practitioner 
assessment of 
cognition 
(GPCOG) 
- Developed for and 
validated in primary 
care 
- Informant component 
useful when initial 
complaint is informant-
based 
- Little or no education 
bias 
- Based on informant 
responses 
- Lacks data on any 
language/culture biases 
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Mini-Cog - Developed for and 
validated in primary 
care 
- No culture/education 
bias 
- Use of different word lists 
may affect failure rates 
 
Memory 
impairment screen 
(MIS) 
- Verbal test (no 
writing/drawing) 
- Little or no education 
bias 
- Does not test executive 
function or visuospatial 
skills 
Short Portable 
Mental Status 
Questionnaire 
(SPMSQ) 
- Verbal test (no 
writing/drawing) 
- Scoring can be 
cumbersome 
- Does not test short-term 
memory 
Short Test of 
Mental Status 
(STMS) 
- Validated in primary 
care 
- Tests many separate 
domains 
- Education/culture bias 
- Studied in well-educated 
subjects 
Stroop test 
 
- Multiple variants 
- Quick administration 
- Easy scoring 
- Some education bias 
Time and Change 
Test (T&C) 
- Very brief 
administration time 
- Little or no education 
bias 
- Strong language/cultural 
bias 
Mini Mental State 
Exam (MMSE) 
 
- Most widely used  
- Brief administration  
- Education/age/language/c
ulture bias   
- Ceiling effect (highly 
educated impaired 
subjects pass)   
- Best performance for at 
least moderate cognitive 
impairment 
Behaviour rating 
inventory for 
executive function 
(BRIEF-A) 
 
- Parent and teacher 
forms  
- Inexpensive  
- Comprehensive 
coverage of 
subdomains of 
executive functioning 
- Used extensively in 
research with good 
sensitivity  
- Easy to administer and 
complete 
- Parent rating are 
susceptible to bias  
- Report of everyday 
executive function does 
not necessarily accurately 
parse subdomains of 
executive function  
 
Clock drawing test 
(CDT) 
 
- Very brief 
administration time  
- Minimal education bias 
- Lacks standards for 
administration and scoring 
CogState 
 
- Developed for repeat 
testing  
- Minimal practice 
effects  
- Practice effects have been 
observed in healthy 
controls during repeat 
assessments in a single 
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- Discriminant ability to 
differentiate patients 
with MCI or AD from 
healthy controls 
comparable to standard 
neuropsychological 
tests 
day 
Rowland universal 
dementia 
assessment 
(RUDAS) 
- Designed for 
multicultural 
populations  
- Little or no 
education/language 
bias  
- Validated in Australian 
community 
- Limited use due to recent 
development 
Short and Sweet 
screening 
instrument (SAS-
SI) 
- Detects dementia better 
than 
neuropsychological 
testing in community 
population 
- Does not test memory 
- Lacks data on any 
education/language/cultur
e 
- biases 
Short Blessed Test 
(SBT) 
- Verbal test (no 
writing/drawing) 
- Education/language/cultur
al/ race bias 
- Scoring can be 
cumbersome 
- Does not test executive 
function 
St Louis 
University Mental 
Status (SLUMS) 
- No education bias 
- Tests many separate 
domains 
- Limited use due to recent 
development 
Trail making - Quick administration 
- Easy scoring 
 
- Possible practice effects 
- Part B more sensitive 
Montreal 
Cognitive 
Assessment 
(MoCA) 
- Designed to test for 
mild cognitive 
impairment   
- Tests many separate 
domains 
- Lacks studies in general 
practice settings   
- Education bias   
- Limited use due to recent 
development 
CANTAB 
Stockings of 
Cambridge 
- Computer 
administration 
- Non-verbal 
administration  
- May lack the sensitivity 
to measure discrete 
cognitive functions in 
healthy populations 
Digit span 
(forward and 
backward) 
- Reliable and valid - Lack of standardised 
procedure 
Weschler Adult 
Intelligence Scale-
Revised (WAIS-R)  
- Reliable - Relatively weak 
assessment of processing 
speed and working 
memory 
- Commonly administered 
by psychologists 
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Rey Auditory-
Verbal Learning 
Test (RAVLT)  
- Easy administration 
 
- Potential education bias 
Rey-Osterrieth 
Complex Figure 
Copy 
- Standardises a 
common stimulus 
- Reliable discriminating 
power 
- Diagnostically 
powerful 
- Identifies possible 
causes of memory 
deficits 
- Scoring system is 
complex and prone to 
error 
Adapted from Best et al. (2015), Pase et al. (2014) and Cordell et al. (2013) (118-120). 
 
An important consideration in cognitive testing is choosing a measure which can 
detect cognitive impairment and which is sensitive to subtle changes in cognitive 
function. This is generally done by comparing a test score to normative data. 
However, many cognitive measures do not provide normative data which is divided 
into age groups and this can become problematic, particularly when assessing 
cognitive function in older adults who are more at risk of cognitive decline (120). 
Further, some of the most commonly used outcome measures in clinical trials listed 
in table 2.1 such as the MMSE and MoCA, are often used as screening tools in a 
clinical setting (120). While these tests are effective in detecting severe and 
pathological impairment, they have been found to be unreliable in detecting MCI 
(120). This can become problematic when testing healthy older adults. While there is 
no ‘gold standard’ tool for detecting cognitive impairment, guidelines developed by a 
workgroup of professionals from the United States of America (USA) with expertise 
in detecting cognitive impairment, suggest that a specific cognitive evaluation is 
required, preferably with a baseline measure, and the inclusion of memory and 
language in the assessment, can enhance detection of impairment (118). 
 
Another limitation is that many of these commonly used cognitive tools are only 
available in hard-copy form which increases the risk for loss of data and researcher 
error when entering/scoring data. More recently, the introduction of computerised 
cognitive testing has overcome some of these limitations through the customisation 
of testing batteries, ease of transport and administration and reduction of researcher 
error as data is automatically recorded. One commonly used computerised test is 
CogState. The CogState Brief Battery computerized test (http://cogstate.com/) is a 
multi-faceted program which assesses a variety of cognitive functions including 
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attention, processing speed, memory and executive function. It provides written 
instructions on a computer screen prior to stimuli being displayed in the form of 
playing cards, a maze or other stimuli depending on the tests selected. Responses are 
given by the participant using minimal keyboard keys or the mouse. The advantages 
of this tool include its versatility in testing a range of cognitive domains through the 
creation of customised batteries and composite scores, as well as its sensitivity for 
use in an older population. CogState has been found to be sensitive to cognitive 
decline in healthy adults as well as adults with MCI (121) and has been validated for 
repeated administration over multiple time points with minimal practice or fatigue 
effects even over a short time period, thus making it a suitable test to detect subtle 
changes (122, 123). It has also been found to be suitable for use in an older 
population with little computer experience and requires limited supervision (124). In 
comparison to the MMSE, it has higher discriminant ability for differentiating 
between healthy individuals and those with MCI (124).  
 
Although there is evidence to suggest that some cognitive tests may be more suitable/ 
reliable or sensitive to cognitive change, it is important to note that all cognitive 
testing is subject to the influence of environmental factors such as the time of 
cognitive testing, room temperature, previous night’s sleep quality and fasting state 
of the participants (125, 126). Thus, it is important to attempt to control and 
standardise these factors when doing repeated cognitive testing in participants, and to 
consider the potential impact of these factors when interpreting the findings of 
cognitive studies. 
 
In summary, there is a wide range of cognitive tools which can be used to measure 
cognitive function. This has led to a lack of consistency between studies making the 
results of cognitive trials difficult to interpret and compare. The limitations of 
traditional pen and paper questionnaires have given rise to the increasing use of 
computerised cognitive testing including CogState. Previous evidence supports the 
use of CogState in healthy older adults for detecting subtle non-pathological 
cognitive change therefore CogState was selected as an outcome measure for this 
thesis. 
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1.2 Cognitive Impairment 
Ageing can affect cognitive abilities at different rates with varying severity and it has 
become apparent that the changes that occur due to the chronological age of the brain 
are not always consistent with the biological age of the brain (88). For most 
populations, there is a premorbid range within which individuals are expected to 
function in terms of their cognitive ability. If performance is sub-standard, this may 
be indicative of cognitive impairment or decline (127). Cognitive impairment can be 
best thought of as a continuum and as illustrated in Figure 2.3, there is a marked 
difference between the gradual decline that comes with ageing compared to 
pathological impairment (12).  
 
 
 
 
 
 
 
 
Figure 2.3: Progression from normal ageing to AD or another dementia (12). 
 
As mentioned above, changes in cognitive function can be assessed across multiple 
domains (128). Age-related declines are generally gradual and minor such as 
forgetting a relative’s birthday (12), whereas pathological declines can be quite rapid 
and severe such as forgetting family members. Those which exceed the expected 
decline rate may be classified as having pathology which is often termed MCI or 
‘cognitive decline without dementia’ (128). MCI is defined as a stage between 
normal cognitive decline and dementia where memory loss is greater than expected 
but does not display other signs of dementia (129). There are four main types of MCI 
which include amnestic, non-amnestic, single domain and multiple domain (12). 
Amnestic impairs memory while non-amnestic spares memory but impairs other 
cognitive abilities such as executive function (12). Single domain MCI, as the name 
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suggests, only affects one cognitive domain while multiple domain MCI impairs 
abilities across multiple domains (12). It is generally accepted that MCI is a 
precursor for dementia and it is currently estimated that individuals with MCI have a 
three to five times higher risk of developing dementia compared to others of similar 
age (130). Indeed, current data suggests that 10% to 15% of individuals with 
amnestic MCI progress to AD each year, which is substantially higher than the 
general population incidence rates of AD of 1% to 2% each year (129).  
 
Dementia is defined by the World Health Organisation (WHO) as a gradual decline 
in cognitive, social and physical functioning due to brain disease or damage not 
attributed to the normal process of ageing (11). It is an umbrella term which is 
associated with over 100 different diseases (2). Common symptoms associated with 
dementia include memory loss, impairment of perception, language and personality 
and severe cognitive decline (2, 131). 
 
There are many types of dementia and each type has different risk factors and 
progression of symptoms. The most common types of dementia are AD, vascular 
dementia, frontotemporal dementia and dementia with Lewy bodies (2). However, it 
is common for these types of dementia to co-exist and so the distinction between 
symptoms and diagnosis of a particular type of dementia becomes difficult (2). 
Throughout this thesis the term dementia will be used in a general sense to refer to 
all types of dementia including comorbidities (of different types of dementia), unless 
otherwise specified. 
 
1.3 Epidemiology of mild cognitive impairment and dementia 
It is estimated that 10% to 20% of older adults aged 65 years and over have MCI 
(12). However, this number may be even larger as MCI can often be under diagnosed 
due to a lack of clinical understanding regarding ‘normal impairment’ in terms of 
cognitive function (132). In 2016 it was estimated that 244 people per day moved 
from the MCI category into the dementia category in Australia, with this predicted to 
almost triple by the year 2056 (133). In 2016, it was estimated that there were 
400,833 people living with dementia in Australia (133) and over 46 million people 
worldwide (134). With our ageing population, it is projected that the number of 
people with dementia in Australia will increase to 1.13 million by 2050 (11).  
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Figure 2.4 Estimated number of people with dementia in Australia in 2016 and 2017, 
by age and sex (133). 
 
As shown in Figure 2.4, the prevalence of dementia increases rapidly after the age of 
60, and those aged 85-89 years have the highest prevalence (133), which has been 
partly attributed to the growth and ageing of our population. This may also explain 
the 2.4-fold increase in mortality rates attributed to dementia between 2001 and 2010 
(2). However, recent studies have found that the prevalence of dementia may in fact 
be slowing (135, 136). This has been suggested to be due to the progression in 
management and treatment of cardiovascular risk factors which have been associated 
with an increased risk for dementia (135). This indicates that early prevention 
methods targeting modifiable risk factors may be beneficial in the fight against MCI 
and dementia.   
 
1.4 Consequences and costs of cognitive impairment 
For older adults, the development of MCI or symptoms of normal age-related decline 
can impose a substantial burden on an individual emotionally as it can represent a 
loss of autonomy (7). For some, this represents the realisation of the beginning of the 
ageing process (7). This can be emotionally distressing for people as they may feel 
that they are being excluded from society and have a decreased sense of self-efficacy 
which can impact on their QoL (7, 8). The financial burden of the progression of 
MCI into dementia or related disorders is also substantial. In 2016, the total 
expenditure on the Australian aged care system related to dementia was estimated at 
$14.25 billion (133). It is expected that within 20 years dementia will rank third for 
the greatest source of health and residential aged care spending (137). Furthermore, 1 
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in 100 hospitalisations were associated with a diagnosis of dementia in 2009-10 (2) 
and in 2010-11, 552,000 visits to general practitioners (GP) could be attributed to 
managing dementia (2).  
 
Dementia is the second leading cause of burden of disease in men aged 85+ years 
and the leading cause of disease burden in women aged 85+ years in Australia (133). 
Even in the early stages of dementia professional care can often be required. The 
level of care required by an individual is assessed using a rating scale of core activity 
limitation which assesses disability (2). Using this scale, limitation can range from 
mild (needs little or no help with core activities) to profound (is unable or always 
needs help with core activities) (2). In 2009 it was estimated that 75% of Australians 
with dementia required a combination of formal (paid or professional) and informal 
(non-professional) care and only 22% relied on informal care alone (2). Furthermore, 
it was estimated that 1 in 3 people with severe dementia were living in the 
community (2). This is important especially considering that 60% of individuals with 
AD will wander, which increases their risk of injury or getting lost (138). In 2015 it 
was estimated that 1.2 million Australians were involved in the care of a person with 
dementia and it has been projected that by 2029 we face a 150,000 carer shortage 
(10).  
 
1.5 Risk factors for cognitive impairment 
There is currently no cure for MCI or dementia. It seems apparent that once MCI has 
developed the progression into severe cognitive impairment can be quite rapid, 
although not all people with MCI will develop dementia (12). In fact, people with 
MCI can remain stable or even improve in regards to their cognitive function (12). 
However, the risk of dementia doubles every 5-6 years over the age of 65 (2, 9) and 
although some pharmacological treatments are available such as cholinesterase 
inhibitors, memantine and other drugs to relieve symptoms, there is currently no cure 
(139). This may be attributed to the fact that the damage to the brain that has 
occurred before patients begin to show symptoms is irreversible (60). This may also 
be due to the under diagnosis of dementia as many of the early symptoms resemble 
those of normal ageing or are thought to be attributed to MCI or other conditions (2). 
Therefore, with consideration for evidence that delaying the onset of dementia by 
one year may result in over 9 million fewer cases of AD globally in the next 40 years 
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(140), there is a need to develop and trial safe and effective interventions at a 
preclinical stage or a younger age to prevent the onset of MCI.  
 
There are many risk factors associated with cognitive ageing and the development of 
MCI and dementia, with the two strongest being increasing age and presence of the 
apolipoprotein E (APOE) ε4 allele (141). Conversely, studies reporting a loss of 
cognitive ability with age have suggested that extrinsic factors rather than intrinsic 
factors of ageing play an important role, which implies that environmental and 
lifestyle risk factors for cognitive decline are important and may be preventable (2, 
95). A number of comprehensive reviews and reports have detailed the quality of 
evidence and direction of associations for common risk factors associated with 
cognitive decline and dementia. A brief summary of the findings of these reviews is 
summarised in Table 2.2. The following section will briefly review the evidence 
related to the role of each of these factors in the development of cognitive decline, 
MCI and dementia. 
 
Table 2.2 Common risk factors association with cognitive decline and a review of 
the quality of the evidence. Adapted from Prince et al. (2014) (142) and Plassman 
et al. (2010) (128). 
 
Risk factor 
Direction of 
association* 
Consistency 
of evidence 
Quality of 
evidence 
Genetic factors 
APOE polymorphisms Positive Consistent High 
BDNF polymorphisms Unknown Inconsistent Insufficient 
Environmental factors 
Low levels of education Positive Moderate High 
Socioeconomic status Negative Consistent Insufficient 
Lifestyle factors 
Exercise Negative Consistent High 
Diet Negative Consistent High 
Social/cognitive engagement Negative Consistent Insufficient 
Alcohol consumption Unknown Inconsistent Insufficient 
Smoking Positive Inconsistent Moderate 
Cardiovascular factors (late life) 
Hypertension Positive Consistent High 
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Obesity Unknown Consistent High 
Type 2 diabetes Positive Consistent High 
Hyperlipidemia Unknown Moderate Moderate 
Psychological factors 
Depression Positive Moderate Insufficient 
*Positive association’ refers to increased risk of cognitive decline and ‘negative 
association’ refers to decreased risk of cognitive decline 
 
 
1.5.1 Genetic factors 
Research findings on the role of genetic factors on cognitive ability are mixed. A 
model fitting meta-analysis found that around 50% of the variance of general 
cognitive ability in monozygotic twins could be accounted for by genetic differences 
(143). However, other studies have found that the influence of heritability for 
cognitive ability increases with age (143). For instance, it has been found that the 
influence of heritability increases from 20% in infancy to 60% in adulthood (144, 
145). Specific research into genetic predisposition has shown common genes such as 
presinilin 1 and 2 (PS1 and PS2) and the APOE gene are associated with cognitive 
decline and AD, which is the most common type of dementia investigated in genetic 
research (143, 146-150). PS1 and PS2 and amyloid beta peptides [A(β)] are 
deterministic genes meaning that individuals with one of these genes are more likely 
to develop AD (150). PS1 and PS2 in particular, have been associated with early 
onset AD especially before the age of 65 years (148, 151) and both selectively 
increase the production of an amyloid known as the amyloidogenic peptide amyloid 
which creates plaques in the brain (151, 152).  
 
Other genes known as susceptibility genes are more common than the deterministic 
genes in the general population and slightly increase the risk of developing AD 
(150). One such gene is the APOE gene which has been associated with an increased 
risk of late onset AD (after the age of 65) (148). In particular, individuals carrying 
the APOE ε4 allele have an increased concentration of insoluble amyloid and a 
decreased ability to repair neuronal damage which contributes to the development of 
amyloid plaques in the brain (153, 154). It has been suggested that since APOE plays 
a role in lipid metabolism, this may also contribute to the development of vascular 
dementia (153). It has also been suggested that there may be an association between 
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dementia and other health conditions including stroke, diabetes and cardiovascular 
disease (CVD) as individuals carrying the APOE ε4 allele are particularly prone to 
developing these conditions (153, 154). These cardiovascular risk factors will be 
discussed in more detail below. 
 
BDNF polymorphisms have also been found to be associated with MCI and dementia 
(116, 155, 156). Increased progression of brain atrophy in healthy adults and those 
with MCI has been associated with having the Met-BDNF allele, especially in 
individuals also carrying the APOE ε4 allele (116). In particular, the polymorphism 
known as Val66Met has been found to be associated with a higher risk for AD (155) 
and this has been suggested to be due to the influence of Val66Met on the 
hippocampus and learning abilities (157). However, there is also evidence which 
contradicts these associations although this has been suggested to be due to specific 
patient characteristics such as gender or ethnicity (155).  
 
In summary most of the research regarding genetic factors as risk factors for 
cognitive decline have focused on AD. One common gene which has been associated 
with an increased risk of cognitive decline is the APOE ε4 allele. This may also 
increase the likelihood of developing cardiovascular conditions which also increase 
the risk for cognitive impairment. BDNF polymorphisms such as Val66Met have 
been associated with an increased risk for AD although further research is warranted 
in this area. 
 
1.5.2 Environmental factors 
There is evidence that environmental factors such as head trauma as a result of an 
accident, maternal smoking, lead poisoning and exposure to toxins and other heavy 
metals, are all implicated in age-related cognitive decline (2, 158, 159). However, a 
systematic review on risk factors for cognitive decline found that there was 
inadequate evidence to assess any association between these factors and cognitive 
decline (128). There is also some evidence for an association between lower 
education status and an increased risk of developing dementia later in life (146, 160, 
161) although this may be due to genetic factors which relate to intelligence or a 
lower level of mental engagement and plasticity (160). A recent review found no 
association between higher levels of education or early childhood factors (e.g. early 
life environment: rural vs urban) and cognitive decline, although it was highlighted 
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that the quality of the existing evidence was low (128). The 2014 World Alzheimer 
Report however, states that years of formal education may increase an individual’s 
cognitive reserve, thereby acting as a protective factor (142). 
 
There is also some evidence that low socioeconomic status is linked to cognitive 
decline (160). This is perhaps not surprising as those with a low socioeconomic 
status often have worse health than those in middle or high socioeconomic status due 
to less healthy lifestyles, less use of preventative health measures and less access to 
healthcare facilities (162). Others have reported that exposure to infections is also 
linked to cognitive decline (160). In support of these findings, a case-control study 
using Swedish twins also found that oral disease and loss of half or more of one’s 
teeth before the age of 35 (indicating poor health status and possibly exposure to 
infection), was associated with a 1.68 greater likelihood of developing dementia 
(160).  
 
In summary there are a large number of reviews and meta-analysis which have 
investigated the risk factors associated with cognitive decline. Head trauma as a 
result of an accident, maternal smoking, lead poisoning and exposure to toxins and 
other heavy metals, low level of education, low socioeconomic status and poor 
healthcare have all been associated with an increased risk for cognitive decline, but 
cause-and-effect has not been established for all these factors.  
 
1.5.3 Lifestyle and cardiometabolic risk factors 
In addition to genetic and environmental factors, there is a growing body of evidence 
suggesting that lifestyle factors can play a role in reducing the risk of dementia and 
related cognitive disorders (161). Lifestyle factors such as an inactive cognitive 
lifestyle and lack of social engagement, alcohol consumption, smoking, 
hypertension, obesity, type 2 diabetes, hyperlipidemia and depression have all been 
shown to influence the risk of cognitive decline and the risk of developing dementia 
(27, 140, 146, 160, 161, 163-165). In particular it has been shown that exercise and 
dietary behaviours may impact on brain health and cognitive function both directly 
and indirectly (161, 166, 167). The focus of this thesis is on the effects of exercise 
and dietary factors in combination on cognitive function in older adults. While this 
will be discussed in detail in subsequent sections, there are a number of other 
lifestyle factors that have been implicated in cognitive decline. 
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Overwhelming evidence from a large number of reviews and meta-analyses have 
found that cardiovascular and cardiometabolic risk factors including obesity, type 2 
diabetes and hyperlipidemia, are strongly linked with cognitive decline (93, 106, 142, 
168). This is not surprising as the brain is the most vascular organ in the body using 
25% of the body’s total oxygen consumption and 15% of the total blood volume 
(169). In addition, one large prospective study which followed 747 cognitively 
normal older adults for 3 years found that individuals taking medication to treat  
hypertension had an 86% increased risk for developing MCI (odds ratio [OR]= 1.86) 
compared to those not medicated for hypertension (170). Other risk factors related to 
cognitive decline are obesity and type 2 diabetes (171). One prospective study in 
cognitively normal older adults found that being overweight or obese was associated 
with lower brain volume and atrophy, particularly in areas including the frontal lobes 
and hippocampus, compared to those with a normal body mass index (BMI) (171). 
Furthermore, a meta-analysis of 19 studies investigating the risk of MCI associated 
with type 2 diabetes found that those with diabetes had an increased risk for MCI 
(risk ratio [RR]=1.21) compared to those without diabetes (172). In regards to 
cholesterol, a meta-analysis found a weak association total serum cholesterol and 
cognitive impairment but a consistent association for mid-life total serum cholesterol 
and the risk for dementia (173). Another systematic review found that the evidence 
for dyslipidemia and cognitive decline was mixed (174). 
 
1.5.4 Inflammation  
Low grade, chronic systemic inflammation has been shown to increase with age and 
the presence of chronic disease (175, 176), and has also been associated with an 
increased risk for cognitive decline and dementia (177). Previous research has shown 
that ageing is associated with a two to four-fold increase in circulating levels of IL-6, 
TNF and C-reactive protein (CRP), common pro-inflammatory cytokines (178). 
Increased levels of pro-inflammatory cytokines have been found to impair growth 
factor signalling not only peripherally, but also in the brain (23). In particular, 
increased brain levels of IL-6 have been reported to be a possible risk factor for AD 
(179). A recent review also found that the vast majority of epidemiological studies 
suggest that use of anti-inflammatory drugs may have a protective effect in regards to 
developing AD, however the results of clinical trials have largely been negative 
(180). 
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1.5.5 Psychological risk factors 
Neuropsychological factors including depression and anxiety have also been 
associated with MCI (163, 181, 182). A systematic review of 27 articles found that 
depression in particular, may be associated with an increased risk for MCI or the 
conversion of MCI to AD (182). This may be consistent with findings suggesting 
that depression may be an early stage of dementia associated with smaller 
hippocampal volumes and CVD (181, 183).  
 
1.5.6 Summary 
In summary an inactive cognitive lifestyle and lack of social engagement, alcohol 
consumption, smoking, and cardiovascular risk factors such as hypertension, obesity, 
type 2 diabetes, hyperlipidemia and depression have all been shown to increase the 
risk of cognitive decline and developing dementia. However, the strength of the 
evidence is mixed. For instance, the data related to the role of alcohol consumption is 
conflicting. While data for increased systemic inflammation as a risk factor for 
cognitive decline for the most part is consistent, a number of clinical trials have 
failed to show any beneficial effects on cognitive function with regards to the effects 
of anti-inflammatory agents. 
 
Part 2. Role of nutrition and dietary factors on cognitive function  
There is a vast amount of research, largely from cross-sectional and epidemiological 
studies, which has examined the role of nutritional factors, including specific 
nutrients, diets, foods, dietary patterns and supplements, on cognitive function. 
Figure 2.5 provides a broad schematic overview of how nutritional factors, along 
with other lifestyle factors, might influence cognitive function and brain health.  The 
underlying mechanisms by which various nutritional factors might influence 
cognition will be discussed later in this thesis.  
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Figure 2.5 Schematic overview of the effect of the proposed effects of nutritional 
factors on cognitive function and brain health. Taken from Dauncey et al. (184). 
 
The following section will briefly review key dietary patterns as well as foods and 
nutrients, including antioxidants, vitamins and omega-3 fatty acids proposed to 
influence cognitive function. Thereafter, the effect of red meat and dietary protein on 
cognitive function and potential biological mechanisms for this effect will also be 
explored. 
 
2.1 Role of dietary patterns on cognitive function  
There is increasing interest into the role of dietary patterns on many health and 
cognitive outcomes in nutrition research. Dietary patterns, also sometimes referred to 
as whole-of-diet analysis can include the assessment of an overall diet style such as 
the Mediterranean diet (185) and other healthy diets informed by national dietary 
guidelines (186), or multivariate statistical approaches to characterise diets using 
reported dietary intake (187). By assessing overall diet, this approach acknowledges 
differences in combinations of food consumption and the importance of examining 
the balance of the various components of dietary intake, rather than just focusing on 
single foods and nutrients in isolation (188). While there are a number of 
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comprehensive reviews on the role of various dietary patterns in maintaining health 
and preventing various health conditions, the following section will provide a brief 
overview of the current literature on the Mediterranean diet, Western-style diet, diets, 
vegan/ vegetarian diets and diets rich in fruits and vegetables on cognitive function. 
 
2.1.1 Mediterranean Diet 
The Mediterranean diet, which is characterised by a high intake of fruits, vegetables, 
legumes, nuts and fish, a high intake of monounsaturated fatty acids, omega-3 fatty 
acids (and low saturated fatty acids), a low-to-moderate intake of dairy products, red 
meat, poultry and eggs, and a moderate intake of alcohol, particularly wine, has been 
associated with a reduced risk of cognitive decline (39-41). Indeed, one review of 
cross-sectional and prospective studies concluded that the Mediterranean diet is 
protective against cognitive decline attributed to vascular or degenerative origin 
(189). Further, another review of prospective studies found that higher adherence to 
the Mediterranean diet in older adults was beneficial for reducing the risk of 
developing MCI, and was also associated with better global cognitive performance, 
particularly for episodic memory (190). These findings are supported by the results 
from a large primary prevention trial for CVD in participants at high vascular risk 
(PREDIMED) which found that in a sub study of 522 participants using data from 
PREDIMED-NAVARRA centre, those allocated to a Mediterranean type diet 
supplemented with either extra virgin olive oil or nuts for 6.5 years had significantly 
higher global cognitive function scores after the intervention when compared to 
participants in the low-fat control diet group (mean differences in MMSE scores 
ranging from 0.51-0.62 between Mediterranean diet plus olive oil vs control diet and 
0.33-0.57 for Mediterranean diet plus nuts vs control diet for tests of cognitive 
function) (191). More recently, another sub study of PREDIMED using data from 
cognitively normal adults from the Barcelona-North study centre found less decline 
in the global cognitive composite score after a median follow-up of 4.1 years for 
those assigned to both Mediterranean diet groups (mean change in MMSE scores for 
Mediterranean diet plus olive oil 0.05 and -0.05 for addition of nuts) compared to the 
control diet (mean change in MMSE scores of -0.38) (192). In contrast, a 2015 
systematic review on the role of the Mediterranean diet on cognitive function found 
that overall, findings to date have been mixed, with only four of six cross-sectional 
studies and only half of the longitudinal studies along with one RCT and three meta-
analyses reporting that better adherence to the Mediterranean diet was associated 
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with less cognitive decline and dementia (193). These mixed findings were attributed 
to potential differences in the classification of the dietary patterns in different 
countries, which may be related to the use of various different assessment tools for 
dietary intake (193). On this basis, it is evident that further studies are still needed to 
evaluate whether the Mediterranean diet can improve cognitive function. 
 
It has been suggested that the mechanism by which the Mediterranean diet might 
reduce the risk for cognitive decline (or improve cognitive function) in older adults 
may relate to the high intake of anti-oxidants associated with this diet, which may  
reduce oxidative stress that has been linked to impaired cognitive function (194). It 
may also relate to the reduction or limiting of foods which are high in sugar, 
saturated fats and salt which have been linked to a decreased risk for cardiovascular 
risk factors (195) that are also associated with cognitive decline. However 
antioxidants and saturated fats can also be found in a variety of other foods in other 
dietary patterns (such as the Western-style diet) and the role of these nutrients in 
regards to cognitive function will be discussed in section 2.2.  
 
2.1.2 Western-style Diet 
In contrast to the Mediterranean diet, Western-style diets, which are typically 
characterised by a higher intake of animal and saturated fats, refined sugars and 
lower intakes of fruits and vegetables, have been associated with poorer cognitive 
function (42-44). For instance, a 3-year prospective study found that higher 
adherence to a Western-style dietary pattern was associated with a decline in 
visuospatial abilities in older adults (196) compared to a Mediterranean diet pattern. 
Principal component analysis of data from the AusDiab study, a population-based 
national survey of non-institutionalised Australian adults, also found that foods 
associated with a Western-style diet was negatively associated with cognitive 
function (197). The potential mechanism by which a Western-style diet may 
adversely influence cognitive function may be relate to an increase in pro-
inflammatory markers and oxidative stress, both of which have been strongly 
implicated in cognitive decline (44, 198). However, one review stated that the 
majority of the current research investigating the relationship between the Western-
style diet and cognitive function has primarily focused on the role of saturated fats 
and simple sugars despite the many other macro and micro-nutrients which could 
also play a role (e.g. protein, salt) (44). This narrow view may be contributing to a 
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negative bias and an inaccurate overview of the effects of the Western-style diet on 
cognitive function overall. 
 
2.1.3 Vegan/ Vegetarian Diets 
Vegan and vegetarian diets, in a similar way to the Mediterranean diet, are rich in 
antioxidants and fibre and low in saturated fats, but do not include seafood, meat or 
meat products (products resulting from the processing of meat) (199). While these 
diets have been shown to be associated with a lower risk of diabetes, CVD and 
obesity (199), there is other evidence which suggests that these diets may lead to 
deficiencies in vitamin B12, creatinine and omega-3 fatty acids (200-202), which 
have been found to be protective of cognitive decline. Further, another five day study 
conducted in 128 young women which supplemented vegetarians with 20g of 
creatinine, found improvements in memory compared to non-vegetarians who were 
also supplemented (202). While this suggests that deficiencies in particular nutrients 
related to vegan and vegetarian diets may cause these diets to be associated with an 
increased risk for cognitive decline, there appears to be very limited studies which 
have specifically investigating the effect of vegetarian or vegan diets on cognitive 
function. However, one cross-sectional study in 404 adults aged 60 years and older 
with and without MCI found that being vegetarian increased the risk for cognitive 
impairment four-fold compared to non-vegetarians (203). 
 
2.1.4 Fruits and Vegetables 
Diets rich in fruits and vegetables have been found to be associated with lower rates 
of heart disease and stroke, which are known risk factors associated with cognitive 
decline (204, 205). However, as identified in a 2012 review there is currently limited 
evidence for a beneficial effect of increased fruit and vegetable intake on cognitive 
function (206). Most of the evidence supporting a positive effect appears to be 
derived from cross-sectional studies (206). When looking at the findings from 
longitudinal cohort studies, there are mixed findings with some studies only 
reporting benefits for either vegetables or fruits but not both (206). In a prospective 
study using data provided over a 10-16 year period from healthy women aged over 
70 years (with a median vegetable intake of 3.1 serves and 2.4 serves for fruits), it 
was found that those who had higher intakes of green leafy vegetables had slower 
rates of cognitive decline (0.05 units which is the equivalent of being 1-2 years 
younger in age) than those who had lower intakes (205). It was also found that the 
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difference in cognitive function between the lowest and the highest quintiles for total 
vegetable intake was equivalent to being 1.5 years younger in age (205). However 
there were no significant findings in regards to fruit intake (205). Consistent with 
these findings, principal component analysis using data from the AusDiab study 
described above, found that for every one unit increases in foods contributing to a 
fruit and vegetable pattern, there was a 1.06-fold decrease in the odds of having 
cognitive impairment (197).  
 
In a similar fashion to the Mediterranean diet, the cognitive benefits associated with 
fruits and vegetables may be attributed to antioxidants. There are also a number of 
vitamins in fruits and vegetables such as B vitamins, vitamin C and vitamin E which 
may also play a role (207, 208) and this is discussed further in the next section. 
 
2.1.5 Summary of dietary patterns and effects on cognitive function 
Dietary patterns can provide a holistic overview of dietary intake and are therefore 
likely to portray realistic effects of foods. Overall, current evidence suggests that 
there may be some benefits of the Mediterranean diet on cognitive function but the 
evidence is not conclusive. In contrast, the Western-style diet has been associated 
with increased oxidative stress and inflammation which may contribute to an 
increased risk for cognitive decline, but again the current evidence is mixed. The 
focus of studies on saturated fats and simple sugars may be contributing to an overall 
negative view of the Western-style diet on cognition. While diets rich in fruits and 
vegetables have been consistently associated with a reduced risk for factors 
associated with cognitive decline such as heart disease, studies have found mixed 
findings for the effects of fruits and vegetables on cognitive decline itself. Further, 
there have been no specific studies looking at vegan/vegetarian diets and their effect 
on cognitive function. 
 
2.2 Role of specific nutrients on cognitive function 
It is important to also consider the roles of individual nutrients and other food-based 
compounds when looking at a whole diet as this can provide an idea as to which 
nutrients or combinations of nutrients are important for preventing or reducing the 
risk for particular health conditions. This can also assist in identifying whole foods 
which may be the most beneficial for health. Some of the most common nutrients 
and compounds associated with cognitive function include antioxidants, B vitamins, 
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vitamin D and other vitamins (e.g. vitamin A, C and E), saturated and trans fats, 
omega-3 fatty acids and polyphenols such as carotenoids and flavonoids. The 
following section will provide a brief overview of the evidence for the role of 
antioxidants, omega-3 fatty acids, vitamins, saturated fats and trans fats, in cognitive 
function.  
 
Antioxidants are proposed to promote brain health and cognitive function due to their 
potential to protect the brain from oxidative stress (207) which has been implicated 
in the early stages of AD (194, 209) due to their ability to reduce the damage from 
free radical reactions (210). However, it is important to note that most of this 
evidence supports the beneficial effects of antioxidants from normal dietary intakes, 
and it has been suggested that elimination of free radicals due to high doses of 
antioxidants from supplementation (mean intakes; beta carotene: 17.8 mg , vitamin 
A: 20 219 IU, vitamin C: 488 mg, vitamin E: 569 IU, and selenium: 99 μg), may 
potentially interfere with the body’s defence mechanisms (211) and may be 
associated with an increased mortality risk (209, 211). A range of different 
antioxidant classes have been shown to be protective against cognitive decline and 
dementia including carotenoids which are fat-soluble antioxidants which may have 
the ability to protect omega-3 fatty acids such as docosahexaenoic acid (DHA), from 
oxidation and have been investigated as a potential biomarker for dementia (212). 
More recently there has been an interest in the effects of polyphenols on cognitive 
function due to the antioxidant properties of polyphenols such as flavonoids and 
phenolic acid (213). Flavonoids and phenolic acid can be found primarily in coloured 
fruits and vegetables such as berries and tomatoes, and evidence suggests that 
flavonoids from whole food and extract and polyphenol consumption are associated 
with small improvements in cognitive function (214), including specific benefits for 
executive function and/or working memory (215).  
 
A large body of research has focused on the effects of omega-3 polyunsaturated fatty 
acids on cognitive function partly due to their proposed role in brain structure and 
function (216) and modulation of inflammation and oxidative stress (208, 210). The 
most prevalent omega-3 polyunsaturated fatty acid (PUFA) in the diet is α-linolenic 
acid which is obtained from plant sources such as nuts, seeds, legumes, grains and 
fruits. However, it is the long chain omega-3 fatty acids DHA and eicosapentaenoic 
acid (EPA) derived from marine algae and oily fish, which have been most 
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consistently associated with physical and cognitive health benefits (217). The omega-
3 DHA constitutes a large proportion of the lipids in the brain (198, 210) and has 
been associated with memory and learning, vascular tone, increased cerebral blood 
flow (218) and reduced inflammation in the brain (198, 210). As a result, it has been 
proposed that omega-3 fatty acids may prevent cognitive decline and the risk of 
dementia via anti-inflammatory effects (175). The findings of a recent systematic 
review of 16 cross-sectional, prospective and RCTs found that omega-3 fatty acids 
were associated with better global cognitive function in five studies as well as less 
cognitive decline in four studies and less cognitive impairment in two studies, with 
six studies reporting no association (219). A reason for these mixed findings may be 
the inclusion of studies which used dietary sources of omega-3 fatty acids (fish) and 
omega-3 supplements, and heterogeneity in the dose used across studies. Despite 
this, a 2014 systematic review of epidemiological studies and RCTs found that 
consuming fish rich in omega-3 fatty acids at least twice a week, was associated with 
slower cognitive decline and better global cognitive performance (208).  
 
There is a growing body of evidence which supports the roles of B vitamins, other 
vitamins such as vitamin D, A, C and E and multivitamin supplements in reducing 
inflammation and oxidative stress (62, 207, 220-222), but the current evidence as to 
whether these factors improve cognitive function and if there is a specific dose 
required, remains mixed. The B vitamins, particularly B6 and B12, have been 
strongly implicated in cognitive function and related disorders (222). This has been 
proposed to be related to their effects on circulating levels of homocysteine, 
production of multiple neurotransmitters and prevention of oxidation (62, 207). 
Supplementation with folate (vitamin B9) along with other B vitamins has been 
shown to potentiate the effects of anti-depressant drugs and to assist in preventing 
cognitive decline (220, 221), however one review reported that clinical trials have 
shown mixed results (222) possibly due to differences in dosage prescribed. Vitamin 
D may also protect against cognitive decline by protecting neurons located in the 
hippocampus and/or reducing systemic inflammation (62), but the evidence for a 
beneficial effect on cognitive function is mixed. Low serum levels of 25-
hydroxyvitamin D have been found to be associated with an increased risk for AD 
(209, 223) and a 2.39 greater chance of developing cognitive impairment compared 
to those with normal (>50 nmol/L) or higher (>66.6 nmol/L) 25-hydroxyvitamin D 
levels (224, 225). In contrast, a recent review of evidence for the effects of vitamin D 
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supplementation on cognitive function found that three out of four intervention 
studies reported no improvement in cognitive outcomes or reduction in the risk for 
MCI or dementia (226). The main limitations of these studies are that many of the 
participants already had sufficient baseline concentrations of 25-hydroxyvitamin D, 
the sample sizes were relatively small (32-63 participants), a range of different doses 
of vitamin D were used and the intervention durations were relatively short (226). 
 
Overall, the evidence for vitamins A, C and E is mixed. Vitamin A, which has been 
implicated in the functioning of the hippocampus (62), has mixed findings cross-
sectionally (227) and a RCT of 1,904 men who had taken beta carotene for a year, 
found that there was no difference in cognitive function compared to those taking a 
placebo (228). However, higher scores for global cognitive and verbal memory 
scores were reported for men taking beta carotene for 18 years compared to those in 
the placebo group (228). With regard to vitamins C and E, which have roles in 
synthesising neurotransmitters, regulating amino acids and the prevention of the 
oxidisation of lipids and PUFAs in the brain (229), there is some cross-sectional 
evidence which suggests that the combination of these two vitamins may be 
associated with a reduced risk for MCI and AD (230, 231). This may not be 
surprising as vitamin E needs vitamin C or other soluble vitamins to assist with the 
removal of free radicals (232). However, the effects for either vitamin alone on 
cognitive function are mixed (227, 230, 233). 
 
A number of RCTs have looked at the effect of multivitamin supplements on 
cognitive function, but the findings have been inconsistent. For instance, a large RCT 
in 910 healthy adults aged over 65 years in the United Kingdom (UK) found no 
beneficial effects for multiple cognitive domains (memory and verbal ability) after 
taking a multivitamin supplement daily for 12 months compared to a placebo (234). 
In contrast, a more recent RCT found improvements in visuospatial memory in 
elderly women with subjective memory complaints after daily multivitamin and 
herbal supplementation for 16 weeks compared to a placebo (235). A meta-analysis 
of 10 RCTs examining the effect of multivitamins on cognitive function found that 
they were effective for improving immediate free recall but not delayed free recall 
memory or verbal fluency (236). Further research is needed in this area particularly 
for other cognitive domains such as executive function.   
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The investigation into the effects of saturated and trans fats on cognitive decline has 
largely focussed on the development of vascular dementia which has been found to 
be influenced by the presence of other physical conditions including stroke, diabetes 
and hypertension (189). These conditions have in the past often be associated with 
diets which are high in saturated and trans fats such as the Western-style diet (189). 
Data from the Rotterdam study, a 2.5-year single centre prospective study conducted 
in individuals aged over 55 years in the Netherlands, showed that an increased intake 
of saturated fats was associated with a 1.9-fold increased risk for cerebrovascular 
dementia (195). This finding is also supported by a review of epidemiological studies 
and a 16-year prospective study in adults over 50 years of age, which found that 
dietary intake of trans and saturated fats were associated with chronic conditions 
such as diabetes and CVD (237, 238) which may increase the risk for cognitive 
decline.  
 
In summary, the observed cognitive benefits for particular dietary patterns, such as 
the Mediterranean diet, may be partly due to their high levels of antioxidants. There 
is some evidence which supports the roles of B vitamins, other vitamins such as 
vitamin D, A, C and E, omega-3 fatty acids and multivitamin supplements in 
reducing inflammation and oxidative stress, although the current evidence for these 
nutrients with regards to dose and benefits for cognitive function remains mixed. 
Similarly, findings from research into the effects of polyphenols including flavonoids 
and phenolic acid and saturated and trans fats on cognition is inconsistent. While this 
section has reviewed the evidence for a number of dietary patterns and nutrients and 
other food-based compounds, the following section will review evidence for the 
effects of different types of protein on cognitive function.  
 
2.3 Effects of dietary protein on cognitive function 
As shown in Figure 2.6, dietary protein is essential for many biological processes as 
it is a good source of many if not all of the essential amino acids (61). Essential 
amino acids are the building blocks which the body cannot produce itself and so they 
must be supplied through dietary sources (239). The potential benefits of protein for 
cognitive health, which include maintaining brain cell function and integrity, are 
thought to be associated with the up regulation of various growth factors and 
neurotransmitters including IGF-1, serotonin and catecholamine (60) which are 
thought to be related to specific essential amino acids (62). 
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Figure 2.6 Importance of adequate dietary protein and associated roles in the body. 
Taken from Guadagni et al. (2009) (240). 
 
The presence of essential amino acids may influence the availability of certain 
neurotransmitters in the brain, which are responsible for modulating functions 
including stress and mood (61, 62). This may be mediated by changes in plasma 
tryptophan and tyrosine levels (49) which play key roles in neurotransmitter 
synthesis (60). Tryptophan has been found to be the precursor for serotonin, a 
neurotransmitter which has been implicated in memory (60). Increasing blood 
plasma concentrations of tryptophan increases the transport of tryptophan across the 
BBB which results in increased activity of serotonin receptors in the brain (1). 
However, transport of tryptophan across the BBB decreases with age (62) which may 
also be a contributing factor to the increased prevalence of depression and anxiety in 
older adults (241). This suggests that by increasing tryptophan intake, there is the 
potential to maintain memory and support mental health. 
    
43 
 
 
Similarly, the amino acid tyrosine is the precursor for several important 
neurotransmitters including dopamine, epinephrine and norepinephrine, which may 
control stress response and working memory (60). The ageing process results in a 
reduction of dopamine in the brain which can lead to a decline in cognitive function 
(45). Thus, increasing dietary protein intake, particularly in older adults, may 
increase the production of these neurotransmitters, and thereby assist in maintaining 
cognitive function (45). 
 
Protein has a number of other important roles within the body including enhancing 
MPS, blood clotting, hormone production and cell repair (61). With regard to brain 
health and cognitive function, protein induces signalling in the gut which in turn 
affects the brain’s response to metabolic functions such as insulin production (61). 
This may be important as there is some evidence which suggests that the brain is an 
‘insulin sensitive organ’ and insulin can influence memory due to an abundancy of 
insulin receptors in areas including the hippocampus and frontal cortex (242). Insulin 
has also been associated with an inhibition for the phosphorylation of tau resulting in 
neurofibrillary tangles, a hallmark of AD (242). There is also some evidence to 
suggest that insulin resistance may be detrimental to memory (242).  
 
There is the possibility of an indirect relationship between muscle health (mass 
and/or strength) and cognitive function. More specifically, there is emerging data that 
a reduction in muscle mass (sarcopenia) is associated with an increased risk for AD 
and cognitive impairment, although the current evidence is mixed. For instance, a 
cross-sectional study in 353 men aged 65 years and over found that sarcopenia was 
independently associated with an increased risk for cognitive impairment (OR= 3.03) 
(14). However, there is also evidence to suggest that cognitive impairment is 
associated with a decrease in muscle strength but not mass (3, 15). One cross-
sectional study in 223 adults aged 40 years and over, reported that those with 
sarcopenia were more likely to have combined physical and global cognitive 
impairment (Montreal cognitive assessment [MoCA] OR=3.46; ascertaining 
dementia OR=3.61) (3). However, it was found that these associations were due to 
low muscle strength as there was no association found with low muscle mass on 
either measure of global cognitive function (3). Similar findings were also found in 
one prospective study with a mean follow-up of 3.6 years in 970 adults with a mean 
age of 80.3 years (15). Each one unit increase in muscle strength was associated with 
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a 43% decrease in the risk of AD and a 34% decreased risk for MCI (15). Another 
six month RCT conducted in older adults with MCI found that improvements in 
strength following high-intensity PRT on two to three days a week, mediated 
improvements in cognitive function as measured by the Alzheimer’s disease 
Assessment Scale-cognitive subscale (ADAS-Cog) (243). There is also evidence to 
suggest that a combination of muscle strength and muscle mass, that is muscle 
quality (isokinetic strength per unit muscle mass), is associated with cognitive 
impairment (16). One large cross-sectional study in 867 adults aged 60 years and 
over found that there was a positive relationship between muscle quality and 
cognitive function (β=0.39 and 0.31 for men and women, respectively) (16). 
Collectively, these studies indicate that there may be some relationship between 
muscle and cognitive function, although the direction and mechanisms behind this 
relationship in terms of causality cannot be inferred from these studies. Therefore, 
these findings may potentially be explained by the possibility that those who are 
cognitively impaired do less physical activity which leads to a loss of muscle mass 
(3, 14). Although the exact mechanisms behind this relationship are currently 
unknown, it has been speculated that these findings may be explained in part by 
various circulating inflammatory markers (e.g. IL-6 and TNF-α) and oxidative stress 
markers, which have been associated with sarcopenia and cognitive decline (3, 14). 
In a similar fashion, the observed relationship between muscle mass and cognitive 
function may be due to exercise-induced increases in serum IGF-1 (244) and BDNF 
(245) levels, which have the ability to pass through the BBB and which may 
potentially benefit cognitive function. Diet also has the potential to influence these 
factors (such as inflammation) and this will be discussed in more detail in section 
2.5. 
 
It is also important to consider the influence of the food source for protein as the 
combination of certain nutrients in particular foods rich in protein may mean that 
some protein sources (e.g. dairy, soy, supplemental) are more beneficial than others 
for cognitive function. For instance, dairy sources of protein may be more beneficial 
for cognitive function than supplemental sources, as dairy foods are often rich in 
other nutrients such as vitamin D (which, as explained earlier, has been found to be 
associated with benefits for cognitive function). While it is beyond the scope of this 
thesis to detail the research on all sources of protein and their effects on cognitive 
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function, a brief summary on the effects of common protein sources on cognitive 
function is detailed below.  
 
2.3.1 Total dietary protein 
For people aged over 70 years, the Australian estimated average requirement (EAR) 
for protein is 65 g/d for men and 46 g/d for women with the recommended dietary 
intake (RDI) being 81 g/d for men and 57 g/d for women (246). However, the 
recommended requirements for older adults are controversial due to the apparent 
‘anabolic resistance’ associated with age, which represents a reduced ability to 
increase MPS in response to protein (amino acids) and/or exercise with advancing 
age. As a result, it has been suggested that older adults may require a greater protein 
intake to promote a net positive protein balance (66, 67). This section will review 
current evidence for the effects of protein intake on cognitive function in older 
adults. Table 2.3 provides a brief overview of studies which have investigated the 
effects of total dietary protein on cognitive function.  
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Table 2.3 A summary of key studies which have examined the association between total dietary protein on cognitive function in older adults 
Author, Year Subjects 
Duration and 
design 
Baseline dietary protein intake Domain Results 
Roberts et al. 2012 
(247) 
Cognitively normal adults 
aged 70-89 years (n=937) 
3.7-year 
Prospective 
Not reported MCI and dementia risk - 
Vercambre et al. 
2009 (248) 
Older women part of the E3N 
cohort aged between 63 and 
68 years (n=4,809) 
13-year follow-up 
study 
Mean daily protein intake 
87.7±24.6 g 
Global cognitive function O 
 
Koh et al. 2015 
(249) 
Community dwelling adults 
mean age 78.2 years (n=48) 
Cross-sectional Mean daily protein intake 81g/d Executive function 
Working memory 
Immediate memory 
Rate of learning 
Visual attention 
Task switching 
O 
O 
O 
O 
O 
O 
Katsiardanis et al. 
2013 (250) 
Community-dwelling elderly 
aged > 65 years (n=557) 
Cross-sectional Mean daily protein intake 
Cognitively normal: women= 
74.8± 28.59g 
Men= 81.0± 23.57g 
Cognitive impairment: 
Women= 75.5± 24.34g 
Men= 82.5± 28.84g 
Global cognitive function O 
 
Aparicio Vizuete et 
al. 2010 (251) 
Institutionalised elderly aged 
65 years and over (n=178) 
 
Cross-sectional Mean daily protein intake  
<50
th
 percentile for age: 
no errors on SPMSQ= 71.01± 
14.30g 
SPMSQ errors>0= 67.63± 12.68g 
 
>50
th
 percentile for age: 
No errors on SPMSQ= 70.02± 
Global cognitive function + 
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12.89g 
SPMSQ errors>0= 67.98± 10.67g 
 
Mori et al. 2010 
(252) 
Community-dwelling adults 
aged 65 years and over 
(n=179) 
Cross-sectional Mean daily protein intake  
High MCS scores on SF-36= 
74.5± 1g 
Low MCS scores on SF-36= 
73.5±1.6g 
Mental health O 
 
Velho et al. 2008 
(253) 
Cognitively normal 
community-dwelling adults 
aged 65 years and over 
(n=187) 
Cross-sectional Mean dietary protein intake 
women = 71.5±1.2g 
men = 78.8±1.9g 
Global cognitive function O 
 
Salerno-Kennedy 
and Cashman 2007 
(254) 
First degree blood relatives of 
AD patients mean age 57.7 
years (n=44) 
Cross-sectional Mean daily protein intake 86g Global cognitive function 
Memory 
Processing speed 
Attention 
O 
Not reported 
Not reported 
Not reported 
Deschamps et al. 
2002 (255) 
French community-dwelling 
older adults aged 68 years 
and over (n=169) 
5- year 
Longitudinal 
Median daily protein intake 1.33 
g/kg/d 
Global cognitive function O 
 
Lee et al. 2001 
(256) 
Korean community-dwelling 
older adults aged 60 and over 
(n=449) 
Cross-sectional Mean daily protein intake 
Women (cognitively normal)= 
57.0±24.5g, 
(inadequate score MMSE) = 
58.4±29.1g, (poor score MMSE) = 
42.5±22.3g 
 
Men (cognitively normal)= 
65.1±25.7g, 
(inadequate score MMSE) = 
63.9±26.4g, (poor score MMSE) = 
60.0±25.0 g 
Global cognitive function + 
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La Rue et al. 1997 
(45) 
Healthy community dwelling 
older adults aged 66-99 years 
(n=137) 
Cross-sectional Median daily protein intake 75g Abstract reasoning 
Verbal memory 
Nonverbal memory 
Visuospatial skills 
O 
+ 
+ 
+ 
Ortega et al. 1997 
(41) 
Healthy adults aged 65-90 
years (n=260) 
Cross-sectional Mean protein intake  
MMSE <28 scores: 72-81 g/d. 
MMSE > 28 scores: 74-82 g/d. 
Global cognitive function 
 
O 
Winograd et al. 
1991 (257) 
Healthy controls (n=29) and 
community-dwelling patients 
with probable or definite 
senile dementia (n=35) aged 
51 years and over 
Cross-sectional Mean dietary protein intake 
women = 76 g/d 
men = 89-99g/d 
Global cognitive function O 
 
Burns et al. 1989 
(258) 
Healthy controls (n=29), 
Community-dwelling adults 
with dementia (n=28), and 
hospitalised adults with 
dementia (n=21) 
Cross-sectional Mean dietary protein intake 
Controls = 44±15.2g, 
Community-dwelling= 61±12.0g, 
Hospitalised = 73±8.3g 
Global cognitive function + 
Goodwin et al. 
1983 (46) 
Non-institutionalised adults 
aged 60-94 years (n=260) 
Cross-sectional Not reported Memory 
Abstract thinking 
+ 
O 
 
Nes et al. 1988 
(259) 
Adults with dementia living 
independently and age-
matched controls (n=32) 
Case-control Mean dietary protein intake 
Controls; Women = 64 g/d, Men = 
75 g/d 
Dementia; Women = 51 g/d, Men 
= 69 g/d 
Not assessed Not 
assessed 
+ significant positive association between protein intake and cognitive function; - significant negative association between protein intake and cognitive 
function; O no association between protein intake and cognitive domains. 
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As shown in Table 2.3, the findings from a number of cross-sectional studies provide 
mixed findings with regard to whether dietary protein intake is associated with 
cognitive function and related disorders in older adults. A cross-sectional study in 
260 non-institutionalised older adults aged 60-94 years found that there was a trend 
for those in the lower 5-10% of protein intake (subclinical malnutrition) to have 
lower scores on memory tests (as measured by the Weschler memory test) when 
compared to those in the top 90% of protein intake (mean score of ~3.5 versus ~6.2)  
(46). However, this trend was found for all other nutrients assessed, indicating that 
adequate energy intake may contribute to maintaining cognitive function. More 
recently a cross-sectional study conducted in 48 community dwelling healthy older 
adults with a mean age of 78.2 years and a mean daily protein intake of 81g 
(equivalent to current recommended levels) found that there was no association 
between total daily protein intake and cognitive function in a number of domains 
including executive function, working memory, immediate memory, rate of learning, 
visual attention and task switching (249). Similarly, one study conducted in 29 
healthy adults and 35 community dwelling patients aged 51 years and over with a 
definite or probable diagnosis of senile dementia found no association between 
nutritional intake and cognitive function as measured by the MMSE and global 
deterioration scale (GDS) (257). However, this study had a small sample size and 
participants were also meeting the recommended daily allowances (RDA) for total 
energy, protein and micronutrients assessed. Overall the evidence from cross-
sectional studies with regard to the effects of dietary protein on cognitive function 
are mixed, which may be due to the fact that the majority of participants in these 
studies had adequate protein intake. While there is some evidence to support a 
positive association, no cause and effect can be determined from these cross-
sectional studies. 
 
There appears to be limited prospective studies which have investigated the effect of 
dietary protein on cognitive function with mixed findings (247, 250, 251, 260, 261). 
One large prospective study was conducted in 937 cognitively normal older adults 
aged 70-89 years and found that dietary patterns with higher percentages of daily 
energy intake from protein (above 20%) was associated with a reduced risk for MCI 
and dementia (upper quartile 0.79 [0.52-1.20]) in fully-adjusted models (247). 
Additionally, a reduced risk was also found for a higher fat intake (upper quartile 
0.56 [0.34-0.91]) but the risk was elevated for a higher intake of carbohydrates 
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(upper quartile 1.89 [1.17-3.06]) (247). This finding suggests that a balanced dietary 
pattern including carbohydrates, fat and protein may reduce the risk for MCI and 
dementia in older adults, rather than protein intake alone.  
 
Several recent reviews on the role of dietary protein on cognitive function have also 
reported mixed findings (60, 260). In a 2013 review examining the role of dietary 
protein intake on cognitive function in clinical (those with chronic health conditions) 
and healthy populations that included a combination of observational, case-control 
and RCTs (34 studies in total), the authors concluded that the evidence is limited and 
inconclusive (60). However, most of these studies (23 out of 34) examined the 
effects of individual amino acids on cognitive function rather than dietary protein as 
a whole. Moreover, a diverse range of neuropsychological tests were used in these 
studies which limits meaningful comparisons (60). More recently, a systematic 
review of 17 observational studies investigating the role of protein and thiamine on 
cognitive function in healthy older adults, found that evidence for an association 
between protein intake and cognitive function was weak and further, there was no 
evidence supporting differences in effects between different sources of protein (260). 
However, it is important to note that despite this conclusion, six out of the 11 studies 
assessing protein intake and cognitive function found positive associations. 
Interestingly, only one out of the eight studies assessing meat as a source of protein 
and its role in cognitive function found that higher meat intake was associated with 
poor cognitive function (260). Further, one study included in the review suggested 
that the consumption of meat may be important for reducing the incidence of AD 
(260). The role of meat in cognitive function will be discussed in more detail later in 
this chapter.  
 
In summary, there are limited case-control studies which suggest that those with a 
diagnosis of dementia have protein intakes which may be due to either a low habitual 
protein intake in the long-term or perhaps those with dementia merely have a lower 
protein intake. As discussed, the research from cross-sectional and prospective 
studies on the effects of dietary protein intake on cognitive function in older adults is 
mixed, although this may possibly be due to the good health and nutritional status of 
participants being assessed. This is reflected in a number of reviews, which also 
indicate a lack of RCTs which have investigated the effects of increasing total 
protein intake on cognitive function. 
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2.3.2 Dairy Protein 
Dairy products are an excellent source of protein. In particular, milk proteins are 
highly digestible and contain all the essential amino acids (262). In addition, dairy 
products, particularly low-fat dairy products, have been suggested to be beneficial to 
health in a number of areas that may indirectly impact cognitive function, including 
weight control, lowering inflammatory markers and cardiovascular risk (1). The 
following section will provide a brief overview of the role of dairy protein on 
cognitive function. The studies which have assessed the effects of dairy protein on 
cognitive function are summarised in Table 2.4. 
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Table 2.4 A summary of key studies which have examined the effect of dairy protein on cognitive function in adults 
Author, Year Subjects 
Duration and 
design 
Groups 
Baseline 
dietary protein 
intake 
Domain Results 
Park & Fulgoni, 
2013 (47) 
Aged 20+ years 
(n= 10,826) 
Cross-sectional 
data from 
NHANES 1988-94 
and 1999-2002 
NA Not reported 20-59 years 
Visuomotor speed 
Psychomotor speed 
Learning and recall 
 
60 years + 
Attention and delayed memory 
Attention, visuospatial skills and 
memory 
 
O 
+ 
O 
 
 
+ 
 
+ 
Crichton, 2012 
(48) 
Overweight and 
obese adults who 
habitually consumed 
low dairy (less than 
2 serves a day of 
dairy) aged 18-75 
years (n=38) 
12-month crossover 
dietary intervention 
trial. 
 
 
1) High dairy (four 
serves a day) 
 
2) Low dairy (one 
serve a day) intake 
of reduced fat, 
alternating to the 
other diet after 6 
months. 
Not reported Processing speed 
Abstract reasoning 
Working memory 
Verbal fluency 
Selective attention 
Verbal memory 
Processing speed 
Executive function 
Visual-spatial scanning 
O 
O 
+ 
O 
O 
O 
O 
O 
O 
Fischer et al. 
2002 (49) 
Healthy males mean 
age 26.3 years 
(n=15) 
Repeated measures 
cross-over design 
over 3 weeks.  
1) protein (75.8g milk 
protein; 1:4 of 
carbohydrate: 
protein) 
Not reported Choice reaction time 
Short term memory 
O 
+ 
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2) carbohydrate 
(18.9g milk 
protein; 4:1 of 
carbohydrate: 
protein) 
 
3) balanced meal 
(47.3g milk 
protein; 1:1 of 
carbohydrate: 
protein) in each 
session. 
Attention O 
+ significant positive association between protein intake and cognitive function; - significant negative association between protein intake and cognitive 
function; O no association between protein intake and cognitive domains. NA; not applicable. 
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Cross-sectionally, evidence suggests that there may be a positive association between 
dairy intake and cognitive function (47). For instance, a cross-sectional study using 
data from over 10,000 adults aged 20 years and over who were included in the 
National Health and Nutrition Examination survey (NHANES) found a significant 
positive trend between total dairy consumption in adults aged 60 years and over and 
scores on the digit-symbol substitution test (DSST) (which is a measure of memory 
and processing speed) compared to non-consumers (no servings of dairy products 
consumed as assessed by a 24 hour dietary recall) (47). Further, it was found that 
consumers (those consuming at least one serving of dairy products as assessed by a 
24 hour dietary recall) of total dairy products (low and full fat milk, cheese and 
yoghurt) were associated with higher percentile scores on the story recall test 
(measuring attention and delayed verbal memory) than non-consumers (47). For 
adults aged 20-59 years, higher global and symbol-digit substitution test (SDST) 
scores (a measure of psychomotor speed) were associated with those in higher 
quartiles for total dairy consumption (>2.0 cup equivalent) compared to non-
consumers (47). There were no significant differences in this age group however for 
the simple reaction time task (SRTT) (visuomotor speed) (47). Due to the cross-
sectional design, cause and effect cannot be inferred from this study, and since this 
study assessed the relationship between overall dairy intake and cognitive function, 
and not specific dairy proteins, it is possible that other nutrients within dairy foods 
may play a role in enhancing cognitive function. 
 
While there is some evidence from cross-sectional studies for a positive association 
between dairy protein and cognitive function, there are limited intervention studies in 
this area. One 12-month intervention trial in 38 overweight and obese adults aged 18-
75 years, who were randomised to consume either low amounts of dairy (less than 2 
serves daily) or high amounts of dairy products (four serves of reduced-fat dairy 
daily), found that high consumption of reduced-fat dairy products was associated 
with a 8% higher performance for working memory (as measured by spatial span 
backwards) than those who consumed dairy products once a day, but there was no 
effect on other cognitive domains (48). However, this study did not look at protein 
content specifically. In contrast, one short-term intervention study which conducted 
three testing sessions over three weeks in 15 healthy young males, found that a single 
protein meal (75.8g milk protein) resulted in the highest percentage for short-term 
memory accuracy performance (as measured by a Bimodal computer-based visual 
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combi test) when compared with a carbohydrate enriched or balanced meal (1:1 ratio 
of protein and carbohydrates) (49). Interestingly, in the first hour after ingestion, the 
carbohydrate meal had a transient positive effect on attention and decision times. 
Although the protein and balanced meals appeared to have similar reaction times 
within the first hour to the carbohydrate meal, the protein and balanced meals 
maintained faster reaction times (as measured by the Wiener Reaktionsgerat test) 
when compared to the carbohydrate meal (49). While this short-term trial suggests 
that additional protein may sustain effects on memory compared to other nutrients, it 
is clear that further long-term trials are needed to evaluate the effects of dairy 
(protein) on cognitive function.  
 
A systematic review of 8 studies examining total dairy consumption and cognitive 
performance in young and older adults found that a higher consumption of whole-fat 
dairy products may be associated with an increased risk for cognitive decline in older 
adults (263). However, the authors stated that the methodological limitations of the 
studies reviewed included the use of non-standardised test batteries, failure to adjust 
for appropriate confounding variables and not reporting specific values of intake 
which were associated with improvements or detriments in cognitive function (263). 
It was also noted that as all of the studies reviewed were cross-sectional or 
prospective in design, more RCTs were needed in order to identify cause-and-effect 
relationships (263). A more recent systematic review reported minimal observational 
data and only one intervention study which actually assessed the effect of dairy 
products on cognitive function (264).  
 
While the mechanistic effects behind the potential benefits for dairy protein on 
cognitive function are unclear, it has been proposed that α-lactalbumin, which is a 
rich source of tryptophan, a precursor for receptors of serotonin which has been 
associated with improvements in depression and sleep, (1, 62) may increase 
serotonin activity counteracting sleep disturbances and a decline in neurogenesis due 
to ageing (1). It has also been suggested that improvements in insulin sensitivity and 
weight management which has been associated with increased dairy intake, may 
reduce the impact of vascular risk factors which may also improve cognitive function 
(265). Although there are nutrients contained in dairy products such as calcium and 
vitamin D which have been associated with benefits for cognitive function (265), 
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there are no studies that have shown that improved insulin sensitivity due to dairy 
protein is associated with improved cognitive function.  
 
2.3.3 Soy Protein 
Unlike other plant sources, soy protein is considered a high quality protein with 
biological values equivalent to animal protein (266). Further, phytoestrogen 
compounds which are highly prevalent in soy have been associated with reductions 
in AD pathology and progression (267). Past research also indicates that estrogen 
may play a role in the hippocampal memory circuit with increased cerebral blood 
flow in this area of the brain in post-menopausal women on estrogen therapy (268). 
Thus, it is possible that soy protein may also have a positive effect on cognitive 
function. Table 2.5 summarises the studies which have investigated the role of soy 
protein in cognitive function. 
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Table 2.5 A summary of key studies which have examined the effect of soy protein on cognitive function in adults 
Author, Year Subjects 
Duration 
and design 
Groups 
Baseline dietary 
protein intake 
Domain Results 
Basaria et al. 2009 
(269) 
Healthy 
postmenopausal 
women mean age 
56 years (n=84) 
12-week 
double-blind 
RCT.  
1) 20g soy protein 
powder containing 
160mg of total 
isoflavones 
 
2) 20g of a taste-
matched whole milk 
protein powder 
Not reported Abstract thinking  
Visual attention  
Executive function  
Visuomotor skills  
Psychomotor speed  
O 
O 
O 
O 
O 
Fournier et al. 
2007 (270) 
Postmenopausal 
women aged 48-
65 years (n=79) 
16-week 
RCT.  
 
1) cow’s milk + 
placebo supplement 
(24g protein) 
 
2) soy milk + placebo 
supplement (18g 
protein and 72mg 
isoflavones per day) 
 
3) cow’s milk + 
isoflavone 
supplement (24g 
protein and 70mg 
isoflavones per day) 
Not reported Selective attention  
Verbal working memory  
Spatial working memory  
Recall and recognition  
Long term memory  
Memory span  
O 
- (soy milk) 
O 
O 
O 
O 
File et al. 2005 
(50) 
Postmenopausal 
women aged 51-
66 years (n=50) 
6-week 
double-blind 
RCT. 
1) daily soy 
supplement (60mg 
soy isoflavone per 
Not reported Episodic memory  
Verbal fluency  
+ 
O 
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 day; no information 
regarding protein 
content) 
 
2) matching placebo 
capsules  
Mental flexibility  
Planning ability  
Sustained attention  
+ 
+ 
O 
Kreijkamp-Kaspers 
et al. 2004 (271) 
Postmenopausal 
women aged 60-
75 years (n=175) 
12-month 
double-blind 
RCT. 
 
1) 25.6g soy protein 
(99mg soy 
isoflavones daily) 
 
2) 25.6g total milk 
protein powder 
Soy group: 100g 
 
Control: 104g  
 
Executive function  
Memory  
Attention  
Verbal skills 
 
O 
O 
O 
O 
Duffy et al. 2003 
(272) 
Postmenopausal 
women aged 50-
65 years (n=33) 
12-week 
double-blind 
RCT. 
 
1) soya supplement 
(60mg total soy 
isoflavones per day; 
no information on 
protein content)  
 
2) placebo 
Control: 15.4±0.5 
% of energy  
 
Soy group: 
15.1±0.5 % of 
energy 
Episodic memory  
Verbal fluency  
Rule reversal  
Planning ability  
Sustained attention 
+ 
O 
+ 
+ 
+ 
Kritz-Silverstein et 
al. 2003 (51) 
Postmenopausal 
women aged 55-
74 years (n=56) 
6-month 
double-blind 
RCT. 
 
1) 55mg of soy-
extracted 
isoflavones (110mg 
total soy isoflavones 
per day; no 
information about 
protein content)  
 
2) placebo 
Not reported Attention  
Verbal memory  
+ (NS) 
+ 
File et al. 2001 
(52) 
Students aged 
21-29 years 
(n=27) 
10-week 
randomised 
intervention 
1) high soya diet 
(100mg total 
isoflavones per day) 
Not reported Attention  
Episodic Memory  
O 
+ 
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study. 
 
 
2) low soya diet (0.5mg 
total isoflavones per 
day) 
 
Semantic memory 
Verbal fluency  
Mental flexibility  
Planning  
O 
O 
+ 
+ 
+ significant positive association between protein intake and cognitive function; - significant negative association between protein intake and cognitive 
function; O no association between protein intake and cognitive domains; NS: non-significant. 
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Several intervention studies have investigated the effects of soy protein on cognitive 
function. A review of 230 RCTs focusing on the role of soy isoflavones in 
menopausal health found eight studies relevant to the effects of soy protein on 
cognitive function (273). The findings of these studies were mixed, with some 
indicating improvements in cognition (memory, executive function, global cognitive 
function and attention) for women aged <65 years following soy and soy isoflavone 
supplementation, but little effect for women aged >65 years (273). The reason(s) for 
the age-related difference remains uncertain, but it may relate to differences in 
estrogen which may influence cognitive function (273). Another 12-month RCT in 
175 postmenopausal women who ingested 25.6 g of soy protein powder daily found 
no differences for multiple domains of cognitive function (including memory, 
attention and verbal ability measured by multiple tests) when compared to a control 
group (271). In this study, protein intake did not increase during the intervention 
which may have impacted the results, and protein intake was already adequate at 
baseline in the women. In contrast, a 6-month RCT in 56 post-menopausal women 
receiving 110 mg isoflavones daily found significant improvements in one verbal 
memory task (category fluency), and non-significant improvements in the other tests 
of verbal memory and the Trails B task (51). Similarly, 6-week RCT in 50 
postmenopausal women who ingested a capsule containing 60 mg of soy isoflavones 
daily found improvements in short-term non-verbal mental flexibility and planning 
as measured by the Intra-dimensional/extra-dimensional (IDED) test from the 
Cambridge Neuropsychological Test Automated Battery (CANTAB) battery and the 
Stockings of Cambridge (SoC) test, respectively, although there were no 
improvements in long-term memory as measured by the Delayed Matching To 
Sample test (DMTS) from the CANTAB, or attention as measured by The Paced 
Auditory Serial Addition Test (PASAT) (50). Similar positive findings were found in 
a 12-week RCT in 33 post-menopausal women ingesting the same amount of 
isoflavones for recall, sustained attention, rule reversal and planning, using similar 
cognitive tests, however no information on protein content was provided (272). More 
recently, a 16-week RCT in 79 post-menopausal women found that soy milk (72 mg 
isoflavones daily) and cow’s milk supplemented with isoflavones (70 mg daily) did 
not improve selective attention, visual long-term memory, or short-term visuospatial 
or working memory compared to cow’s milk alone (270). These findings were 
supported in another 12-week study in which 84 post-menopausal women received 
20g soy protein daily (269). However, in the study by Fournier and colleagues (270), 
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the protein content of the cow’s milk was higher than that of the soy milk (24 g/day 
and 18 g/day respectively) which may explain the lack of findings for cognitive 
function. Other limitations of this study included the short duration and small, well-
educated sample. Overall, intervention studies have reported beneficial effects for 
soy isoflavone supplementation on cognitive function however the majority have 
been conducted in post-menopausal women which limits the generalisability of these 
findings to the rest of the population. 
 
In contrast to the studies conducted in post-menopausal women, one 10-week 
intervention of a high soya diet (100 mg/d of total isoflavones) conducted in 27 male 
and female students aged 21-29 years, showed significant improvements in 
immediate and delayed recall and mental flexibility (rule shifting and reversal as 
measured by the IDED and SoC) compared to those on a low soya diet (0.5 mg total 
isoflavones a day) (52). However, these diets were matched for protein content and 
these findings were suggested to be due to the isoflavone phytoestrogen content 
contained in the high soya diet. Estrogen has been found to be associated with 
increased cerebral blood flow and improvements in memory in post-menopausal 
women and male transsexuals treated with estrogen (52).  
 
Overall, there are some studies which report beneficial effects for soy protein on 
cognitive function in post-menopausal women, possibly due to the estrogen 
contained in soy protein. While the majority of the existing evidence has been 
conducted in this age-group, one study reported improvements in cognitive function 
in a younger age group. Further studies are needed as the generalisability of the 
findings from post-menopausal studies to the general population is poor. 
 
2.3.4 Protein Supplementation 
To date, relatively few studies have examined the effects of protein supplementation 
alone on cognitive health and function (Table 2.6). However, there is some evidence 
that supplementation with whey protein, a high quality protein that is rapidly 
absorbed and digested, has acute beneficial effects on cognitive performance in older 
adults (53). For instance, one study conducted in 22 adults aged 61 to 79 years which 
randomised participants to consume a single 300 ml drink (774 kJ except placebo 
which was 0 kJ) containing either 50.5 g of whey protein, carbohydrate (glucose) or 
fat (safflower oil), found that 15 minutes post ingestion of the whey protein drink, 
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immediate and delayed recall was improved compared to the placebo and the rate of 
forgetting was also reduced (53). Specific cognitive benefits were also observed for 
the carbohydrate and fat supplemented drinks indicating that memory improved due 
to the ingestion of any type of energy source (53). Despite this, only the protein 
enriched drink improved the rate of forgetting suggesting that protein ingestion may 
influence a specific aspect of memory (53). The mechanisms underlying the 
beneficial effects of whey protein on cognition remain uncertain, but could relate 
indirectly to whey protein induced improvements in blood lipids and triglycerides 
(274), which have been associated with poor cognitive function (195). Alternatively, 
there is evidence that the branched chain essential amino acid leucine, which plays a 
major role in stimulating MPS and can stimulate insulin production (275), may also 
be beneficial for improving multiple cognitive domains due to the abundance of 
insulin receptors throughout the brain. Despite this, one 8-week RCT conducted in 
30 young and fit men found that daily supplementation with 6.2 g leucine and 19.7 g 
whey protein did not improve cognitive function compared to a placebo (276). 
However, the results of this study may not be generalizable to older adults and there 
appears to be no studies which have directly investigated the effects of leucine 
supplementation on cognitive function in healthy older adults. 
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Table 2.6 A summary of key studies which have examined the effect of protein supplementation on cognitive function in adults 
Author, 
Year 
Subjects 
Duration 
and design 
Groups 
Baseline dietary 
protein intake 
Domain Results 
Van der 
Zwaluw et 
al. 2014 
(277) 
Pre-frail and frail 
older adults mean 
age 79±8 years 
(n=65) 
24-week 
intervention 
study 
 
1) 15g protein drink twice daily 
 
2) placebo drink twice daily 
Protein group 
78±26 g/day  
 
Placebo 74±14 
g/day 
Global cognitive function  
Episodic memory  
Direct recall  
Working memory  
Information processing  
Selective attention  
Executive function  
Reaction time  
O 
O 
O 
O 
O 
O 
O 
+ 
Tieland et al. 
2012 (278) 
Frail elderly aged 
65 years and over 
(n=65) 
24-week 
RCT 
1) 2 x 15g milk protein 
concentrate daily 
 
2) placebo 
Protein group 
78±4 g/day 
 
Placebo 74±4 
g/day 
Global cognitive function O 
 
 
 
Walker et al. 
2010 (276) 
Fit young men 
mean age= 26.9 
years (n=30) 
8-week RCT 
 
1) 19.7g/d whey protein + 
6.2g/d leucine  
 
2) a calorie –equivalent placebo 
Not reported Attention  
Memory  
O 
O 
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Kaplan et al. 
2001 (53) 
Adults aged 61-79 
years (n=22) 
Intervention 
study (acute 
effects) 
 
1) 50.5g whey protein (300ml 
drink) 
 
2) Carbohydrate (300ml drink)  
 
3) safflower oil (300ml drink) 
  
4) a non-energy placebo 
(300ml drink) 
Not reported Memory  
Executive function 
Attention  
+ 
O 
O 
+ significant positive association between protein intake and cognitive function; - significant negative association between protein intake and 
cognitive function; O no association between protein intake and cognitive domains. 
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In contrast to the above findings demonstrating a positive effect of protein 
supplementation on cognitive function, an 8-week RCT in 30 fit (majority men) 
young adults found no differences in cognition after 8 weeks of supplementation 
with 39.4 g whey and 12.4 g of leucine daily, compared to the placebo (276). 
However, it is worth noting that roughly half of the participants in each group for 
each test showed improvements of 5% or greater over the 8 weeks (276). The lack of 
any effect in this study may be due to the fact that the participants were young, fit 
men who were likely to be cognitively healthy. More recently, a 24-week RCT in 65 
frail and pre-frail older adults who received a drink containing 15 g of protein twice 
daily, found that the protein group improved their reaction time (as measured by a 
computerised finger-cuing task) more than the control group, although no other 
improvements were observed for any other cognitive domain including memory, 
attention, information processing and executive function (277). A potential reason 
for the lack of benefit observed in other cognitive domains is that it is unclear 
whether the protein supplement increased protein intake throughout the intervention 
as this was not reported. Further, participants had an adequate habitual protein intake 
at baseline and most did not have MCI which may have attenuated any effects of the 
intervention (277).  
 
2.3.5 Animal Protein 
There are limited intervention studies which have investigated the effects of animal 
protein on cognitive function (Table 2.7). One 3-week RCT in 23 healthy young men 
aged 19-31 years, found that a high animal protein (low fat pork, beef, chicken, milk 
and cheese) diet (3.0 g/kg/d) was associated with improvements in reaction time and 
a decrease in errors (as measured by Go/No-Go test), compared to the usual protein 
group (1.5 g/kg/d) (55). No significant differences were observed between groups for 
sustained attention or global cognitive function although the high protein group had a 
significant improvement in their global cognitive function (as measured by the 
Addenbrooke Cognitive Examination [ACE]) whereas the usual protein group did 
not (55). The improvements in reaction time were suggested to be due an increased 
phenylalanine and tyrosine intake in the high protein group when compared to the 
usual protein group. Phenylalanine which is precursor for tyrosine, may assist in the 
synthesis of various neurotransmitters including dopamine and norepinephrine (55). 
Further, the high protein group had a higher intake of B vitamins compared to the 
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usual protein group at baseline which may have influenced the outcomes. Although 
this study suggests that lean animal products may be beneficial for cognitive 
function, it does not differentiate between the effects of different types of meat and 
dairy products on cognitive function.  
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Table 2.7 A summary of key studies which have examined the effect of animal protein on cognitive function in adults 
Author, 
Year 
Subjects 
Duration 
and design 
Groups 
Baseline dietary protein 
intake 
Domain Results 
Requejo et 
al. 2003 
(279) 
Cognitively normal 
adults aged 65–90 
years (n=68) 
Prospective 1) MMSE scores ≥ 28 
and age <75 years 
 
2) MMSE scores ≥ 28 
and age >75 years 
 
3) MMSE <28 and age 
<75 years 
 
4) MMSE scores <28 
and age >75 years 
 
Mean daily meat intake 
 
MMSE scores ≥ 28 and 
<75 years= 138.5± 77.7 
g/d 
>75 years= 98.9 g/d 
 
MMSE scores < 28 and 
<75 years= 127.6± 60.9 
g/d 
>75 years= 126.3± 66.6 
g/d 
 
Global cognitive function O 
 
Barberger-
Gateau et al. 
2007 (280) 
Non-demented 
adults aged 65 
years and over 
(n=8,085) 
4- year 
follow up 
study 
Meat intake classified as  
1) 2-3 times per week 
 
2) 4-6 times per week 
 
3) Daily 
Not reported Incidence of AD and 
dementia 
O 
 
Katsiardanis 
et al. 2013 
(250) 
Community-
dwelling elderly 
aged > 65 years 
(n=557) 
Cross-
sectional 
1) Cognitively normal 
(MMSE score ≥24) 
 
2) Cognitive 
impairment (MMSE 
score <24) 
Mean MedDiet Score (0-
55) for meat and meat 
product intake 
 
Cognitively normal: 
women= 19.8 ± 12.27 
Men= 22.0 ± 10.25 
Global cognitive function O 
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Cognitive impairment: 
Women= 18.8 ± 11.47 
Men= 24.0 ± 14.67 
Aparicio 
Vizuete et al. 
2010 (251) 
Institutionalised 
elderly aged 65 
years and over 
(n=178) 
 
Cross-
sectional 
1) No errors on 
SPMSQ and <50
th
 
percentile for age 
 
2) No errors on 
SPMSQ and >50
th
 
percentile for age 
 
3) SPMSQ errors >0 
and <50
th
 percentile 
for age 
 
4) SPMSQ errors >0 
and >50
th
 percentile 
for age 
Mean daily meat intake  
 
No errors on SPMSQ and 
<50
th
 percentile for age= 
98.14 ± 41.67g 
 
No errors on SPMSQ and 
>50
th
 percentile for age= 
93.05 ± 39.81g 
 
SPMSQ errors>0 and 
<50
th
 percentile for age= 
105.55 ± 40.38g 
 
SPMSQ errors>0 and 
>50
th
 percentile for age= 
88.90 ± 35.73g 
 
Global cognitive function - 
Mori et al. 
2010 (252) 
Community-
dwelling adults 
aged 65 years and 
over (n=179) 
Cross-
sectional 
SF-36 MCS scores 
(High MCS and Low 
MCS based on 
standardised score 
classified by age, 
60–69 years = 52.0 and 
≥70 years = 51.7 ) 
Mean daily meat intake  
High MCS scores= 44.0± 
3.3g 
 
Low MCS scores= 55.3± 
5.3g 
Mental health O 
 
Rahman et 
al. 2007 
(261) 
Community-
dwelling adults 
mean age 67 years 
Cross-
sectional  
Yes or no to intake of 
pork, beef and turkey 
based on Verbal FFQ 
Not reported Global cognitive function O 
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(n=1,056) (Yes: 
Once or twice a week, or 
most days, or every day. 
 
No: Less often than once 
a week, or never.) 
Lee et al. 
2001 (256) 
Community-
dwelling adults 
aged 60 years and 
over (n=449)  
 
Cross-
sectional 
MMSE-Korean 
Version scores 
1) Poor: ≤19 
2) Inadequate: 20–23  
3) Normal: ≥24 
Mean daily Meat intake 
 
Poor MMSE 
Men: 46.7 ± 47.3g 
Women: 20.7 ± 31.1g 
 
Inadequate MMSE 
Men: 40.9 ± 50.2g 
Women: 34.6 ± 57.1g 
 
Normal MMSE 
Men: 39.2 ± 47.4g 
Women:37.7 ± 52.5g 
 
Global cognitive function O 
 
Charlton et 
al. 2016 (54) 
Older adults living 
in aged care 
facilities aged over 
60 years (n=31) 
mean age= 78±6.2 
years 
12-week 
intervention 
study. 
 
Pre-prepared meals 
containing either 
chicken (25.2 g protein) 
or pork (28.2 g protein) 
to substitute 4 meals per 
week 
Mean protein intake: 
81±23.4g (protein intake 
by group not reported) 
Verbal memory  
Semantic memory 
Executive function  
Short term memory  
+ (chicken) 
O 
O 
O 
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Jakobsen et 
al. 2011 (55) 
Healthy men aged 
19-31 years (n=23) 
3-week RCT. 
 
1) usual protein diet 
(1.5g/kg) 
 
2) high-protein diet 
(3.0g/kg) 
Usual protein group: 
1.5±0.3 g/kg /d 
 
High protein group: 
1.7±0.2 g/kg /d  
Global cognitive function  
Reaction time 
 
O 
+ 
+ significant positive association between protein intake and cognitive function; - significant negative association between protein intake and cognitive 
function; O no association between protein intake and cognitive domains. 
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Cross-sectionally, one review of 16 studies found that there was no evidence to 
support an association between different types of protein (including different sources 
of meat) and cognitive function (260). Overall, eight studies in this review were 
identified which investigated meat protein sources and cognitive function, one of 
which found a negative association between increased meat intake and cognitive 
function while the other studies found no significant associations (260). On the other 
hand, one of these studies found that an increased meat intake (4-6 times a week) 
was associated with a lower incidence of AD than when meat was consumed less 
than three times a week (280).  The authors suggested that these conflicting findings 
may have been due the range of cognitive tests used across studies as well as 
differences in the macro and micronutrient profiles of foods used as the protein 
source which may have also impacted on cognitive function (260). 
 
A 12-week RCT conducted in 31 older adults aged over 60 years living in aged care 
facilities which substituted four meals per week with chicken (containing 25.2 g 
protein) or pork (28.1 g protein) as the main protein source, found that the chicken 
group had higher (23%) verbal memory scores after six weeks when compared to the 
pork group, but there were no differences between the groups after 12 weeks (54). 
There were also no improvements in any other cognitive domain including executive 
function and short term memory, for the pork group (54). The authors suggest that 
these findings be interpreted with caution as the sample sizes in each group did not 
meet the required calculated sample size in order to reach statistical power and so 
this may have contributed to the lack of findings for the other cognitive domains. 
Additionally, protein intake after the 12 weeks did not significantly differ from 
baseline and it appears that the protein intake for the total sample actually decreased 
(baseline: 81.0±23.4 g; 12 weeks: 72.6±18.7 g), indicating that it was unlikely to be a 
difference in protein intake which can explain these findings. Further, there was no 
control group used as a comparison which makes is difficult to determine whether 
the decrease in protein was due to the consumption of the meals although 
interestingly, the nutritional composition of the meals provided was similar in most 
aspects  (energy: 1528 kJ; 1661 kJ, protein: 28.1 g; 25.2 g, fat: 8.8 g; 14.3 g, 
carbohydrate: 40.3 g; 38.2g, sodium: 739 mg; 752 mg, for pork and chicken 
respectively) and hence does not explain the difference between the groups with 
regard to the verbal memory scores. This suggests that some types of animal protein 
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may be more beneficial for cognitive function than others and perhaps this is due to 
differences in other nutrients which play a role in cognitive function. 
 
In summary, there are limited RCT’s which show beneficial effects of animal protein 
on cognitive function. However, these studies do not differentiate between different 
sources of protein which may differ in nutritional composition and thus their effects 
on cognitive function. With regard to the studies which have differentiated between 
sources of protein and investigated the effects on cognitive function, the findings are 
mixed and further research is needed in this area, particularly for red meat. The 
existing research for red meat will be reviewed in the section below.   
 
2.4 Effect of meat protein on cognitive function 
In the past, a high red meat intake (primarily processed meats) has been linked with 
an increased risk for cognitive decline (56, 57). For instance, one study investigating 
the association between overall meat intake versus fish intake on cognitive function 
in adults aged 65 years and over living in developing countries found that total meat 
intake was directly associated with higher prevalence of dementia when compared to 
fish intake (281). The link between red meat intake and an increased risk for 
cognitive decline has largely been attributed to the reported negative impact of red 
meat on various aspects of health including cancer risk (57), cardiovascular health 
(56) and other chronic diseases such as diabetes (282). However, others have 
suggested that these findings should be attributed to the saturated fat content of red 
meat (283). This may be supported by the findings of one meta-analysis of 20 studies 
investigating the effect of red and processed meat on various cardiovascular 
conditions which found that processed meats, but not red meat, increased the risk for 
vascular diseases considerably (RR=1.42 coronary heart disease; RR= 1.19 type 2 
diabetes) (284). An interesting consideration highlighted in the discussion which may 
explain these findings was that processed meats were found to contain higher 
calories and percent energy from fat and lower percent energy from protein when 
compared to red meat (284).  
 
This highlights a potential problem with the broad term ‘meat intake’ which often 
combines multiple cuts and types of meat with large variations in nutritional content. 
This term has the potential to neglect the differences in nutritional composition of 
different types of meat and potentially their different effects on cognitive function. 
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For instance, “high” fat and sodium content in processed meats compared to 
unprocessed and fresh meats (283, 285) included in the broad ‘meat intake’ category, 
has been associated with  an increased risk for cancer, obesity, cognitive decline and 
other cardiovascular factors (56, 57). However, in Australia, the 1995 National 
Nutrition Survey (286) and more recently, the 2011-12 Australian Health Survey 
(287), found that red meat contributed less than 10% of dietary saturated fat intake 
and that there is an increasing trend for consumers to buy trimmed red meat or to 
trim it themselves (286). Therefore, lean red meat trimmed of fat, may be beneficial 
for cognitive function when considered separately from processed meats included in 
‘total meat intake’ although there are very limited studies which have assessed the 
effects of different types of meat on cognitive function (260).  
 
The following section will provide a brief overview of the nutrients in red meat 
which may contribute to benefits for cognitive function. Following this, the evidence 
for the effects of red meat, particularly lean red meat, on cognitive function will be 
explored.  
 
2.4.1 Nutritional benefits of red meat for cognitive function 
Current Australian dietary guidelines recommend that adults consume a maximum of 
455 g or 3-4 serves of trimmed red meat per week (63, 64). Red meat is a rich source 
of essential amino acids and protein (239) and contains other important 
micronutrients which may be beneficial for cognitive function. For instance, 100 g of 
cooked red meat contains 28-36 g of protein, 94% of which is digestible (59), and 
provides over two-thirds of the daily requirement of bioavailable vitamin B12 and at 
least a quarter of requirements for iron and zinc (59). Further, lean red meat is a good 
source of omega-3 PUFAs. The potential benefits of specific nutritional components 
of red meat in regard to cognitive function are briefly discussed below. 
 
2.4.2 Omega-3 Fatty Acids 
Meat is a source of the long chain omega-3 PUFA docosapentaenoic acid (DPA) 
(59). As described above, current research supports an association between the 
omega-3s EPA and DHA (found primarily in fish) and cognitive function however, 
there is limited evidence to support a positive effect of DPA on cognitive function. 
One recent review including studies using human platelets and cells, dogs and aged 
rats, reported that it may have beneficial effects via a reduction in inflammation, 
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preventing angiogenesis and reducing age-related effects in aged rats due to 
oxidative stress, although there was limited evidence for effects on cognitive 
function in humans (288). Furthermore, one case-control study in middle aged men 
found that levels of DPA were inversely associated with risk for coronary heart 
disease (289) which has been associated with cognitive decline. Despite this, there 
seems to be no studies which show that DPA is markedly increased through 
increased consumption of meat, and whether this would impact upon cognitive 
function. 
 
2.4.3 B vitamins 
Lean red meat is a rich source of B vitamins including B6 and B12, which are 
proposed to improve cognitive function and protect against brain lesions partly 
through the removal of homocysteine (207, 290, 291). Vitamin B6 has been 
implicated in the production of multiple neurotransmitters in the brain (62, 207) 
while B12 has been found to possibly delay the onset of dementia (62). It has also 
been found that intakes consistent with RDI’s for B12 are associated with better 
memory for older women and a deficiency is associated with a two-fold risk for 
severe depression (62). In the United States of America, meat has been found to 
contribute between 19.7% and 40% of vitamin B12 intake (292). Furthermore, in 
Australia, it has been found that women of childbearing age who consume less than 
two serves of red meat a week have lower intakes of vitamin B12 (286). Collectively 
these findings indicate that increasing red meat intake may represent an important 
strategy to increase a person’s intake of B vitamins, but whether this leads to 
improved cognitive function remains uncertain as there have been no studies to date 
which have explicitly investigated this relationship. 
 
2.4.4 Iron 
Red meat, compared to poultry or fish, is a rich source of heme iron which is also 
more bioavailable than the non-heme iron found in plant sourced foods (293). Iron is 
essential for oxygenation, myelination and synthesis of neurotransmitters (62) and 
low intakes have been found to be associated with poorer cognitive performance 
(41). For instance, a cross-sectional study evaluating the effect of iron deficiency on 
cognitive function in geriatric patients found that MMSE scores were lower and 
dementia incidence was higher in patients with iron deficiency (294). Conversely, 
one review stated that evidence from a limited number of studies suggested that iron 
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obtained through meat sources may be linked to an increased risk for CVD which is 
associated with an increased risk for cognitive decline, although this may be related 
more to the saturated fat content in the meat and not necessarily the iron itself (295).  
 
2.4.5 Zinc 
Red meat is also a rich source of bioavailable zinc which is essential for maintaining 
homeostasis and which also has the ability to act as a neurotransmitter for 
intercellular functioning (296). For instance, 100 g of beef or lamb provides a quarter 
of the RDI for zinc in adults (Australian RDI 8-14 mg/d) (59). Zinc also has 
antioxidant and anti-inflammatory properties (297) and has been reported to be 
beneficial to areas of the brain including the hippocampus and amygdala (298). 
While zinc is found in a range of foods (e.g. spinach, various seeds, dark chocolate, 
brown rice),  zinc deficiency can be caused by high consumption of foods rich in 
phytate such as various nuts, seeds and legumes (an indigestible ligand which 
prevents the absorption of zinc), as well as low consumption of foods rich in zinc 
(299). For example, fruits and vegetables are particularly low in zinc in comparison 
to red meat (62). In fact, it has been reported that 50% of the world’s population is at 
risk of zinc deficiency (300) and 30% is affected by zinc deficiency (184). Those at 
high risk of zinc deficiency include children in developing countries (301), the 
elderly as zinc levels decline with age (302), vegetarians and those with chronic 
illness (303). Deficiencies in dietary zinc have been associated with reduced brain 
volume and neurons in rats (62) and increased systemic inflammation (303). 
Additionally, one RCT conducted in older adults without zinc deficiency showed 
improvement in two areas of cognitive function after zinc supplementation for six 
months; spatial working memory and visual search (298). More recently, a 
systematic review and meta-analysis of 18 observational and RCTs investigating the 
relationship between zinc status and indices of cognitive function in children and 
adults found that nine studies reported a positive association between zinc status and 
one or more measures of cognitive function. There was no significant effect of zinc 
supplementation on cognitive function as a whole in children, and it was not possible 
to conduct a meta-analysis for studies in adults as there was only one RCT and four 
observational studies (304).  
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2.4.6 Effect of red meat on cognitive function 
To date, the relationship between red meat intake and cognitive function has been 
investigated in longitudinal studies which included red meat as part of a larger 
dietary pattern with multiple food components with the majority of findings 
suggesting a negative association (56, 281, 305, 306). In contrast, cross-sectional 
studies have reported no association between meat intake and cognitive function 
(250, 252, 256, 261, 279, 280). However, a recent prospective study conducted in 
475 Chinese older adults found that a moderate or high meat (including meat, poultry 
and roasted meats) score dietary pattern (tertiles 2-3) was protective against decline 
in attention (β = 0.20–0.22), although a high meat score dietary pattern was also 
associated with a decline in verbal-fluency (β= -0.19) (305). Despite the potential 
nutritional benefits of red meat for cognitive function, there appears to be only one 
longitudinal study which has assessed the effects of red meat alone (rather than as a 
part of an overall dietary pattern) on cognitive function. This study was conducted in 
144 infants and found that for every 2.3 g/d of meat (red and white meat) consumed 
there was a one point increase in the psychomotor development index (PDI) (307). 
Further, there appears to be a lack of cross-sectional studies (without the inclusion of 
processed meats) or RCTs which have investigated the effects of red meat on 
cognitive function in older adults. Due to the lack of research in this area, the main 
focus of the study in this thesis will be to investigate the effects of protein through 
the consumption of lean red meat, on cognitive function in older adults. 
 
2.5 Mechanisms underlying protein-related improvements in cognitive function 
The effects of protein consumption on cognitive function may be partially explained 
by the interaction of essential amino acids with a number of different growth and 
neurobiological markers (61) including IGF-1, BDNF and VEGF as well as 
inflammatory markers and zinc. Each of these will be discussed below. 
 
2.5.1 IGF-1 
IGF-1 is important for neurogenesis, proliferation and the transport of amino acids 
and protein synthesis with circulating levels declining with age (107, 108). However, 
there is some evidence that dietary protein, particularly animal and soy protein (and 
protein supplementation), can modulate levels of IGF-1 (308). For instance, one 
study conducted in 10 healthy volunteers found that refeeding using diets which had 
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variable protein dosages but adequate energy (35 kcal energy/kg and 0.2, 0.4 and 1.0 
g/kg protein) following 5 days of fasting resulted in significant increases in IGF-1, 
even at the lowest level of protein (0.31 U/ml increase) (309). A dose response was 
also observed with a 0.52 U/ml increase for 0.4 g/kg protein and an increase of 1.04 
U/ml for 1.0 g/kg protein (309). However, when fed the energy variable diets (and 
1.0 g/kg protein), no changes in IGF-1 were observed (309) indicating that there may 
be an adequate energy intake threshold which must be met before protein begins to 
have an effect on IGF-1 levels.  
 
Previous research has also shown that IGF-1 can cross the BBB and this suggests 
that increases in peripheral IGF-1 can influence levels of IGF-1 in the brain (111). 
Hence, IGF-1 may be one of the mechanisms by which increased dietary protein 
might improve cognitive function. Currently, there has been little research which has 
investigated the protein-induced effects of IGF-1 on cognitive function. One cross-
sectional study conducted in 1535 men and women with a median age of 74 years 
reported a trend between the highest tertile of IGF-1 (≥105 ng/ml) and cognitive 
function (executive function and verbal abilities) (110). Further, a meta-analysis on 
the effects of IGF-1 on cognitive function in healthy older adults found a significant 
positive correlation between serum IGF-1 and all measures of cognitive function 
(effect size of 0.57) (109). Lastly, a 2-week intervention conducted in 60 older adults 
at risk of malnutrition found that IGF-1 significantly increased following 
supplementation with a 200ml oral supplement (16 g of protein, 12 g of fat and 60 g 
of carbohydrate) and changes in IGF-1 were negatively associated with levels of pro-
inflammatory markers such as IL-6 and TNF-α, which have been associated with 
cognitive decline (310). Together these studies suggest that increases in IGF-1 due to 
dietary protein may be beneficial for cognitive function, although there appears to be 
no studies which have directly assessed if there is a cause-and-effect relationship. 
 
2.5.2 VEGF 
VEGF is thought to play a role in cognitive function due to its main role in 
angiogenesis and homeostasis of adult vasculature (311). There is also an association 
between increased levels of VEGF and amyloid plaques in AD (312-314). Although 
previous research has found that diets low in red and processed meats are attributed 
to lower rates of certain cancers (312, 314), it is the fat content from these meats 
which has been associated with the onset of particular cancers (such as colon and 
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bowel cancer) (314). Therefore, VEGF and proteins from lean red meats may still be 
beneficial to health. However, currently there is no research that has been conducted 
investigating the effects of a protein-enriched diet on VEGF levels or potential 
benefits including cognitive function.  
 
2.5.3 BDNF 
Adequate BDNF levels are important for preventing neuronal death, memory and 
learning and circulating levels decrease with age (77). There is evidence that 
peripheral levels of BDNF can be increased by diet, particularly dietary restriction 
(315-317). In animals, it has been found that intermittent fasting and caloric 
restriction are beneficial for enhancing and maintaining cognitive functioning 
through interactions with BDNF levels (315-318). Further, decreases in hippocampal 
concentrations of BDNF have also been observed in animal models when fed a high 
saturated fat diet (319), which suggests that higher intakes of saturated fats may be 
detrimental for cognitive function. 
 
In humans however, there is very limited research on the effects of diet on BDNF 
and cognitive function. Several studies show similar findings to the animal models 
with one review on the impact of diet and exercise on brain plasticity and disease 
reporting that diets high in saturated fats were associated with a decrease in BDNF 
concentrations (320). Another study on the effects of a high fat/refined sugar diet on 
brain structure and function also found that BDNF levels decreased after consuming 
this diet for as little as two months and up to two years (115). Moreover, there is 
evidence that increasing dietary intake of zinc, which is found in abundance in red 
meat, may influence BDNF levels (321). While these studies suggest that dietary 
factors can enhance BDNF concentrations peripherally, there is no research into 
whether dietary protein can influence cognitive function through an increase in 
BDNF concentrations.  
 
2.5.4 Zinc 
It has been suggested that the associations between protein intake and cognitive 
performance may be related to the role of zinc (42). High concentrations of zinc are 
found in the synaptic vesicles of neurons and this is thought to play a role in 
releasing neurotransmitters, myelination and motor development (300). As such, 
 79 
 
reduced concentrations of neuronal zinc have been implicated in the formation of 
amyloid plaques common in AD (62).  
 
There is evidence to suggest that the effects of zinc may be due to interactions with 
IGF-1 and neurobiological markers such as BDNF and VEGF. As zinc is able to pass 
through the BBB, circulating levels of zinc may be indicative of levels of neuronal 
zinc which could be used to predict cognitive function through its effects on 
neurobiological markers (321). Figure 2.7 shows the potential relationship between 
zinc and cognitive function.  
Figure 2.7. Relationship between zinc, IGF-1, BDNF, VEGF and cognitive function. 
Adapted from Szewcyk et al. (2011) (321). 
Zinc has been associated with cell proliferation and IGF-1 (322). IGF-1 along with 
insulin has been shown to affect cellular zinc metabolism (322). Zinc deficiency on 
the other hand, has been found to reduce levels of IGF-1 suggesting that zinc may 
influence cognitive function via an indirect effect (297).  
 
Research suggests that the hippocampus is more sensitive to zinc than the cortex 
(321) and it has been found that zinc deficiency in the hippocampus may impair 
cognitive function by decreasing levels of BDNF (323) although excessive zinc 
supplementation can have an unfavourable effect on BDNF (323). However, there is 
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evidence that contradicts this which demonstrates that total brain concentrations of 
zinc may not be easily influenced by serum zinc concentrations despite hippocampal 
concentrations being sensitive to serum levels (323). Perhaps this is due to the 
interaction of zinc with IGF-1 and BDNF which are highly prevalent in the 
hippocampus, although further research is needed to confirm this. In addition, zinc 
along with copper, has also been found to increase VEGF levels (78) although these 
findings have not been applied in the context of cognitive function. 
 
In summary, there is evidence that zinc has the ability to pass through the BBB and 
interact with IGF-1 and neurobiological markers, however it is unclear whether the 
ingestion of lean red meat or dietary protein enhances these effects. Further research 
into bioavailable zinc concentration obtained through dietary intake and its 
relationship with cognitive function is needed. 
 
2.5.5 Inflammation 
Chronic inflammation is characterised by elevated concentrations of inflammatory 
markers systemically which can lead to an increased risk for many diseases (178). 
Ageing is associated with prolonged inflammation and evidence suggests that this 
can have a detrimental effect on cognitive health (175). However, it has been 
suggested that inflammation may be able to be controlled or reduced through diet and 
particular nutrients. For instance, a recent review of observational and intervention 
studies on nutrition and inflammation in older adults found that there is an anti-
inflammatory effect for n3-PUFA intake, but not for vitamin D or whey protein 
supplements (324). In contrast, one study using data from the Whitehall II cohort 
study found that a dietary pattern reminiscent of a Western-style diet (red meat, 
processed foods and a lower intake of wholegrains) was associated with elevated 
levels of IL-6 and accelerated cognitive decline (325). However, increases in 
inflammation due to Western-style diet may be attributed to an increased intake of 
saturated fats and a lower intake of foods rich in anti-oxidants. There is some 
evidence which suggests that animal protein may not have any negative effect on 
inflammation and by extension, cognitive decline when saturated fats are removed. 
An 8-week study in 60 men and women aged over 20 years in which participants 
were randomised to either maintain their normal diet or partially replace energy from 
carbohydrate foods with 200 g/d of lean red meat however, found that increased lean 
red meat intake does not increase inflammation or markers of oxidative stress (58).  
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While there is certainly evidence that diet can modulate inflammation and some 
evidence suggesting that protein and lean red meat does not have a negative effect on 
inflammation, it has also been suggested that the effects of dietary protein to 
maintain availability of amino acids and modulate inflammation may be influenced 
by other lifestyle factors such as exercise (240). This will be discussed further in the 
next section. 
 
Part 3: Role of exercise in cognitive function 
In the last decade, there has been a developing interest in the area of ‘Active Ageing’ 
and the role that physical activity and exercise may play in reducing chronic disease 
as well as declines in physical and cognitive function, allowing QoL to be 
maintained into old age (326). Indeed, it is widely recognised that regular exercise 
can reduce the risk of a broad range of chronic diseases including CVD, obesity, type 
2 diabetes and certain cancers (22, 29). Given that the global ageing population has 
led to an increase in the prevalence of these chronic diseases, and the association 
between these conditions and an increased risk for a decline in cognitive function, it 
is not surprising that there has been extensive research into the effect of exercise on 
cognitive function.  
 
Overall, the current evidence indicates that exercise has the potential to protect 
against age-related cognitive decline and the onset of dementia and related disorders 
(22, 23, 35, 161, 276, 327). For instance, one systematic review of RCTs found that 
eight out of 12 studies demonstrated that exercise improved cognitive function in 
both healthy and cognitively impaired older adults (328). However, despite the 
reported benefits of exercise for cognitive function, the specific benefits of different 
types of exercise (e.g. aerobic training, resistance training, and multi-component 
training) and training doses (frequency, intensity, duration) on cognitive function in 
both healthy older adults and those with MCI, dementia or related disorder remains 
uncertain. The following section will review some of the findings for the effects of 
different modes (and dose) of exercise, particularly aerobic training, PRT and the 
combination, on cognitive function in healthy older adults and those with MCI and/or 
dementia. 
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3.1 Aerobic Training 
There is considerable evidence indicating that higher levels of aerobic fitness and 
regular aerobic training are associated with greater cognitive function and may slow 
or even prevent age-related cognitive decline, even in high risk individuals (e.g. 
those who have genetic risk for dementia) (21-36, 176). For instance, one cross-
sectional study in 90 community-dwelling women aged 51-81 years found that 
aerobic fitness was positively associated with memory performance, particularly in 
those carrying the APOE-Ɛ4 genotype (329). Further, a larger prospective study in 
349 healthy adults aged over 55 years reported that fitness level (measured by peak 
VO2) at baseline was predictive of executive function and attention six years later 
with those in the lowest tertile of peak VO2 showing the greatest decline in MMSE 
score compared to those in the higher tertile (-0.5 difference in mean decline on 
MMSE between lowest and highest VO2 tertile) (330). Additionally, one 6-year 
prospective study found that changes in cognitive function were related to basal 
aerobic fitness in healthy older adults (330). Those who had lower aerobic fitness 
levels at baseline (lowest tertiles: 12.3 to 18.6 and 14.8 to 23.4; middle tertiles: 18.7 
to 22.7 and 23.5 to 28.9; highest tertiles: 22.8 to 36.1 and 29.0 to 45.7 mL/kg min
-1 
for women and men respectively) experienced greater cognitive decline than higher 
aerobic fitness levels (330). Collectively, these findings suggest that a higher level of 
aerobic fitness tends to be protective against cognitive decline, even in high risk 
individuals, although further research is still warranted to determine if there is a 
threshold of fitness associated with long-term cognitive benefits.  
 
It has been previously reported that there is a dose-response relationship between 
aerobic fitness and cognitive function (331) and this is thought to be related to an 
increase in aerobic fitness associated with increased levels of exercise (332). While 
cognitive benefits have been reported following low doses of exercise training (40-
75% of heart rate reserve on three to five days a week for a total of 75 minutes per 
week for 26 weeks), increased benefits for visuospatial function have been reported 
at higher doses (150-225 minutes per week at the same intensity and frequency) 
(331). This is further supported by evidence which indicates that changes in aerobic 
fitness are a better predictor of cognitive benefits than the dose of exercise (331). In 
part support of this notion, a Cochrane review of 11 studies investigating the 
effectiveness of aerobic exercise training (with varying dosage) on cognitive function 
in non-cognitively impaired older adults, found that eight of these studies reported a 
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mean increase of 14% in aerobic fitness which was associated with improvements in 
cognitive function, including motor function, auditory attention, processing speed 
and visual attention (effect sizes ranging from 0.26 to 1.17) (333). This indicates that 
there may be a threshold with regard to the change in aerobic fitness for cognitive 
benefits to occur. However, a recent 26-week RCT conducted in non-demented older 
adults aged 65 years and older reported that a 4.8% change in aerobic fitness was 
associated with changes in cognitive function (334), suggesting that this threshold for 
cognitive benefits may be much lower than previously reported. In contrast, a 6-
month RCT conducted in 60 healthy sedentary older adults reported that changes in 
aerobic fitness were associated with improvements in functional connectivity 
between the right mid-temporal areas and frontal and parietal regions, but decreased 
functional connectivity between the left hippocampus and contralateral precentral 
gyrus (335). However, changes in aerobic fitness did not predict changes in cognitive 
function in this study (335). Similarly, a meta-regression of 37 studies investigating 
the relationship between aerobic fitness and cognitive function, found that there was 
no significant linear or curvilinear relationship between aerobic fitness effect sizes 
and cognitive function effect sizes (336). However, these mixed findings may be 
related to numerous factors including the dose of training and gender as these factors 
have been found to moderate the effects of fitness on cognitive function (36). 
 
The benefits of aerobic training for cognitive function in healthy older adults and 
clinical populations appear to extend across a number of specific cognitive domains. 
This section will focus on several reviews and meta-analyses due to the vast amount 
of data available. One review of 33 cross-sectional and longitudinal studies on the 
effects of aerobic training on cognitive function in healthy older adults found that six 
months of moderate-intensity aerobic training (intensity not defined) produced 
significant improvements in cognitive function, most notably in the domain of 
executive function (337). Further, a systematic review of 23 RCTs investigating the 
effects of exercise on cognition in older adults with and without cognitive decline 
found that five out of 15 studies conducted in cognitively healthy adults reported 
benefits for information processing, executive function and memory in healthy older 
adults, while five out of eight studies conducted in adults with cognitive decline 
reported benefits in general cognitive function, executive function and memory 
(338). Unfortunately the magnitude of the benefits (effect sizes) were not reported 
and the authors of this review made note of a number of limitations regarding the 
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trials reviewed, which included diversity in the populations assessed and the exercise 
protocols (dose of exercise) utilised amongst studies. Despite this, another meta-
analysis of 29 RCTs with a treatment duration exceeding one month and a mean age 
of 18 years or above which included stringent inclusion criteria to overcome the 
majority of these limitations, found that aerobic training was associated with modest 
improvements in attention and processing speed (effect size=0.158), executive 
function (effect size=0.123) and memory (effect size=0.128) in healthy and non-
healthy adults (339). Similarly, the results from an earlier meta-analysis of 30 RCTs 
conducted in adults aged 65 years or over with cognitive impairment found that in 12 
trials, aerobic training reversed cognitive decline in adults with dementia (effect size 
0.57) (37). More recently, a meta-analysis of 11 RCTs assessing the effects of 
aerobic training on cognitive function in older adults with MCI found significant 
improvements in global cognitive function and smaller improvements in memory, 
specifically immediate and delayed recall, although no significant improvements 
were found for attention, executive function, verbal fluency or visuospatial ability  
(340). Collectively, these findings suggest that aerobic training can have beneficial 
effects on cognitive function in both healthy and high risk individuals. 
 
Despite evidence supporting the role of aerobic training for improving cognitive 
function in healthy older adults, there is some evidence that the intensity and 
duration of the exercise are important parameters which may influence the outcomes. 
As briefly mentioned above, a common limitation among studies included in the 
multiple reviews and meta-analyses is the heterogeneity in the frequency, duration 
and intensity of exercise prescribed. There is some evidence to suggest that intensity 
rather than duration of exercise is more important. For instance, one large cross-
sectional analysis of 1927 healthy adults aged 45-70 years reported that there were 
no significant associations between the time spent participating in physical activity 
and various cognitive domains including processing speed, memory, mental 
flexibility and global cognitive function (341). However, the intensity of weekly 
physical activities (expressed in metabolic equivalent [MET]s/week) was found to be 
associated with all of the above domains (341). Specifically, those with higher 
weekly MET scores (3.76 to 7.12 METs) had higher scores for processing speed, 
mental flexibility, memory and overall cognitive function (341). This is supported by 
the findings from an RCT examining the effects of acute aerobic exercise in men 
aged 60-74 years which found that reaction times were reduced after moderate (50% 
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VO2max) exercise compared to light (30% VO2max) aerobic exercise (342). However, 
there seem to be no studies (other than acute studies) which have compared the effect 
of high-intensity exercise with lower intensities on cognitive function in older adults, 
despite evidence suggesting a dose-response relationship between intensity of 
aerobic exercise and cognitive function. 
 
The frequency of the exercise also seems to be of debate with vast differences across 
studies and interventions. For example, one large prospective study of 1740 healthy 
older adults with a mean follow-up of 6.2 years, found that the risk of developing 
dementia was significantly reduced in adults exercising three or more times a week 
when compared to those exercising less than three times a week (hazard ratio: 0.62) 
(343). One 26-week RCT conducted in 101 healthy adults aged 65 years and over 
compared the effects of different frequencies of moderate-intensity aerobic exercise 
(75 mins/week, 150 mins/week, 225 mins/week completed across 3-5 days a week) 
on cognitive function and found that in a per-protocol analysis, visuospatial 
processing and attention improved with any frequency of exercise (331). 
Specifically, there was a dose-response effect for visuospatial processing although 
results were similar for 75 and 150 minutes per week (331). Verbal memory and 
reasoning were also found to improve compared to baseline although the control 
group also improved indicating a practice effect (331). Similarly, one review of 12 
high-quality RCTs investigating the effectiveness of exercise for cognitive function 
in older adults found that studies with an exercise duration of six weeks performed at 
least three times a week for 60 minutes, were effective for improving cognitive 
function in cognitively normal and impaired adults (328). However, all of these 
studies had similar doses and so this does not provide much information on any 
differing effects of exercise at lower or higher doses. Further research is therefore 
needed with regard to duration, frequency and intensity of aerobic exercise to 
determine if there is a threshold for improvements in cognitive function for older 
adults. 
 
3.2 Progressive resistance training (PRT) 
It is well established that PRT can produce significant and marked improvements in 
muscle strength, mass and size (17). More recently, there has been an increased 
interest into the effect of PRT on cognitive function due to a possible link between 
muscle and cognitive function (15, 16, 19, 20). This section will briefly discuss the 
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current evidence for the effects of PRT on cognitive function, followed by potential 
mechanisms which may explain any beneficial effects. 
 
In a large cross-sectional analysis using data from 2157 adults aged 65-85 years from 
the NHANES study, Loprinzi et al. found that after adjusting for a number of factors 
including age, sex, ethnicity, CRP, smoking and physical activity, muscle 
strengthening activities were significantly and positively associated with cognitive 
function (βadjusted=3.4; 95% confidence interval [CI]: 1.7–5.1; P<0.001) (344). 
Further, those doing aerobic exercise or muscle strengthening activities or both, were 
found to have higher executive function scores than those not doing aerobic exercise 
or muscle strengthening activities or both (344). Although not directly examining the 
effects of PRT on cognition, one prospective study with a mean follow-up of 3.6 
years found that greater muscle strength at baseline was associated with a 43% 
reduced risk of developing AD in adults aged 54-100 years (15). It was also found 
that a high level of muscle strength (90
th
 percentile) was associated with a 48% 
decrease in the risk of developing MCI compared to a low level of muscle strength 
(10
th
 percentile) (15). These results suggest that improvements in muscle strength 
which are consistently reported with PRT may result in a lowered risk for cognitive 
decline.  
 
As summarised in Table 2.8, there are a number of RCTs which have investigated 
the effects of PRT on cognitive function (345-351).  
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Table 2.8 Summary of key studies which have examined the effect of PRT on cognitive function in older adults 
Author, Year Subjects 
Duration and 
design 
Groups Key Findings 
    Domain PRT> Control 
Effect of PRT Dose
†
 
 
de Camargo 
Smolarek et 
al. 2016 (346) 
N= 66 healthy 
women with a 
mean age of 
66 years 
12- week 
RCT. 
1) Three times weekly 
moderate-intensity (60-75% 
of 1-RM) resistance training 
 
2) Controls 
Global cognitive function 
 
+ NA 
Ikudome et al. 
2016 (345) 
N= 170 
healthy older 
adults aged 
52-81 years 
12-week non-
randomised 
trial.  
1) body mass-based home 
exercise program (intensity 
not defined) 
 
2) controls  
Information processing  
Inhibitory control  
Attention  
Working memory  
Timing ability  
O 
+ (NS) 
O 
+ 
O 
NA 
Suo et al. 
2016 (351) 
N=100 with 
dementia 
prodome MCI 
with an 
average age of 
70.1 years 
6 month RCT 1) twice weekly high-intensity 
(80-92% of 1-RM) PRT 
 
2) Computerised cognitive 
training (CCT) 
 
3) Twice weekly high-intensity 
PRT+ CCT 
 
4) Control 
Global cognitive function 
Memory 
+ (PRT) 
O 
NA 
Best et al. 
2015 (349) 
N= 155 
healthy 
women aged 
2 year follow-
up of 52-week 
RCT.  
1) once weekly high-intensity 
resistance training  
 
Verbal memory 
Executive function 
O 
+ 
+ (frequency)* 
O 
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65-75 years 2) twice weekly high-intensity 
resistance training * 
 
3) twice weekly balance and 
tone training 
Bolandzadeh 
et al. 2015 
(352) 
N= 42 healthy 
community-
dwelling 
women aged 
65-75 years 
with white 
matter lesions 
52-week RCT. 1) once weekly PRT (no 
intensity defined) 
 
2) twice weekly PRT* (no 
intensity defined) 
  
3) twice weekly balance and 
toning 
White matter lesions  
Executive function  
+ *only 
NR 
+ (frequency)* 
NR 
Ruiz et al. 
2015 (350) 
N= 20 older 
adults aged 90 
years and over 
living in a 
nursing home 
8-week RCT.  1) light-moderate intensity (10-
12 on 20 point BORG scale) 
aerobic and PRT three times 
a week 
 
2) control 
Global cognitive function  O NA 
Liu-Ambrose 
et al. 2012 
(353) 
N=52 
community-
dwelling 
women aged 
65-75 years 
12 month 
single-blind 
RCT. 
1) once weekly resistance 
training (no intensity 
defined) 
 
2) twice weekly resistance 
training * (no intensity 
defined) 
 
3) twice weekly balance and 
tone training 
Selective attention and 
conflict resolution  
+ * only + (frequency)* 
Anderson-
Hanley et al. 
2010 (347) 
N= 32 
community 
dwelling 
4-week RCT. 1) Two-three times weekly 
resistance training (intensity 
not defined) 
Executive function  
Information processing  
+ 
O 
NA 
  
8
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adults aged 
between 55 
and 85 years 
 
2) exercise waiting list 
(controls) 
 
Kimura et al. 
2010 (354) 
N=119 aged 
over 65 years 
12-week 
single blind 
RCT.  
1) twice weekly 1.5 hour 
strength training sessions 
(60% of 1-RM)  
 
2) health education classes 
twice a month 
Reaction time  O NA 
Liu-Ambrose 
et al. 2010 
(348) 
N=155 
community-
dwelling men 
and women 
aged 65-75 
years 
12-month 
single-blind 
RCT.  
1) once weekly resistance 
training (intensity not 
defined) 
 
2) twice weekly (intensity not 
defined) 
  
3) twice weekly balance and 
tone training 
Selective attention and 
conflict resolution  
Set shifting  
Working memory  
+ 
 
O 
O 
NR 
 
O 
O 
Cassilhas et 
al. 2007 (73) 
N=62 
sedentary 
males aged 
65-75 years 
24-week RCT. 1) Control 
 
2) moderate intensity (50% of 
1-RM) PRT 
  
3) high intensity PRT (80% of 
1-RM) 
Short term memory  
Attention  
Long term memory  
+ 
+ 
+ 
O 
O 
O 
+ significant positive association between PRT and cognitive function; - significant negative association between PRT and cognitive function; O no 
association between PRT and cognitive domains. NA: not assessed; NS: non-significant; NR: not reported. † dose includes frequency, duration and 
intensity of exercise. 
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A 3-month non-randomised trial conducted in 170 older adults aged between 52 and 
81 years found that performance on the Go/No-Go reaction and serial subtraction 
tasks (measures of inhibition and memory) improved following a body mass based 
home strength exercise program performed six days a week, although the only 
significant between group difference was for memory when compared to a non-
exercise control group (345). There were no improvements on measures of 
processing speed, attention or reaction time (345). A limitation of this study is the 
large difference in the numbers of participants in the intervention versus control 
group (144 versus 26) due to participants being recruited separately for each group 
(345). Further, participant characteristics such as education which may influence 
cognitive function, were not taken into account in this study and the intensity of the 
training may not have been sufficient to induce cognitive benefits (345). In contrast, 
one 12-week RCT conducted in 66 healthy women with a mean age of 66 years 
found that moderate-intensity (60-75% of 1-repitition maximum [RM]) resistance 
training performed three times a week improved cognitive capacity by 19% as 
measured by the MoCA, compared to controls (346). These findings are supported 
by another 4-week study in 32 community-dwelling older adults aged between 55 
and 85 years which found that performance on the Digit Span Backward test and 
Stroop colour C (executive function) test improved following a resistance training 
program performed two to three times a week compared to those on an exercise 
waiting list; there were no improvements in other cognitive tests of executive 
function (Color Trails 2 test, Digit Span Forwards) or information processing (Digit 
Span Forward, Stroop A & B, Color Trails 1 and Letter Digit Substitution Test 
[LDST]) (347). It was suggested that the lack of findings in these tests may have 
been due to subtle effects of the exercise across multiple cognitive domains and the 
tests used may not have been sensitive enough to detect these subtle changes (347). 
For instance, a limitation of this study noted by the authors was the lack of 
consistency between the three tests used which were designed to assess executive 
function (347).  
 
Despite this, other studies have found benefits for PRT on cognitive function with 
less frequent training. One 12-month RCT in 155 community-dwelling adults aged 
65-75 years found that once weekly and twice weekly high-intensity PRT (increased 
using the 7-RM method) improved selective attention and conflict resolution as 
measured by the Stroop test (12.6 % and 10.9% improvements respectively) 
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compared to a twice-weekly balance/tone training control (0.5% decline) (348). 
More recently, a follow-up study (two year follow-up post training) of these 
participants to investigate the long term effects of high-intensity resistance training 
on cognitive function reported that the benefits were maintained (349). In this study, 
it was found that both once and twice weekly high-intensity resistance training 
improved executive function (as measured by the Stroop test, Trail Making test, 
Backward digit span and DSST) two years after the intervention (standardized 
difference [d]=.31–.48) and twice weekly resistance training improved memory as 
measured by the RAVLT (d=.45), when compared to balance and toning exercises 
(349). While this suggests that PRT may have the potential to have a long-term 
influence on cognitive function even after training cessation, the mechanism(s) 
underlying these long-term benefits remains unknown. In contrast to this study, one 
8-week RCT conducted in 20 men and women aged 90 years and over living in a 
nursing home, found no changes in cognitive function as measured by the MMSE 
following light-moderate intensity (increasing from 30% of 1-RM to 70% of 1-RM) 
PRT (mainly leg press) performed three times a week compared to the control group 
(350). However, limitations of this study include the short duration and the lack of 
sensitivity of the measure (MMSE) used to assess cognitive function. Given the age 
of the participants, it would be expected that they would have a high level of age-
related decline at baseline, and thus would be more sensitive to the effects of the 
program with more scope to improve. Thus the lack of effect observed in this study 
may be related to the use of the MMSE as this may not have been sensitive enough to 
pick up on subtle changes over a short duration.  
  
Consistent with the mixed findings reported above, several reviews of RCTs have 
also reported contrasting results with regard to the effects of PRT on cognitive 
function (355, 356). One review of the effects of resistance training on mental health 
which included depression, anxiety, self-esteem, chronic pain, fatigue, cognitive 
function and sleep, found that there were seven RCTs which had specifically 
investigated the effects on cognitive function in healthy older adults (355). All of 
these studies reported small to moderate positive effects on cognitive function with 
the largest effects found for memory, although in three of these studies the changes 
were not significant (355). These studies however, had the limitation of small sample 
sizes (8-17 per group). More recently, a review of 10 studies investigating the effects 
of PRT on cognitive function in healthy older adults reported mixed findings when 
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comparing the exercise to no exercise groups or other exercise modalities (356). This 
was suggested to be due to differences in participant characteristics, exercise designs 
and tests of cognitive function among studies (356). 
 
There is evidence to suggest that PRT has beneficial effects on cognitive function in 
those who are already cognitively impaired. One meta-analysis of 41 RCTs (21 
conducted in older adults with cognitive impairment and 20 in those without) found 
moderate to large effects sizes (ES=0.49 to 0.51) for resistance training in 
cognitively impaired individuals (357).  Further, there was no significant difference 
in terms of the effect sizes for resistance training on cognitive function in cognitively 
impaired or cognitively normal older adults, suggesting that baseline cognitive status 
does not appear to influence the effects of PRT on cognitive function (357). 
 
Although there are guidelines outlined by the American College of Sports Medicine 
(ACSM) for PRT with regard to improving muscle strength and hypertrophy in older 
adults (356), the dose of PRT which is the most beneficial for cognitive function is 
still a topic for debate. As discussed above, there is some evidence for beneficial 
effects of once weekly PRT on cognitive function although other studies have found 
no benefits following training three times a week (350). There is also some evidence 
to suggest that high-intensity PRT is more beneficial for cognitive function compared 
to lower intensities (348-350). This is further supported by other studies which have 
reported that PRT can have acute effects on different cognitive domains based on the 
intensity of the training (358). For instance, one RCT conducted over two days in 68 
young men and women (mean age 26 years) found that a 30 minute bout of PRT 
resulted in a linear relationship between exercise intensity and processing speed and 
a quadratic relationship between intensity and executive function (358). This acute 
study indicates that high-intensity exercise (100% of 10-RM) was more beneficial for 
processing speed, while moderate-intensity (70% of 10-RM) was more beneficial for 
executive function (358). The reason(s) for the varying effects is not clear although it 
has been suggested that the dose-response relationship between exercise and 
cognitive performance may be dependent on the cognitive demands of the task (359). 
Similarly, a RCT conducted in 210 community-dwelling older adults with a mean 
age of 75.3 years, found that while there were no differences in memory between 
controls and a group undertaking six months of theraband resistance training three 
days a week, changes in resistance throughout the intervention were a significant 
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predictor of change in memory performance (360). Taken together, the current 
findings suggest that dosage of PRT is important for predicting exercise-induced 
changes in cognitive function, but questions still remain as to what represents the 
optimal dose.  
 
3.3 Multi-component exercise programs 
As already discussed, there is some evidence that both aerobic training and PRT can 
independently influence cognitive function in older adults, but it is possible that the 
combination may be even more efficacious (360). The following section will briefly 
review the current evidence for the effects of multi-component exercise programs, 
specifically aerobic combined with PRT, on cognitive function in older adults. 
 
As shown in table 2.9, there are a number of RCTs which have investigated the 
effects of multi-component training on cognitive function in older adults with mixed 
results.
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Table 2.9 Summary of key studies which have examined the effect of multi-component exercise on cognitive function in older adults 
Author, 
Year 
Subjects 
Duration 
and design 
Groups Key Findings 
    Domain Ex>control Multi Ex > Ex 
Tarazona-
Santabalbina 
et al. 2016 
(361) 
N=100 frail, 
sedentary adults 
with a gait speed 
less than 
0.8m/sec. Mean 
age 80 years 
24-week 
RCT 
 
1) moderate-intensity (75% of 
1-RM) multi-component 
exercise program 
(proprioception, aerobic, 
strength, and stretching 
exercises) 5 days a week 
  
2) control group 
Global cognitive function  + NA 
Bossers et 
al. 2015 
(362) 
N=109 adults 
with dementia, 
mean age 85.5 
years 
9-week 
RCT with 
9-week 
follow-up 
 
1) combined group (two 
walking and two strength 
sessions 50-85% of 
maximum heart rate or 12-
15 RPE a week)  
 
2) aerobic group (four walking 
sessions 50-85% of 
maximum heart rate or 12-
15 RPE a week) a week)  
 
3) social group/control (four 
social visits a week) 
Global cognitive function  
Verbal memory  
Visual memory  
Executive function  
 
+ group 1 only 
+ group 1 only 
+ group 1 only 
+ 
+ 
+ 
+ 
+ 
Sink et al. 
2015 (363) 
N=1476 
sedentary adults 
24-month 
RCT 
1) moderate intensity multi-
component training 
Global cognitive function  O NA 
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aged 70-89 years 
at risk of 
mobility 
disability but 
who could walk 
400m 
 program (walking, strength, 
flexibility, and balance 
training) (two centre-based 
visits per week and home-
based activities 3-4 times 
per week). 
 
2) health and education 
workshops (weekly for the 
first 26 weeks and monthly 
thereafter)/ control 
Working memory  
Memory recall  
Visuospatial ability 
Language  
Executive function  
 
O 
O 
O 
O 
O 
NA 
NA 
NA 
NA 
NA 
 
Bossers et 
al. 2014 
(364) 
N=33 
institutionalised 
dementia 
patients, mean 
age 85.2 years  
6-week 
single-
blind, non-
randomised 
pilot study 
 
1) aerobic + strength training 5 
days a week for 6 weeks 
(12-15 on RPE scale).  
 
2) social group/ control (social 
visits for the same duration 
and frequency). 
Global cognitive function  
Visual attention  
Verbal memory  
Executive function  
 
O 
+ (NS) 
O 
O 
 
 
NA 
NA 
NA 
NA 
 
Nascimento 
et al. 2014 
(365) 
N=67 adults with 
and without 
MCI, average 
age ~67 years 
16-week 
non-
randomised 
intervention 
1) control group 
 
2) moderate intensity (60-80% 
maximal heart rate) multi-
component training group 
(aerobic, resistance and 
balance/motor coordination) 
Global cognitive function  
Executive function  
Attention 
 
+ (MCI+training) 
+ (MCI+training) 
+ (MCI+training) 
NA 
NA 
NA 
Vaughan et 
al. 2014 
N=49 cognitively 
normal women 
16-week 
RCT 
1) A 60 minute multi-
component exercise class 
Inhibition  + NA 
  
9
6
 
(366) aged 65-75 years  (cardiovascular, strength 
and motor fitness training) 
twice a week. 
 
2) control 
Verbal fluency  
Working memory  
Information processing 
Attention 
Executive function  
+ 
O 
O 
+ 
+ 
NA 
NA 
NA 
NA 
NA 
Forte et al. 
2013 (367) 
N= 42 
community-
dwelling older 
adults, mean age 
69.8 years 
3-month 
RCT 
 
1) multi-component training 
(prioritizing neuromuscular 
coordination, balance, 
agility, and cognitive 
executive control, 60-80% 
of 1-RM) 
 
2) PRT twice weekly (60-80% 
of 1-RM) 
Inhibition  
Executive function  
NA 
NA 
+ (visually 
PRT) 
+ (visually 
PRT) 
Cancela 
Carral et al. 
2007 (368) 
N= 62 
community-
dwelling women, 
average age 68.4 
years 
5-month 
RCT 
 
1) aquatic exercise + high-
intensity strength training 
(75% of 1-RM) 5 days a 
week 
 
2) aquatic + calisthenics 
training, 5 days a week 
Global cognitive function  NA NR 
+ significant positive association between exercise and cognitive function; - significant negative association between exercise and cognitive function; O no 
association between exercise and cognitive domains. MCI: mild cognitive impairment; NA: not assessed; NS: non-significant; NR: not reported; RPE: rate of 
perceived exertion. 
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A 5-month RCT conducted in 62 community-dwelling women aged over 65 years 
found that both aquatic plus high-intensity strength training (75% of 1-RM) and 
aquatic plus calisthenics performed five days a week improved executive function (as 
measured by the MMSE) (water exercises combined with strength training mean 
change of 2.61 versus mean change of 5 for the aquatic plus calisthenics training) 
(368). However, it was not stated whether there were differences between the groups. 
A 24-week RCT conducted in 100 frail, sedentary adults with a mean age of 80 years 
also found that those who participated in a moderate-intensity multi-component 
exercise program (consisting of proprioception, aerobic, strength, and stretching 
exercises) on five days a week, had improved cognitive function as measured by the 
MMSE compared to the control group (exercise group mean 28.9 versus control 
mean 25.9) (361).  
 
In contrast, a large 24-month RCT which allocated 1476 sedentary adults aged 70-89 
years who were at risk of mobility disability to either a multi-component physical 
activity intervention (walking, strength, flexibility, and balance training) (two centre-
based visits a week combined with home-based activities 3-4 times a week) or health 
and education programs (weekly for the first 26 weeks followed by monthly session 
thereafter), found that there were no significant differences between the groups for 
any measure of cognitive function (363). There was also no between group 
differences in the incidence of MCI, dementia or the combination (363). However, a 
moderate association between changes in physical function (walking and strength 
training as measured by the Community Healthy Activities Model Program for 
Seniors [CHAMPS]) and executive function and global cognitive function was 
observed, although this did not differ between the groups (363). One limitation of 
this study is that the health education group included cognitive and social aspects 
which may have inadvertently led to improvements in cognitive function (363). 
Further, it was suggested that perhaps the cognitive effects of the intervention waned 
throughout the study (potentially due to a decline in adherence over time for some 
participants) and were not captured within the testing period (363). In contrast, a 3-
month RCT conducted in 42 community dwelling adults aged 65-75 years found that 
twice-weekly training of either multi-component training (prioritising neuromuscular 
coordination, balance, agility, and cognitive executive control) or PRT improved 
inhibition (as measured by the Random number generation task) and executive 
function (as measured by the Trail making tests) (367). It was also found that the two 
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types of training impacted inhibition through different pathways. For instance, multi-
component training directly affected inhibitory capacity while PRT influenced 
inhibition through gains in muscle strength (367). This highlights a potential 
difference in pathways by which different types of exercise can influence cognitive 
function and the potential for a relationship between muscle and cognitive function. 
This also offers support for the theory that multi-component exercise may be the 
most efficacious for cognitive function as it may take advantage of multiple 
pathways enhancing multiple aspects of cognitive function in different ways. 
 
Promising findings for the potential benefits of multi-component exercise on 
cognitive function have also been found for those with MCI and dementia. A 9-week 
RCT conducted in 109 adults with dementia which randomised participants to either 
a combined training program (two walking and two strength sessions per week), 
aerobic group (four walking sessions a week) or a social group (four social visits a 
week), found that the combined program resulted in higher scores for global 
cognition (as measured by the MMSE), visual memory, verbal memory and 
executive function compared to the social group, and higher scores for executive 
function in the aerobic group compared to the social group (362). However, nine 
weeks post intervention, cognitive scores reverted back to baseline, indicating that 
maintaining exercise in dementia patients may be clinically important for slowing 
disease progression (362). In contrast, one 6-week non-randomised pilot study in 33 
institutionalised dementia patients found no significant differences between an 
exercise group receiving aerobic and strength training and a social group 
participating in social visits on five days a week, on any measure of cognitive 
function (364). However, non-significant improvements of up to 22% and 13% were 
found for the exercise group and social group respectively, on tests measuring visual 
attention (364).   
 
There have been a limited number of meta-analyses and reviews which have 
investigated the effect of multi-component exercise on cognitive function in older 
adults. A meta-analysis of 18 intervention studies found that an exercise program 
with multiple modalities was found to enhance cognitive function more than just 
aerobic exercise alone (ES= 0.59 versus ES=0.41) (36). A similar finding has been 
found in people with MCI and dementia (ES=0.57) (37). More recently, a meta-
analysis of 39 studies investigating the effect of exercise on cognitive function in 
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adults aged over 50 found that exercise including aerobic, resistance training and 
multi-component exercise, all improved cognitive function, regardless of cognitive 
status (ES= 0.24, 0.29 and 0.33 respectively) (369). Further, it was found that a 
duration of 45-60 minutes at a moderate intensity was the most effective for 
cognitive benefits, independent of cognitive status (369).  
 
3.4 Mechanisms underlying exercise-related improvements in cognitive function 
The mechanism(s) responsible for the benefits of various modalities of exercise 
training on cognitive function may be attributed to potential structural changes in the 
brain as well as changes in various neurobiological and/or inflammatory markers (21, 
176, 353). For instance, aerobic exercise has been found to increase grey and white 
matter volume in healthy older adults (370), specifically in the hippocampus which is 
the region of the brain that is particularly important for memory (371, 372). Regular 
aerobic training has also been shown to increase cerebral blood flow, change various 
hormonal levels (e.g. epinephrine and corticosterone) (26, 32), improve endothelial 
function and decrease markers of oxidative stress and vascular inflammation, by 
reducing the effects of pro-inflammatory cytokines and increasing concentrations of 
certain growth factors such as IGF-1 which have been associated with cognitive 
function (176). Similarly, there is also evidence for changes in brain structure and 
function associated with PRT. One 12-month RCT in 52 community-dwelling 
women aged 65-75 years found that changes in hemodynamic activity (blood flow to 
active neuronal tissue) in two regions of the brain associated with response 
inhibition, occurred concurrently with improvements in task performance, following 
twice weekly PRT (353). Additionally, secondary analysis of 42 women aged 
between 65 and 75 years with evidence of white matter lesions who participated in a 
52-week RCT, found that twice weekly resistance training was associated with a 
slower progression of white matter lesions when compared to resistance training 
once a week or balance and toning exercises (352). While the progression of white 
matter lesions was not associated with change in executive function (352), the 
changes in executive function were suggested to be due to the observed decrease in 
white matter atrophy after two years, and potential increases in IGF-1, a growth 
factor which has been associated with improvements in cognitive function (349). The 
relationship between exercise-induced structural and functional changes in the brain 
and cognitive function is briefly summarised in Figure 2.8. 
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Figure 2.8: Graphical illustration of proposed neurological and cognitive changes 
due to exercise-induced physiological changes. Taken from Paillard et al. (2015) 
(373).  
 
As previously mentioned, exercise-induced increases in various neurotrophic factors 
may also be important for cognitive function, and there is evidence that both aerobic 
exercise and PRT may be associated with changes in various circulating biomarkers 
including IGF-1 BDNF, VEGF and inflammation. These neurotrophic, growth and 
inflammatory factors can be induced through contractions of muscle, and can also act 
directly on the brain as they can cross the BBB (30). Thus, each of these markers 
may offer independent and perhaps synergistic effects on cognitive function (23) and 
will be discussed in further detail below. Figure 2.9 provides an overview of this 
proposed relationship (23). 
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Figure 2.9. Proposed exercise-induced relationship between IGF-1, BDNF and 
VEGF on cognitive function. Adapted from Cotman et al. (2007) (23); *BBB, blood 
brain barrier. 
 
3.4.1 IGF-1  
Previous research has shown that peripheral (and central nervous system) levels of 
IGF-1 can increase after aerobic training (374), resistance training (21, 25, 34, 375, 
376) and multi-component exercise interventions (377) in older adults. However, 
there is also evidence that these training modalities have no effect or may even 
decrease IGF-1 levels (244, 375, 377-380). These conflicting findings may be related 
to a number of factors including the dose (frequency, duration, intensity) of the 
exercise and health status of the participants. While it is beyond the scope of this 
thesis to provide a comprehensive review of all the available studies, a brief 
overview of the effects aerobic, resistance and multi-component exercise training 
will be provided below. 
 
For aerobic training, it remains uncertain whether training intensity is a critical factor 
for stimulating an increase in IGF-1 levels as many previous studies have failed to 
observe changes following moderate and high-intensity aerobic training (375, 377-
379, 381). For instance, several studies reported no effect of moderate-intensity (60-
85% of heart rate reserve) aerobic training on IGF-1 levels in healthy women (aged 
50 and older) (375, 377, 378). Contrary to these findings, a 15-week RCT conducted 
in postmenopausal breast cancer survivors which reported a decrease in serum IGF-1 
levels (but an increase in IGF binding protein [IGFBP]-3) following moderate-
intensity aerobic training on three days a week (70-75% of peak oxygen 
consumption) (381). It was suggested that this may be related to a possible reduction 
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in hepatic and muscle insulin resistance due to the exercise training which may in 
turn reduce IGF-1 bioavailability, although this was not tested specifically (381). 
Despite these findings, studies which have used high-intensity aerobic training have 
also reported no effect on IGF-1 levels. For instance, one 12-month RCT in 320 
inactive post-menopausal women found that 225 minutes per week of moderate to 
high intensity (70-80% of heart rate reserve) aerobic training did not significantly 
change levels of IGF-1 (379). In contrast, one six month RCT conducted in 33 older 
adults with MCI found increases in levels of plasma IGF-1 following high-intensity 
aerobic exercise (75-85% of heart reserve) on four days a week when compared to a 
control group (374). It is possible that the health status of the participants may be one 
factor that influences the IGF-1 responses to exercise, with increases in IGF-1 levels 
more likely in those who are less healthy (and presumably with lower basal levels). 
However, another six month RCT conducted in 28 older adults with glucose 
intolerance found that aerobic exercise on four days a week (75-85% of heart 
reserve) failed to increase IGF-1 levels (382). Given that these studies were similar 
with regard to the dose of exercise prescribed, this suggests that the type of health 
condition may also be important. 
 
There is some evidence that IGF-1 levels increase following resistance training (25, 
375, 376). For instance, one review of cross-sectional, prospective studies and RCTs 
reported that resistance training increased serum IGF-1 in older adults in two 
prospective studies, but not in a third (21). The lack of effect in the third study was 
suggested to be related to an age-related increase in basal levels of IGFBP-1 which 
can inhibit IGF-1 (383). As such, measuring IGFBP’s which modulate the systemic 
and local effects of IGF-1 (384) as opposed to serum IGF-1, which may be a more 
accurate and stable marker to measure and gauge exercise-related effects (384). In 
contrast, another review reported that most studies have found no effect of PRT on 
levels of IGF-1 with the exception of one report in older adults with low baseline 
levels of IGF-1 (380). Further, there is evidence that IGF-1 levels in older adults may 
decrease following 12 weeks of PRT (75-80% of 1-RM) (244). These findings were 
explained by the fact that the decreases in IGF-1 were inversely related to increases 
in lean body mass, which suggests that circulating IGF-1 may be recirculated into 
muscle tissue when building muscle (244).  
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Exercise intensity is another factor which may potentially explain the mixed 
evidence for the effect of resistance training on IGF-1 levels. For instance, one 12-
week RCT conducted in 35 healthy older women found that high-intensity resistance 
training (75-85% of 1-RM) performed on three days a week increased IGF-1 levels 
compared to an aerobic training group and a control group (375). In contrast, another 
8-week RCT conducted in healthy older adults reported that IGF-1 levels remained 
stable following moderate-intensity PRT (60-70% of 1-RM) performed three times a 
week (385). Further, one 24-week RCT conducted in 43 older sedentary men aged 
65-75 years found that high-intensity PRT (80% of 1-RM) on three days a week 
increased serum IGF-1 levels compared to a control group (376). This evidence 
suggests that high-intensity PRT may be more effective than lower intensities for 
increasing IGF-1 levels in healthy older adults.  However, when PRT is combined 
with other exercise modalities, the effect of the intensity of the exercise on IGF-1 
levels is limited. A 12-week RCT conducted in healthy middle aged women found 
that combined exercise (aerobic exercise: 60-80% of heart rate reserve and resistance 
training: 50-70% of 1-RM) did not increase IGF-1 levels compared to the control 
group or an aerobic training group (377). A possible explanation for the lack of effect 
may be related to the relatively moderate exercise intensity, particularly the 
resistance training component, given that previous studies using single modality 
exercise have found a beneficial effect on IGF-1 levels following moderate to high 
intensity exercise (74, 375, 386, 387), however further research is needed to 
determine this.  
 
As reported previously, increases in serum IGF-1 have been proposed to play an 
important role in improving cognitive function in older adults (107, 108). Indeed, the 
findings from one meta-analysis which examined the effects of IGF-1 on cognition in 
healthy older adults reported a significant positive association between circulating 
levels of IGF-1 and cognition (effect size of 0.6) (109). Further, a 24-week RCT in 
62 sedentary men aged between 65 and 75 years found that moderate (50% of 1-RM) 
and high intensity (80% of 1-RM) PRT twice weekly, both increased IGF-1 and 
improved all aspects of cognitive function (executive function, short-term memory, 
attention and long-term memory) compared to the control group (73). Moreover, 
IGF-1 levels were positively correlated with cognitive function, suggesting that 
higher IGF-1 levels were associated with improved cognitive function (73). In 
contrast, a 12-week RCT in 119 healthy adults aged 65 years and over found that 
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twice-weekly moderate intensity (60% of 1-RM) resistance training did not increase 
serum IGF-1 levels, and there were no improvements in executive function compared 
to the control group (354). The authors suggested that the lack of change in IGF-1 
and subsequently cognitive function, may have been due to the short length of the 
intervention (354), although it is possible that the intensity of the exercise was 
insufficient to elicit an increase. In part support of this, a longer study conducted in 
48 healthy males aged between 65 and 79 years, observed increases in IGF-1 levels 
following 12 months of high-intensity PRT (75-80% of 1-RM) performed for 40 
minutes on three days a week which were inversely correlated (r = -0.47) with 
cognitive decline, specifically in the visual attention domain (74). Taken together, 
these findings suggest that moderate to high-intensity PRT may have beneficial 
effects on IGF-1 which may mediate some of the improvements observed in 
cognitive function. 
 
In summary, the effects of aerobic training and PRT on IGF-1 are mixed, although 
this may be related to the difference in training prescription [dose (duration and 
intensity)] across studies. However, the findings appear to suggest that higher 
intensities of both aerobic and resistance training are required to stimulate an 
increase in IGF-1 levels. Further, although the effect of multi-component exercise 
programs on serum IGF-1 levels in older adults remains unclear due to the limited 
studies in this area, the available evidence suggests that moderate-intensity multi-
component exercise may be insufficient to increase IGF-1 levels in healthy older 
adults. This should be investigated further, as evidence suggests that exercise-
induced increases in IGF-1 may be important for cognitive function.  
 
3.4.2 BDNF 
There are mixed findings with regard to the effects of aerobic exercise on serum 
BDNF levels (21, 374, 388, 389). These conflicting findings may be related to a 
number of factors, including the exercise intensity prescribed across different studies. 
For instance, one 6-month RCT conducted in 33 adults with a mean age of 70 years 
found that high-intensity aerobic exercise (75-85% of heart rate reserve for 45 to 60 
min/d, on four days a week) increased levels of BDNF for men, but decreased levels 
in women, despite women showing improvements in multiple tests of executive 
function (374). The lack of change reported for the women was proposed to be due to 
changes in glucoregulation and insulin sensitivity which improved in women and not 
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men, and which have been associated with BDNF (374). More recently, a meta-
analysis of 29 studies found that the exercise intensity of aerobic training was not 
associated with changes in BDNF levels (390). Despite this, the recommendations of 
a recent review suggest that adherence to the international exercise guidelines (30 
minutes of moderate intensity exercise on five days a week) may be sufficient to 
induce exercise-related increases in neurotrophic factors (388).  
 
Exercise duration is another potentially important factor that may be important for 
stimulating an increase in circulating BDNF levels, although the evidence for what 
may be considered an optimal duration is unclear. One review found that moderate-
intensity aerobic exercise over a short duration (<5 weeks) was associated with an 
increase in serum BDNF concentrations, although findings were less consistent when 
considering aerobic exercise over a longer period (from five weeks onward) (21). 
More recently, a review of 32 intervention and observational studies (mostly 
conducted in young adults), reported that data from 14 out of 15 observational and 
RCTs found that BDNF levels increased post aerobic exercise and four of six studies 
found that BDNF levels increased following chronic (duration ranging from two 
sessions up to 12 weeks) aerobic exercise (389). Despite these positive findings, 
whether exercise-induced increases in BDNF levels are related to other training 
factors, such as the frequency of the exercise, requires further study.  
 
The effect of PRT on BDNF levels appears to be a rapidly growing area, although 
the current evidence is mixed. One 2013 review of five studies found that only one 
study had investigated the effect of resistance training on peripheral levels of serum 
BDNF in older adults (245). That study reported increases in BDNF following 10 
weeks of PRT (75% of 1-RM) on three days a week in older pre-frail and frail 
women (391). In contrast, a 2016 meta-analysis of 29 studies found that in the 12 
studies which assessed the effects of PRT on BDNF, none found a change in 
peripheral BDNF concentrations following exercise (390). These mixed findings 
may be related to the dose of PRT, however there is evidence that increases in BDNF 
can occur irrespective of PRT duration, with a 2016 review reporting that acute and 
chronic exercise can increase plasma and/or serum BDNF levels in healthy adults 
(388). This may be related to other evidence which has found that BDNF levels 
return to sub-baseline levels 15-60 minutes following exercise (regardless of exercise 
intensity) and that with each exercise session, increases in neurotrophic factors 
 106 
 
gradually become larger as a result of engaging in more physical activity (388). In 
contrast, one 12-week RCT conducted in healthy older adults suggests that intensity 
of PRT may be important for increasing BDNF levels (392). In this study it was 
found that only mixed-low intensity PRT (60 repetitions at 20% of 1-RM followed 
by 10-20 repetitions at 40% of 1-RM) was effective for increasing serum BDNF 
levels when compared to high-intensity PRT (two sets of 10-15 repetitions at 80% of 
1-RM) and low-intensity PRT (80-100 repetitions at 20% of 1-RM) (392). It was 
suggested that this may be related to the number of reps leading to volition fatigue 
although the mechanisms behind this are unclear.  
 
There is also some evidence for beneficial effects of multi-component training on 
peripheral BDNF concentrations. For instance, one 16-week RCT conducted in 49 
healthy women aged between 65 and 75 years found that a 60 minute session of 
multi-component exercise (aerobic, resistance and motor fitness training) twice a 
week (intensity not reported), increased BDNF levels compared to the control group 
(366). However, as this study was only conducted in women, these results may be 
related to previous evidence suggesting that estrogen is associated with increases in 
BDNF (393) and whether a similar result would have been observed in men is 
unknown.  
 
The cognitive health of participants may be an important factor for increasing BDNF 
levels, as there is some evidence that BDNF levels are altered in those with cognitive 
impairment including AD (155), thus potentially making them more sensitive to the 
effects of the intervention. Despite this, one 16-week RCT in 67 older adults aged 60 
years and older, with and without MCI, reported that multi-component exercise 
increased levels of BDNF and reduced concentrations of TNF-α and IL-6 in both 
training groups (MCI + training and no MCI + training) compared to the control 
groups (365). Further, multi-component exercise resulted in improvements in 
executive function and attention in the training group for participants with MCI 
(365). Taken together with the above findings, this suggests that BDNF levels can 
improve regardless of cognitive status, and changes in BDNF levels and cognitive 
function may be related. 
 
The evidence for whether exercise-induced changes in BDNF are related to cognitive 
function is limited although there are some positive findings. For instance, one 12-
month RCT conducted in 90 adults with a mean age of 67 years found that there 
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were no differences in serum BDNF concentrations following moderate-intensity 
walking on three days a week compared to those in a stretching/toning control group, 
although changes in BDNF were found to mediate the effects of exercise on 
performance in the task-switch task (394). Additionally, another 12-month RCT 
found that changes in serum BDNF levels following moderate-intensity aerobic 
exercise on three days a week, were positively associated with changes in anterior 
hippocampal volume (an area of the brain associated with memory) in healthy older 
adults (395). In contrast, one 3-month study conducted in 40 healthy older adults 
(aged >60 to 77 years old) in which participants were pseudo-randomly assigned to 
either moderate-intensity treadmill exercise three times a week or a muscle 
relaxation/ stretching control group, found that changes in BDNF levels were not 
associated with changes in cognitive function (378). This was suggested to be due to 
the large fluctuations in BDNF levels observed on an individual level throughout the 
study (378).  
 
Taken together, the current evidence indicates that exercise interventions up to 12 
weeks for aerobic training may be optimal for increasing BDNF levels, although the 
duration required for increases in BDNF following PRT is unclear. Multi-component 
exercise can elicit a beneficial effect however other factors relating to the training, 
such as the intensity, may also play a role. Despite this, evidence suggests that there 
may be some potential benefits for cognitive function related to changes in BDNF 
levels induced by aerobic training and multi-component exercise, but further research 
is still needed in this area. 
 
3.4.3 VEGF 
There are limited studies which have investigated the effects of exercise on VEGF, 
although there is evidence that peripheral levels of VEGF increase in animals 
following aerobic exercise (388). Similarly for humans, a systematic review of 10 
studies in adults with an average age of 60 years found that four studies reported an 
increase in serum VEGF levels following aerobic exercise (396). From this evidence, 
the health status of participants appears to be an important factor, as these studies 
were conducted in older adults with various diseases (peripheral arterial occlusive 
disease and obese women); those studies which included healthy controls reported no 
exercise-induced increases in VEGF levels (396). This is further supported by the 
findings of a 3-month study conducted in 40 healthy older adults (aged >60 to 77 
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years old) in which participants were pseudo-randomly assigned to either moderate-
intensity treadmill exercise three times a week or a muscle relaxation/ stretching 
control group (378). There were no significant differences for changes in serum 
VEGF (or IGF-1 or BDNF) levels compared to the control group (378). The authors 
suggested that this may have been due to the short duration of the study, as well as 
possible deteriorations in BDNF associated with ageing, as BDNF concentrations 
assessed post exercise have been suggested to influence VEGF levels (397). 
 
To our knowledge, only one study has investigated the effect of multi-component 
training on VEGF levels. This 12-week RCT conducted in 20 older obese women 
reported increases in VEGF concentrations following moderate-high intensity 
aerobic, yoga and resistance band training on three days a week, compared to a 
control group (398). Further evidence is needed to determine whether multi-
component exercise is an effective strategy to increase VEGF levels in healthy older 
people.   
 
Despite the lack of evidence for whether exercise increases VEGF levels, there is 
evidence from one study that exercise-induced increases in VEGF are associated 
with changes in cognitive function (399). One 12-month RCT in 65 older adults with 
a mean age of 66 years found that exercise-induced increases in serum VEGF, IGF-1 
and BDNF were associated with increased temporal lobe connectivity between the 
bilateral parahippocampus and middle temporal gyrus in those allocated to an aerobic 
training group (supervised walking sessions beginning at 10 minutes and increased 
gradually to 40 minutes over seven weeks) compared to a flexibility, toning and 
balance training group (399). Further, higher baseline levels of VEGF were 
associated with greater training-induced changes in functional connectivity (399), 
which suggests that a minimum basal level of VEGF may be important for predicting 
exercise-related benefits for cognitive function, although further research is needed 
to confirm this.  
 
In summary, there is some evidence to suggest that aerobic and multi-component 
exercise may induce changes in VEGF levels, but whether this has any effect on 
cognitive function either directly or indirectly, is unclear.  
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3.4.4 Inflammation 
There has been extensive research which has examined the effect of exercise on 
markers of inflammation which extends beyond the scope of this thesis, thus this 
section will provide a brief overview of the findings of several reviews and meta-
analyses and relevant RCTs for aerobic exercise, PRT and multi-component training.  
 
Aerobic exercise in particular, has been associated with anti-inflammatory properties 
and several reviews have reported beneficial effects of aerobic exercise for lowering 
levels of inflammation in older adults (400, 401). However, these reductions are 
commonly associated with a decrease in fat mass which is a major source of 
inflammation (178, 400). Nonetheless, decreased concentrations of CRP and IL-6 
following aerobic exercise have been observed after adjustment for BMI (400). 
Further, one review which included three aerobic training studies reported that 
reductions in CRP were greatest following high-intensity exercise (75-80% of VO2 
max) (402), suggesting that intensity may be an important factor to consider when 
aiming to reduce inflammation. 
 
With regard to PRT, one review also found that weight loss was an important 
indicator of whether changes in inflammation were observed (403). While there is 
some evidence from RCTs for beneficial effects of PRT on inflammation 
independent of changes in weight (or fat), one recent review found that three out of 
three studies failed to report any significant effect of PRT on serum IL-6 in healthy 
and inactive adults (402). Further, the evidence for the effects of PRT on CRP were 
inconsistent with only one of the three studies reporting a reduction in CRP (402). 
That study was conducted in older adults whereas the other two were in middle-aged 
and young adults (402). This suggests that other factors such as the age of 
participants and the dose of the exercise may be important factors to consider. This is 
supported by the fact that the most consistent evidence for a beneficial effect of PRT 
for reducing inflammation has been found following high-intensity PRT in those 
aged 65 years and over (402). Additionally, another review reported that evidence 
from observational studies suggest that CRP is more sensitive to the dose of exercise 
than other markers such as IL-6 and TNF-α (403). This review found that moderate-
intensity exercise lowered CRP levels in older adults (403). Further, study duration 
also appears to be an important factor for reducing inflammation through PRT. Data 
from one review of RCTs revealed that six months of a PRT exercise intervention or 
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more, was more effective in reducing inflammation than those with a shorter duration 
(403). However, whether these are important factors for inducing cognitive changes 
via reductions in inflammation, requires investigation. 
 
There are limited studies which have investigated the effect of multi-component 
exercise on inflammation with mixed findings. One 12-week RCT conducted in 29 
younger adults (18-35 years) and 31 older adults (65-85 years) which divided 
participants into physically active or inactive groups, found that serum CRP 
decreased in both younger and older physically inactive groups following aerobic 
and resistance training (70-80% of heart rate reserve and 1-RM) on three days a 
week compared to the physically active group which maintained their regular 
exercise (404). However, there were no changes in circulating levels of IL-6, IL-β or 
TNF-α (404). This may be explained by small acute, transient changes in these 
markers in response to the exercise which may have acted to downregulate CRP 
production, but which remained undetected as these markers were not assessed 
acutely (404). In part support of this study, a 3-month study conducted in nine older, 
frail and obese adults (65-80 years) found that three 90 minute training sessions a 
week (endurance, strength and balance exercises at 75-80% of peak heart rate and 
65-80% of 1-RM) did not significantly change plasma concentrations of CRP or 
TNF-α (405). However this study was likely underpowered due to the small sample 
size as a 40% reduction in TNF-α was observed (405). More recently, a 16-week 
RCT conducted in 67 older adults aged 60 years and older with and without MCI 
found that multi-component exercise training reduced concentrations of serum TNF-
α and IL-6 in both training groups (MCI + training and no MCI + training) compared 
to the control groups (365). This suggests that improvements in inflammation 
following multi-component exercise appear to occur irrespective of cognitive status 
and this may be related in part, to previous evidence which shows that those with 
cognitive impairment have increased levels of inflammation (180), potentially 
increasing their sensitivity to the effects of the intervention. Further, improvements 
in executive function and attention as measured by the MoCA were also observed for 
the training group for participants with MCI (365), suggesting that the reductions in 
inflammation may have potentially influenced cognitive function. 
 
While there is evidence from multiple intervention studies which suggests that 
exercise can up regulate anti-inflammatory cytokines, decrease pro-inflammatory 
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cytokine release and prevent cognitive decline (25), research investigating whether 
any exercise-related changes in inflammation are related to improvements in 
cognitive function are still needed. 
 
3.4.5 Summary 
In summary, there are currently a number of RCTs which support a positive effect of 
aerobic, resistance and multi-component training on various circulating growth, 
neurological and inflammatory markers, which are important for cognitive function 
in older adults, although further research is needed to determine whether there is an 
optimal dose or type of exercise which can induce sufficient changes in these 
markers and related improvements in cognitive function. While there is some 
evidence that multi-component exercise training may be more efficacious compared 
to single exercise modalities due to the influence that different modalities may have 
on the various pathways associated with cognitive improvement, not all studies 
report beneficial effects. These mixed findings may be due to the range of training 
dosage (varying frequency, intensity, duration) used across multiple studies which 
makes it difficult to determine whether there is an optimal dosage that is likely to be 
the most beneficial for improving cognitive function. However, there is some 
evidence that moderate intensity exercise can induce some beneficial effects on 
cognitive function, although there are mixed findings with regard to the effects of 
high-intensity exercise in comparison to lower intensities for aerobic exercise and 
PRT. Despite this, further research is still warranted into the effects of different types 
of exercise training on the brain and various circulating neurotrophic factors, and 
how these relate to cognitive function.  
 
Part 4. Effects of the combination of exercise and nutrition including dietary 
protein, on cognitive function 
As previously reported, there are a number of intervention studies which have 
investigated the effects of exercise, particularly PRT, combined with various 
nutritional factors (including increased dietary protein or protein supplementation) on 
muscle and functional outcomes in older adults. However, there is currently limited 
evidence on the effects of the combination on cognitive function in older adults. This 
section will summarise the current evidence related to the effects of exercise 
combined with a various nutritional factors, on cognitive function in older adults. 
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There is some evidence to suggest that exercise in combination with a healthy diet 
may be beneficial for cognitive function. The Finnish Geriatric Intervention Study 
(FINGER) aimed to prevent cognitive impairment and disability, through a two-year 
RCT conducted in 1190 older adults aged 60-77 years who had an increased risk for 
dementia and cognitive function at or slightly below the mean for the Finnish 
population (406). The control group received general health advice which included 
oral and written information regarding strategies to maintain a healthy diet, physical 
and social activities and management of vascular factors and disability prevention 
(406). The intervention group received a nutrition, exercise and cognitive 
intervention in addition to the general health advice and were required to participate 
in 1) individual and group nutrition sessions which tailored their diet to meet Finnish 
Nutrition Recommendations, 2) supervised and individually tailored PRT (1-3 times 
a week) in combination with aerobic training (2-5 times a week) and postural 
exercises, and 3) computer-based cognitive training focusing on executive function, 
working memory, episodic memory and mental speed (406). After two years, it was 
found that there was a small but significantly greater improvement in the total score 
for the neuropsychological testing battery for the intensive intervention versus the 
control group (mean change in Z-score 0.16 versus 0.20 respectively, P=0.03) (406). 
Additionally, there were significantly greater improvements in the intervention 
compared to control group with regard to executive function (as measured by the 
Category fluency test, digit span test, concept shifting test, Trail making test and 
Stroop test) (mean change in Z-score 0.11 versus 0.05, P<0.05) and processing speed 
(as measured by DSST, concept shifting test and Stroop test) (mean change Z-score 
0.10 versus 0.04, P<0.05), but not memory (visual paired associates test, immediate 
and delayed recall, logical memory immediate and delayed recall and word list 
learning and delayed recall) (406). While this study provides some encouraging 
results with regard to the efficacy of a multifactorial intervention on cognitive 
function, others have reported mixed findings. Two-year interim data from a 4-year 
RCT conducted in 1335 healthy adults aged between 57 and 78 years which 
randomised participants to one of six groups: 1) reference (health education), 2) 
aerobic exercise (moderate-intensity [60% maximum] 5 days a week), 3) resistance 
training (moderate-intensity 2-3 days a week), 4) diet (nutrition counselling with a 
main goal of substituting unsaturated for saturated fat and to increase the intake of 
fibre and antioxidants), 5) combined diet and aerobic training or 6) combined diet 
and resistance training, found no differences between the groups for cognitive 
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function as assessed by the Consortium to Establish a Registry for Alzheimer’s 
Disease (CERAD) battery and MMSE (407). However, secondary analyses revealed 
that within group improvements in VO2 max were associated with improvements in 
immediate memory in all groups (except the reference group), delayed memory in 
the diet group, and verbal memory in the aerobic training group, but there were no 
differences between the groups (407). A limitation of this study was that in the 
intention-to-treat analysis, max VO2 remained unchanged and actually decreased in 
some participants in the exercise groups (407), suggesting that the training was not 
sufficient enough to result in a change in aerobic fitness which may have suppressed 
any overall effect of the intervention on cognitive function. This may have been due 
to the fact that the training was unsupervised due to the large sample size (407). 
Although there were some cognitive benefits in both of these studies, taken together, 
the effects of combining an exercise and nutrition intervention (healthy diet) on 
cognitive function remains unclear. 
 
With regard to the effect of exercise training combined with increased dietary protein 
on cognitive function, the findings from the limited studies available have reported 
mixed results. A secondary analysis of a 24-week RCT investigating the effects of a 
PRT program (50-75% of 1-RM) with and without additional protein 
supplementation (2 x 15g milk protein concentrate daily) or no exercise program 
with and without protein supplementation on muscle mass in frail and pre-frail adults 
aged over 65 years, assessed the effects of the intervention on cognitive function 
(327). It was found that those in the PRT group who had protein supplementation 
improved their performance in the information processing domain (as measured by a 
Finger precuing task) compared to the non-exercise group who also were 
supplemented (mean change: 0.08 ± 0.51 versus -0.23 ± 0.19 respectively) (327). 
This indicates that the exercise but not the addition of protein was associated with an 
improvement in information processing (327). In contrast, the non-exercise group 
who were supplemented improved their verbal fluency (as measured by Verbal 
Fluency Tests and animals & Letter P Word Learning Tests) compared to the PRT 
plus protein supplementation group, although no reason was given to explain this 
surprising finding (327). Further, improvements in attention and working memory 
(as measured by the Digit span task and Stroop Colour-Word test) were observed in 
the exercise group without supplementation when compared to the non-exercise 
group without supplementation (327). It is unclear however, whether the change 
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differed to that of the PRT plus protein group. Overall, this study provides some 
preliminary evidence for the beneficial effects of PRT and protein supplementation 
alone and in combination on various domains of cognitive function, although further 
studies are needed in order to determine the effect of dose and source of protein on 
cognitive function given that this was a secondary analysis. 
 
Although the above findings provide some preliminary evidence to support the 
potential added benefits of exercise combined with a general nutritional intervention 
(including protein) for improving cognitive function in older adults, the findings of a 
2016 systematic review of 67 RCTs conducted in healthy older adults (43 studies) 
and mammals (24 studies in rodents) found only three human studies which had 
investigated the effects of the combination of physical exercise and nutrition on 
cognitive function (408). These studies included the study by Van de rest and 
colleagues mentioned above (327), one which investigated endurance exercise in 
combination with vitamin E supplementation (409), and another which investigated 
the effects of PRT in combination with creatinine supplementation (410). The 
consensus from these three studies was that there was no additive effects. However, 
there was an additive effect for DHA when combined with exercise  in rodent studies 
(408). The lack of findings from the human studies was suggested to be due to a 
discordance between the types of exercise and nutrition interventions chosen and the 
cognitive domains (and neurobiological markers) they were likely to affect (408). 
For instance, some studies may have chosen an exercise intervention which has been 
shown to affect executive function and a nutrition intervention shown to affect 
working memory, therefore lowering the chance that the combination of the two 
interventions would result in an added benefit in either cognitive domain compared 
to either intervention alone. Therefore, future studies which include cognitive 
function as the primary outcome, should consider whether previous research shows 
that each aspect of their intervention is likely to affect the same cognitive domain (or 
neurobiological markers) in order to determine any true added benefits. 
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1
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Table 2.10 Summary of key studies which have examined the effect of multi-component exercise in combination with various nutritional factors 
on cognitive function in older adults 
Author, 
Year 
Subjects 
Duration 
and design 
Groups 
Key Findings 
Domain Ex>control Nut>control Ex+Nut>control 
Ngandu et al. 
2015 (406) 
N=1190 older 
adults aged 60-
77 years, with 
increased risk 
for dementia 
2-year RCT 1) Control group 
 
2) PRT+ cognitive 
training + 
nutrition 
Global cognitive function 
Executive function 
Memory 
Processing speed 
 
NA 
NA 
NA 
NA 
 
NA 
NA 
NA 
NA 
 
+ 
+ 
O 
+ 
van de Rest 
et al. 2014 
(327) 
N=127 frail and 
pre-frail adults 
aged 65 years 
and over 
Secondary 
analysis of a 
24-week 
double-blind 
RCT 
1) PRT (50-75% of 
1-RM) + placebo 
drink 
 
2) placebo drink 
only 
 
3) PRT + protein 
drink (2 x 15g 
milk protein 
concentrate daily) 
 
4)   protein drink  
only  
Episodic memory 
Working memory and 
attention 
Processing speed 
Executive function 
 
O 
+ 
 
O  
O 
O 
O 
 
O 
+ 
O 
O 
 
O 
O 
Tieland et al. 
2012 (70) 
N= 62 frail 
elderly aged 65 
24-week 
RCT 
1) Twice weekly 
PRT + protein 
Global cognitive function O O O 
  
1
1
6
 
years and over supplementation 
(2 x 15g milk 
protein 
concentrate) 
 
2) Twice weekly 
PRT + placebo 
 
 
 
 
 
 
 
 
 
 
 
 
Komulainen 
et al. 2010 
(407) 
N= 1335 adults 
aged 57-78 
years 
2-year 
interim data 
from an 
ongoing 4-
year RCT 
 
1) reference group 
 
2) aerobic exercise 
 
3) PRT 
 
4) nutrition 
counselling (diet 
group) 
 
5) aerobic exercise + 
nutrition 
counselling 
 
6) PRT + nutrition 
counselling 
Global cognitive function O O O 
Wu et al. 
2008 (411) 
Rats weighing 
200-240g 
12 days 1) DHA 
supplementation 
 
2) DHA + exercise 
 
3) exercise only 
 
4) control 
Learning and memory O O + (DHA+ exercise 
vs DHA alone) 
+ there was a difference between the groups in favour of the intervention; O no difference between the groups regardless of whether both groups improved or 
decreased; - difference between the groups in favour of the control (not the intervention group) 
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Despite the mixed findings from combined exercise and nutrition interventions on 
cognitive outcome measures, there is some evidence from animal and human studies 
to support potential additive benefits from the combination of exercise and nutrition 
interventions on various neurobiological and inflammatory markers associated with 
cognitive function. One 4-week RCT conducted in 154 male mice found that the 
combination of a complex dietary supplement (Acetyl-L-Carnitine 14.4mg, 
Acetylsalicylic Acid 2.5mg, Alpha-Lipoic Acid 0.72mg, β-carotene 50 IU, 
bioflavonoids 4.32mg, chromium picolinate 1.44 µg, cod liver oil 5.04 IU, coenzyme 
Q 10 0.44 mg, DHEA 0.15 mg, flax seed oil 21.6 mg, folic acid 0.01 mg, garlic 26.6 
µg, ginger 7.2 mg, gingko biloba 1.44 mg, ginseng 8.64 mg, green tea extract 7.2 mg, 
L-Glutathione 0.36 mg, magnesium 0.72 mg, melatonin 0.01 mg, N-Acetyl Cysteine 
7.2 mg, potassium 0.36 mg, rutin 0.72 mg, selenium 1.08 µg, vitamins B1 0.72 mg, 
B3 0.72 mg, B6 0.72 mg, B12 0.72 µg, vitamin C 3.6 mg, vitamin D 2.5 IU, vitamin 
E 1.44 IU and zinc 0.14 mg) which was designed to reduce inflammation and 
oxidative stress, had beneficial effects on indicators of cognitive function including 
doublecortin (DCX)-positive cell count (a marker of neurogenesis), hippocampal 
concentrations of BDNF and peripheral levels of VEGF in stressed mice, compared 
to stressed mice who received either intervention alone (412). Another study 
conducted in rats found that a combination of DHA dietary supplementation and 
exercise had added beneficial effects for spatial learning (as measured by the Morris 
water maze task), hippocampal BDNF and a reduction in hippocampal oxidised 
protein levels compared to exercise or DHA dietary supplementation alone (411). 
From a human clinical perspective, a limitation of these studies is that they were 
conducted in animals which may not be representative of the effects that may occur 
in humans, although it does provide preliminary evidence for the additive effects of 
the combination of exercise and certain nutritional factors on these markers.  
 
With regard to human intervention trials, one RCT conducted in 100 healthy women 
aged between 60 and 90 years found that four months of moderate-intensity PRT in 
combination with a protein-enriched diet achieved through the consumption of lean 
red meat across two meals (~160g consumed on six days a week), resulted in a 16% 
reduction in serum IL-6 and a 10% greater increase in IGF-1 compared to PRT alone 
(72). Whether this was associated with improvements in cognitive function is not 
known as it was not assessed, but this study provides some evidence that exercise 
combined with increased dietary protein may improve certain markers linked to 
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cognitive function. In contrast, another 24-week RCT conducted in 55 healthy 
physically active women aged 65-70 years found that a combination of PRT and core 
stability exercise (twice a week at an intensity of 75-80% of 1-RM) with a healthy 
diet (44% of energy from carbohydrates [fiber intake >25g per day], 36% of energy 
from fat [mainly monounsaturated and polyunsaturated fatty acids], 20% of energy 
from protein and an n-6/n-3 ratio <2) had no effect on serum CRP or IL-6 (413). This 
was most likely due to the low baseline levels of these inflammatory markers in the 
participants in this trial. However, a decrease in a pro-inflammatory precursor 
arachidonic acid and an increase in serum n-3 DHA was observed in the training plus 
healthy diet group compared with controls and PRT alone (413), suggesting additive 
effects of diet combined with exercise on inflammation. More recently, a 12-week 
RCT conducted in 30 healthy men with a mean age of 45 years randomised to 
receive a multi-component exercise program (high-intensity resistance training, 
interval sprints, stretching and endurance training) on four days a week in 
combination with normal dietary protein intake (1.0 g/kg bodyweight per day) or 
increased dietary protein (2.0 g/kg bodyweight per day), found that BDNF declined 
in response to the high protein diet although not significantly, whereas IGF-1 
declined (non-significantly) in the normal protein group and increased significantly 
in the high protein group (414). Taken together, these studies provide some evidence 
for the beneficial effects of exercise combined with increased dietary protein or a 
healthy diet on some markers of inflammation, but there are mixed findings from 
limited studies which have investigated the effects of the combination on 
neurobiological markers and associated effects with regard to cognitive function.  
 
In summary, there are mixed findings with regard to the effects of exercise in 
combination with nutrition interventions on cognitive function. Specifically, there are 
very limited studies which have assessed the effect of exercise in combination with 
dietary protein on cognitive function, and the current available evidence is mixed 
which is likely to be due to a number of factors including differences in the dose 
(frequency, intensity and duration) of the training and the type and dose of protein, 
addition of other interventions such as cognitive training and a discordance between 
the types of interventions chosen and targeted cognitive domains. Despite this, there 
is some evidence that the combination influences various neurobiological and 
inflammatory markers which are associated with cognitive function. The lack of 
findings from current studies is therefore thought to potentially be due to a 
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discrepancy between exercise and the nutrition intervention with regard to the 
neuronal mechanisms they are affecting, hence leading to no added beneficial effects 
from the combination. Further studies which incorporate exercise and nutrition 
interventions which are thought to act on the same mechanisms are needed in order 
to assess any added benefits on cognitive function in older adults. 
 
Part 5. Quality of Life 
Ageing is commonly associated with a decline in functional performance due to the 
development of chronic conditions and this is often accompanied by a decline in QoL 
(415). The WHO defines QoL as an individual’s perception of their position in life in 
the context of the culture and value systems in which they live and in relation to their 
goals, expectations, standards and concerns (416). Both objective and subjective 
constructs are used when evaluating QoL, and measurement tools which assess 
health-related QoL (HR-QoL) specifically, include both subjective and objective 
components which can be useful in evaluating the impact of specific conditions at an 
individual level (11, 415). The terms QoL and HR-QoL are often used 
interchangeably, however HR-QoL differs as it only looks at areas of QoL which are 
most affected by health or illness (including physical or mental health), whereas QoL 
is a more global measure (e.g. global life satisfaction, good health, adequate housing, 
employment, personal and family safety, interpersonal relationships, education, and 
leisure pursuits) (417, 418). It is important to measure HR-QoL as it can be used to 
monitor declines or improvements in function due to various interventions and 
treatments (419), for a number of different conditions and normal age-related 
decline. Further, reduced HR-QoL is associated with an increased likelihood of 
developing depression and related disorders, which have been implicated in the 
development of dementia (4-6). Therefore, the assessment and maintenance of QoL 
and HR-QoL in healthy and cognitively impaired older adults is important due to our 
ageing population which has an increased risk of developing chronic conditions and 
consequently suffering a decline in HR-QoL.  
The definition of HR-QoL and types of measures which can be used to assess it are 
quite broad and given that there is limited evidence for the effect of various factors 
on HR-QoL, this section will also discuss related concepts such as wellness (an 
active and intentional action which leads to improved well-being) (420) and 
depression, which can both affect HR-QoL. Therefore, the focus of this section will 
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be on the effects of various dietary patterns, nutrients and exercise on HR-QoL and 
related concepts. The terms ‘QoL’ and ‘HR-QoL’ will be used where appropriate and 
will not be used interchangeably. 
 
5.1 Effect of dietary patterns on HR-QoL and related concepts 
It is well established that diet can have a positive impact on many aspects of health, 
which can prevent the onset of chronic disease (188). There is also emerging 
research which has investigated the relationship between HR-QoL and related 
concepts in older adults and measures of the whole diet such as specific dietary 
patterns (the assessment of one or more overall diet styles present in a given group of 
people) or diet quality (dietary scoring methods informed by a priori guidelines and 
recommendations) (188).  
 
It is important to consider the role of overall dietary patterns in HR-QoL in addition 
to the role of specific foods and nutrients, as dietary patterns (and measures of diet 
quality) recognise that foods are consumed in complex combinations altering the 
balance of different components of dietary intake which may be important for 
preventing and managing chronic disease (188). For instance, one systematic review 
of 34 studies found that four out of five studies investigating the relationship between 
dietary indices and overall QoL, reported a positive association, while seven out of 
eight studies investigating the relationship between dietary indices and measures of 
physical function of frailty, reported positive associations (188). More specifically, 
one recent review concluded that the Mediterranean diet may be associated with 
improvements in intellectual, emotional and physical wellness, whereas the Western-
style diet was found to be associated with poorer emotional and physical wellness 
(420). However, evidence in this area is mixed with one large prospective study with 
a three year and nine year follow-up conducted in 2,388 older adults aged 60 years 
and over, reporting that a healthy diet (determined by the creation of a healthy diet 
index with scores above the median for the cohort being classed as ‘healthy’) was not 
related to HR-QoL (421). This may be explained by the possibility that those 
adhering to a healthy diet did so for health reasons (i.e. a greater number of chronic 
health conditions than those not adhering to a healthy diet). Thus, any benefits of the 
healthy diet may have been attenuated by the negative impact of chronic disease 
(421).  
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While there have been some cross-sectional and prospective studies which have 
investigated the effect of overall nutritional status and diet quality on HR-QoL and 
related concepts in older adults and the elderly, the findings overall are mixed with 
the need for further studies (188). At present, cause-and-effect cannot be established 
from the available studies and they provide no information about the role that 
specific dietary factors or nutrients may have on HR-QoL in older adults.   
 
5.2 Effect of nutrients on HR-QoL and related concepts 
There have been various studies which have investigated the effects of nutrients, 
including omega-3 fatty acids, saturated and trans fats, vitamins D and C and zinc on 
HR-QoL and related concepts in older adults (207, 208, 220, 229, 302, 422-429).  
 
Currently, there is some evidence that omega 3 fatty acids may be beneficial for HR-
QoL in those who are already cognitively impaired (430), as well as for lowering 
depressive symptoms and improving HR-QoL scores in older depressed women 
(422). This is thought to be due to the role of n-3 fatty acids in the central nervous 
system (modulating neurotransmitters) and the finding from other studies where 
those with depressive symptoms or mood disorders have lower levels of long-chain 
PUFAs n-3 (422). Further, a recent review found that omega-3 PUFAs have been 
associated with improvements in intellectual and emotional wellness, with 
antioxidants also associated with intellectual and physical wellness, whereas 
saturated fats were found to be negatively associated with intellectual and 
occupational (satisfaction with job/ career) wellness (420). Similarly, there is 
evidence that decreasing intake of saturated and trans fats can improve HR-QoL in 
adults with pre-hypertension (428), due to a decreased risk for cardiovascular health 
problems (increased risk of stroke, coronary heart disease and diabetes) (189, 289). 
However it is unclear whether there are similar benefits for healthy older adults, or 
those who are cognitively impaired. 
 
There are very limited studies with mixed findings which have investigated the effect 
of various vitamins on HR-QoL in older adults. Vitamins A, C, D and E are all 
regarded as common antioxidants which have been associated with a reduction in 
various inflammatory and oxidative stress markers (207, 208, 229, 427), which has 
been associated with an increased risk for a number of chronic conditions and 
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thereby may negatively impact upon HR-QoL. Higher intakes of carotene, vitamin C 
and vitamin E intake have been associated with lower odds (OR: 0.36, 0.33 and 0.33 
respectively) of depressive symptoms in men, however, no effect has been observed 
for vitamin A or D and the effects for women are unclear (431). Vitamin D 
deficiency has also been linked to depression (432) and reductions in HR-QoL (4-6), 
with cross-sectional evidence suggesting that consumption of less than half of the 
RDA for vitamin D (<400 IU/day) in women is associated with significantly lower 
HR-QoL than those consuming >400 IU/day (425). In healthy adults, one systematic 
review of 15 RCTs reported that there was no effect of vitamin D supplementation 
(dose ranging from a single dose of 300,000 IU to 7.1 years of 400 IU/day) on HR-
QoL, and benefits for clinical populations (e.g. Crohn’s disease, osteoporosis, heart 
failure, chronic pain) were only reported following short-term supplementation (≤6 
months) (427). With regard to vitamin E, six months of daily supplementation with 
400 IU vitamin E (tocopherol) in older adults with hypercholesterolaemia has been 
associated with no improvements in HR-QoL (433). Currently, there are limited 
studies which have investigated the effects of B vitamins on HR-QoL, despite 
deficiencies being associated with an increased risk for chronic diseases (434), which 
can have a negative impact on HR-QoL and well-being. However, supplementation 
with folate along with other B vitamins has been shown to potentiate the effects of 
anti-depressant drugs (220). In contrast, other RCTs conducted in older adults with 
MCI reported no beneficial effect of daily vitamin B supplementation on QoL, HR-
QoL or depression scores compared to a placebo (423, 424).  
 
While there is currently limited research on the effects of zinc on HR-QoL in healthy 
older adults, there is some evidence to suggest that adults with low dietary intakes of 
zinc (<7 mg/day) may have an increased risk for depression (429). This may be due 
to the antioxidant and anti-inflammatory properties of zinc (297) which have been 
found to be beneficial for areas of the brain including the amygdala (298), which is 
closely linked to depression. A large cross-sectional study examining the relationship 
between dietary zinc and psychosocial dimensions, nutrition and lifestyle in older 
adults aged 60-84 years in five European countries, found that countries with lower 
dietary intakes of zinc (<11 µM) due to a smaller variety of zinc-enriched foods, 
reported higher depression scores (GDS scores >5) compared to countries with diets 
rich in zinc (302). This suggests that foods rich in zinc may be beneficial for 
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improving well-being although further research into the effects of dietary zinc on 
HR-QoL and well-being is needed. 
 
While this section has reviewed the evidence for a number of dietary patterns and 
nutrients and other food-based compounds, the following section will review 
evidence for the effects of different types of protein on cognitive function.  
 
5.3 Effect of protein on HR-QoL and related concepts 
There is some research indicating that low intakes of protein are negatively 
associated with physical and mental aspects of HR-QoL (435, 436). For instance, one 
cross-sectional study conducted in 50 non-terminal cancer patients found that a low 
protein intake (23.3% did not fulfil 1 g/kg daily) was associated with a poorer 
perception of physical functioning with regard to HR-QoL as measured by the 
European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire version 3.0 (435). However, a 3-month study conducted in cancer 
outpatients found that there were no HR-QoL improvements following a nutritional 
intervention (18 g protein daily) which led to an increased intake of protein when 
compared to an oral nutrition supplement without additional protein (437). This was 
suggested to be related to the advanced stage of cancer in some participants and 
possible associated side effects of consuming the supplement such as abdominal 
fullness or nausea (437). Another 12-week RCT conducted in 104 malnourished 
home residents with a mean age of 88.5 years also found that HR-QoL (as measured 
by the EuroQoL) and protein intake were significantly higher in the group receiving 
oral nutrition supplements compared to dietary advice (change in EuroQoL scores 
[mean ± standard error (SE)] nutrition supplement: 0.50 ± 0.04 vs dietary advice: 
0.36 ± 0.05, [P=0.005]) (436). Another systematic review of 36 RCTs, although not 
directly examining HR-QoL, found that a high protein oral nutritional supplement 
(>20% energy from protein) was associated with better health-related outcomes (less 
hospital readmissions and complications as well as improved functional outcomes) in 
a range of patient groups (including chronic obstructive pulmonary disease [COPD], 
hip fracture, acute illness, elderly in care, gastrointestinal disease, cancer) (438). 
 
Despite some mixed findings for the effect of protein on HR-QoL, those beneficial 
effects which have been reported may be related to a decreased risk of frailty (439). 
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For instance, a five-year prospective cohort study using data from 24,417 women 
aged 50-79 years enrolled in the Women’s Health Initiative Observational Study, 
found that a 20% increase in dietary protein was associated with a 12% lower risk of 
frailty classification (440). As frailty is often classified by low levels of physical 
activity, muscle weakness, weight loss and loss of endurance (441), this can impact 
on a person’s physical function and independence, and hence HR-QoL. This is 
supported by the findings of one 12-week RCT conducted in 14 heart failure patients 
which found improvements in the physical component of HR-QoL as measured by 
the Minnesota Living with Heart Failure questionnaire and muscle function 
following a high protein diet (40% total energy from carbohydrates, 30% from 
protein, and 30% from fat), compared to a standard protein diet (55% total energy 
from carbohydrates, 15% from protein, and 30% from fat) or conventional diet (low 
in saturated fat and rich in whole grains, vegetables, and fruit) (442). Further, one 3-
week RCT conducted in young healthy males (aged 19-31 years) found that there 
was no difference in HR-QoL as measured by the short-form (SF)-36 or muscle 
function when comparing a high protein diet (3.0 g protein/kg of bodyweight) to a 
usual protein diet (1.5 g protein/kg of bodyweight) (55). The lack of effect in this 
study may be related to the fact that the participants were healthy young men and/or 
that usual protein intakes were 1.5 g/kg/d, which is well above the recommended 
levels. Furthermore, the association between increased muscle function and HR-QoL 
was not assessed in this (or any) of the above studies. To our knowledge, the study 
by Jakobsen and colleagues is only one of two studies (the other is discussed below) 
which has investigated the effect of dietary protein on HR-QoL in healthy adults. 
This is important as protein is important for building muscle, particularly in older 
adults, and so an increased dietary protein may result in a decreased loss in muscle 
mass and risk of frailty, thus reducing the risk for a decline in HR-QoL. However, 
further research is necessary to test this hypothesis and the current findings for the 
effect of protein on HR-QoL overall, are unclear. 
 
5.4 Effect of red meat on HR-QoL and related concepts 
There is limited evidence for the effect of red meat on HR-QoL with only one RCT 
investigating the effect of lean red meat on QoL in healthy older adults. A 4-month 
RCT conducted in 100 community-dwelling older women aged 60-90 years reported 
additional benefits for the physical component summary score (PCS) and overall 
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HR-QoL as measured by the SF-36, for women who received 160 g/d lean red meat 
(consumed across two meals a day on six days a week) combined with PRT, 
compared to PRT alone (418). It was suggested that improvements in muscle 
strength could explain this improvement as there was an 18% greater improvement in 
the lean red meat group compared to the PRT group (72), and changes in muscle 
strength, were found to be positively associated with changes in overall HR-QoL 
(418). This suggests that lean red meat may be beneficial for improving QoL even in 
healthy adults with baseline scores above the Australian normative data. However, 
this study used a dose of lean red meat which is well above the recommendations and 
so it is unclear whether a lower dose in line with the current recommended intake 
would result in similar benefits. 
 
There is also limited evidence for the effect of red meat on related concepts to HR-
QoL with one review highlighting that there are mixed findings when it comes to the 
effect of ‘meat intake’ on wellness (420). However, it was suggested that there may 
be a potentially U-shaped relationship between meat intake and wellness (420) 
indicating that too little or too much red meat may have negative effects. Based on 
these findings, the authors recommended that older adults should adhere to 
recommendations regarding the intake of meat (3-4 serves of trimmed red meat per 
week or no more than 455 g per week) (63, 64) and should eat lean cuts to minimise 
the intake of saturated fats (420). Although there are few studies which have 
investigated the relationship between red meat and HR-QoL in older adults, a 
number of studies have reported an association between red meat intake and markers 
of chronic disease and depression which are known to impact on HR-QoL. One large 
cross-sectional study using data from 1984 from 69,017 women aged 38 to 63 years 
enrolled in the Nurses’ Health Study found that when consumed as part of a Western 
diet, meat intake was associated with a higher risk for coronary heart disease, which 
has been associated with impairments in intellectual and physical wellness (443). In 
contrast, another cross-sectional study in 1,046 women aged 20 to 93 years observed 
an increased risk for major depressive disorder (MDD)/dysthymia [OR= 2.18 (95% 
CI: 1.11, 4.29)] and anxiety disorders [OR= 1.91 (95% CI: 1.07, 3.41)] as well as an 
increase in the presence of psychological symptoms when meat intakes were below 
the recommended intakes (64). While no explanation was given for this finding, 
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these findings were independent of age, socioeconomic status, health behaviours, 
BMI and overall energy intake. 
 
Taken together, these findings suggest that when processed and fatty cuts of meats 
are consumed as part of a Western diet and consumed in large quantities above what 
is included in dietary recommendations, meat intake may be detrimental to mental 
health, however there may be benefits of leaner cuts of meat at moderate levels of 
intake when consumed as part of a healthy dietary pattern. This indicates the 
potential for a U-shaped relationship between meat-intake and wellness, indicating 
that meat intake may perhaps be beneficial for HR-QoL up to a certain intake. 
However, studies which investigate the effects of meat intake on HR-QoL are needed 
rather than wellness, to determine any relationship. 
 
5.5 Summary of diet-related effects on HR-QoL and related concepts 
In summary, there is emerging research indicating that a Mediterranean diet may 
provide some beneficial effects on HR-QoL and well-being in healthy older adults 
compared to a Western-style dietary pattern. There are also a number of studies 
which also suggest that certain nutrients including omega-3 fatty acids and a 
reduction in saturated and trans fats may provide some beneficial effects on HR-QoL 
and other related concepts which impact on HR-QoL such as depressive symptoms 
and chronic disease, however the role of other vitamins such as vitamin D, A, C and 
E remain unclear. Further, there are limited studies which have investigated the 
effect of other nutrients including zinc and protein on HR-QoL and related concepts, 
with emerging evidence suggesting that there may be a role for lean red meat in 
reducing declines in HR-QoL related outcomes, although this requires further study.  
 
5.6 Role of exercise in HR-QoL and related concepts 
A reduced ability to be physically active and subsequent decreases in muscle strength 
and endurance have all been shown to influence HR-QoL, which may be due in part 
to a loss of independence (444). Therefore maintaining physical function and muscle 
strength through physical activity and exercise may be beneficial for maintaining 
HR-QoL and well-being, particularly in older adults. While there is some evidence 
from cross-sectional and prospective studies and RCTs indicating that regular 
physical activity and exercise training can improve overall QoL and many of its 
subdomains in older adults, questions still remain with regard to what type and dose 
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of physical activity or exercise training might be optimal and whether these 
beneficial effects occur in healthy and at risk groups (e.g. those with chronic 
disease). The following section will provide an overview of the effect of general 
physical activity and exercise on HR-QoL and related concepts such as depression, 
as well as the specific effects of aerobic exercise and PRT, in older adults. 
  
As indicated above, there is some evidence which suggests that there is a beneficial 
effect of general exercise and physical activity on QoL and depression in older 
adults. One 5-year follow-up study of 174 older adults with a mean age of 67 years 
who completed a six-month exercise RCT (randomised to receive either moderate-
intensity walking three times a week or stretching-toning program three times a week 
[control]) found that habitual physical activity levels at one year of follow-up was 
associated with improved psychological constructs including self-efficacy, self-
esteem and positive affect which were in turn, associated with greater QoL (as 
measured by the Satisfaction With Life Scale) (445). Further, changes in physical 
activity were found to be associated with increases in physical self-esteem and 
positive affect (mood) with the latter having a direct influence on improvements in 
QoL in this study (445). The benefits to affect and self-esteem were thought to be 
related to the social cognitive theory which suggests that increases in self-efficacy 
may mediate the relationship between physical activity and QoL (445). Similarly, a 
meta-analysis of 56 RCTs conducted in healthy and clinical populations 
(rehabilitation or disease management) including those with musculoskeletal, 
neurological and pulmonary conditions as well as cancer, CVD, rheumatoid arthritis, 
renal disease and fibromyalgia, found that exercise interventions overall had a 
positive effect on overall QoL three to six months following an intervention in 
rehabilitation patients but not in healthy or disease management groups (446). 
Despite the lack of an overall improvement in QoL in healthy populations, it was 
found that physical and psychological domains of QoL did improve in this group 
(446). With regard to the training dose, light-intensity (not defined) exercise 
conducted in group settings improved QoL overall, although improvements in 
physical aspects of QoL were reported following moderate-intensity exercise (446). 
The benefits for QoL following light-intensity but not moderate-intensity exercise 
were thought to be potentially due to the presumably low fitness level of participants 
as aerobic fitness has previously been found to effect a person’s enjoyment of higher 
intensity exercise (446). Overall, it appears that while changes in habitual physical 
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activity may be related to QoL in healthy older adults, the effect of exercise may be 
greatest for clinical populations.   
 
There is also some evidence to suggest that physical activity and exercise may also 
be beneficial for depression, which is related to HR-QoL. One review of 67 
observational studies and RCTs investigating the effect of physical activity on 
depression in adults aged 17 years and over found that both short (<1 hour per week) 
and long duration (up to 554 minutes per day) physical activity was associated with a 
reduced likelihood of depression with vigorous intensities being more strongly 
associated than lower intensities (447). Further, exercise has been found to decrease 
depressive symptoms and increase HR-QoL in individuals with AD (448), suggesting 
that exercise may also be beneficial for improving certain components of HR-QoL in 
those who are cognitively impaired. However, a potential limitation to these findings 
is that it has previously been suggested that there is no optimal dosage of exercise 
which is beneficial for depressive symptoms as beneficial effects have been found at 
multiple intensities and doses (447), although this has not been thoroughly 
investigated. 
 
There have also been a number of studies which have investigated the effects of 
different modalities of exercise such as aerobic training and PRT on HR-QoL. With 
regard to aerobic exercise, the available data indicates that aerobic exercise is 
beneficial for improving both HR-QoL and depression (23, 30, 449). For instance, 
one review reported that moderate-intensity aerobic exercise (such as walking, 
aerobics or aerobic training) was beneficial for improving behavioural, affective and 
mood aspects of HR-QoL, although there was also some evidence for a positive 
affect following low intensity, high intensity and self-selected intensities of aerobic 
exercise (30). Further, one RCT conducted in 46 sedentary men aged between 60 and 
75 years found a decrease in depression and anxiety ratings in those participating in 
an aerobic exercise program on three days a week for six months, compared to those 
who were sedentary (mean decrease of 5.74 and 0.69 respectively for Geriatric 
depression scale [GDS] scores and 12.22 and 2.87 for trait anxiety as measured by 
Spielberger State -Trait Anxiety Inventory [STAI]) (449). Further, improvements in 
all domains of the SF-36 (a measure of HR-QoL) was found for the exercise group 
compared to the control group (449). In line with these findings, a review of the 
effects of exercise on brain health found that aerobic exercise can be as effective as 
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pharmacological anti-depressants as a treatment for depression (23). In contrast, a 
meta-analyses of 14 RCTs found that there was no difference between aerobic and 
non-aerobic exercise (such as PRT) modalities for reducing depression, although it 
was noted that further research was warranted due to a lack of RCTs in clinical 
populations with adequate follow up (450). This suggests that other types of exercise 
such as PRT may be equally beneficial for improving HR-QoL and depression. In 
support of this, an 8-month RCT conducted in 50 healthy older adults aged over 60 
years found that those randomised to an aerobic training (70-80% of maximal heart 
rate) or resistance training (80% of 1-RM) group which trained on three days per 
week, improved their physical component scores compared to the controls (451). 
While the improvements in the physical component score were more marked in the 
resistance training compared to the aerobic training group (10.0 ± 15.3 versus 2.1 ± 
12.2 respectively), improvements for the general health score were similar in both 
groups (16.8 ± 17.0 versus 14.4 ± 19.7 for resistance and aerobic training 
respectively). In contrast, the improvements in the mental health score were greater 
in the aerobic group (2.9 ± 27.0 versus 21.9 ± 37.3 for resistance and aerobic training 
respectively) (451). This suggests that although either aerobic or PRT can induce 
similar improvements in overall HR-QoL independently, they may do this by 
influencing different aspects of HR-QoL. This suggests that the type of exercise may 
be important when designing an intervention to target specific aspects of HR-QoL, 
and it indicates that multi-component exercise may have added benefits for HR-QoL 
overall compared to single modalities.  
 
Research suggests that PRT can increase neural recruitment and activation of 
muscles, which may contribute to improvements in physical functional outcomes 
(452) which may subsequently improve HR-QoL. The findings of one recent study 
support the notion of maintaining muscle for HR-QoL, reporting poorer nutritional 
status, cognitive function, HR-QoL and increased depression in hospitalised older 
adults with low muscle strength (handgrip strength less than 30 kg and 20 kg in men 
and women respectively) compared to those with normal muscle strength, over a six 
month period (453). In addition to this, one 12-week intervention study conducted in 
49 healthy older men aged 60-81 years found improvements in the role physical, 
general health and physical component summary score following strength training 
three times a week, despite baseline scores being above the population average (454). 
Similar results were reported in another study which examined the long term effects 
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of a 12-week twice-weekly PRT program (60% of 1-RM) on HR-QoL in 135 older 
adults aged 65 years and over. In this study, they found that physical functioning, 
role physical and mental health domains (as measured by the SF-36) improved 
significantly in the training group post-intervention and one year following the 
intervention (role physical and physical functioning only), when training was 
maintained (455). In the de-training group (training not continued post-intervention), 
scores for vitality and mental health domains as well as physical functioning and 
general health, decreased one year post-intervention (455). However, no domain 
scores were lower one year post-intervention than at baseline (455), indicating that 
positive effects of exercise on HR-QoL can be sustained even if training is not 
continued. This highlights the importance of maintaining training to ensure that HR-
QoL is also maintained. The declines in the mental health domains was suggested to 
be due to a potential decline in positive feelings relating to the social interaction 
provided through the group training sessions, which may have influenced HR-QoL 
ratings (455). This is supported by the findings of another 12-week RCT conducted 
in 119 adults aged 65 years and over, which found that only the mental health 
domain (as measured by the SF-36) was improved in the twice-weekly PRT group 
(60% of 1-RM) when compared to the control group (354).  
 
With regard to the dose of PRT, one review which included studies that examined the 
acute effects of low or high-intensity PRT reported that these studies have obtained 
divergent results on HR-QoL, which may be due to differences in the length of time 
between post-exercise and assessment of HR-QoL in acute studies (30). For example, 
acute studies which assess HR-QoL immediately following exercise (within a couple 
of hours) may capture the effects of fatigue related to the exercise which may result 
in lower HR-QoL scores, compared to studies which assess HR-QoL after the 
participants have had time to recover from the immediate sessions (e.g. one week 
following exercise). This review however, did not acknowledge studies which have 
investigated the long term effects of PRT on HR-QoL. Another review found that 
lower exercise intensities in general were associated with greater enjoyment and 
persistence whereas moderate intensities were preferred and associated with positive 
psychological responses in fitter adults (446). In clinical populations however, lower 
intensities were associated with benefits for HR-QoL compared to higher intensities 
(446). A limitation of this review however, was that the exercise types were all 
grouped together and could not be analysed separately due to the small number of 
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studies in each group (446). Thus, it cannot be determined whether certain intensities 
for particular types of exercise are more beneficial than others for HR-QoL. Further 
research into the long and short-term effects of PRT on HR-QoL, are needed.  
 
Taken together, the findings above suggest that aerobic and PRT may independently 
have beneficial effects on HR-QoL in older adults, but may act on different aspects 
of HR-QoL. On this basis, it is likely that the combination of aerobic and resistance 
training would be most beneficial to improving multiple measures of HR-QoL. 
However, currently the research into the effects of a multi-component exercise 
program on HR-QoL is unclear. A recent meta-analysis of 36 RCTs investigating the 
effects of physical activity and psychological well-being in older adults found that 
the combination of aerobic and resistance exercise had the smallest effect size 
compared to each type of exercise alone for psychological well-being (31). However, 
it was noted that a limitation of at least half of the studies included in the meta-
analysis was that they used life satisfaction as a measure of HR-QoL rather than 
more specific outcome measures (31) such as the Assessment of QoL instrument 
(AQoL) or the perceived well-being scale (PWB) (415). Despite this, a systematic 
review of 15 RCTs which included multi-component exercise comprising aerobic, 
strength and balance training in older adults found that generally, there was no 
improvement in functional or HR-QoL outcomes (456). However, it was noted that 
seven of the studies incorporated a home-based intervention (456), which may have 
impacted on execution and intensity of the exercise and any potential social 
interaction, thereby potentially limiting the effects of the training on HR-QoL. 
Further research investigating the effects of a multi-component exercise program, 
namely aerobic combined with resistance training, is required before conclusions 
about the benefits on HR-QoL can be drawn.  
 
5.7 Effects of multi-component exercise in combination with protein on HR-QoL 
and related concepts 
Given that there is some evidence that various nutritional factors and exercise may 
independently improve various factors relating to HR-QoL and related concepts (e.g. 
muscle strength, muscle function, depressive symptoms), it is possible that the 
combination of exercise and nutrition may result in additive benefits. The following 
section will summarise the current research from studies assessing the effect of 
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exercise (including multi-component exercise interventions) in combination with 
various nutrition interventions on HR-QoL and related concepts in older adults.  
 
A small number of RCTs have been conducted in older adults which suggest a 
potential beneficial role for the combination of exercise and nutrition intervention for 
HR-QoL. For instance, one 12-week prospective study conducted in 91 
institutionalised adults aged 70 years and over found that twice daily intake of a 
200ml oral nutritional supplement (300 kcal, 20 g protein, 3g fiber, 500 IU vitamin D 
and 480 mg calcium) in combination with balance, flexibility and PRT (intensity not 
reported) on five days a week, improved HR-QoL scores as measured by the 
EuroQoL-5 Dimensions visual analogic self-rating scale by 6% after six weeks and 
5% after 12 weeks (457). A limitation of this study however, was the lack of a 
control group (or training only group) and so it is unclear whether this is a true 
representation of the effect of the combination of the supplement and the training, as 
opposed to a placebo effect or the effects of the training alone. Another 12-week 
RCT conducted in 89 pre-frail women aged 70 years and over found that once a 
week strength and balance exercises (intensity not reported) combined with a 
cooking class and nutritional education with a focus on protein and vitamin D, 
improved HR-QoL outcomes for the physical component score and role physical, 
bodily pain and role emotional domains compared to the exercise alone and control 
group (458). Further, a 12-week RCT conducted in 130 sarcopenic older adults 
reported similar improvements in mental component summary (MCS) scores, and a 
greater benefit in PCS scores following a moderate intensity multi-component 
exercise program combined with an amino acid/whey-protein (22 g/d) and vitamin D 
(100 IU/d) enriched supplement, compared to exercise alone (459). While these 
findings provide some evidence that a multi-component exercise and nutrition 
intervention can have some beneficial effects on HR-QoL in the frail elderly, to our 
knowledge, only one previous study has investigated the effects in healthy older 
adults with promising results. A 4-month RCT conducted in 100 healthy older 
Australian women aged 60-90 years who participated in PRT and balance/agility 
training twice a week and were randomised to receive either 160 g/d (cooked) lean 
red meat consumed across two meals/day, six days/week or ≥1 serving/day 
carbohydrates (control), found that there was an added benefit for PCS scores in the 
meat group compared to those receiving exercise alone, despite participants having 
little physical functional impairment at the beginning of the study (418). However, 
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no benefit for MCS scores were observed in either group although this may have 
been related to the high baseline HR-QoL scores (418). Further research in this area 
is warranted as longer study durations may have benefits for MCS and it is unclear 
whether meat intake in line with current dietary guidelines would promote similar 
benefits for PCS. 
 
5.8 Mechanisms underlying changes in HR-QoL and related concepts 
There are a number of circulating neurobiological and inflammatory markers which 
may potentially explain the beneficial findings for exercise and nutrition intervention 
to improve HR-QoL, well-being and depression in older adults. The potential role of 
these markers is similar to those discussed for cognitive function. Further, there is 
considerable overlap with regard to the influence of nutrition and exercise on these 
markers for HR-QoL, which will be discussed below.  
  
5.8.1 IGF-1 
As IGF-1 is found in the hippocampus, a region which is involved in the aetiology of 
depression, decreases in serum levels of IGF-1 may influence hippocampal 
concentrations and hence increase the risk of depressive symptoms and decrease HR-
QoL (376, 460). IGF-1 has been found to be a primary regulator of depressive 
symptoms and has been used in the treatment of depression, along with BDNF (23). 
There is some evidence that IGF-1 can reduce circulating pro-inflammatory 
cytokines which could impair BDNF signalling in the brain (23). This suggests that 
IGF-1 could play an important role in improving HR-QoL in older adults, although 
no study has established a clear link between circulating IGF-1 levels and HR-QoL 
in older adults. However, there is some cross-sectional evidence which suggests a 
link between IGF-1 and depression. Analyses of data from a 3-year cohort study in 
adults aged 55-85 years living in Amsterdam found that at baseline, concentrations of 
IGF-1 with the range >11.5 to ≤15.5 nmol/L decreased the probability of developing 
minor depression in men (OR: 0.35 [95% CI: 0.15-0.82]) when compared to high 
concentrations (>15.5 nmol/L) (460). In women, it was found that low IGF-1 
concentrations (≤11.5 nmol/L) increased the probability of developing MDD (OR: 
2.66 [95% CI: 0.89-7.89]) (460). At follow-up however, there were no significant 
associations found for men whereas for women, concentrations of IGF-1 between 
11.5 and 15.5 nmol/L were associated with a decreased risk for minor depression 
when compared to high concentrations (OR: 0.43 [95% CI: 0.19-0.95]) (460). In 
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contrast, another cross-sectional study conducted in healthy postmenopausal women 
found that there were no consistent relationships observed between levels of IGF-1 
and HR-QoL, although the authors did not speculate why this was the case (461). 
The lack of studies and conflicting findings with regard to the relationship between 
IGF-1 and HR-QoL in healthy adults warrants further studies in order to establish if 
there is a causal relationship. 
 
5.8.2 BDNF 
There is some evidence to suggest that BDNF may be used as a biomarker for MDD 
(462). One study compared BDNF serum levels in patients with moderate symptoms 
of MDD to healthy gender-matched controls and found that serum levels of BDNF 
were lower in people with MDD compared to the controls (462). However it was also 
noted that there were no associations between BDNF levels and the clinical variables 
of HR-QoL, cognitive impairment and depression, although this was reported to be 
due to a lack of severity in depressive symptoms observed in the patients, meaning 
that HR-QoL and cognitive function was not sufficiently impaired (462). In contrast, 
a meta-analysis found that in depressed patients pre- and post-antidepressant 
treatments, changes in depression scores and BDNF were positively related (β=0.23, 
[95% CI: 0.04-0.41], P=0.02) (463). Further research into the relationship between 
BDNF and HR-QoL is needed. 
 
5.8.3 VEGF 
There are no studies to our knowledge which have focused on the relationship 
between VEGF and HR-QoL in healthy or cognitively impaired adults. However, 
due to the ability of VEGF to increase brain permeability (464), VEGF may 
upregulate IGF-1 and BDNF, which may potentially reduce depressive symptoms 
and improve HR-QoL. Therefore, the role of VEGF in maintaining and improving 
HR-QoL in older adults is an area which requires investigation.  
 
5.8.4 Inflammation 
There is some cross-sectional evidence which suggests that lower levels of various 
inflammatory markers may play a role in HR-QoL for healthy adults. For instance, 
one large cross-sectional study of 3,005 older adults aged 57 to 85 years found that 
CRP levels were significantly negatively associated with HR-QoL (generally feeling 
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happy and happiness with relationships) (465). Another cross-sectional study 
conducted in 160 adults aged 19-40 years found that serum concentrations of 
interferon-γ (an inflammatory marker which can affect brain function and induce 
depressive symptoms) were lower in the high happiness group (scores exceeding 
5.50 on the Japanese subjective happiness scale) who also had significantly higher 
scores for HR-QoL domains, including general health, vitality, emotional role and 
mental health, than the low happiness group (scores below 4.25 on the Japanese 
subjective happiness scale) (466). However, no significant differences were found 
between the high and low happiness groups for IL-6 or TNF-α (466). It has been 
suggested that the mechanism behind the beneficial effects of reducing inflammation 
on HR-QoL is via a reduction in oxidative stress. Oxidative stress has been linked to 
the onset of cognitive decline as well as various chronic diseases including CVD, 
arthritis and cancer (467), and so reducing the onset of chronic disease may be 
beneficial to HR-QoL. These findings suggest that by reducing overall chronic low-
grade systemic inflammation or particular inflammatory markers, HR-QoL may be 
improved although further research is needed to test this hypothesis.  
 
5.8.5 Social and psychological factors  
It is well established that support groups are effective for maintaining and improving 
mental health in many populations (468-471). However, there is some suggestion 
that group activities or exercise may also be beneficial for mental HR-QoL, due to 
positive feelings relating to the social interaction (455 Kimura, 2010 #459). For 
instance, one 12-week RCT conducted in 119 adults aged 65 years and over, found 
that only the mental health domain (as measured by the SF-36) was improved in the 
group participating in twice-weekly, group-based PRT (60% of 1-RM) when 
compared to a group attending health education classes in which participants 
received 1.5 hours of lectures on health promotion twice a month (354). This may be 
explained by an increased opportunity to engage in social conversation in the training 
sessions as opposed to the education classes where participants were required to 
listen to lectures. Similar results were reported in another study which examined the 
long term effects of a 12-week twice-weekly group-based PRT program (60% of 1-
RM) on HR-QoL in 135 older adults aged 65 years and over. In this study, mental 
health, physical functioning and role physical domains (as measured by the SF-36) 
improved significantly in the training group post-intervention and one year following 
  
136 
 
the intervention (role physical and physical functioning only), when training was 
maintained (455). In contrast, those who do not participate in group activities have 
been shown to be more likely to have lower mental HR-QoL (455). Further, there is 
some evidence that those who cease group activities may experience a decline in 
mental scores for HR-QoL compared to those who continue to participate in group 
based activities (455). For instance, scores for vitality and mental health domains as 
well as physical functioning and general health, decreased one year post a 12-week 
twice-weekly group-based PRT program (60% of 1-RM) in a de-training group 
(training not continued post-intervention) (455). Together, these findings indicate 
that group exercise sessions may be more beneficial for maintaining and improving 
HR-QoL in older adults compared to individual training and should be a key 
consideration when designing exercise interventions for older adults designed to 
optimise HR-QoL. 
 
Part 6. Summary 
Prevention of age-related losses in muscle mass, strength and function as well as 
cognitive function are important for older adults and the elderly, as these age-related 
losses have been shown to be associated with an increased risk of chronic disease as 
well as pathological cognitive impairment and reduced HR-QoL. Modification of 
lifestyle risk factors including physical activity and diet have both been reported to 
play a role in preventing or slowing these age-related losses. PRT is the most 
effective strategy to optimise muscle mass and strength, while challenging balance 
training is particularly effective for improving physical function and reducing falls 
risk which has been associated with reduced HR-QoL. While most previous studies 
have focused on the effects of aerobic exercise training on cognitive function, with 
some positive results, there is also a growing body of evidence that PRT can provide 
some cognitive benefits. More recently, there have been some studies which have 
reported added benefits of multi-component exercise training on cognitive function 
(and potentially HR-QoL) over single modality exercise. It has been proposed that 
this added benefit may be due to a diversity or overlap of particular underlying 
factors or mechanisms which have been related to cognitive impairment, such as 
exercise-induced changes in circulating growth, neurobiological and inflammatory 
markers. However, little research has been conducted into the effects of a multi-
  
137 
 
component training program on cognitive function and HR-QoL in healthy 
community-dwelling older adults.  
 
Nutritional modification has also been established as an effective way to improve 
cognitive function, with recent studies investigating the effects of dietary protein. 
Dietary protein is particularly important for older adults as they may require higher 
intakes to reap the same health benefits as their younger counterparts. Although these 
calls for increased protein are mainly related to its role in promoting muscle protein 
synthesis to prevent or slow age-related losses in muscle mass, emerging research 
suggests that there may be a relationship between muscle mass and strength with 
cognitive function and HR-QoL. Evidence also suggests that an increased intake of 
dietary protein may stimulate the release of various growth, neurobiological and 
inflammatory markers which have been associated with cognitive function and 
improvements in HR-QoL. Indeed, some favourable effects have been reported 
however, the majority of previous studies have focused on protein supplementation 
(dairy, whey, soy) rather than increasing the intake of protein-rich foods. This is 
important as maintaining an increased intake of protein from dietary sources is likely 
to be more feasible and sustainable compared to taking a tablet, powder or fortified 
drink each day. Thus, the combination of a multi-component exercise program and 
increased dietary protein may offer an added benefit on cognitive function and HR-
QoL (and muscle) in older adults compared to multi-component exercise alone. 
 
Lean red meat is the major source of dietary protein in Australia, however there are 
limited studies which have investigated the benefits (or adverse effects) of lean red 
meat on cognitive function. Despite this, there is a sound rationale to support the 
hypothesis that increased consumption of lean red meat may improve cognitive 
function. Red meat contains all the essential amino acids which is critical for muscle 
growth, and contains other important nutrients that have been associated with 
improvements in cognitive function, such as omega 3, zinc, vitamin B12 and vitamin 
D. While there is some evidence that an increased meat intake may have negative 
effects on cognitive health, which has largely been attributed to a high intake of 
saturated and trans fats in untrimmed or processed meats, there have been no long-
term studies which have investigated the effects of an increased dietary protein 
intake achieved through the consumption of lean red meat combined with multi-
component exercise, on cognitive function in older adults.  
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Given that a third of the global population is predicted to be aged over 60 by the year 
2050 (1) and the prevalence of dementia in Australia alone is expected to reach 1.13 
million (9), it is important to develop evidence-based prevention strategies for 
healthy older adults which can target muscle loss as well as declines in cognitive 
function and HR-QoL. Evaluating the efficacy of a lifestyle-based intervention which 
incorporates multi-component exercise and an increased intake of dietary protein, 
may inform the development of more precise nutrition and exercise guidelines for 
healthy older adults, thus preventing an increase in the burden of chronic disease in 
years to come.   
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3.1 Study Design 
The Seniors Thinking Exercise and Protein Study (STEPS) was a 24-week 
community-based RCT involving healthy community-dwelling men and women 
aged 65 years and over who were randomly allocated to either: 1) a diet enriched 
with protein achieved through the consumption of lean red meat (two 80 g servings 
of cooked red meat) three days per week in combination with a multi-component 
exercise program comprised of aerobic and PRT (Ex+Meat), or 2) a diet containing 
additional carbohydrates [≥1 serving (~75 g cooked) of rice and/or pasta or one 
medium potato] consumed on three days in combination with the multi-component 
exercise program [control exercise (Ex+CHO)]. On the non-training days, the 
Ex+Meat group were instructed to maintain their usual diet whilst those in the 
Ex+CHO group were asked to continue to incorporate larger servings of breads, 
cereals, rice, pasta and vegetables (carbohydrates) into their normal diet. While more 
specific details about the intervention are provided below in section 3.5, all 
participants were also provided with a vitamin D3 supplement (1000 IU) to be taken 
daily, and advised to maintain a healthy diet comprised of two serves of fruit, five 
serves of vegetables and two to three serves of calcium-rich foods such as dairy, 
sardines, tofu, sesame seeds, beans and kale, for the duration of the trial. The study 
was managed by the Institute for Physical Activity and Nutrition Research from the 
Burwood campus of Deakin University (Melbourne, Victoria, Australia). The study 
was approved by the Deakin University Human Research Ethics Committee (HREC 
2013–166), and registered with the Australian and New Zealand Clinical Trials 
Registry (ACTRN12613001153707). 
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The primary aim of the STEPS study was to investigate whether a modest increase in 
dietary protein achieved through the consumption of lean red meat three days per 
week, when combined with a multi-component exercise program, can enhance 
muscle mass, size and strength and cognitive function in community-dwelling older 
adults. The primary aim of this thesis was to investigate whether the intervention 
could enhance cognitive function and HR-QoL in community-dwelling older adults. 
The secondary aims of this thesis were to: 1) examine the effects of a protein-
enriched diet combined with a multi-component exercise program on various 
neurobiological and inflammatory markers, insulin like growth factor 1 (IGF-1), and 
bioavailable zinc, and 2) evaluate the association between baseline and changes in 
muscle mass, size, strength and function with measures of cognitive function and 
HR-QoL, as well as baseline and changes in various growth, neurobiological and 
inflammatory markers, and bioavailable zinc with measures of cognitive function and 
HR-QoL. 
 
Figure 3.1: Flow diagram of the 6-month intervention trial 
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3.2 Participants 
A total of 154 community dwelling adults (58 men and 96 women) aged 65 years and 
over (mean ± standard deviation [SD]: 70.7 ± 4.1 years) living in metropolitan and 
surrounding areas of Melbourne, Australia were recruited for this study.  
 
3.2.1 Recruitment 
Recruitment and testing of participants was staggered over two years (cohort 1 and 2) 
to aid in the implementation of the intervention but the start date was the same for 
each year (April). Recruitment of participants into the trial was achieved through a 
variety of methods, including advertising in local newspapers and magazines, word 
of mouth, distribution of flyers to relevant community notice boards and 
presentations at local community centres. All interested participants were screened 
for eligibility over the telephone based on the criteria outlined below.  
 
3.2.2 Screening and Eligibility Criteria  
Participant screening consisted of a four step process. First, interested participants 
were screened over the telephone (Appendix A) and were excluded based on the 
criteria outlined in Table 3.1. Participants were not excluded if they were already 
taking vitamin D supplements, but were required to substitute their supplements with 
the vitamin D that were supplied as part of the trial to ensure consistency across all 
participants in terms of the type and dose of vitamin D used. Second, eligible 
participants were required to obtain approval from their general practitioner (GP) to 
clear them of any contraindicated medical conditions to exercise, based on the 
ACSM guidelines (472) (Appendix B). In some cases (n=10), the GP requested that 
an exercise tolerance test (stress test) be conducted at the Clinical Exercise Learning 
Centre (CELC) at Deakin University, Burwood Campus, prior to granting approval 
to participate. Any specific recommendations from this assessment were given to the 
exercise trainers to help guide exercise prescription. Third, participants were asked to 
complete the Geriatric Depression Scale (GDS) and Short Portable Mental Status 
Questionnaire (SPMSQ) to evaluate whether they were cognitively intact and 
exhibited no signs of depression. Those with a score greater than six on the GDS 
and/or a score greater than two on the SPMSQ were excluded from the study as this 
has been shown to be indicative of potential depression and MCI respectively (473, 
474). For participants who were excluded based on this criteria participant consent 
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was obtained to forward their results onto their GP and they were encouraged to 
discuss these results with them in further detail. The final screening step was to 
evaluate the participants’ renal function (estimated glomerular filtration rate [eGFR]) 
from a fasted, morning blood sample. This is a sensitive measure of renal impairment 
and was assessed as the consumption of a high protein diet has been suggested to 
affect renal function in those with renal impairment (475). Those with an eGFR 
<45ml/min/1.73m
2 
were excluded and their GP notified of the result. 
 
Table 3.1 STEPS study exclusion criteria 
Exclusion criteria 
 Current participation in structured progressive resistance training >1 week in 
the past three months 
 Current participation in regular moderate intensity physical activity ≥150 
minutes/week over the last three months 
 BMI >40 kg/m2 
 Not willing to consume lean red meat or carbohydrates three times a week for 
24 weeks 
 Not willing to take a vitamin D supplement (1000 IU) each day for 24 weeks 
 Not willing to commit to attending the exercise program three times a week 
for 24 weeks 
 Currently taking insulin to treat diabetes 
 Hip or spine fracture within the last year preventing full participation in the 
PRT program 
 Renal impairment (eGFR<45 ml/min) or disease or currently on dialysis 
 Chronic liver disease 
 Coeliac disease diagnosis 
 Ulcerative colitis or Crohns disease 
 Current cancer or terminal illness 
 Osteoarthritis which restricts walking upstairs or gripping a weight 
 Taking oral corticosteroids 
 GP consent not obtained or failed to pass the exercise tolerance/stress test 
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3.3 Consent  
All participants were required to read and sign a plain language statement and 
consent form before commencement of the intervention and testing (Appendix C). 
Signed GP consent forms were also obtained for each participant. 
 
3.4 Randomisation 
Participants were randomised at the level of the individual into either the Ex+Meat 
(n= 77) or Ex+CHO group (n= 77) by an independent researcher, stratified by gender 
in blocks of four using a computer-generated random number sequence in Microsoft 
Excel. Couples were randomised to the same condition to avoid any potential 
contamination. Neither the participants nor the research staff were blinded to the 
group allocation. 
 
3.5 Intervention 
3.5.1 Exercise Program 
All participants were required to attend an individually tailored and supervised multi-
component exercise program with balance/mobility exercises, on three non-
consecutive days a week for 24 weeks. All training was conducted at local 
community health and fitness centres in metropolitan Melbourne and surrounding 
areas at no cost to the participant. Managers of targeted centres were invited to be a 
host site for the study through email and/or phone contact. A total of 15 facilities 
(Aqualink Box Hill, Aqualink Nunawading, Aquarena Aquatic and Leisure Centre, 
Ascot Vale Leisure Centre, Ashburton Pool and Recreation Centre YMCA, 
Booroondara YMCA, Cardinia Life YMCA, Carlton Baths YMCA, Caulfield 
Recreation Centre, Croydon Leisure and Aquatic Centre, Eltham Leisure Centre 
YMCA, Hawthorn Aquatic and Leisure Centre, Knox YMCA, Monash Aquatic and 
Recreation Centre and Peninsula Aquatic and Recreation Centre) agreed to take part 
in the study. Managers recommended suitable and qualified exercise training staff to 
supervise the sessions, who then attended a ‘train-the-trainers’ session which 
explained the theory/rationale behind the aims of the study, details about the required 
number of exercises, sets and repetitions and how to appropriately implement and 
progress exercises, and safety considerations. They were provided with instruction 
booklets and example programs to aid them with their supervision. They were also 
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provided with a folder containing participants’ personal details including any 
relevant medical history, the doctor’s signed consent form and exercise tolerance test 
results where applicable. Trainers were instructed to document any injuries or 
adverse events in this folder and maintained regular contact with the researchers 
through email every four weeks. All trainers were reimbursed for their time 
supervising the exercise program through the research funds.  
 
Prior to commencing the training program, participants attended an orientation 
session at their designated gym to meet their trainers, other participants and to 
become familiar with the rules, regulations and layout of the gym, as well as the aims 
of the training program and how to complete the exercise cards correctly. All 
participants were also provided with an information booklet with contact information 
and a summary of the information covered in the orientation session. 
 
Each exercise session was approximately 60-80 minutes in duration and included the 
following components: 1) a warm-up and cool-down incorporating 15-20 minutes of 
aerobic training (e.g. cycling, stepping); 2) at least two challenging balance/mobility 
and postural exercises, and 3) 30-40 minutes of moderate to high intensity PRT. All 
exercise sessions were supervised by qualified exercise trainers and were conducted 
in small groups where possible (2-10 per group). The size of each group was 
determined by the location of participants relative to the available training facilities 
(i.e. some facilities had multiple training groups as there were many [<10] 
participants living close to a given gym). 
 
The 24-week program was divided into three phases (mesocycles), each eight weeks 
in duration, whereby new aerobic, PRT, balance/mobility and core/postural exercises 
were prescribed to ensure progression and provide variety and to maintain interest. 
Where possible, exercise sessions were conducted prior to lunch or dinner so that the 
participants were able to consume their prescribed meal type as close to the training 
as possible. More specific details about each of the training components is provided 
below.  
 
3.5.2 Aerobic exercises 
Participants were prescribed 15-20 minutes of aerobic training as part of their warm-
up for each session. This included walking or running on a treadmill, stationary 
cycling, stepping or rowing exercises. The aerobic component was also permitted to 
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be completed outside the gym environment, which was recorded on the exercise card 
(Appendix D). Training intensity was monitored (self-report) using the 10-point Borg 
Rating of Perceived Exertion (RPE) scale (476). Participants attended an orientation 
session prior to beginning the exercise program in which this scale was explained. 
Participants were advised to complete aerobic training at an RPE of 5-8 which 
corresponds to ‘hard’ to ‘very hard’. It was the responsibility of the trainers to ensure 
that this level of exertion was understood by participants and maintained throughout 
the program. 
 
3.5.3 Progressive resistance training (PRT) 
Participants were prescribed seven PRT exercises during each session with three of 
these exercises focusing on the lower body, two on the arms/shoulders, one on the 
back/lower trunk and one on the chest/upper trunk. Trainers were provided with 
example programs which they could tailor to each participant based on any pre-
existing injuries and abilities. These programs included exercises such as, but not 
limited to, bridges, squats, lunges, step-ups, hip extension, hip adduction, abduction 
and flexion using machines, leg curls, calf raises, shoulder press, dips, bicep curls, 
seated row, abdominal crunches and chest press (Appendix E). Trainers were 
instructed to only substitute exercises with others that targeted the same muscle 
groups. For the first two weeks of each new program, participants were required to 
complete three sets of 12-15 repetitions with light to moderate weights to allow 
familiarisation with the execution of the exercises and equipment (free weights and 
machines) and were advised to work at an RPE of 3-4 (‘somewhat hard’) to minimise 
injury risk. For the remainder of the program participants were required to complete 
three sets of 8-12 repetitions of each exercise at an intensity of 5-8 on the 10-point 
Borg scale, which corresponds to ‘hard’ to ‘very hard’ exertion. For each exercise 
participants would begin with three sets of eight repetitions and progress to a 
maximum of 12 repetitions, increasing by one repetition each time (session). Once 
three sets of 12 repetitions could be completed with good form, the weight was 
increased and the repetitions reduced to eight.   
 
3.5.4 Core/postural and balance/mobility exercises 
Participants also completed two specific core and/or postural exercises in each 
session to improve posture and trunk stability to assist with balance and reduce the 
risk of lower back injuries. The main muscle groups targeted for these exercises were 
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the rotator cuff (supraspinatus, infraspinatus, teres minor, and subscapularis), 
scapular stabilisers (middle and lower trapezius, rhomboid major and minor, and 
serratus anterior), lumbo-pelvic-hip complex and the transverse abdominis. 
Examples of exercises included shoulder shrugs, wall push-ups and pelvic tilt. The 
number of repetitions varied for each of the exercises (e.g. rotator cuff and scapular 
stabilizers 10-15 reps and abdominals 10-50 reps) (Table 3.2).  
 
Participants were also prescribed two challenging balance/mobility exercises with a 
focus on activities of daily living. Examples of these exercises included tandem or 
single leg stance, mini trampoline jumps, heel-toe-walk and heel lifts (Table 3.3). 
Trainers were instructed to monitor participants closely when performing these 
exercises, particularly new exercises, for safety. The type of balance/mobility 
exercise and the level of difficulty regarding progression was determined by the 
trainer in accordance with each participant’s individual ability. These exercises were 
progressed in a number of ways including incorporating equipment such as Bosu 
balls, fit balls and weights, by instructing the participant to close their eyes or turn 
their head while performing the exercise, narrowing the base of support or by adding 
a secondary task. 
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Table 3.2 Structure of the STEPS program and training doses  
Mesocycle/ Microcycle Aerobic Training
† 
Moderate-intensity PRT Balance/Core Training 
Program Week Dose Intensity* Sets Reps Intensity* Sets Dose** Intensity
# 
#1 
1-2 15-20 mins 5-8 3 12-15 3-4 2 Varied 8 
3-4 15-20 mins 5-8 3 8-12 5-8 2 Varied 8 
5-6 15-20 mins 5-8 3 8-12 5-8 2 Varied 8 
7-8 15-20 mins 5-8 3 8-12 5-8 2 Varied 8 
#2 
9-10 15-20 mins 5-8 3 12-15 3-4 2 Varied 8 
11-12 15-20 mins 5-8 3 8-12 5-8 2 Varied 8 
13-14 15-20 mins 5-8 3 8-12 5-8 2 Varied 8 
15-16 15-20 mins 5-8 3 8-12 5-8 2 Varied 8 
#3 
17-18 15-20 mins 5-8 3 12-15 3-4 2 Varied 8 
19-20 15-20 mins 5-8 3 8-12 5-8 2 Varied 8 
21-22 15-20 mins 5-8 3 8-12 5-8 2 Varied 8 
23-24 15-20 mins 5-8 3 8-12 5-8 2 Varied 8 
RPE= Rate of Perceived Exertion; *Intensity measured as RPE with an RPE of 3-4 corresponding  to ‘somewhat hard’ and 5-8 corresponding to ‘hard’ to 
‘very hard’ on the 10-point BORG rating scale. ** Reps for balance (e.g. 10-20 reps or 30 - 60 seconds) and core training (e.g. 10-50 reps) varied dependent 
on the exercise being performed. 
†
Aerobic training included walking on treadmill, jogging, rowing machine, stationary bike etc. The aim was to work up to 
20 minutes of aerobic exercise by the end of the 24 weeks. 
# 
Intensity measured as rate of perceived difficulty where 8 corresponds to ‘very hard’ on a 10 
point scale. Rest interval was 1-2 minutes for PRT, 60 seconds for core exercises and 30-60 seconds for balance exercises.  
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Table 3.3 Recommended balance and mobility exercises and progressions 
 
 
 
Category 1  
 Fit Ball Exercises 
Category 2 
Standing Balance Exercises 
Category 3 
Dynamic Functional Exercises 
   
1.1  Arms folded / toes / heel lifts / leg raises 2.1  Feet together / tandem / single leg stance 3.1  Heel toe walk: forward / backward / turn 
1.2  Single / double arm raises / leg raises 2.2  Forward / backward / lateral weight shifts 3.2  Marching / hopping on foam / Bosu ball 
1.3  Forward / backward lean 2.3  Standing / squat / single leg balance -  Bosu 
3.3  Mini trampoline jumps (single/double) with 
stabilisation 
1.4  Weight shifts / dynamic ball bounce 2.4  Foot tapping / ball rolling / single leg reach 3.4  Foam / Bosu / Disc: lunge / shuffle / jumps 
   
Progressions Progressions Progressions 
a.  Unsupported a.  Unsupported a.  Introduce obstacles / turns 
b.  Increasing the amplitude of the movement b.  Unilateral arm raises b.  Increase or decrease speed of movement 
c.  With head turning c.  With head turning c.  Try a different angle / add a weight 
d.  Eyes closed 
d.  Eyes closed 
 
d.  Add a secondary task 
e.  Reduce base of support e. Reduce base of support  
f.   Add a secondary task f.  Add a secondary task  
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3.5.5 Protein-enriched Diet 
Participants who were randomised to the Ex+Meat group were asked to consume two 
portions of lean red meat (total ~220 g raw weight) on the days that they participated 
in the exercise program. The goal was to achieve a modest increase in overall dietary 
protein intake to a level of at least 1.3 grams per kilogram (g/kg) on each of the 
training days. A dose of 220 g raw weight of red meat equates to 160 g of cooked 
meat and 45 g of protein. Participants were advised to consume one portion (~80 g 
cooked serving per meal) prior to, and one after, their training session (e.g. lunch and 
dinner) as there is emerging evidence that a divided dose of protein spread 
throughout the day may be more effective for enhancing muscle protein synthesis 
than a single large dose in the evening (477). If participants had a morning training 
session or this arrangement was not suitable on a particular day, they were advised to 
consume both portions after their training session (if possible). All participants were 
asked to prepare the meals themselves, but were provided with written instructions 
and recipes to aid in consuming the red meat provided. The meat was supplied every 
four weeks by a local butcher and delivered frozen to the participants’ home, at no 
cost to the participant. The lean red meat was supplied in 110 g portion packs and 
included varied cuts of beef, lamb and veal trimmed of visible fat, with the personal 
preferences of participants taken into consideration. For non-training days, 
participants were advised to maintain their normal diet. Participants residing with 
partners were supplied with double the quantity of meat for practicality purposes in 
terms of meal preparation. Participant compliance was monitored using compliance 
diaries which were completed daily (see section 3.9). On the non-training days, 
participants were advised to maintain to their usual diet and to continue to aim for a 
healthy diet incorporating two serves of fruit and five serves of vegetables daily and 
2-3 serves of calcium-rich foods (e.g. dairy, sardines, tofu, sesame seeds, beans and 
kale).  
 
3.5.6 Carbohydrate (control) Diet 
Participants randomised to the carbohydrate (control) group were instructed to 
consume their usual diet, incorporating a minimum of half a cup of uncooked rice or 
pasta or one medium sized potato (~25-35 g of carbohydrates) three times a week on 
each of the training days. The provision of rice/pasta was designed to keep the 
participants’ dietary protein intake to less than 1.1 g/kg per day and to ensure that 
  
151 
 
both groups received the same level of attention from researchers. This was not 
designed as an isoenergetic diet, but aimed to ensure that the participants were 
ingesting enough protein to meet the Australian EAR and that their intake of protein 
was below that being provided to the red meat group. Participants in this group were 
supplied with packs of pasta and rice every 12 weeks and provided with written 
instructions and recipes to assist in maintaining this diet. Supplies for partners were 
provided where needed. Compliance with this diet was monitored using compliance 
diaries completed daily (see section 3.9). On the non-training days, participants were 
advised to continue to incorporate larger servings of breads, cereals, rice, pasta and 
vegetables (carbohydrates) and smaller amounts of protein foods (e.g. meat, fish and 
chicken) into their usual diet, and were encouraged to maintain a healthy diet that 
included the recommended amounts of fruits and vegetables and dietary calcium.  
 
3.5.7 Vitamin D supplementation 
All participants (in both groups) were required to take one capsule of vitamin D 
(1000 IU) (Ostelin, Australia) daily to try and ensure serum 25-hydroxyvitamin D 
concentrations were ≥50 to 60 nmol/L, which is the current recommended level for 
Australian adults (478). Participants were supplied with a single bottle of Ostelin 
vitamin D capsules containing 250 capsules, free of charge. At the completion of the 
study participants were asked to return their bottle and all remaining capsules were 
counted to determine compliance. 
 
3.6 Primary Outcome measures 
This thesis is one component of a larger trial where the primary outcomes were 
muscle mass, size and strength, and cognitive function. The main focus of this thesis 
is cognitive function and HR-QoL. Although it is beyond the scope of this thesis to 
detail the methods used to measure muscle mass and function, some measures of 
these outcomes will be included as an indication of whether the exercise program had 
an effect. A summary of the primary and secondary outcome measures and other 
related parameters assessed for this thesis is shown in_Table_3.4. The primary 
outcome measures for this study (thesis) were cognitive function and HR-QoL. The 
secondary outcome measures included various neurobiological and inflammatory 
markers, insulin like growth factor 1 (IGF-1), and bioavailable zinc. Changes in 
muscle mass, size, strength and function are also included as a way of describing the 
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effectiveness of the intervention on common muscle physiological and functional 
outcomes.  
Table 3.4 STEPS outcome and compliance measures 
Variables Collection Method Data Collection (week) 
Primary Outcomes 0 12 24 
Cognitive function    
 Global cognitive function CogState (all tests) x x x 
 Working Memory-Learning OCL and ONB x x x 
 Psychomotor-Attention IDN and DET x x x 
 Executive function BRIEF-A x  x 
  GMLT x x x 
 HR-QoL SF36-v2 x  x 
Secondary Outcomes     
Neurotrophic and inflammatory markers    
 Serum Zinc Fasted serum sample x x x 
 Serum VEGF Fasted serum sample x x x 
 Serum BDNF Fasted serum sample x x x 
 Serum IGF-1 Fasted serum sample x x x 
 Inflammatory markers IL-6, IL-8, IL-10, TNF-α x x x 
 Serum hs-CRP Fasted serum sample x x x 
 Adiponectin Fasted serum sample x x x 
 Homocysteine Fasted plasma sample x x x 
 Muscle strength 3-RM Leg press 
Knee extensor 
x  x 
 Muscle function 4-m walk and FSST x  x 
 Lean tissue mass DXA scan x  x 
 Fat mass DXA scan x  x 
 Percentage body fat DXA scan x  x 
Additional Measures 
 Anthropometry Height and weight x  x 
 Diet* 2 x 24hr food diary x x x 
 Physical activity CHAMPS questionnaire x  x 
 Health and medical history Lifestyle Questionnaire x  x 
 Depression and anxiety HADS x  x 
 Memory Complaints MAC-Q x  x 
 Vitamin D status Assay [25(OH)D] x  x 
* Diet assessed every 4 weeks; OCL, One card learning; ONB, One back working memory; IDN, Identification 
task; DET, Detection task; GMLT, Groton Maze Learning task; BRIEF-A, Brief Rating Inventory of Executive 
Function- Adult; SF36-v2,  Self-administered short form version 2; HADS, Hospital Anxiety and Depression 
Scale; IL, Inter-leukin; TNF-α, tumour necrosis factor; hs-CRP, high sensitivity C reactive protein; CHAMPS, 
Community Healthy Activities Model Program for Seniors; RM, repetition maximum; FSST, four square step 
test; DXA, Dual energy X-ray absorptiometry; MAC-Q: memory assessment questionnaire; 25(OH)D, 25-
hydroxyvitamin D 
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3.6.1 CogState 
Participants were required to complete a series of cognitive tests on the ‘CogState’ 
computer program at baseline, 12 and 24 weeks. The CogState Brief Battery 
computerized test (http://cogstate.com/) is a multi-faceted program which assesses a 
variety of cognitive functions including attention, processing speed, memory and 
executive function. This test is versatile as particular tests can be chosen to create a 
custom battery depending on the outcomes that are being investigated and multiple 
tests can be combined to create composite scores. This test has been found to be 
sensitive to cognitive decline in healthy adults as well as adults with MCI (121) and 
has been validated for repeated administration over multiple time points with 
minimal practice or fatigue effects even over a short time period, thus making it a 
suitable test to detect subtle changes (122, 123). It has also been found to be suitable 
for use in an older population with little computer experience and requires limited 
supervision (124). In comparison to the MMSE, another popular neuropsychological 
test, it has higher discriminant ability for differentiating between healthy individuals 
and those with MCI (124).  
 
For this study, participants were asked to complete five tasks from the CogState 
battery on a laptop with a mouse and headphones provided. The tests utilised 
included: 1) Groton Maze Learning Task (GMLT); 2) Detection task (DET); 3) 
Identification task (IDN); 4) One Card Learning Task (OCL), and 5) One Back 
Working Memory Task (ONB). Prior to each test, participants were given a verbal 
set of instructions reinforcing the instructions written on the screen. Participants were 
given a practice trial(s) prior to undertaking each test. A description of the five tasks 
is provided below. 
 
Groton Maze Learning Task (GMLT) 
The GMLT is a test designed to assess memory, executive function and problem 
solving. In this test, participants are exposed to a 10 by 10 grid (Figure 3.2). They are 
required to begin the task by clicking on the blue tile in the top left hand corner. The 
tile then lights up with a green tick before returning to blue. Participants are asked to 
find the hidden 28-step pathway through the grid (through trial and error) and to 
remember that path. Participants do this by clicking on adjacent tiles until they find 
the correct tile. Correct tiles are indicated by a green tick and incorrect tiles are 
indicated by a red cross. If an incorrect tile has been selected, participants have to 
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click on the last correct tile that they selected and select another adjacent tile. Once 
the next correct tile has been found, participants have to find the next correct tile by 
following the same process. Participants are asked to not double back along the path 
or to select tiles that are located diagonally to a correct tile. Participants complete the 
path when they reach the tile in the bottom right hand corner of the grid. Following 
this, participants are required to remember and find the same pathway using the same 
method another five times. This task is scored using the total number of errors that 
the participant makes. The lower the score, the better their performance. 
            
 
Figure 3.2: Example of the Groton Maze Learning Task 10 by 10 grid. 
 
Detection Task (DET) 
The DET is a test designed to assess processing speed and psychomotor functioning. 
In this task, participants are shown the patterned (back) side of a playing card in the 
centre of the screen. As soon as the card is flipped over to the picture side (the joker), 
participants are required to press the ‘K’ key on the keyboard (Figure 3.3). If 
participants are too quick in their response (i.e. they press ‘K’ before the card has 
turned over), they will hear an error sound. This task continues until 35 correct 
responses have been recorded. This task is scored using speed in milliseconds and 
mean reaction times for correct responses. This is averaged and normalised using a 
log10 transformation where lower scores correspond to better performance. 
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Figure 3.3: Instructions (top panel) and illustration (lower panel) of the card flipped 
to the Joker for the Detection Task test. 
 
Identification Task (IDN) 
The IDN task assesses choice reaction time and visual attention. For this task, 
participants are shown the patterned (back) side of a playing card in the centre of the 
screen, as in the DET. As soon as the card flips over to the picture side, the 
participants have to decide as quickly as they can, whether the card is red. If the card 
is red, participants press the ‘K’ key to indicate ‘yes’. If the card is black, they press 
the ‘D’ key to indicate ‘no’, the card is not red (Figure 3.4). The task ends after 30 
correct responses have been recorded. This task is scored using speed in milliseconds 
and mean reaction times for correct responses. This is averaged and normalised using 
a log10 transformation where lower scores correspond to better performance. 
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Figure 3.4: Instructions (top panel) and illustration (lower panel) of the card flipped 
to the red card for the Identification Task test.  
 
One Card Learning Task (OCL) 
The OCL is designed to assess attention and visual recognition memory. Participants 
are shown the patterned (back) side of a playing card in the centre of the screen. 
When the card is flipped over, the participants have to indicate whether or not they 
have seen that card before in this task, by pressing the corresponding ‘yes’ and ‘no’ 
keys on the keyboard (Figure 3.5). If the participants answer incorrectly, an error 
sound will be heard. In this task, six cards are randomly drawn from the deck and 
repeated throughout the task, and the first response will always be ‘no’ as there has 
been no previous card shown to the participant. This task ends after 88 trials. This 
test is scored using the proportion of correct responses, using an arcsine square-root 
transformation to normalise the data. Higher scores correspond to better 
performance. 
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Figure 3.5: Instructions (top panel) and illustration (lower panel) for the One Card 
Learning Task. 
 
One Back Working Memory Task (ONB) 
The ONB is a similar task to the OCL and assesses working memory and attention. 
Participants are shown the patterned (back) side of a playing card in the centre of the 
screen. When the card is flipped over, participants have to indicate whether or not 
that card is the same as the card immediately prior to that card, using the appropriate 
‘yes’ and ‘no’ keys on the keyboard. If the participant incorrectly identifies the card, 
an error sound will be heard. The first response is always ‘no’ as there is no card 
prior to the first card. The task ends after 30 correct responses have been recorded. 
This test is scored using the proportion of correct responses, using an arcsine square-
root transformation to normalise the data. Higher scores correspond to better 
performance. 
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Figure 3.6: Instructions (top panel) and illustration (bottom panel) for the One Back 
Working Memory Task.  
 
Composite Scores 
Raw scores were transformed into a z-score using the mean and standard deviation of 
the total sample in the study at baseline. Three composite variables were created. The 
combined cognitive scores (global cognitive function) for each participant was 
calculated by averaging the z-scores from all tests. The working memory-learning 
composite scores were calculated by averaging the z-scores from OCL and ONB 
measures. The psychomotor-attention composite scores were calculated by averaging 
the z-scores from IDN and DET measures. Higher scores on these composites 
indicate better performance and cognitive function (479). 
  
3.6.2   Behaviour Rating of Inventory of Executive Function-Adult Version 
(BRIEF-A) questionnaire 
Participants were also required to complete a self-report of executive function at 
baseline and 24 weeks using the Behaviour Rating of Inventory of Executive 
Function-Adult Version (BRIEF-A) questionnaire. This is a self-report measure 
comprised of 75 questions. These questions make up nine non-overlapping 
theoretically and empirically derived clinical scales that provide a measure of various 
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aspects of executive functioning. These scales include: inhibit, self-monitor, 
plan/organize, shift, initiate, task monitor, emotional control, working memory, and 
organization of materials (480). For each question, a response of never, sometimes or 
often was recorded for how often in the last month each behaviour listed had been a 
problem. Each response corresponds to a number score of one to four respectively 
and these were summed to provide scores for each of the subdomains. The inhibit, 
shift and emotional control subdomains were summed together to provide a 
behavioural regulation index (BRI) score and the other subdomains were summed to 
provide a metacognition index score (MI) (480). Lastly, the BRI and MI were 
summed to provide an overall global executive composite (GEC) summary score 
(480). 
 
3.6.3 Health-related Quality of Life (HR-QoL) 
To assess HR-QoL, the self-administered Short Form (SF36) (version 2) 
questionnaire, with permission from the Medical Outcomes Trust (Boston, MA, 
USA), was administered at baseline and week 24. This measure is widely used to 
assess HR-QoL across mental and physical domains and available in multiple 
languages. This questionnaire consists of 36 items which make up eight subscales 
shown in Figure 3.7: physical functioning, bodily pain, general health, vitality, social 
functioning, mental health and role-emotional and role-physical, which refer to 
problems in work-related or daily activities resulting from physical or mental health 
(481, 482).  
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Figure 3.7: Derivation of subscales for SF-36v2. Taken from Ware, J. (483). 
 
Scores for the eight subscales were calculated according to the summative method of 
calculating the mean of the items for each subscale. Subscales where more than 50% 
of the items were missing were not calculated. The SF36-v2 results were reported 
using norm-based scores using previously published Australian data (484). The data 
was normalised to reported data from the 2004 South Australian Health Omnibus 
survey to allow for appropriate and meaningful comparisons for changes in scores 
across the eight subscales (484). This allows for the changes in subscales to be 
assessed on the same scale and will account for cultural differences in various 
populations with regard to the meaning of HR-QoL.  
 
The eight subscales can be converted into two measures of overall physical and 
mental health, known as the physical component summary scale (PCS) and mental 
component summary scale (MCS). The PCS and MCS were calculated based on a 
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factor analysis of the eight domains among participants in the 2004 South Australian 
Health Omnibus Survey (484). The use of norm-based weights gives each domain 
score a mean of 50 and a standard deviation (SD) of 10, allowing change in scores to 
be assessed on a comparable scale. 
 
3.7 Secondary Outcome Measures 
Secondary outcome measures assessed include various neurobiological and 
inflammatory markers, IGF-1, homocysteine and bioavailable zinc, as measured in 
serum or plasma, and measures of muscle strength and function, muscle mass and fat 
mass. 
 
3.7.1 Biochemical and hormonal markers 
All participants were required to attend a commercial pathology clinic at baseline, 12 
and 24 weeks to provide a 24-hour urine sample and a fasted morning (8-10am) 
venous blood sample. All blood was sent to a central laboratory that is a National 
Association of Testing Authorities Royal College of Pathologists Australasia 
accredited pathology laboratory. High sensitivity C-reactive protein (hs-CRP) was 
measured by an immunoturbidimetric assay from Roche Diagnostics, Mannheim. 
Serum creatinine, urea and albumin were analysed using standardized techniques. 
Glomerular filtration rate (eGFR) was calculated using the participants’ serum 
creatinine, age and gender in accordance with the appropriate Chronic Kidney 
Disease Epidemiology Collaboration 9CKD-EPI formula as outlined by Johnson et al 
(485). Five (1 ml) serum aliquots were also collected and stored at -80°C so that the 
following parameters could be assessed in a single batch at the completion of the 
study: serum IGF-1, 25-hydroxyvitamin D, BDNF, VEGF, adiponectin and a battery 
of pro-inflammatory and anti-inflammatory cytokines, including IL-6, interleukin-8 
(IL-8), TNF-α and interleukin-10 (IL-10). Serum bioavailable zinc was also 
measured. A brief description of the methodology related to each of these measures 
is provided below.  
 
 Serum interleukin (IL)-6 (IL-6), IL-8, IL-10 and tumor necrosis factor-
alpha (TNF-α): were measured using the Milliplex T Cell high-sensitivity 
human cytokine panel (Millipore Billerica, MA USA) as per manufacturers’ 
recommendations with an intra-assay % coefficient of variation (CV) of 5.9-
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11.7% and an inter-assay % CV of 7.3-15.7%. Serum adiponectin was assayed 
using a Procarta kit (Affymetrix Fremont CA USA) with an intra-assay % CV of 
6.8% and an inter-assay % CV of 8.4%. Any measure falling below the 
detection threshold were assigned the value for the assay’s lowest detectable 
limit (IL-6, 0.16 pg/ml, IL-8, 0.06 pg/ml; IL-10, 0.40 pg/ml; TNF-α, 0.07 pg/ml; 
adiponectin, 0.20 μg/ml). 
 
 Serum concentrations of BDNF and VEGF: were determined by enzyme-
linked immunosorbent assay (ELISA) using a commercially available ELISA set 
(Duo Kit ELISA; R & D Systems, Minneapolis, MN, USA) as per 
manufacturer’s instructions with an intra-assay % CV of 3.9-5.9% and an inter-
assay % CV of 4.4-14.7%. All inflammatory and neurological markers were 
analysed off-site at Cardinal Bio-Research (New Farm, QLD, Australia). Any 
measure falling below the detection threshold was assigned the value for the 
assay’s lowest detectable limit (VEGF, 1.6 pg/ml; BDNF, 0.22 ng/ml). 
 
 Serum IGF-1: was determined using the Immulite 2000 IGF-1 
chemiluminescent immunometric assay (Siemens Healthcare Diagnostics, IL, 
USA), with an intra-assay % CV of 3.1 and inter-assay % CV of 6.2. Serum 
Vitamin B12 was measured using the ADVIA Centaur VB12 competitive 
immunoassay (ADVIA Centaur, Siemens, NY USA), a competitive 
immunoassay which uses direct chemiluminescent technology. The intra-assay 
% CV was 3.5 and the inter-assay % CV was 4.8. Serum IGF-1 was analysed at 
Melbourne Health Shared Pathology Service, Royal Melbourne Hospital 
(Parkville, Victoria, Australia). 
 
 Serum folate: was measured at baseline only using the ADVIA Centaur Folate 
competitive immunoassay (ADVIA Centaur, Siemens, NY USA), which uses 
direct chemiluminescent technology. The intra-assay % CV was 6.1 and the 
inter-assay % CV was 6.2. Folate was analysed at Melbourne Health Shared 
Pathology Service, Royal Melbourne Hospital (Parkville, Victoria, Australia).  
 
 Serum 25-hydroxyvitamin D: was assessed using a validated liquid 
chromatography/mass spectrometry/mass spectrometry (LC/MS/MS) method on 
an Applied Biosystems 4000 Q Trap LC/MS/MS system (RDDT Laboratories, 
Bundoora, VIC, Australia). The intra-assay % CV was 3.9% and the inter-assay 
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% CV was 2.8%.  Samples were foil-wrapped until measured to protect from 
light damage. Serum 25OHD was analysed at Monash Health (Monash Medical 
Centre, Clayton, VIC, Australia). 
 
 Plasma homocysteine was determined using the Immulite 2000 competitive 
immunoassay (Siemens Medical Solutions Diagnostics, CA USA) with an inter-
assay % CV of 9.9 and an intra-assay % CV of 8.1%. Plasma homocysteine was 
analysed at Monash Health (Monash Medical Centre, Clayton, VIC, Australia). 
  
 Serum bioavailable zinc: was measured using flame atomic absorption 
spectrophotometry by direct aspiration (Varian SpectrAA-800) at the 
Department of Human Nutrition, University of Otago, New Zealand. The inter-
assay % CV was 4.9%. 
 
 APOE- ε4: was assessed through a venous blood sample. Genetic determination 
of ApoE allelic status (APoE-ε3 [rs7412] and APoE-ε4 [rs429358]) was 
performed using a polymerase chain reaction (PCR)-based assay designed with 
the MassARRAY Assay Design 4.0 software (Agena Bioscience). The initial 
PCR step involved 45 cycles with an annealing temperature of 56
o
 C. The PCR 
products were treated with shrimp alkaline phosphatase for 15 minute at 37
o
 C 
and denatured at 85
o
 C for 5 minutes. The final iPLEX extension step involved 
40 cycles of lots of five cycles between 52
o
 C and 85
o
 C. The resulting iPLEX 
extension products were desalted using SpectroCLEAN resin (SEQUENOM, 
San Diego, USA), then spotted on SpectroCHIPs GenII (SEQUENOM, San 
Diego, USA) and analysed with the MassARRAY Analyser Compact MALDI-
TOF MS (Agena Bioscience, San Diego, USA). Participants were categorised as 
possessing at least one copy of the ε4 allele from the APOE gene (ε4 carrier) or 
no copies of this polymorphism (non-ε4). 
 
3.7.2 Muscle Function 
Gait speed was assessed by the 4-metre walk test. This test has been shown to have a 
high retest reliability in healthy older adults (intraclass correlation coefficient [ICC]= 
0.96-0.98) (486). The 4-metre walk test requires participants to walk in a straight line 
at their normal walking speed across four metres. Participants were instructed to 
begin walking at their normal speed two metres prior to and continue walking two 
metres past the 4-metre marker to account for acceleration and deceleration, ensuring 
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that a measure of usual walking speed is measured. This test was timed by the Swift 
Speedlink Performance Equipment systems (http://spe.com.au/). Participants were 
given one practice trial before completing two test trials. The fastest time (to the 
nearest millisecond) was recorded. The short-term CV for repeated measurements of 
this test in our laboratory was 0.67%. 
 
The Four Square Step Test (FSST) is a test designed to assess dynamic standing 
balance and stepping speed in four different directions (487). This test has been 
shown to have good retest reliability (ICC= 0.98) and high interrater reliability 
(ICC= 0.99) (487). As shown in Figure 3.8, two canes are positioned perpendicular 
to each other on the ground to create four squares. For this test, participants were 
required to step forward, sideways and backwards over the canes as quickly as 
possible, moving firstly in a clockwise direction and then counter-clockwise 
direction. The time (in seconds) to complete the test was recorded using a stopwatch. 
Participants were given one practice trial before completing two test trials and the 
fastest time taken to complete the sequence was recorded as the final score. The trial 
was not counted if both feet did not touch the ground in each square or if the 
participant hit one of the canes. The short-term CV for repeated measurements in our 
laboratory was 4.81%. 
                                           
Figure 3.8: Set up and instructions for the Four Square Step Test 
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3.7.3 Muscle Strength 
Muscle strength was assessed by a 1-RM leg press estimated from a 3-RM test 
performed on a leg press weight machine (Calgym Synergy Omni leg press). 
Participants initially completed 8-10 repetitions with a light load to warm up 
(estimated 50% of 3-RM). Following a brief two minute rest, a further 6-8 repetitions 
were then performed with a heavier load which was increased incrementally until 
only three repetitions with the correct technique could be performed. The weight 
prior to a participant failing to complete three repetitions with correct form was taken 
as the 3-RM result. The following formula, developed by Wathen (Wathen 1994), 
was then used to predict one-repetition maximum strength:  
 
1RM = 100 x [3RM load] / (48.8 + 53.8 x e
(-0.075x3)
).   
 
The short-term CV for repeated measurements of this test in our laboratory was 
2.04%.  
 
3.7.4 Body composition 
Total body and regional (arms and legs) lean tissue mass, fat mass and percentage 
body fat was assessed by dual energy x-ray absorptiometry (DXA) conducted on the 
Lunar Prodigy DXA scanner (Lunar Prodigy, GE Lunar Corp., Madison WI, 
software version 12.30.008). Appendicular lean mass was calculated as the sum of 
arms and legs lean mass. Daily Quality Assurance (QA) scans using phantom 
scanning procedures were conducted every day prior to testing. All participants were 
instructed to remove all clothing (including bra but excluding underwear) and 
removable jewellery, and to change into a gown provided. All scans were conducted 
with the participant supine and in the centre of the scanning bed unless otherwise 
stated. All participants were instructed to keep as still as they could throughout each 
scan. Notes were recorded for unusual positioning and the same researcher scanned 
participants at follow-up where possible to ensure the same positioning and minimise 
inter-rater variability.  
 
A total body scan was performed ensuring all areas of the body were inside the 
scanning regions. Participants were positioned supine with their palms flat on the 
bed, so that the top of their head was approximately 5 cm below the top of the 
scanning region. For individuals who did not fit within the scanning region, the 
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medial side of their hands were placed on the bed or the left half of the body was 
scanned only. For analysis, the scan was divided into sub-regions as per the 
definitions below (Figure 3.9). 
 
 
 Head: Cut line placed just below the chin. 
 Left and right ribs: Cut lines positioned lateral to the spine and just superior to the 
pelvis. 
 Left and right arms: Cut lines were positioned on the most medial border of the 
humeral head. It was also ensured that no soft tissue from other regions 
overlapped with this region. 
 Left and right legs: Cut lines were angled mid-way through the femoral neck. All 
leg soft tissue was included in this region. 
 Pelvic: Cut lines created a triangular region by intercepting the mid-point of the 
femoral neck and being placed just above the most superior point of the pelvis. 
 
 
Figure 3.9 Sub-regions within total body DXA scan. 
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 3.8 Other measures 
3.8.1 Anthropometry  
Height, without shoes, was measured using a stadiometer to the nearest 0.5 cm. 
Weight was measured with minimal clothing (gowns) using calibrated electronic 
digital scales, to the nearest kg (Seca, model 708).  
 
3.8.2 Diet 
Participants were required to complete two 24-hour diet history records (Appendix F) 
on two allocated days each month for the duration of the study. These days included 
one training day (when participants consumed red meat or additional carbohydrates) 
and a non-training day. Participants were required to provide as much detail as 
possible regarding brand names, cooking methods and recipes for foods and 
beverages consumed in the past 24 hours. The 4000 for Health Food Model Booklet 
(published by the Victorian Government Department of Human Services, Melbourne, 
Victoria, 2009) and other household measures including measuring cups, plates, 
bowls and glasses were used to assist in estimating food portion sizes. Researchers 
checked records for completeness and clarified any missing or ambiguous data at 
each time point. Information from these diet history records were used to assess total 
daily dietary energy (kilojoules, kJ) and nutrient intakes including total fat (g), 
saturated fat (g), protein (g and g/kg), carbohydrates (g), calcium (mg), zinc (mg) and 
iron (mg) and percentage of total energy from carbohydrates, fat and protein using 
Foodworks 8 (Foodworks, Xyris Software, Highgate Hill, Australia). 
 
3.8.3 Physical activity 
Habitual physical activity was assessed using the Community Healthy Activities 
Model Program for Seniors (CHAMPS) self-report questionnaire. This is designed 
specifically to assess the total time spent (hours per week) performing leisure and 
recreational physical activities in older adults and has previously been found to be 
reliable, valid and sensitive to change in this demographic (488). Participants were 
required to record the weekly frequency and duration of participation in various 
physical activities in a ‘typical week’ with consideration of the preceding four weeks. 
The results are reported as estimated kilojoules (kJ) per week for total physical 
activity and moderate-vigorous activity. 
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3.8.4 Health and medical history 
Health and medical history was assessed using a lifestyle questionnaire (Appendix 
G). This collected information on alcohol intake, previous medical history (including 
cardiovascular disease risk) and dosage of current prescription and non-prescription 
medications. Information regarding conditions such as high blood pressure, 
stroke/hemiplegia, AD, Parkinson’s disease, heart disease, cancer, angina, heart 
attack, impaired memory, epilepsy, neurological/ brain damage, vitamin D 
abnormality, diabetes type 1 and diabetes type 2, were also collected. Typical weekly 
alcohol intake (g/d) was also recorded and was calculated using Foodworks 8 
(Foodworks, Xyris Software, Highgate Hill, Australia). 
 
Medications were classified into the following categories: anti-hypertensives 
(angiotensin converting enzyme inhibitors, AT1-receptor blockers, calcium channel 
blockers, angiotensin II antagonists, beta-blockers, class III beta blocker, anti-
arrhythmic drugs and anti-angina drugs), lipid-lowering (hypolipidemic agents), 
nonsteroidal anti-inflammatories (histamines), anti-depressants (including anxiety 
medication and sleeping agents), thiazide diuretics, steroidal anti-inflammatories, 
pain relief, supplements (vitamins, minerals, fatty acid supplements and herbal 
agents) and other (antibiotics, analgesics, hyperacidity/ digestive, gout, erectile, 
eye/ear drops, vitamin B12, Parkinson’s disease and other central nervous system 
medication, anticonvulsants, antiemetics and laxatives). Participants were also 
required to report any changes to medications or any new medications throughout the 
duration of the study.  
 
3.8.5 Depression and Anxiety 
Depression and anxiety can impact on cognitive function and hence were measured 
for inclusion in analyses as a potential confounding variable. The Hospital Anxiety 
and Depression Scale (HADS) assessed depression and anxiety at baseline and week 
24. This is a 14-item self-report questionnaire that is divided into two subscales 
where seven questions assess cognitive and emotional aspects of anxiety and the 
other seven questions evaluate cognitive and emotional aspects of depression (489). 
The HADS has previously been reported to have good sensitivity and specificity 
(0.80), and have moderate to strong correlations between 0.49 and 0.83 with other 
popular tests (490). Participants respond by indicating their response on a four-point 
likert scale. The value of each response is between zero and three and these scores 
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are summed together to form the two domains. Higher scores indicate a greater 
severity of anxiety or depression (489).  
 
3.8.6 Memory Complaints 
The Memory Assessment Questionnaire (MAC-Q) comprises six questions related to 
memory functioning in everyday situations. Participants were asked to compare and 
rate their current memory ability to when they were aged 40. The total score ranges 
from seven to 35, where greater scores indicate subjective memory loss. Scores 
greater than or equal to 25 have been found to be suggestive of age-associated 
memory impairment (491).  
 
3.9 Compliance measures 
3.9.1 Exercise Compliance  
Compliance with the exercise program was monitored via the six exercise cards (one 
exercise card per four weeks of training). Participants were required to document the 
duration and RPE for the aerobic component as well as the amount of weight lifted 
for each exercise along with the repetitions, sets and RPE for all strength and balance 
exercises, for every training session. Moreover, at each training session the exercise 
trainers documented attendance/non-attendance for each participant and contacted 
the research staff if participants missed multiple sessions consecutively. The exercise 
cards were collected by research staff from each health and fitness centre every four 
weeks throughout the intervention. Compliance was calculated by dividing the 
number of sessions attended throughout the 24 weeks by the number of sessions 
prescribed and then multiplying by 100. Overall compliance for the study was 
calculated as the average across all participants.  
 
3.9.2 Red meat and Carbohydrate Compliance 
Compliance diaries (calendars) (Appendix H) were utilised to monitor participant 
compliance with the red meat or carbohydrate diets. These compliance diaries were 
completed daily throughout the duration of the 24-week period. Those randomised to 
the Ex+Meat group recorded how many serves of meat they consumed at lunch 
and/or dinner and indicated whether or not this was a training day. Similarly, those 
randomised to the Ex+CHO group recorded how many serves of pasta, rice or potato 
they ate on each of the days of the week, indicating whether or not it was a training 
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day. Participants posted a completed compliance diary sheet to the researchers at the 
end of each 4-week period and compliance was calculated by dividing the number of 
serves consumed by the number that should have been consumed. Overall 
compliance was calculated as the average across all participants. 
 
3.9.3 Vitamin D Compliance 
Compliance with taking the vitamin D supplements was assessed by counting 
returned tablets at the end of the 24-week period and dividing this number by the 
number of supplements that should have been taken (day one was counted as the first 
day of the intervention while the last day was follow-up testing). 
 
3.10 Adverse events 
At the end of each 4-week period participants were required to document any 
exercise-related adverse events including injuries related to the exercise program 
(Appendix I). An adverse event was defined as an intervention-related event 
resulting in absence from, or modification to, the exercise program. All exercise-
related adverse events forms were collected monthly so that the researchers were 
able to follow-up on any adverse events.  
 
3.11 Sample size calculations 
The number of participants required for STEPS was based on power calculations for 
the expected changes in total body lean mass, lower limb muscle strength and 
cognitive function, particularly executive function. Based on a previous 4-month 
RCT conducted in community-dwelling older women (72), it was estimated that 152 
older adults in each group would provide >80 % power (P<0.05, two tailed) to detect 
a 0.5 kg and 18% difference for the change in total body lean mass and leg muscle 
strength between the Ex+Meat and Ex+CHO group, assuming a standard deviation of 
0.9 kg and 30 %, respectively. This calculation also allowed for attrition rates up to 
20%. 
 
With regard to cognitive function, it was difficult to calculate the sample size for this 
thesis as this was the first study to investigate the effects of exercise combined with a 
protein-enriched diet on cognitive function compared to exercise alone in older 
adults, at the time the study was designed. However, a large number of studies have 
reported improvements in cognitive function following exercise-related 
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interventions. For instance, interventions assessing the effects of aerobic training, 
PRT or their combination on cognitive function have reported moderate effect sizes 
on cognitive function (d= 0.41 to 0.59) (36, 356, 492) particularly executive function 
and processing speed.  
 
Whether increased dietary protein can improve cognitive function remains uncertain 
due to the limited data available, but it was hypothesised that a modest increase in 
dietary protein (1.3 g/kg/day) combined with exercise would result in a moderate 
effect (f = 0.20). Using scores on the CogState GMLT (a measure of executive 
function) and the Detection Task (a measure of reaction time and processing speed) 
(mean ± SD: 64±18 and 2.56±0.07 respectively), from a pilot study conducted in 72 
healthy older adults aged 65 years and over, it was anticipated that a sample size of at 
least 140 would provide 80 % power with an alpha value set at less than 0.05 (two-
tailed), to determine a moderate effect size (f = 0.20) assuming a 0.6 correlation 
among repeated measures. Although a larger effect may be observed, the estimate 
based on this conservative effect size suggests that with 76 participants in both the 
Ex+Meat and the Ex+CHO group (allowing for 20% attrition), this study will be 
adequately powered to detect a moderate effect (f= 0.20). 
 
This study is also the first to investigate the effects of exercise combined with a 
protein-enriched diet on HR-QoL. However, there are limited studies which have 
demonstrated an effect of dietary factors on HR-QoL. For instance, a 3-week RCT in 
23 healthy men aged 19-31 years found a difference between men on a high-protein 
diet (3.0 g protein/kg body weight) compared to men on a usual protein diet (1.5 g 
protein/kg body weight) on PCS (mean change -0.6) and MCS (mean change +0.2) 
measures of the SF36-v2 (55). Further, a 12-week RCT conducted in 89 pre-frail 
women aged 70 years and over found that strength and balance exercises when 
combined with cooking classes with a focus on education regarding protein and 
vitamin D, improved QoL outcomes compared to exercise alone and controls (458). 
With regard to exercise, one 12-week RCT in older adults found a difference 
between the strength training (three days a week) and the control group for 
satisfaction with life (mean change -2.17 compared to 2.38) (493). Based on these 
limited findings, a moderate to large effect size (0.31 to 0.68) was calculated for the 
effects of a protein-enriched diet combined with a multi-component exercise 
program on HR-QoL. Based on a conservative estimate of 0.31, it is estimated that 
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with 49 participants in each group (allowing for 20% attrition) we will have 80% 
power to detect a moderate effect (0.31) after 24 weeks, with an alpha value set at 
less than 0.05 (two-tailed). 
 
3.12 Statistical analyses 
Detailed information about the statistical analysis will be provided within each of the 
results chapters (Chapter 4 and 5). Briefly, statistical analyses were conducted on an 
intention-to-treat (ITT) basis using STATA statistical software version 14.0 
(STATA, College Station, TX, USA). Wherever possible, all data from every 
randomised participant was included in analyses. Data from participants who 
withdrew from the exercise program or intervention was included if end point 
measures were obtained.  
 
3.13 Intellectual property and funding 
All data that was collected was de-identified and stored in password protected files 
and locked filing cabinets, and complies with Victorian and Commonwealth privacy 
laws. This study was funded by a grant provided by Meat and Livestock Australia 
(MLA).  
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Chapter 4 
 
Effects of a protein-enriched diet with lean red meat combined with 
multi-component exercise on cognitive function, neurobiological and 
inflammatory markers in community-dwelling older adults, compared to 
multi-component exercise alone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
175 
 
4.1 Introduction  
Healthcare burden associated with chronic disease is projected to increase in coming 
years due in part to the global ageing population (1). This increase in chronic disease 
has been proposed to be related, at least in part, to age-related losses in muscle mass, 
strength and function (3) as well as a decline in cognitive function, which can impact 
on activities of daily living and HR-QoL. Dementia is the leading cause of disability 
in older Australians and ranks third for cause of disability burden overall (2). In 
2009-10, the total expenditure on the Australian aged care system related to dementia 
alone, was estimated at $4.9 billion (2) and it is expected that within the next 20 
years, dementia will rank third for the greatest source of health and residential aged 
care spending (137). Although there is no one single cause of cognitive decline, there 
is evidence that physical activity and dietary habits may play a role in reducing the 
risk of age-related reductions in cognitive function. More recently, muscle loss has 
also been associated with an increased risk for cognitive decline and dementia (3, 
15). Together, this suggests that the maintenance of muscle through the modification 
of exercise and dietary factors may assist in preventing cognitive and functional 
decline, and lessen the future burden on healthcare.  
 
Previous research has shown that regular exercise training including aerobic training 
and PRT, can improve cognitive function in older adults (22, 23, 35, 161, 276, 327). 
However, many questions still remain with regard to the optimal dose (intensity, 
duration and frequency) of training required to elicit such benefits. There is also 
emerging evidence that multi-component training programs which incorporate a 
combination of exercise modalities, can improve cognitive function with the added 
advantages of improving muscle mass, strength and function (361, 363, 367). 
Whether multi-component training is more effective at improving cognitive function 
compared to single modality training remains uncertain, but it has been suggested 
that the beneficial effects of multi-component training may be related to differing 
effects of each modality on the underlying mechanisms important for multiple 
cognitive domains (367). Previous research has indicated that some of the cognitive 
benefits of aerobic and PRT may be related to exercise-induced changes in 
circulating levels of various growth and neurobiological factors such as IGF-1, 
BDNF and potentially VEGF, as well as markers of chronic low grade systemic 
inflammation (73, 74, 349, 385). However, the different exercise modalities may also 
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have other divergent effects on physiological mechanisms associated with cognitive 
change, which may lead to greater benefits in different cognitive domains. For 
instance, the cognitive benefits associated with aerobic exercise have been suggested 
to be due largely to an increased cerebral blood flow (337, 371) whereas there is 
emerging evidence that exercise-induced gains in muscle mass and/or strength may 
mediate improvements in cognitive function and brain health (3, 14, 15, 243). For 
instance, a six month RCT conducted in older adults with MCI found that 
improvements in muscle strength following high-intensity PRT on two to three days 
a week, mediated improvements in cognitive function as measured by the 
Alzheimer’s disease Assessment Scale-cognitive subscale (ADAS-Cog) (243). This 
suggests that multi-component exercise training which can induce changes in 
multiple mechanisms important for cognitive function and targets improvements in 
fitness, muscle health and function, may be more efficacious than a single modality 
of exercise for improving cognitive function in older adults.  
 
There has been considerable research conducted into the effects of various dietary or 
nutritional factors on cognitive function, but the evidence with regard to the optimal 
dietary approach to improve or prevent cognitive decline remains uncertain. The 
Mediterranean diet, characterised by a high intake of fruits, vegetables, legumes, nuts 
and fish, a high intake of unsaturated fatty acids, has been associated with a reduced 
risk of cognitive decline when compared with a Western-style diet, which is 
characterised by a high intake of animal and saturated fats, refined sugars and lower 
intakes of fruits and vegetables (39-44). More recently, there has been emerging 
evidence that increased dietary protein may play a role in maintaining or improving 
cognitive function (52, 54, 55). While there is some promising data from intervention 
trials showing that protein supplementation (dairy, soy, whey) may have a positive 
effect on certain cognitive domains (e.g. memory) in older adults (45-51, 53, 251, 
256, 258, 272, 277), there are few studies which have investigated the effects of an 
increased intake of protein-rich foods on cognitive function (52, 54, 55). One large 
prospective study conducted in 937 cognitively normal older adults aged 70-89 years 
found that dietary patterns with higher percentages of daily energy intake from 
protein (>20%) was associated with a 21% reduced risk for MCI and dementia 
(upper quartile 0.79 [0.52-1.20]) (247). However, a limitation of this study is that 
they did not specifically examine the effects of different types of dietary protein (e.g. 
red meat, processed meat, vegetable protein) on cognitive function.  
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In Australia, the major source of dietary protein is red meat however, there are very 
few studies which have investigated the effects of animal protein on cognitive 
function. One 3-week RCT in 23 healthy young men aged 19-31 years, found that a 
high animal protein (low fat pork, beef, chicken, milk and cheese) diet (3.0 g/kg) was 
associated with improvements in reaction time and a decrease in errors, compared to 
the usual protein group (1.5 g/kg) (55). No significant differences were observed 
between groups for sustained attention or global cognitive function, although the 
high protein group had a significant improvement in global cognitive function (55). 
Another 12-week intervention study conducted in 31 older adults aged over 60 years 
living in aged care facilities which substituted four meals per week with chicken 
(25.2 g protein) or pork (28.1 g protein) as the main protein source, found that the 
chicken group had higher (23%) verbal memory scores after six weeks when 
compared to the pork group (54). However, there were no improvements in any other 
cognitive domain including executive function and short term memory, for the pork 
group (54). Despite these encouraging findings, questions still remain as to whether 
greater red meat intake is associated with beneficial or adverse effects on cognitive 
function in older adults, given that there are some concerns that increased red meat 
intake might increase inflammatory markers and CVD risk. However, there is a 
rationale to support a beneficial effect of lean red meat. In addition to containing all 
the essential amino acids which provide the building blocks for muscle, lean red 
meat has the added advantage of containing other important nutrients such as omega-
3 fatty acids, iron, zinc, vitamins B12 and B6 and possibly vitamin D, all of which 
have been associated with benefits for cognitive function (58, 59).  
 
At present, the precise underlying mechanism(s) for the potential effects of increased 
protein on cognitive function remains uncertain. However, there is evidence that 
dietary protein can stimulate the release of various growth, neurobiological and 
inflammatory markers which have been associated with improved cognitive function 
(61). For instance, it has been shown that dietary protein can modulate levels of IGF-
1 (308), however the effects of protein on BDNF, VEGF and various inflammatory 
markers are less well understood. A previous 4-month study conducted in healthy 
older women which examined the effects of PRT combined with increased lean red 
meat intake consumed on six days a week, found a 10% greater increase in IGF-1 
and a 16% reduction in the level of IL-6, a pro-inflammatory marker, as well as 
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increases in muscle mass and strength, compared to PRT alone (72). While these 
findings support the notion that the combination of increased dietary protein via lean 
red meat and exercise may have added benefits for improving some of the factors 
underlying improvements in cognitive function, such a high consumption of red meat 
(well above the current recommended dietary guidelines) is neither feasible nor 
practical in the ‘real-world’. In Australia, the current dietary guidelines recommend 
no more than 455g (3-4 serves) of red meat per week  (63), but whether this level of 
intake can increase dietary protein intake to a level sufficient for enhancing the 
responses of skeletal muscle to PRT and provide added benefits for cognitive 
function is unknown. 
 
Given the potential link between muscle and cognitive function, along with some 
promising evidence to support a positive effect of multi-component exercise 
programs and increased dietary protein on cognitive function in older adults, 
combining these two approaches may provide some added cognitive benefits 
compared to exercise alone. However, to our knowledge, there are no long-term 
intervention studies which have investigated whether increased dietary protein 
achieved through the consumption of lean red meat can enhance the effects of a 
multi-component exercise program on cognitive function and various growth, 
neurobiological and inflammation markers associated with both cognitive and muscle 
health, in community-dwelling older adults. 
 
4.2 Aims and Hypotheses 
The aim of this 24-week RCT was to investigate the effects of a multi-component 
exercise program comprised of aerobic, PRT and balance/mobility training 
performed three days a week combined with either a protein-enriched diet achieved 
through consuming lean red meat on training days, or carbohydrates (control), on 
cognitive function in older community-dwelling adults. Secondary aims were to: 1) 
investigate the effect of the intervention on various growth, neurobiological and 
inflammatory markers and bioavailable zinc which has been related to cognitive 
function, and 2) conduct an exploratory analysis to evaluate whether baseline or 
changes in the various growth, neurobiological and inflammatory markers, and 
bioavailable zinc as well as muscle mass, strength and function, were associated with 
changes in cognitive function in this cohort of community-dwelling older adults. 
 
  
179 
 
 
It was hypothesised that: 
(1) A protein-enriched diet combined with a multi-component exercise program will 
result in greater improvements in cognitive performance compared to multi-
component exercise alone in community-dwelling older adults.  
 
(2) There will be greater improvements in the concentrations of circulating 
inflammatory and neurobiological markers, IGF-1 and bioavailable zinc for those 
receiving the protein-enriched diet when compared to the controls.  
 
(3) Baseline levels of circulating inflammatory markers and concentrations of 
neurobiological markers, IGF-1 and bioavailable zinc as well as measures of muscle 
mass, strength and function, will be associated with changes in cognitive function. 
 
(4) Changes in muscle mass, strength and function as well as growth, neurobiological 
and inflammatory markers will be associated with changes in cognitive function. 
 
4.3 Methods 
The methods for this study have been described in detail in Chapter 3. However, a 
brief outline of the methods directly related to this study is provided below. 
 
4.3.1 Participants 
One hundred and fifty-four community-dwelling older adults (58 men and 96 
women) aged 70.7 ± 4.1 years (mean ± SD) from Melbourne and surrounding area 
were recruited to take part in this study. All participants were generally healthy and 
obtained GP consent prior to beginning the study to ensure that they did not have any 
contraindicating medical conditions to the exercise program (based on the ACSM 
guidelines), and were screened for depression and cognitive decline. Participants 
were also screened for any signs of impaired renal function prior to the study. Sixty-
eight participants were recruited in the first year and 86 in the second year. 
 
4.3.2 Intervention 
The study was a 24-week community-based trial that comprised of a multi-
component exercise program including aerobic training, PRT and balance training, 
combined with a protein-enriched diet achieved by eating lean red meat, three days a 
week. The PRT took place across fifteen local health and fitness centres across 
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Melbourne and was implemented by qualified exercise trainers. Participants in the 
Ex+Meat group were advised to consume two serves (220 g total raw weight) of lean 
red meat (beef, lamb, veal) on each of their three training days (three days a week) 
while those in the Ex+CHO group were advised to consume at least one serve of 
carbohydrates (one medium sized potato or ½ cup of cooked rice or pasta). All 
participants were asked to take a 1000 IU/d vitamin D3 supplement. An independent 
researcher used a computer generated random numbers table (Microsoft Excel) to 
randomise participants. 
 
4.3.3 Measurements 
A detailed description of the outcome measures used in this RCT is provided in 
Chapter 3. A brief outline is provided below. 
 
Anthropometry 
Height and weight were measured using standardised procedures with height being 
recorded to the nearest 0.1 cm and weight to the nearest 0.1 kg. BMI was calculated 
using the formula: BMI=weight (kg)/ height (m)
2
. 
 
Medical history, lifestyle, physical activity and dietary status 
A lifestyle questionnaire was used to collect information on medical history, non-
prescription and prescription medication use, smoking history and average weekly 
alcohol intake (g/d) at baseline and 24 weeks. Medications were classified into the 
following categories: anti-hypertensives, lipid-lowering, nonsteroidal anti-
inflammatories, anti-depressants (including anxiety medication and sleeping agents), 
thiazide diuretics, steroidal anti-inflammatories, pain relief, supplements (vitamins, 
minerals, fatty acid supplements and herbal agents) and other. Information on 
smoking history was coded as one of the following: non-smoker, current smoker or 
ex-smoker. The CHAMPS questionnaire was used to assess moderate to vigorous 
habitual physical activity (kJ per week) at baseline and 24 weeks. Two 24-hour food 
diaries were used to assess dietary status and Foodworks 8 (Foodworks, Xyris 
Software, Highgate Hill, Australia) was used to estimate total energy intake, 
carbohydrate, fat, protein and calcium intake and percentage of total energy from 
carbohydrates, fat and protein every four weeks.  
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Body composition 
Total body and regional (arms and legs) lean tissue mass (LTM) and fat mass (FM) 
(both in kg) was assessed using DXA (Lunar Prodigy, GE Lunar Corp., Madison WI, 
software version 12.30.008) at baseline and week 24. Appendicular lean mass (ALM, 
kg) was calculated by summing the lean mass for both right and left arms and legs 
derived from the total body scan.  
 
Muscle function and strength 
Muscle function and strength was assessed at baseline and 24-weeks. Muscle 
function was assessed using the four square step test (FSST) (seconds), timed up and 
go test (TUGT) (seconds), sit-to-stand (STS) (seconds) and 4-metre walk (m/sec). 
Lower limb muscle strength was assessed using a 1-RM leg press estimated from a 
3-RM test performed on a leg press weight machine (Calgym Synergy Omni leg 
press) on the dominant leg. 
 
Cognitive function 
Cognitive function was assessed using CogState computerised battery and BRIEF-A 
questionnaire at baseline, 12 and 24 weeks. As discussed in Chapter 3, the CogState 
test is a computerised battery of tests which can assess various cognitive domains 
including executive function, working memory and learning and psychomotor and 
attention. For this study, participants completed the following CogState battery of 
tests: Groton Maze Learning Task (GMLT), Detection Task (DET), Identification 
Task (IDN), One Card Learning Task (OCL) and the One Back Learning Task 
(ONB). The scores from these individual tests were then combined to create 
composite scores for global cognitive function, the cognitive brief battery (CBB), 
working memory/ learning and psychomotor/attention (Table 4.1). The BRIEF-A 
questionnaire was also used to assess executive function. The scores were combined 
to create composite scores: the behavioural regulation index (BRI), a measure of 
inhibition, emotional control, and self-monitoring, the metacognition index (MI), a 
measure of initiative, working memory, planning, task monitoring and organization, 
and the global executive composite (GEC).   
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Depression 
The Hospital Anxiety and Depression Scale (HADS) assessed depression and anxiety 
at baseline and week 24. This is a 14-item self-report questionnaire that is divided 
into two subscales where seven questions assess cognitive and emotional aspects of 
anxiety and the other seven questions evaluate cognitive and emotional aspects of 
depression (489). It is scored on a four-point likert scale with the results reported as 
the sum of all 14 items, and the sum for each of the two subscales. Higher scores 
indicate higher levels of anxiety or depression. 
 
Blood markers 
All participants provided a fasted, morning (8–10am) venous blood sample at 
baseline, 12 and 24 weeks. All blood was sent to a central laboratory and serum 
aliquots were collected and stored at –80 °C so that the following parameters could 
be assessed in a single batch at the completion of the study: serum IGF-1, 25-
hydroxyvitamin D, homocysteine, vitamin B12, BDNF, VEGF, adiponectin, IL-6, 
IL-8, IL-10 and TNF-α. Serum bioavailable zinc was also measured using flame 
atomic absorption spectrophotometry by direct aspiration (Varian SpectrAA-800). 
High sensitivity C-reactive protein (hs-CRP) was measured by an 
Immunoturbidimetric assay from Roche Diagnostics, Mannheim. APOE status was 
assessed using a venous blood sample. Genetic determination of ApoE allelic status 
was performed using a polymerase chain reaction (PCR)-based assay and 
Table 4.1 Cognitive outcome measures  
  Data Collection (week) 
Cognitive Function                      Collection Method 0 12 24 
Global cognitive function CogState (all tests) x x x 
Cognitive Brief Battery OCL, ONB, IDN, DET x x x 
Working Memory-Learning OCL and ONB x x x 
Psychomotor-Attention IDN and DET x x x 
Executive function BRIEF-A x  x 
  GMLT x x x 
OCL, One card learning; ONB, One back working memory; IDN, Identification task; DET, 
Detection task; GMLT, Groton Maze Learning task; BRIEF-A, Brief Rating Inventory of 
Executive Function 
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participants were categorised as either carriers (possessing at least one copy of the ε4 
allele from the APOE gene) or non-carrier (no copies of this polymorphism).  
 
Adverse events 
Participants were asked to complete an adverse events form every 4 weeks to report 
any adverse events (AE) associated with the intervention. Details including type of 
injury/AE, date of injury/AE, treatment required and whether the injury/AE was pre-
existing, were recorded.  
 
Compliance 
Compliance with the exercise training was monitored using exercise cards every four 
weeks and calculated by dividing the total number of exercise session attended out of 
the total number prescribed. Compliance with the lean red meat and carbohydrates 
was monitored using diet compliance calendars which were completed daily and 
mailed back every four weeks. The total compliance was calculated in the same way. 
 
4.3.4 Statistical analysis 
Statistical analysis was conducted on an ITT basis using STATA statistical software 
version 14 (STATA, College Station, TX, USA).  
 
Multiple linear regression was used to assess the cross-sectional association between 
composite scores for cognitive function and selected muscle outcomes [appendicular 
lean mass, lower leg muscle strength and muscle function (mobility and gait speed)]. 
Data from both groups were pooled and results were analysed adjusting for sex 
(model 1) and then for age, sex, ethnicity, BMI, education, smoking status, history of 
CVD, depression, habitual physical activity (model 2) and APOE genotype (model 3) 
(Appendix J). All values reported are unadjusted beta coefficients with 95% CI. An 
adjusted Bonferroni P-value of 0.0125 was used to determine significance to account 
for multiple comparisons. 
 
Baseline characteristics between the groups were compared by using independent t 
tests for continuous variables and chi-square tests for categorical variables. All data 
was checked for normality and the following variables were log transformed prior to 
analysis: IGF, BDNF, VEGF, adiponectin, hs-CRP, homocysteine, TNF-α, IL-6, IL-
8, IL-10 and vitamin B12. 
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General Linear Mixed Models with random effects were used to assess time, group 
and group-by-time interactions. All results were analysed unadjusted and adjusting 
for the following covariates for each of the different outcome measures:  
 Body composition: age, sex and change in habitual moderate to vigorous 
physical activity.  
 Muscle function and strength: age, sex and change in habitual moderate to 
vigorous physical activity. 
 Cognitive function: age, sex, ethnicity, BMI, education, smoking status, 
history of CVD, depression, change in habitual moderate to vigorous physical 
activity (model 2) and APOE-Ɛ4 genotype (model 3) (Appendices K and L).   
 Neurobiological markers and inflammation: age, sex, change in habitual 
moderate to vigorous physical activity, BMI and APOE-Ɛ4 genotype (model 
3) (Appendices M through O). 
 
A per protocol analysis was also conducted based on ≥66% compliance with the 
exercise and ≥80% compliance with the lean red meat. Between-group differences 
were calculated by subtracting within-group changes from baseline for the Ex+Meat 
group from within-group changes for the Ex+CHO group after 24 weeks. For the log 
transformed data, the percentage change in these variables represented the absolute 
difference from baseline in log transformed data multiplied by 100. All data is 
presented as means ± SD or 95% CI and the significance level was set at P<0.05 
(Appendices P through to V). A secondary analysis was also conducted to assess 
whether there were any gender interactions for each outcome.  
 
An exploratory analysis was also conducted using multiple linear regression to assess 
whether there were any associations between the absolute changes cognitive function 
with baseline and absolute changes in appendicular lean mass, leg muscle strength 
and function (mobility and gait speed) as well as various circulating growth, 
neurotrophic and inflammation markers which were log transformed. The results 
were adjusted for sex and group (model 1) and then sex, group, education, age, 
smoking status, depression, change in physical activity, history of CVD (model 2) 
and APOE genotype (model 3). All values reported are unadjusted beta coefficients 
with 95% CI. The significance level was set using the Bonferroni correction method 
by dividing 0.05 by the number of comparisons (Appendices W through to AH). 
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4.4 Results 
4.4.1 Baseline Characteristics 
Table 4.2 provides an overview of the participant characteristics at baseline. Sixty-
two percent of the participants were female and the mean age and BMI was 70.7 
years (age range 65 to 84 years) and 27.9 kg/m
2 
respectively. A total of 35.1% of the 
participants were classified as overweight and 31.8% as obese. Thirty-six percent 
were either ex or current smokers (current smokers n=3) and a higher proportion of 
participants in the Ex+Meat group had a history of CVD (presence of heart disease, 
stroke or heart attack) compared to those in the Ex+CHO group (Ex+Meat, n=17; 
Ex+CHO, n=6) (Chi-square P=0.013). Six (4%) participants (Ex+Meat, n=2; 
Ex+CHO, n=4) had an eGFR between 45-59 ml/min which may be indicative of mild 
kidney damage. The number of APOE-4 carriers also differed significantly between 
the groups (Ex+Meat n=11; Ex+CHO n=22, P=0.037). There were no differences 
between the groups with regard to any other baseline characteristic listed in Table 
4.2. 
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Table 4.2 Baseline characteristics of the multi-component exercise and lean red meat 
(Ex+Meat) and control (carbohydrate) multi-component exercise (Ex+CHO) group 
Characteristic Ex+Meat Ex+CHO 
N 77 77 
Women, n (%) 48 (57%) 48 (57%) 
Age (years) 71.2 ± 4.0 70.3 ± 4.3 
Height (cm) 165.0 ± 8.8 165.3 ± 9.9 
Weight (kg) 76.1 ± 17.2 76.9 ± 18.7 
BMI (kg/m
2
) 27.8 ± 5.1 27.9 ± 5.5 
   Overweight (BMI 25-29.9), n (%) 32 (42%) 22 (29%) 
   Obese (BMI ≥ 30), n (%) 22 (29%) 27 (35%) 
Ex-smoker/ current smoker, n (%) 30 (39%) 26 (34%) 
Ethnicity, n (%)   
   Caucasian 66 (86%) 63 (82%) 
   Non-Caucasian 11 (14%) 14 (18%) 
Education, n (%)   
   High school or lower 43 (56%) 39 (51%) 
   University or higher 34 (44%) 38 (49%) 
Moderate- vigorous PA kJ per week 7897 ± 7555 8017 ± 7547 
Consume alcohol, n (%) 44.2% 40.3% 
Alcohol intake, g/d 13.3 ± 13.1 14.1 ± 11.4 
Number of health conditions 2.05 ± 1.72 2.23 ± 1.84 
History of CVD, n (%) 17 (22%) 6 (8%)* 
MCI, n (%) 3 (3.9%) 5 (6.5%) 
APOE-4 carrier , n (%) 11 (14%) 22 (29%)* 
25-Hydroxyvitamin D (nmol/L) 83.6 ± 23.0 83.0 ± 28.0 
   Insufficient (<75 nmol/L), n (%) 20 (26%) 26 (34%) 
   Deficient (<50 nmol/L), n (%) 5 (7%) 4 (5%) 
Values represent number and percentage or mean ± standard deviations. *P<0.05 versus Ex+Meat. 
BMI, body mass index; APOE, apolipoprotein E; Caucasians included those born in Australia, 
Northern Europe, Canada, USA and New Zealand; Non-Caucasians included those born in Southern 
Europe, Asia, the Middle East,  India and Sri Lanka, Pacific Islands, Africa, South and Central 
America, Aboriginal Australians and Strait Torres Islanders; MCI, mild cognitive impairment; PA, 
physical activity; CVD, cardiovascular disease. 
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4.4.2 Association between muscle outcomes and cognitive function at baseline 
The associations between cognitive function and the various muscle outcomes at 
baseline are shown in Table 4.3. An adjusted Bonferroni P-value of 0.0125 was used 
to determine significance to account for multiple comparisons. There was a 
significant positive association between global cognitive function and ALM 
(P=0.001) and lower leg muscle strength (P<0.001), which persisted after adjusting 
for covariates in model 2 and 3. Executive function (GMLT) was positively 
associated with ALM and muscle strength in model 1 only (P=0.010 and P=0.003 
respectively). Mobility (FSST) was negatively associated with global cognitive 
function and executive function (both model 1 only, P=0.011 and P=0.004 
respectively). No associations were observed between psychomotor/attention scores, 
working memory/learning composite scores or executive function (GEC) with ALM, 
muscle strength or any measure of function. 
  
 
1
8
8
 
 
Table 4.3 Cross-sectional association between global cognitive function and composite scores with appendicular lean mass, muscle strength, gait 
speed and mobility. 
 ALM Muscle strength
1
 Gait speed
2 
Mobility
3 
 β (95% CI) P value β (95% CI) P value β (95% CI) P value β (95% CI) P value 
Global Cognitive Function 
  Model 1 0.04
 
(0.02, 0.07)* 0.001 0.00 (0.00, 0.01)* 0.000 0.49 (0.04, 0.94) 0.032 -0.07 (-0.12, -0.02)* 0.011 
  Model 2 0.04 (0.01, 0.07)* 0.009 0.00 (0.00, 0.01)* 0.008 0.29 (-0.18, 0.76) 0.227 -0.04 (-0.10, 0.01) 0.121 
Executive Function (GMLT) 
  Model 1 0.06 (0.01, 0.11)* 0.010 0.01 (0.00, 0.01)* 0.003 0.58 (-0.23, 1.38) 0.161 -0.14 (-0.23, -0.04)* 0.004 
  Model 2 0.03 (-0.01, 0.08) 0.149 0.00 (-0.00, 0.01) 0.102 0.12 (-0.70, 0.94) 0.775 -0.10 (-0.20, -0.01) 0.033 
Executive Function (GEC) 
  Model 1 0.11 (-0.34, 0.56) 0.00 0.00 (-0.04, 0.04) 0.00 -4.90 (-12.69, 2.89) 0.01 0.16 (-0.75, 1.08) 0.00 
  Model 2 0.09 (-0.31, 0.49) 0.32 0.01 (-0.02, 0.05) 0.31 -0.88 (-7.92, 6.17) 0.32 -0.46 (-1.28, 0.37) 0.33 
Working Memory/ Learning 
  Model 1 0.04
 
(0.01, 0.08) 0.019 0.00 (0.00, 0.01) 0.022 0.43 (-0.18, 1.05) 0.164 -0.05 (-0.12, 0.03) 0.201 
  Model 2 0.04 (0.00, 0.07) 0.041 0.00 (-0.00, 0.01) 0.066 0.24 (-0.40, 0.89) 0.457 -0.02 (-0.09, 0.06) 0.633 
Psychomotor/ Attention 
  Model 1 0.04 (-0.01, 0.08)
 
 0.132 0.00
 
(-0.00, 0.00)
 
 0.695 -0.00 (-0.80, 0.80) 0.991 0.04 (-0.00, 0.08) 0.051 
  Model 2 0.03 (-0.02, 0.08) 0.186 0.00 (-0.00, 0.00) 0.882 -0.06 (-0.87, 0.76) 0.892 0.03 (-0.01, 0.07) 0.166 
All values represent unadjusted beta-coefficients (β) with 95% confidence interval (CI). Model 1: adjusted for sex, Model 2: adjusted for education, age, sex, smoking status, 
depression, habitual physical activity and history of CVD. Calculated Bonferroni p-value of 0.0125 was used to assess significance. *P<0.013. ALM: Appendicular lean mass, 
GEC: global executive composite, 
1 
Leg press 3-RM muscle strength;
 2 
Gait speed assessed from the 4-m walk test; 
3 
Mobility was assessed using the four square step test (FSST). 
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Figure 4.1 Cross-sectional associations between global cognitive function with 
appendicular lean mass, muscle strength, gait speed and mobility. 
Figure 4.2 Cross-sectional associations between executive function (Groton Maze 
Learning Task) with appendicular lean mass, muscle strength, gait speed and 
mobility.  
 
 
r=0.27, P=0.001 r=0.29, P<0.001 
r=0.17, P=0.032 r=-0.21, P=0.011 
Global Cognitive Function 
Executive Function (GMLT) 
r=0.21, P=0.010 r=0.24, P=0.003 
r=0.11, P=0.161 r=-0.23, P=0.004 
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Figure 4.3 Cross-sectional associations between working memory/learning 
composite scores with appendicular lean mass, muscle strength, gait speed and 
mobility. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Cross-sectional associations between psychomotor/attention composite 
scores with appendicular lean mass, muscle strength, gait speed and mobility. 
Working Memory/Learning Composite 
r=0.19, P=0.019 r=0.19, P=0.022 
r=0.12, P=0.164 r=-0.12, P=0.201 
Psychomotor/Attention Composite 
r=0.15, P=0.132 r=0.14, P=0.695 
r=0.08, P=0.991 r=-0.12, P=0.051 
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4.4.3 Study attrition, compliance and adverse events  
Study Attrition 
Nine participants (6%) withdrew from the study and did not complete the 24-week 
testing (Ex+Meat n=4; Ex+CHO n=5), leaving 145 (94%) for the final analysis. 
Reasons for withdrawal included medical (Ex+Meat: n=2; Ex+CHO: n=4), time 
(Ex+Meat: n=0; Ex+CHO: n=1) and loss of interest in the study (Ex+Meat: n=2; 
Ex+CHO: n=0). Participants who withdrew from the study did not differ from the 
remaining participants at baseline, with the exception of memory complaints. Those 
who remained in the study reported a higher mean score for memory complaints than 
those who withdrew (24.92 versus 20.78, P<0.01). Please see Chapter 3 for the full 
study design flow chart. 
 
Compliance 
There were a total of 72 exercise sessions over the 24-week period and the mean 
compliance was ~78% and was no different between the Ex+Meat [77.9%, (95% CI: 
73.5, 82.2)] and Ex+CHO [78.6% (95% CI: 73.9, 83.2)] group (P=0.82).  
 
Mean compliance with the lean red meat was 87.0% (95% CI, 82.4, 91.5) while 
mean compliance with the carbohydrates was 91.3% (95% CI: 86.1, 96.4). 
Compliance with the vitamin D supplementation was ~94% and was no different 
between the Ex+Meat [94.6%, (95% CI: 92.2, 97.0)] and Ex+CHO [92.6%, (95% CI: 
89.9, 95.3)] group (P=0.26).  
 
Adverse Events 
There were no serious adverse events associated with the intervention. Overall 13 
participants ceased training for a given period due to injury or pain but returned to 
training, while three participants withdrew from the exercise but returned for follow-
up testing. Of those who withdrew from the exercise, two did so due to aggravation 
of a pre-existing injury or pain, while one withdrew due to a new complaint (bulging 
lumbar discs) that was deemed not to be related to the intervention. Of those who 
ceased training for a given period, two of the adverse events (complaints/injuries) 
occurred in the first four weeks, three occurred in weeks five to eight, three occurred 
in weeks nine to 12, three occurred in weeks 13 to 16, one occurred in weeks 17 to 
20 while one occurred in the last four weeks. The body sites affected included the 
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shoulder (n=2), back (n=2), foot (n=1), gluteal region (n=1), knee (n=3), wrist (n=2) 
and other (n=2). Ten of these injuries required medical treatment. The average 
duration of training cessation was ~3 sessions (range 1 to 4).  
 
4.4.4 Habitual/ Leisure Time Activity 
Habitual moderate-vigorous physical activity was not different between the groups at 
baseline (Table 4.2), and did not change (excluding the intervention exercise 
program) significantly after 24 weeks in either group [mean change kJ per week 
(95% CI): Ex+Meat -207 (95% CI, -1958, 1544); Ex+CHO 1783 (95% CI, 118, 
3448)]. However, there was a trend for an increase (P=0.07) in the Ex+CHO group. 
 
4.4.5 Diet  
Table 4.4 summarises the results of the dietary assessment. There were no significant 
differences between the two groups at baseline. The results after 12 and 24 weeks are 
presented for both training and non-training days as the Ex+Meat group consumed 
the red meat on each of the three training days. Mean protein intake, when expressed 
as percentage energy from protein, increased significantly in the Ex+Meat group on 
the training days after both 12 and 24 weeks compared to the Ex+CHO group 
(group-by-time interaction: 12 weeks P<0.001; 24 weeks P<0.01). Similar results 
were observed for protein intake expressed as g/d or g/kg/d (Figure 4.5). At baseline, 
29% of males and 31% of women had a protein intake <1.0 g/kg/d. The average 
dietary protein intake, expressed as g/kg/d, at baseline for all participants was 1.25 ± 
0.44 g/kg/d. This increased throughout the study on the training days to 1.42 g/kg/d 
at 12 weeks and 1.40 g/kg/d at 24 weeks in the Ex+Meat group, which represents an 
18% increase from baseline (both P<0.01). Protein intake (g/kg/d) in the Ex+CHO 
group did not change during the study (Figure 4.5). Dietary iron and zinc intake also 
increased in the Ex+Meat group throughout the study and was greater than in the 
Ex+CHO group after 12 and 24 weeks (group-by-time interaction, P ranging <0.01 to 
<0.001). However, there were no between group differences with regard to changes 
in total energy or fat (including saturated fat) intake between the groups after 12 or 
24 weeks. 
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Figure 4.5: Mean (±SE) dietary protein (g/kg/d) on the training and non-training 
days in the Ex+Meat (●) and Ex+CHO (○) group at baseline, 12 and 24 weeks. 
*P<0.05, **P<0.01 versus baseline; † P<0.05 versus change from Ex+CHO.  
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Table 4.4 Mean estimated dietary intakes at baseline, 12 and 24 weeks on the training and non-training days in the exercise and lean red meat 
(Ex+Meat) and exercise and control carbohydrate (Ex+CHO) group. 
  12 weeks 24 weeks 
 Baseline Non-Training Training Day Non-Training Training Day 
Total energy, kJ/d      
   Ex+Meat 8317 ± 2764 8619 ± 2712 8305 ± 2501 8408 ± 2864 8492 ± 2778 
   Ex+CHO 7977 ± 2025 8924 ± 2998 * 8161 ± 2617 8483 ± 2815 8300 ± 2756 
Protein, g/d      
   Ex+Meat 91.8 ± 27.3 101.8 ± 34.0 * 102.4 ± 21.5 †a 95.2 ± 31.6 103.5 ± 29.3 † 
   Ex+CHO 90.4 ± 25.4 96.1 ± 34.6 86.4 ± 27.2 93.1 ± 29.6 92.6 ± 34.6 
Protein, g/kg/d 
   Ex+Meat 1.26 ± 0.44 1.42 ± 0.53* 1.42 ± 0.39 †a 1.29 ± 0.52 1.40 ± 0.46 † 
   Ex+CHO 1.24 ± 0.05 1.34 ± 0.60 1.22 ± 0.56 1.29 ± 0.50 1.28 ± 0.53 
Protein, % total      
   Ex+Meat 18.8 ± 3.5 20.3 ± 5.4 *
a 
21.5 ± 4.6 
#
 
c 
19.4 ± 4.9 21.1 ± 4.9 
# c
 
   Ex+CHO 19.2 ± 4.0 18.4 ± 5.1 18.2 ± 4.7 19.1 ± 5.2 19.0 ± 4.5 
Carbohydrates, g/d      
   Ex+Meat 205 ± 74 204 ± 82 201 ± 73 203 ± 76 203 ± 82 
   Ex+CHO 200 ± 72 210 ± 80 207 ± 78 204 ± 85 207 ± 83 
CHO, % total energy 
   Ex+Meat 41.9 ± 7.4 40.0 ± 9.1 41.1 ± 7.9 41.5 ± 9.4 40.3 ± 8.5 
   Ex+CHO 42.2 ± 8.0 40.3 ± 9.3 43.3 ± 8.5 41.1 ± 10.9 42.3 ± 9.5 
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Fat, g/d      
   Ex+Meat 78.0 ± 33.1 79.3 ± 33.4 74.7 ± 35.8 78.9 ± 39.1 75.1 ± 36.7 
   Ex+CHO 71.9 ± 22.7 84.3 ± 36.7 * 75.7 ± 34.1 78.2 ± 36.7 74.4 ± 32.7 
Fat, % total energy      
   Ex+Meat 34.2 ± 6.6 33.5 ± 7.1 32.2 ± 9.0 33.6 ± 7.9 31.8 ± 8.9 * 
   Ex+CHO 33.4 ± 6.3 34.9 ± 7.7 33.7 ± 7.5 33.8 ± 9.6 32.9 ± 9.2 
Saturated fat, g/d      
   Ex+Meat 28.8 ± 14.7 29.6 ± 16.2 27.2 ± 16.9 28.8 ± 16.2 27.5 ± 15.9 
   Ex+CHO 27.0 ± 11.1 28.4 ± 13.5 27.2 ± 14.4 29.1 ± 17.5 27.4 ± 14.8 
Iron, mg/d      
   Ex+Meat 12.1 ± 4.3 12.5 ± 4.6 14.3 ± 5.0 
#
 
b 
12.3 ± 5.2 14.6 ± 5.5 
# b 
   Ex+CHO 12.3 ± 5.5 12.7 ± 6.7 11.9 ± 3.6 12.9 ± 5.6 12.2 ± 4.9 
Zinc, mg/d      
   Ex+Meat 11.3 ± 4.2 11.7 ± 4.2 16.4 ± 3.7 
#
 
c 
10.8 ± 3.9 16.0 ± 5.0 
#
 
c 
   Ex+CHO 11.1 ± 3.7 10.9 ± 5.2 10.2 ± 3.7 11.3 ± 4.9 11.0 ± 5.6 
Calcium, mg/d      
   Ex+Meat 850 ± 343 969 ± 415 *
a 
898 ± 478 
a 
936 ± 423 
a 
888 ± 386 
   Ex+CHO 927 ± 399 889 ± 355 867 ± 409 849 ± 378 * 807 ± 368 * 
All values are unadjusted means ± SDs. * P<0.05 
†
 P<0.01 
# 
P<0.001 within group difference; 
a 
P<0.05 
b
 P<0.01 
c 
P<0.001 between-group difference for the change over 
time (group-by-time interaction). 
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4.4.6 Medications 
Table 4.5 provides a summary of the types of medications the participants were 
taking at baseline and 24 weeks. More than 80% of participants in each group were 
taking some form of prescribed medication at baseline (Ex+Meat, 88.3%; Ex+CHO, 
84.4%) and this did not change throughout the intervention. The median number of 
medications taken ranged from two in the Ex+CHO group to three in the Ex+Meat 
group. The most common type of medication taken were anti-hypertensives 
(Ex+Meat, 57%; Ex+CHO, 44%). Throughout the study, most participants’ anti-
hypertensive use remained unchanged (Ex+Meat, 92.2%; Ex+CHO, 87%). Three 
participants commenced anti-hypertensive medication during the intervention 
(Ex+Meat: n=1, Ex+CHO: n=2) and three participants ceased their anti-hypertensive 
medication (Ex+Meat: n=0, Ex+CHO: n=3), but there was no significant difference 
between the groups with regard to changes in anti-hypertensive use. Fifty-three 
(34.4%) participants were taking lipid-lowering medication at baseline with two 
participants in the Ex+Meat commencing lipid-lowering medication and two 
participants ceasing medication in the Ex+CHO group throughout the intervention. 
However, there were no significant differences between the groups with regard to 
changes in lipid-lowering medication. There were no significant baseline differences 
or differences in the change to antidepressant or non-steroidal anti-inflammatory 
drug (NSAID) medication between the groups.  
 
Table 4.5 Number and proportion (percentage) of participants in the exercise and 
lean red meat (Ex+Meat) and exercise and control carbohydrate (Ex+CHO) group 
taking medications at baseline and 24 weeks 
 Ex+Meat n=77 Ex+CHO n=77 
 
Prescribed medication 
Baseline 
n (%) 
24 weeks 
n (%) 
Baseline 
n (%) 
24 weeks 
n (%) 
Taking medication 68 (88.3) 67 (87.0) 65 (84.4) 65 (84.4) 
NSAID medication 6 (7.8) 6 (7.8) 2 (2.6) 2 (2.6) 
Antidepressant medication 7 (9.1) 6 (7.8) 14 (18.2) 10 (13.0) 
Anti-hypertensives 44 (57.1) 43 (55.8) 34 (44.2) 31 (40.3) 
Lipid-lowering 30 (39.0) 31 (40.3) 23 (29.9) 20 (26.0) 
NSAID; non-steroidal anti-inflammatory drug 
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4.4.7 Body Composition 
DXA Lean Tissue Mass 
For total body lean mass, there were similar significant gains for both groups after 24 
weeks (mean change ± SD: Ex+Meat: 0.76 ± 1.2 kg, P<0.001; Ex+CHO: 0.58 ± 1.0 
kg, P<0.001), but no differences for the change between the groups. When 
considering lean mass of the arms and legs separately, there was a significantly 
greater 0.07 kg gain in arm lean mass in the Ex+Meat compared to the Ex+CHO 
group (P<0.05). For leg lean mass, the Ex+Meat group experienced a significant 0.17 
kg gain relative to baseline and there was a non-significant 0.08 kg gain in the 
Ex+CHO group, but the between group difference for the change over 24 weeks was 
not significant (P=0.29). 
 
For appendicular lean mass, there was a trend (P=0.07) for a greater gain in the 
Ex+Meat compared to the Ex+CHO group [net difference for the change (95% CI): 
0.16 kg (-0.02, 0.34)], which was due to a significant increase of 0.34 kg (P<0.001) 
in the Ex+Meat group compared to a non-significant 0.18 kg gain in the Ex+CHO 
group. All results remained unchanged after adjusting for age, sex and habitual 
physical activity. 
 
DXA Fat Mass 
For total body fat mass, there were similar significant reductions in both groups after 
24 weeks (Ex+Meat: -0.75 kg, P<0.001; Ex+CHO: -0.65 kg, P<0.001). As such, 
there was no significant difference for the change between the groups. As shown in 
Table 4.6, fat mass in both the arms and legs tended to decrease in both groups after 
24 weeks, but these changes were not significantly different from baseline. All 
results remained unchanged after adjusting for age, sex and habitual physical 
activity. 
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Table 4.6 Mean baseline weight, total body and regional (arms and legs) lean mass and fat mass and appendicular lean mass for the exercise and 
red meat (Ex+Meat) and exercise and control carbohydrate (Ex+CHO) group and the mean within-group changes and net differences between 
the groups for the change after 24 weeks. 
 Baseline Values and Within-Group Changes  
 Ex+Meat Ex+CHO Intervention Effects 
 
Mean ± SD or  
(95% CI) 
P-value Mean ± SD or  
(95% CI) 
P-value Net Difference  
(95% CI) 
P-values 
Model 1  | Model 2 
Total Body 
Weight      
  Baseline, kg 76.1 ± 17.1  76.9 ± 18.7    
  Absolute  Δ 24-weeks 0.02 (-0.41, 0.46) 0.913 -0.02 (-0.42, 0.37) 0.899 0.04 (-0.53, 0.63) 0.867 | 0.965 
Total body lean mass      
  Baseline, kg 44.36 ± 10.38  44.44 ± 10.87    
  Absolute  Δ 24-weeks 0.76 (0.47, 1.05) 0.000 0.58 (0.35, 0.82)
 
0.000 0.18 (-0.20, 0.55) 0.353 | 0.369 
Total body fat mass      
  Baseline, kg 28.31 ± 11.02  28.95 ± 11.71    
  Absolute  Δ 24-weeks -0.75 (-1.17, -0.33) 0.000 -0.65 (-0.99, -0.32)
 
0.000 -0.10 (-0.63, 0.43) 0.718 | 0.653 
Regional 
Appendicular lean mass      
  Baseline, kg 19.41 ± 5.11  19.67 ± 5.67    
  Absolute  Δ 24-weeks 0.34 (0.20, 0.47) 0.000 0.18 (0.05, 0.30) 0.004 0.16 (-0.2, 0.34) 0.070 | 0.062 
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Arm lean mass      
  Baseline, kg 4.79 ± 1.47  4.88 ± 1.63    
  Absolute  Δ 24-weeks 0.17 (0.13, 0.21) 0.000 0.10 (0.05, 0.15)
 
0.000 0.07 (0.01, 0.14) 0.029 | 0.014 
Leg lean mass      
  Baseline, kg 14.62 ± 3.71  14.78 ± 4.09    
  Absolute  Δ 24-weeks 0.17 (0.05, 0.28) 0.003 0.08 (-0.02, 0.18) 0.124 0.09 (-0.06, 0.24) 0.236 | 0.254 
Arm fat mass      
  Baseline, kg 2.97 ± 1.36  2.97 ± 1.39    
  Absolute  Δ 24-weeks -0.02 (-0.07, 0.02) 0.273 -0.05 (-0.11, 0.01) 0.078 0.03 (-0.05, 0.10) 0.470 | 0.559 
Leg fat mass      
  Baseline, kg 9.27 ± 4.50  9.34 ± 4.83    
  Absolute  Δ 24-weeks -0.09 (-0.22, 0.05) 0.193 -0.09 (-0.21, 0.03) 0.099 0.01 (-0.17, 0.18) 0.934 | 0.945 
All baseline values are unadjusted means ± SDs. All change values are unadjusted means (95% CI) and were calculated from the absolute difference from baseline. Mean net 
differences (95% CI) were calculated by subtracting the within-group changes for the Ex+Meat group from the within-group changes for the Ex+CHO group after 12 and 24 
weeks. Adjusted model included age, change in physical activity and sex. 
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4.4.8 Muscle strength and function 
After 24-weeks, both groups had a significant 26 to 27% increase in lower limb (leg 
press) muscle strength (P<0.001) and a 37 to 40% increase in isometric knee 
extensor strength (P<0.01). However, there were no significant differences between 
the groups for the change over time.  
 
With regard to muscle function, there was a significant group-by-time interaction for 
the change in gait speed (P<0.05) after 24 weeks, which was due to a significant 
mean 0.05 m/sec deterioration in the Ex+CHO group with no changes in the 
Ex+Meat group. For the FSST, both groups significantly improved after 24 weeks 
(Ex+Meat -0.70 seconds, P<0.001; Ex+CHO -0.27 seconds, P<0.05), and there was a 
trend for a greater improvement in the Ex+Meat group (P=0.07). All the above 
results remained unchanged after adjusting for age, sex, and habitual physical 
activity.
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Table 4.7 Mean baseline muscle strength and function in the exercise and lean red meat (Ex+Meat) and exercise and control carbohydrate group 
(Ex+CHO), and the mean within-group changes and net differences between the groups for the change after 24 weeks. 
 Baseline Values and Within-Group Changes  
 Ex+Meat Ex+CHO Intervention Effects 
 
Mean ± SD or  
(95% CI) 
P-value 
Mean ± SD or  
(95% CI) 
P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  | Model 2 
Muscle Strength      
1-RM (Leg Press)      
  Baseline, kg 126.6 ± 51.1  131.2 ± 53.6    
  % Δ 24-weeks 26.0 (18.6, 33.4) 0.000 27.05 (19.1, 35.0) 0.000 -1.0 (-11.8, 9.8) 0.688 | 0.698 
Knee extensor strength      
  Baseline, kg 25.8 ± 10.2  25.6 ± 11.8    
  % Δ 24-weeks 40.2 (22.7, 57.8) 0.000 37.1 (23.5, 50.6)
 
0.001 3.2 (-18.9, 25.2) 0.378 | 0.527 
Muscle Function      
4 metre walk (gait speed)      
  Baseline, m/sec 1.38 ± 0.18  1.40 ± 0.21    
  Absolute  Δ 24-weeks 0.00 (-0.03, 0.43) 0.773 -0.05 (-0.10, -0.01) 0.012 0.06 (0.00, 0.11) 0.042 | 0.052 
Four square step test      
  Baseline, sec 8.89 ± 1.98  8.43 ± 1.43    
  Absolute  Δ 24-weeks -0.70 (-1.02, -0.38) 0.000 -0.27 (-0.58, 0.03) 0.046 -0.42 (-0.86, 0.14) 0.072 | 0.049 
All baseline values are unadjusted means ± SDs. All change values are unadjusted means (95% CI) and were calculated from the absolute difference from baseline. Mean net 
differences (95% CI) were calculated by subtracting the within-group changes for the Ex+Meat group from the within-group changes for the Ex+CHO group after 12 and 24 
weeks. Adjusted model included age, sex, body mass index and change in physical activity as covariates. 
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4.4.9 Cognitive function   
For all cognitive outcome measures, the results for both unadjusted and adjusted 
models are shown in Table 4.8 and Figures 4.6 and 4.7. APOE genotype was also 
included as a covariate in a third model but in most cases did not affect the results. 
Any changes due to the addition of APOE genotype into the model are reported in 
the text. 
 
Groton Maze Learning Task (Executive function) 
For the GMLT, both groups experienced a similar non-significant 0.15 to 0.16 SD 
improvement after 12 weeks but a significant 0.33 to 0.39 SD improvement after 24 
weeks (P<0.01 to <0.001). However, since the magnitude of improvement was 
similar between the groups, there was no group-by-time interaction for the change 
after 12 or 24 weeks. 
 
Detection Task (Psychomotor function/attention) 
For DET, there was a significant mean 0.39 SD decrease in the Ex+CHO group 
(P<0.01) with no change in the Ex+Meat group after 12 weeks, which resulted in a 
significant group-by-time time interaction for the change over time (P<0.05). 
However, this disappeared after adjusting for covariates (P=0.141). Further, after 24 
weeks, there was no between group difference for the change over time nor any 
within group changes relative to baseline in either group.  
 
Identification Task (Attention/processing speed) 
For IDN, there were no significant group-by-time interactions after 12 or 24 weeks, 
but the Ex+CHO group experienced a significant mean 0.25 SD decrease (P<0.05) 
after 12 weeks with no change observed in the Ex+Meat group (-0.05 SD) (Table 
4.8). The results did not change after adjusting for covariates. 
 
One Card Learning (Working memory/visual learning) 
For OCL, there was a significant group-by-time interaction after 12 weeks (P<0.05) 
which was driven by a mean 0.23 SD improvement in the Ex+CHO group (P<0.05) 
with no change in the Ex+Meat group (-0.06 SD). However, in the fully adjusted 
model which included APOE genotype as a covariate, the group-by-time interaction 
after 12 weeks was no longer significant (P=0.068). After 24 weeks, there was a 
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further improvement in the Ex+CHO group (mean change, 0.38 SD, P<0.001) and a 
non-significant gain in the Ex+Meat group (mean change, 0.11 SD, P=0.285), which 
resulted in a similar trend for a difference in the change between the groups (group-
by-time interaction, P=0.085). These results remained unchanged after adjusting for 
covariates.  
 
One Back Working Memory Task (Working memory/learning) 
For ONB, there was a significant group-by-time interaction for the change after 24 
weeks and this persisted after adjusting for covariates. This was driven by significant 
improvements in the Ex+CHO group at 12 and 24 weeks (mean change: 0.23 SD and 
0.34 SD increase respectively) as there were no changes in the Ex+Meat group (0.04 
SD and 0.06 SD) (Table 4.8).  
 
Working Memory/Learning composite 
For the working memory/ learning composite score, there were significant mean 0.24 
and 0.27 SD greater improvement in the Ex+CHO compared to the Ex+Meat group 
after both 12 weeks (P=0.008) and 24 weeks (P=0.007) which persisted in the 
adjusted models. These were due to significant mean increases of 0.23 SD (P<0.001) 
and 0.36 SD (P<0.001) after 12 and 24 weeks in the Ex+CHO group as mean scores 
for the Ex+Meat group remained unchanged (-0.01 SD and 0.09 SD respectively).   
 
Psychomotor/Attention composite 
The psychomotor/attention composite scores decreased in the Ex+CHO group after 
12-weeks (mean change, -0.32 SD, P<0.001), with no change in the Ex+Meat group 
(-0.02 SD, P=0.785), leading to a significant group-by-time interaction for the 
change after 12 weeks (P<0.05). However, after adjusting for APOE genotype, this 
interaction disappeared. There were no significant within group changes in either 
group after 24 weeks nor was there any group-by-time interaction.  
 
Cognitive Brief Battery Composite 
For the CBB, there was a significant improvement in both groups after 24 weeks 
(Ex+Meat 0.12 SD; Ex+CHO 0.21 SD) but there was no group-by-time interaction.  
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Combined Cognitive Score (Global cognitive function) 
For global cognitive function, there was no change in either group after 12 weeks 
(Ex+Meat 0.01 SD; Ex+CHO 0.05 SD) but a significant increase after 24 weeks in 
the Ex+Meat (mean change: 0.17 SD, P<0.01) and Ex+CHO group (mean change, 
0.26 SD, P<0.001). However, there were no differences in the change between the 
groups after either 12 or 24 weeks. All results remained unchanged after adjusting 
for covariates.  
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Table 4.8 Mean baseline CogState cognitive function Z-scores for the exercise and lean red meat (Ex+Meat) and exercise and control carbohydrate 
(Ex+CHO) group, and the mean within-group changes and net differences between the groups for the change after 12 and 24 weeks. 
 Baseline Values and Within-Group Changes  
 Ex+Meat Ex+CHO Intervention Effects 
 
Mean ± SD or  
(95% CI) 
P-value 
Mean ± SD or  
(95% CI) 
P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  | Model 2 
GMLT (Z scores total errors)      
  Baseline -0.02 ± 0.97  0.02 ± 1.04    
  Absolute  Δ 12-weeks 0.16 (-0.05, 0.37) 0.123 0.15 (-0.04, 0.34) 0.127 0.01 (-0.27, 0.29) 0.920 | 0.929 
  Absolute  Δ 24-weeks 0.39 (0.19, 0.60) 0.000 0.33 (0.13, 0.52) 0.001 0.07 (-0.21, 0.35) 0.613 | 0.634 
Psychomotor/attention (DET Task Z scores for speed) 
  Baseline -0.14 ± 1.01  0.14 ± 0.98    
  Absolute  Δ 12-weeks 0.00 (-0.33, 0.32) 0.989 -0.39 (-0.66, -0.12) 0.001 0.39 (-0.03, 0.80) 0.035 | 0.141 
  Absolute  Δ 24-weeks 0.15 (-0.12, 0.42)
 
0.326 0.05 (-0.18, 0.28)
 
0.951 0.09 (-0.26, 0.44) 0.477 | 0.714 
Attention/processing speed (IDN Task Z scores for speed) 
  Baseline -0.13 ± 0.99  0.13 ± 1.00    
  Absolute  Δ 12-weeks -0.05 (-0.25, 0.16) 0.629 -0.25 (-0.44, -0.05) 0.006 0.21 (-0.08, 0.49) 0.123 | 0.228 
  Absolute  Δ 24-weeks 0.15 (-0.03, 0.32)
 
0.095 0.06 (-0.13, 0.25) 0.616 0.09 (-0.16, 0.34) 0.387 | 0.479 
       
       
  
 
2
0
6
 
       
Working memory/learning (OCL Task Z score for accuracy) 
  Baseline 0.09 ± 1.01  -0.09 ± 0.99    
  Absolute  Δ 12-weeks -0.06 (-0.28, 0.15) 0.634 0.23 (0.00, 0.45) 0.017 -0.29 (-0.60, 0.19) 0.047 | 0.075 
  Absolute  Δ 24-weeks 0.11 (-0.16, 0.38)
 
0.285 0.38 (0.16, 0.61) 0.000 -0.27 (-0.62, 0.08) 0.085 | 0.143 
Working memory/learning (ONB Task Z score for speed) 
  Baseline 0.03 ± 1.01  -0.03 ± 1.00    
  Absolute  Δ 12-weeks 0.04 (-0.13, 0.20) 0.626 0.23 (0.06, 0.39) 0.004 -0.19 (-0.42, 0.04) 0.077 | 0.076 
  Absolute  Δ 24-weeks 0.06 (-0.09, 0.21) 0.316 0.34 (0.17, 0.50) 0.000 -0.28 (-0.50, -0.05) 0.017 | 0.012 
Working Memory/Learning Composite      
  Baseline 0.06 ± 0.75  -0.06 ± 0.76    
  Absolute  Δ 12-weeks -0.01 (-0.15, 0.12) 0.867 0.23 (0.09, 0.36) 0.000 -0.24 (-0.43, -0.05) 0.023 | 0.015 
  Absolute  Δ 24-weeks 0.09 (-0.08, 0.25) 0.181 0.36 (0.22, 0.50) 0.000 -0.27 (-0.49, -0.06) 0.008 | 0.010 
Psychomotor/Attention Composite      
  Baseline -0.14 ± 0.85  0.14 ± 0.87    
  Absolute  Δ 12-weeks -0.02 (-0.24, 0.19) 0.785 -0.32 (-0.51, -0.13) 0.000 0.30 (0.01, 0.58) 0.018 | 0.085 
  Absolute  Δ 24-weeks 0.15 (-0.02, 0.32) 0.097 0.06 (-0.12, 0.23) 0.762 0.09 (-0.15, 0.33) 0.314 | 0.518 
Cognitive Brief Battery Composite      
  Baseline -0.04 ± 0.65  0.04 ± 0.66    
  Absolute  Δ 12-weeks -0.02 (-0.15, 0.11) 0.749 -0.05 (-0.17, 0.08) 0.446 0.03 (-0.15, 0.21) 0.753 | 0.917 
  Absolute  Δ 24-weeks 0.12 (0.00, 0.23) 0.033 0.21 (0.09, 0.33) 0.001 -0.09 (-0.26, 0.07) 0.419 | 0.313 
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Global Cognitive Score      
  Baseline 0.00 ± 0.57  0.00 ± 0.57    
  Absolute  Δ 12-weeks 0.01 (-0.10, 0.12) 0.899 0.05 (-0.05, 0.16) 0.291 -0.05 (-0.20, 0.10) 0.508 | 0.347 
  Absolute  Δ 24-weeks 0.17 (0.08, 0.26) 0.001 0.26 (0.15, 0.38) 0.000 -0.09 (-0.24, 0.05) 0.288 | 0.230 
All baseline values are unadjusted means ± SDs. All change values are unadjusted means (95% CI) and were calculated from the absolute difference from baseline. Mean net 
differences (95% CI) were calculated by subtracting the within-group changes for the Ex+Meat group from the within-group changes for the Ex+CHO group after 12 and 24 
weeks. Adjusted model included age, sex, education, smoking status, depression at baseline, change in physical activity and history of CVD as covariates. GMLT, Groton 
Maze learning; DET, detection task; IDN, identification task; OCL, one card learning task; ONB, one back working memory task. 
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Figure 4.6: Mean absolute changes in Z-scores (± 95% CI) from baseline to 12 and 
24 weeks for Groton Maze Learning task, Identification task, Detection task, One 
Card Learning task and the One Back working memory task score in the Ex+Meat 
(●) and Ex+CHO (○) group. #P<0.05 between-group difference in the change from 
baseline † P<0.05 within-group difference relative to baseline. 
Baseline  12 weeks 24 weeks 
Baseline  12 weeks 24 weeks Baseline  12 weeks 24 weeks 
Baseline  12 weeks 24 weeks Baseline  12 weeks 24 weeks 
# 
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Figure 4.7: Mean absolute changes in Z-scores (± 95% CI) from baseline to 12 and 
24 weeks for the working memory/learning composite score, psychomotor/attention 
composite score, cognitive brief battery composite score and combined cognitive 
score in the Ex+Meat (●) and Ex+CHO (○) group. #P<0.05 between-group 
difference in the change from baseline † P<0.05 within-group difference relative to 
baseline. 
 
BRIEF-A Questionnaire 
As shown in Table 4.9, there were no significant within group changes or between 
group differences (group-by-time interactions) for the BRIEF-A behavioural 
regulation index (BRI), a measure of inhibition, emotional control, and self-
monitoring, the metacognition index (MI), a measure of initiative, working memory, 
planning, task monitoring and organization, or the global executive composite (GEC) 
(Table 4.9). The results remained unchanged after adjusting for covariates.
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Table 4.9 Mean baseline T-scores for the BRIEF-A cognitive scores in the exercise and lean red meat (Ex+Meat) and exercise control 
carbohydrate (Ex+CHO) group, and mean within-group changes and net differences between the groups for the change after 24 weeks 
 Baseline Values and Within-Group Changes  
 Ex+Meat Ex+CHO Intervention Effects 
 
Mean ± SD or  
(95% CI) 
P-value 
Mean ± SD or  
(95% CI) 
P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  | Model 2 
BRI      
  Baseline, T-score 51.34 ± 10.22  49.53 ± 9.17    
  Absolute Δ 24-weeks -1.16 (-2.90, 0.57) 0.161 0.00 (-1.65, 1.65) 0.972 -1.16 (-3.54, 1.21) 0.298 | 0.307 
MI      
  Baseline, T-score 52.40 ± 9.25  51.30 ± 11.06    
  Absolute Δ 24-weeks -0.08 (-1.89, 1.73) 0.930 -0.35 (-2.18, 1.49) 0.775 0.27 (-2.29, 2.82) 0.894 | 0.896 
GEC      
  Baseline, T-score 52.01 ± 9.14  50.57 ± 9.91    
  Absolute  Δ 24-weeks -0.52 (-2.26, 1.22) 0.534 -0.14 (-1.83, 1.55) 0.930 -0.38 (-2.79, 2.03) 0.698 | 0.698 
All baseline values are unadjusted means ± SDs. All change values are unadjusted means (95% CI) and were calculated from the absolute difference from baseline. Mean net 
differences (95% CI) were calculated by subtracting the within-group changes for the Ex+Meat group from the within-group changes for the Ex+CHO group after 12 and 24 
weeks. Adjusted model included age, sex, education, smoking status, depression at baseline, history of CVD and change in physical activity as covariates. BRI, behavioural 
regulation index; MI, metacognition index; GEC, global executive composite. 
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4.4.10 Neurobiological markers and inflammation  
IGF-1 
For IGF-1, both groups experienced a similar significant increase after 12 weeks 
(Ex+Meat: 7.7%; Ex+CHO: 6.6%, both P<0.001) and 24 weeks (Ex+Meat: 5.3%, 
Ex+CHO: 6.6%, both P<0.01). As a result, there were no group-by-time interactions 
(Table 4.10). The results remained unchanged after adjusting for age, sex, change in 
habitual moderate to vigorous physical activity and BMI. 
 
BDNF 
For serum BDNF, there were no significant within group changes or between group 
differences after 12 or 24 weeks. However, there was a trend for the Ex+Meat group 
to experience a decrease in serum BDNF after 24 weeks (-7.0%, P=0.06), which led 
to a trend for a between group difference in the change after 24 weeks (P=0.08). 
These results did not change after adjusting for covariates (Table 4.10). 
 
VEGF 
There were no significant within group changes or between group differences for the 
change in VEGF after 12 or 24 weeks in the unadjusted and adjusted models (Table 
4.10). 
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Table 4.10 Mean baseline serum IGF-1, BDNF and VEGF values in the exercise and lean red meat (Ex+Meat) and exercise and control carbohydrate 
(Ex+CHO) group, and mean within-group changes and net differences between the groups for the change after 12 and 24 weeks. 
 Baseline Values and Within-Group Changes  
 Ex+Meat Ex+CHO Intervention Effects 
 
Mean ± SD or  
(95% CI) 
P-value 
Mean ± SD or  
(95% CI) 
P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  | Model 2 
IGF-1      
  Baseline, nmol/L 17.5 ± 4.9  16.7 ± 4.7    
  %∆ 12-weeks 7.7 (4.9, 10.6) 0.000 6.6 (2.6, 10.7) 0.000 1.1 (-3.9, 6.0) 0.624 |  0.735 
  %∆ 24-weeks 5.3 (1.6, 9.0) 0.001 6.6 (2.9, 10.2) 0.001 -1.2 (-6.3, 3.9) 0.769 |  0.644 
BDNF      
  Baseline, ng/mL 21.8 ± 7.9  20.8 ± 7.7    
  %∆ 12-weeks -4.9 (-12.2, 2.5) 0.170 -1.7 (-7.1, 3.8) 0.509 -3.2 (-12.2, 5.9) 0.460 | 0.328 
  %∆ 24-weeks -7.0 (-13.6, -0.5) 0.061 0.2 (-4.7, 5.2) 0.989 -7.3 (-15.4, 0.8) 0.129 | 0.091 
VEGF      
  Baseline, pg/mL 372.2 ± 282.2  442.7 ± 578.7    
  %∆ 12-weeks 0.5 (-8.4, 9.4) 0.828 -5.0 (-12.5, 2.4) 0.159 5.5 (-6.0, 16.9) 0.390 | 0.539 
  %∆ 24-weeks -6.4 (-20.1, 7.4) 0.362 0.3 (-6.3, 6.9) 0.964 -6.7 (-21.7, 8.4) 0.416 | 0.341 
All variables were log transformed prior to analysis. All baseline values are unadjusted means ± SDs. All change values are unadjusted means (95% CI) and were calculated 
from the absolute difference from baseline in log-transformed data multiplied by 100. Mean net differences (95% CI) were calculated by subtracting the within-group changes 
for the Ex+Meat group from the within-group changes for the Ex+CHO group after 12 and 24 weeks. P values for all measures were based on log-transformed data. Adjusted 
model included age, sex, BMI and change in physical activity as covariates. IGF-1, insulin like growth factor-1; BDNF, brain-derived neurotrophic factor; VEGF, vascular 
endothelial growth factor. 
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Figure 4.8: Mean percentage changes (± SEM) from baseline for insulin like growth 
factor-1 (IGF-1), brain-derived neurotrophic factor (BDNF) and vascular endothelial 
growth factor (VEGF) in the Ex+Meat (●) and Ex+CHO (○) group. #P<0.05 
between-group difference in the change from baseline † P<0.05 within-group 
difference relative to baseline. All change values were calculated from the absolute 
difference from baseline in log-transformed data multiplied by 100. Mean net 
differences (95% CI) were calculated by subtracting the within-group changes for the 
Ex+Meat group from the within-group changes for the Ex+CHO group after 12 and 
24 weeks, based on log-transformed data. 
† † 
† † 
Baseline     12 weeks       24 weeks 
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Adiponectin and Inflammatory Markers 
For adiponectin, there were no within group changes or group-by-time interactions 
after 12 or 24 weeks. However, after 12 weeks, there was a trend for a group-by-time 
interaction (P= 0.07) which was due to a small 4.5% decrease in the Ex+CHO group 
(P=0.064) and a non-significant 0.9% change in the Ex+Meat group. These results 
did not change after adjusting for covariates (Table 4.11). For the inflammatory 
markers hs-CRP, IL10, IL-8, IL-6 and TNF-α, there were no significant within group 
changes or between group differences for the changes after 12 or 24 weeks. All 
results remained unchanged after adjusting for covariates (Table 4.11). 
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Table 4.11 Mean baseline values for adiponectin and the various inflammatory markers in the exercise and lean red meat (Ex+Meat) and exercise and 
control carbohydrate (Ex+CHO) group, and mean within-group changes and net differences between the groups for the percent change after 12 and 24 
weeks. 
 Baseline Values and Within-Group Changes  
 Ex+Meat Ex+CHO Intervention Effects 
 
Mean ± SD or  
(95% CI) 
P-value 
Mean ± SD or  
(95% CI) 
P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  | Model 2 
Adiponectin      
  Baseline, µg/ml 5.15 ± 3.14  5.00 ± 3.14    
  %∆ 12-weeks 0.9 (-2.6, 4.3) 0.705 -4.5 (-9.2, 0.3) 0.064 5.3 (-0.5, 11.2) 0.090 | 0.109 
  %∆ 24-weeks -0.6 (-4.5, 3.2) 0.714 -3.5 (-8.9, 1.9) 0.121 2.9 (-3.8, 9.5) 0.312 | 0.476 
hs-CRP      
  Baseline, mg/L 2.13 ± 2.89  2.05 ± 2.42    
  %∆ 12-weeks 5.3 (-17.0, 27.6) 0.521 13.0 (-9.3, 35.4) 0.190 -7.8 (-39.1, 23.5) 0.644 | 0.846 
  %∆ 24-weeks 15.0 (-5.9, 35.8)
 
0.150 13.1 (-3.7, 29.8)
 
0.200 1.9 (-24.6, 28.4) 0.903 | 0.815 
IL-10      
  Baseline, pg/mL 11.95 ± 21.60  9.39 ± 10.98    
  %∆ 12-weeks -7.0 (-24.2, 10.3) 0.402 -1.0 (-20.3, 18.3) 0.905 -5.9 (-31.6, 19.8) 0.645 | 0.511 
  %∆ 24-weeks 3.9 (-15.0, 22.9)
 
0.673 -5.8 (-25.8, 14.2) 0.504 9.7 (-17.6, 37.0) 0.441 | 0.574 
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IL-8      
  Baseline, pg/mL 16.24 ± 10.96  15.01 ± 10.96    
  %∆ 12-weeks -2.3 (-12.8, 8.1) 0.691 3.0 (-3.7, 9.7) 0.495 -5.3 (-17.6, 6.9) 0.471 | 0.379 
  %∆ 24-weeks 0.8 (-7.8, 9.3)
 
0.828 5.0 (-3.3, 13.2) 0.241 -4.2 (-16.0, 7.6) 0.577 | 0.535 
IL-6      
  Baseline, pg/mL 4.79 ± 8.71  4.37 ± 7.04    
  %∆ 12-weeks -5.8 (-17.8, 6.1) 0.593 1.8 (-13.0, 16.6) 0.745 -7.6 (-26.6, 11.3) 0.554 | 0.565 
  %∆ 24-weeks 1.3 (-13.2, 15.8)
 
0.855 -4.6 (-21.6, 12.4) 0.547 5.9 (-16.3, 28.0) 0.565 | 0.551 
TNF-α      
  Baseline, pg/mL 10.06 ± 3.60  10.43 ± 4.20    
  %∆ 12-weeks -1.2 (-5.4, 3.0) 0.984 2.5 (-2.5, 7.5) 0.360 -3.7 (-10.2, 2.7) 0.535 | 0.424 
  %∆ 24-weeks 3.4 (-3.4, 10.1)
 
0.252 -1.0 (-7.1, 5.1) 0.701 4.4 (-4.6, 13.4) 0.275 | 0.280 
All variables were log transformed prior to analysis. All baseline values are unadjusted means ± SDs. All change values are unadjusted means (95% CI) and were calculated 
from the absolute difference from baseline in log-transformed data multiplied by 100. Mean net differences (95% CI) were calculated by subtracting the within-group changes 
for the Ex+Meat group from the within-group changes for the Ex+CHO group after 12 and 24 weeks. P values for all measures were based on log-transformed data. Adjusted 
model included age, sex, BMI and change in physical activity as covariates. CRP, C-reactive protein; IL, interleukin; TNF-α, tumor necrosis factor. 
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Figure 4.9: Mean percentage changes (± SEM) from baseline for adiponectin, C-
reactive protein, tumor necrosis factor-α, interleukin-10, interleukin-8 and 
interleukin-6 in the Ex+Meat (●) and Ex+CHO (○) group. #P<0.05 between-group 
difference in the change from baseline † P<0.05 within-group difference relative to 
baseline. All change values were calculated from the absolute difference from 
baseline in log-transformed data multiplied by 100. Mean net differences (95% CI) 
were calculated by subtracting the within-group changes for the Ex+Meat group 
from the within-group changes for the Ex+CHO group after 12 and 24 weeks, based 
on log-transformed data. 
α 
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Homocysteine 
For homocysteine, there were no within group changes or between group differences 
after 12 weeks. After 24 weeks, there was a significant but modest 3.0% increase in 
the Ex+CHO group (P<0.05) with no change in the Ex+Meat group (-1.1%, 
P=0.571), leading to a trend for a significant difference between the groups 
(P=0.066), which became significant in the adjusted model (P<0.05) (Table 4.12).  
 
Zinc 
For serum zinc, there were no significant within group changes or between group 
differences for the change after 12 or 24 weeks. The results did not change after 
adjusting for covariates (Table 4.12). 
 
Vitamin B12 
For vitamin B12, there was a significant 5.1% reduction in the Ex+CHO group 
(P<0.05) and no change in the Ex+Meat group (0.8%, P=0.487) after 12 weeks. This 
led to a trend for a significant group-by-time interaction (P=0.050). After 24 weeks, 
there was also a borderline significant group-by-time interaction for the change in 
serum vitamin B12 (P=0.053), which was due to a non-significant 6.5% increase in 
the Ex+Meat group (P= 0.258) and a 4.2% decrease in the Ex+CHO group 
(P=0.111). The group-by-time interactions became significant after 12 and 24 weeks 
in the adjusted models (Table 4.12). 
 
Serum 25-hydroxyvitamin D  
For serum 25-hydroxyvitamin D, there were similar significant increases in both 
groups after 24 weeks (Ex+Meat: 10.8 SD; Ex+CHO:  8.8 SD, both P<0.001).  As 
such, there was a significant time effect but no group-by-time interaction. The results 
did not change after adjusting for covariates (Table 4.12). 
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Table 4.12 Mean baseline values for serum homocysteine, zinc, vitamin B12 and 25-hydroyxvitamin D in the exercise and lean red meat (Ex+Meat) and 
exercise and control carbohydrate (Ex+CHO) group, and the mean within-group change and net between group difference for change after 12 and 24 weeks. 
 Baseline Values and Within-Group Changes  
 Ex+Meat Ex+CHO Intervention Effects 
 
Mean ± SD or  
(95% CI) 
P-value 
Mean ± SD or  
(95% CI) 
P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  | Model 2 
Homocysteine      
  Baseline, umol/L 11.1 ± 2.6  11.0 ± 2.6    
  %∆ 12-weeks 0.7 (-2.0, 3.5) 0.621 1.8 (-0.7, 4.4) 0.189 -1.1 (-4.8, 2.6) 0.604 | 0.422 
  %∆ 24-weeks -1.1 (-4.3, 2.2) 0.571 3.0 (0.1, 5.9) 0.036 -4.1 (-8.4, 0.2) 0.066 | 0.044 
Zinc      
  Baseline, ug/dL 77.6 ± 10.3  78.6 ± 10.2    
  %∆ 12-weeks 2.7 (-0.2, 5.5) 0.160 0.3 (-2.6, 3.2) 0.688 2.4 (-1.6, 6.4) 0.199 | 0.260 
  %∆ 24-weeks 2.41 (-0.8, 5.6)
 
0.163 -0.74 (-3.5, 2.0)
 
0.334 3.2 (-1.0, 7.3) 0.098 | 0.156 
Vitamin B12      
  Baseline, pmol/L 318.8 ± 148.3  335.13 ± 182.46    
  %∆ 12-weeks 0.8 (-3.6, 5.2) 0.487 -5.1 (-10.3, 0.0) 0.042 6.0 (-0.8, 12.7) 0.050 | 0.039 
  %∆ 24-weeks 6.5 (-2.0, 15.1)
 
0.258 -4.2 (-9.8, 1.4) 0.111 10.7 (0.6, 20.8) 0.053 | 0.035 
25-hydroyxvitamin D      
  Baseline, nmol/L 83.6 ± 23.0  83.0 ± 28.0    
  Absolute ∆ 24-weeks 10.8 (6.9, 14.6)
 
0.000 8.8 (4.6, 12.9) 0.000 2.0 (-3.7, 7.6) 0.462 | 0.630 
All variables were log-transformed prior to analysis. All baseline values are unadjusted means ± SDs. All change values were calculated from the absolute difference from 
baseline in log-transformed data multiplied by 100. Mean net differences (95% CI) were calculated by subtracting the within-group changes for the Ex+Meat group from the 
within-group changes for the Ex+CHO group after 12 and 24 weeks. Adjusted model included age, sex, BMI and change in physical activity as covariates.  
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Figure 4.10: Mean percentage changes (± SEM) from baseline for homocysteine, 
vitamin B12, serum zinc and 25-hydroyxvitamin D in the Ex+Meat (●) and Ex+CHO 
(○) group. #P<0.05 between-group difference in the change from baseline † P<0.05 
within-group difference relative to baseline. All change values were calculated from 
the absolute difference from baseline in log-transformed data multiplied by 100. 
Mean net differences (95% CI) were calculated by subtracting the within-group 
changes for the Ex+Meat group from the within-group changes for the Ex+CHO 
group after 12 and 24 weeks, based on log-transformed data. 
 
4.4.11 Secondary analysis 
A secondary analysis was performed to investigate if there were any gender 
interactions for all variables. There were no gender interactions found for measures 
of body composition, muscle strength, muscle function or cognitive function nor any 
of the neurobiological or inflammatory markers, with the exception of IL-6 (P<0.05) 
and TNF-α (P<0.01) after 24 weeks. For TNF-α, the interaction was driven by an 
increase in women in the Ex+Meat relative to the Ex+CHO group (mean change: 
0.09 SD, P<0.05); there were no changes in either group for the men. For IL-6, there 
was a decrease in men in the Ex+Meat relative to the Ex+CHO group (mean change: 
† 
† 
# 
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-0.16 SD and 0.11 SD, respectively; group-by-time interaction P=0.067) while for 
women, there was an increase in the Ex+Meat relative to the Ex+CHO group (mean 
change: 0.12 SD and -0.14 SD respectively, group-by-time interaction P=0.062). 
 
4.4.12 Per protocol (PP) analysis 
A per protocol analysis was also conducted which included participants in both 
groups who had ≥66% compliance with the PRT, and those who achieved ≥80% 
compliance with the lean red meat. This analysis included 58 participants in the 
Ex+Meat group and 64 participants in the Ex+CHO group. All results for the group-
by-time interactions remained the same except the following (Table 4.13): 
 For appendicular lean mass, there was a significant group-by-time interaction 
in both the unadjusted and adjusted models (both P<0.05) (Ex+Meat 0.40 SD; 
Ex+CHO 0.19 SD, both P<0.01). 
 For arm lean mass, the group-by-time interaction in the unadjusted model 
was no longer significant although a trend persisted (P=0.060) despite the 
magnitude of change being similar to that of the ITT.  
 For gait speed, the net difference for the change over time was similar to the 
ITT, but the group-by-time interaction in the unadjusted model was no longer 
significant (P=0.06).  
 For the FSST, the within group change in the Ex+CHO group was similar to 
the ITT but it was no longer significant (P=0.140) which led to a borderline 
significant group-by-time interaction in the adjusted model (P=0.058). 
 For the DET and OCL task, the group-by-time interactions for the change 
after 12 weeks were no longer significant (P=0.119 and P=0.188 
respectively), although the magnitude of change was similar to the ITT.  
 For the ONB task, the group-by-time interaction for the change after 12 
weeks became significant (P<0.05), which was driven by a mean 0.25 SD 
increase in the Ex+CHO group (P<0.01) with no change in the Ex+Meat 
group (-0.01 SD, P=0.928).  
 For the psychomotor/attention composite scores, the group-by-time 
interaction for the change after 12 weeks was no longer significant, although 
there was still a trend in the unadjusted model (P=0.072). This may have been 
due to a smaller decrease in the Ex+CHO group compared to the ITT (-0.26 
SD versus -0.32 SD respectively). 
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 For homocysteine, the significant group-by-time interaction after 24 weeks 
was no longer significant (P=0.072). 
 For vitamin B12, the within group change after 12 weeks for the Ex+Meat 
group was borderline significant [mean change: 4.0% (95% CI: -0.7, 8.7), 
P=0.055]. As such, there was a significant net difference for the change after 
12 weeks [-9.7% net difference (95% CI: -17.0, -2.4)] and 24 weeks [-7.6% 
net difference (95% CI: -15.4, 0.00). 
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Table 4.13 Significant group-by-time interactions for unadjusted and adjusted models for the per-protocol analysis compared to the intention-to-
treat analysis for body composition, muscle function, cognitive function, neurobiological markers, growth factors and inflammation.  
 12 Weeks 24 Weeks 
 ITT PP ITT PP 
 Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted 
Total body and regional body composition 
  Weight - - - - X X X X 
  Total body lean mass - - - - X X X X 
  Total body fat mass - - - - X X X X 
  Appendicular lean mass - - - - X X √ √ 
  Arm lean mass - - - - √ √ X √ 
  Leg lean mass - - - - X X X X 
  Arm fat mass - - - - X X X X 
  Leg fat mass - - - - X X X X 
Muscle Strength and Function 
  1-RM (Leg Press) - - - - X X X X 
  Knee extensor strength - - - - X X X X 
  4 metre walk (gait speed) - - - - √ X X X 
  Four square step test - - - - X √ X X 
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Cognitive Function 
  GMLT (Z scores total errors) X X X X X X X X 
  DET Task (Z scores speed) √ X X X X X X X 
  IDN Task (Z scores speed) X X X X X X X X 
  OCL Task (Z scores accuracy) √ X X X X X X X 
  ONB Task (Z scores speed) X X √ √ √ √ √ √ 
  Working Memory/ Learning √ √ √ √ √ √ √ √ 
  Psychomotor/ Attention √ X X X X X X X 
  Cognitive Brief Battery X X X X X X X X 
  Global Cognitive Score X X X X X X X X 
  Behavioural regulation Index - - - - X X X X 
  Metacognition Index - - - - X X X X 
  Global Executive Composite - - - - X X X X 
Neurobiological markers, growth factors and inflammation 
  IGF-1 X X X X X X X X 
  BDNF X X X X X X X X 
  VEGF X X X X X X X X 
  Adiponectin X X X X X X X X 
  hs-CRP X X X X X X X X 
  IL-10 X X X X X X X X 
  IL-8 X X X X X X X X 
  IL-6 X X X X X X X X 
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  TNF-α X X X X X X X X 
  Homocysteine X X X X X √ X X 
  Zinc X X X X X X X X 
  Vitamin B12 X √ √ √ X √ √ √ 
  25-hyrdoxyvitamin D - - - - X X X X 
X: no significant group-by-time interaction; √: significant group-by-time interaction; -: interaction not assessed. ITT, intention-to-treat; PP, per protocol; GMLT, Groton Maze 
learning; DET, detection task; IDN, identification task; OCL, one card learning task; ONB, one back working memory task; IGF-1, insulin like growth factor-1; BDNF, brain-
derived neurotrophic factor; VEGF, vascular endothelial growth factor; CRP, C-reactive protein; IL, interleukin; TNF-α, tumor necrosis factor. 
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4.4.13 Exploratory analysis 
Exploratory analysis of the association between the changes in cognitive function 
with baseline ALM, muscle strength and function in all participants combined is 
shown in Appendices W through to AH. A Bonferroni adjusted P-value of 0.0125 
was used to assess significance to allow for multiple comparisons. There were no 
associations found between changes in cognitive function with baseline ALM, 
muscle strength, gait speed or mobility, with the exception that changes in the 
working memory/learning composite were negatively associated with ALM 
(P=0.010). When assessing the relationship between the changes in cognitive 
function with changes in ALM, strength or function, there were no significant 
associations found (Appendix X). 
 
A Bonferroni adjusted P-value of 0.0167 was used to assess significance for any 
association between baseline levels and changes in various growth and neurotrophic 
factors as well as homocysteine, vitamin B12 and bioavailable zinc, while an 
adjusted P-value of 0.008 was used to assess significance between changes in 
cognitive function and inflammatory markers. Changes in executive function 
(GMLT) were positively associated with baseline levels of BDNF (P=0.005) while 
changes in the behavioural regulation index were negatively associated with baseline 
levels of BDNF (P<0.011) (Appendices Y and Z). There were no associations 
observed between changes in cognitive function with changes in growth and 
neurotrophic factors as well as inflammatory markers and bioavailable zinc.  
 
4.5 Discussion  
The main finding from this 24-week RCT in community-dwelling older adults was 
that a multi-component exercise program was associated with improvements in a 
number of cognitive domains including global cognitive function and executive 
function, but the provision of a protein-enriched diet achieved through the 
consumption of lean red meat (2 x ~80 g cooked) on each of the three training days, 
did not enhance these benefits. In fact, for working memory and learning there was a 
greater improvement in the Ex+CHO compared to the Ex+Meat group. Both groups 
experienced similar significant increases in lower limb muscle strength and a 
reduction in total body fat mass, but there was a greater improvement in arm lean 
mass and a net benefit in gait speed in the Ex+Meat group, with a trend for a greater 
net gain in appendicular lean mass as well as mobility after 24 weeks. However, 
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there were no changes in any circulating growth, neurobiological or inflammatory 
markers throughout the intervention in either group, with the exception of IGF-1 
which increased in both groups.  
 
To our knowledge, only one previous trial has investigated the effect of increased 
dietary protein combined with exercise on cognitive function in older adults (70). A 
24-week RCT in 62 frail elderly found that twice daily protein supplementation (2 x 
15 g milk protein concentrate) combined with twice weekly PRT had no effect on 
cognitive function as assessed by the MMSE (70). Secondary analysis using a 
factorial design which combined data from the above study (70) and another 
previous 24-week study in older frail and pre-frail adults by this group which 
included twice daily protein supplementation (2 x 15 g milk protein concentrate) or 
placebo without exercise (278), also failed to detect any synergistic interaction of a 
protein-enriched milk drink combined with twice-weekly PRT on any cognitive 
domain (episodic memory, attention and working memory, information processing 
speed and executive function) (327). However, the authors noted that the study was 
only powered for main effects and not exercise-protein interactive effects. 
Subsequent post-hoc analyses revealed that exercise combined with the protein-
enriched milk was associated with a net benefit in information processing speed 
compared to the protein-enriched milk alone, but the opposite was observed for 
verbal fluency (327). Furthermore, attention and working memory was found to 
improve following PRT alone compared to the non-exercise group (327). While it is 
difficult to explain the contrasting findings from this trial, in our study we observed 
that both groups experienced a significant 0.17 to 0.26 SD exercise-related 
improvement in global cognitive function and a 0.33-0.39 SD improvement in 
executive function (GMLT) after 24 weeks, but there was no added benefit for any 
cognitive domain with the additional protein (red meat) to the exercise program. In 
contrast, there was a significant improvement in working memory and learning in the 
Ex+CHO compared to the Ex+Meat group after both 12 and 24 weeks. The reason(s) 
for these conflicting findings and the lack of any additive benefits from the protein 
(red meat) may be related to a number of factors, including the relatively short 
duration of our study, the type, quality, dose and spread (within group change or 
between group difference) of total protein intake, the level of protein intake at 
baseline, and potential changes (or lack thereof) in other outcome measures 
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associated with cognitive function including circulating growth factors, 
neurobiological and inflammatory markers as well as muscle mass and strength.  
 
The mixed findings with regard to the effects of dietary protein alone or protein 
combined with exercise on cognitive function in older adults may be related in part, 
to the different type/source of protein used (e.g. dairy, soy, supplemental, animal) 
(41, 45, 46, 60, 247, 254, 257, 259, 260, 278). There is some promising data from 
multiple intervention trials supporting both acute and long-term effects (up to 24 
weeks) of increased dietary protein (e.g. dairy, supplemental, animal) on certain 
cognitive measures (memory and reaction time) (48, 49, 53-55, 277). However, 
whether similar cognitive benefits can be achieved with animal protein rich foods 
such as red meat remains uncertain as the limited observational studies (250-252, 
256, 261, 279) and intervention trials have reported contrasting results (54, 55). The 
findings from our study indicate that the consumption of two 80 g (cooked) serves of 
high-quality lean red meat consumed as part of a mixed meal for lunch and dinner on 
each of the three exercise training days was not effective for improving cognition in 
community-dwelling healthy older adults. While this could be explained in part by 
the fact that we included healthy older adults with above average protein intakes 
(mean ~1.25 g/kg/d) who were cognitively intact, a 3-week RCT in 23 healthy young 
men aged 19-31 years found that a high animal protein (low fat pork, beef, chicken, 
milk and cheese) diet that increased protein intake to 3.0 g/kg/d was associated with 
improvements in reaction time and a decrease in errors compared to the usual protein 
group (1.5 g/kg/d), as well as an improvement in global cognitive function compared 
to baseline (55). However, since this study was limited to young, healthy men, 
increased total protein intakes to 3.0 g/kg/d, used a range of different types of animal 
protein and did not include resistance training, it is difficult to directly compare the 
findings to our study. Nevertheless, these findings provide some evidence that an 
acute increase in protein intake via meat and dairy sources in healthy adults can lead 
to some improvements in cognitive function. 
 
As reported above, there is some evidence from one 24-week intervention trial in 
pre-frail and frail older adults that combining dairy protein supplementation (2 x 15 g 
milk protein concentrate) with exercise which supports a positive effect on certain 
cognitive domains (e.g. reaction time, processing speed) (327). While the underlying 
mechanism(s) contributing to these benefits remain uncertain, it has been proposed 
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that the consumption of milk or dairy products may have beneficial effects on 
cognitive health via improvements in cardiovascular risk factors, reduced oxidative 
stress, increased vitamin B12 and/or increased serotonin levels via tryptophan, which 
is an amino acid precursor of serotonin. In part support of this notion, one review 
found that while the intake of dairy products is associated with improvements in a 
number of these factors (e.g. systolic blood pressure, type 2 diabetes and insulin 
resistance, risk of stroke and heart disease) (1), whether dairy-related improvements 
in these factors are associated with improvements in cognitive function is unclear. 
Lean red meat is a rich source of many of the above nutrients and minerals which 
have been shown to have a beneficial effect on cognitive function. For instance, 100 
g of cooked red meat will provide over two-thirds of the daily requirement of 
bioavailable vitamin B12 and at least a quarter of the requirements for bioavailable 
zinc and iron (59). Indeed, there is some evidence that the consumption of red meat 
contributes between 20% and 40% of vitamin B12 intake in the United States of 
America (292). In Australia, it has been found that women of childbearing age who 
consume less than two serves of red meat a week have lower dietary intake of 
vitamin B12 (286). This is important because low serum vitamin B12 status has been 
shown to be associated with more rapid cognitive decline (494). Conversely, there is 
some evidence that vitamin B12 supplementation has positive effects on circulating 
levels of homocysteine which is important as homocysteine has been associated with 
the development of  brain lesions (207, 290, 291). In our study, there was a trend 
(P=0.05) for a between-group difference in the change of serum vitamin B12 levels 
after 12 and 24 weeks which was due to a 6.5% increase in the Ex+Meat group and a 
5.0% decrease in the Ex+CHO group. There was also a net benefit to serum 
homocysteine levels in the Ex+Meat group, which was driven largely by a 3.0% 
increase after 24 weeks in the Ex+CHO group. However, the net benefit to the 
Ex+Meat group for these measures were relatively modest (4 to 11%) which may 
explain the lack of any additive effects in our trial. Furthermore, exploratory analysis 
showed that neither baseline nor changes in serum vitamin B12 and homocysteine 
were associated with changes in any measure of cognitive function.   
 
As previously mentioned, red meat is a rich source of essential amino acids and 
protein (239), with 100 g of cooked red meat containing 28-36 g of high-quality 
protein (59), 94% of which is highly digestible (59), contributing to its high protein 
quality. Protein quality is important as it takes into consideration essential amino acid 
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content, digestibility, amino acid bioavailability, and the quantity of the limiting 
essential amino acid, which limits the rate at which protein synthesis can occur (495). 
Thus it is possible that differences in the protein quality of various foods may 
partially explain the contrasting results between our study and others which have 
used different sources of protein (or foods with different levels/types of protein), in 
terms of cognitive function. For instance, milk protein sources compared to beef, 
have slightly higher scores for digestibility of indispensable amino acids (1.4 versus 
1.1), and biological value (91 versus 80), meaning that it is slightly more digestible 
and used more efficiently in the body (495). This is important as amino acids are 
thought to influence neurotransmitters which may be important for cognitive 
function (60, 62). For instance, red meat is a rich source of the essential amino acid 
tryptophan (415 mg per 100 g of red meat) which is a pre-cursor for serotonin. 
Serotonin plays an important role in depression, pain and endocrine (hormonal) 
regulation (105) and has been associated with neurogenesis and synaptic plasticity, 
particularly for memory (1, 47, 62, 88, 263, 265). However, paradoxically, there is 
evidence to suggest that protein-rich foods do not increase levels of tryptophan and 
serotonin in the brain, despite an increase in tryptophan in the blood (496-500). This 
has been suggested to be related to the larger concentration of other essential amino 
acids such as leucine from protein, which competes with tryptophan for uptake into 
the brain (496-500). It is difficult to speculate whether this was a contributing factor 
to the lack of effect on cognitive function in our study, as tryptophan and serotonin 
levels were not measured and the effects of red meat on levels of tryptophan have not 
been specifically investigated.  
 
While there is limited and mixed evidence for the effect of increased meat intake on 
cognitive function, previous data from some longitudinal studies suggests an 
association between increased meat intake and an increased risk for cognitive decline 
(56, 281, 305, 306). This has been suggested to be related to an increase in saturated 
and trans fat content in meat products (including processed and untrimmed cuts of 
meat) categorised under ‘red meat’ in these studies, which may contribute to an 
increase in cardiovascular disease risk (56, 189). This is important as cardiovascular 
health is well established to be an important risk factor for cognitive decline (135, 
153, 154). In part support of this, one meta-analysis of 20 studies investigating the 
effect of red and processed meat on various cardiovascular conditions found that 
processed meats, but not red meat, increased the risk for vascular related diseases 
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(RR=1.42 coronary heart disease; RR=1.19 type 2 diabetes) (284). However, whether 
a greater intake of red meat and any associated increased risk for cardiovascular 
disease is related to cognitive decline, remains unknown. In our study, total and 
saturated dietary fat intake did not change in either group, with the exception of total 
fat intake on non-training days after 12 weeks which increased in the Ex+Meat 
group. Further, there were no adverse effects of the increased red meat on any 
cardiovascular disease risk factor [e.g. serum cholesterol, blood lipids or blood 
pressure (data not reported)]. Collectively, these findings imply that the consumption 
of lean red meat in accordance with Australian dietary guidelines (3-4 serves per 
week) and in combination with exercise is safe and does not have any negative 
effects on cardiovascular health in healthy older adults. Alternatively, this may also 
be related in part, to the fact that participants undertook a structured exercise 
program three times a week, which may have blunted any potential adverse effects of 
an increased meat intake. 
 
For older adults, current international consensus guidelines recommend a daily 
protein intake of at least >1.2 to 1.5 g/kg body weight or 20-40 g of high quality 
protein ingested following PRT to promote MPS and muscle hypertrophy (68, 69). 
As discussed above, there is some evidence to support a link between dietary protein 
and cognitive function (53, 247), but whether there is an optimal level or dose of 
protein that is needed to optimise cognitive function in older adults remains 
unknown. In a study of 178 institutionalised older adults, positive associations were 
observed between higher protein (~70 g/day) and meat intake (~93 g/day) and 
improved cognitive function (reduced errors) (251). Further, a recent prospective 
study conducted in 475 Chinese older adults found that a moderate or high meat 
(including meat, poultry and roasted meats) dietary pattern score (tertiles 2-3) was 
protective against decline in attention (β = 0.20–0.22), although a high meat dietary 
pattern score was also associated with a decline in verbal-fluency (β= -0.19) (305). 
Several other cross-sectional studies have also reported no association between meat 
intake and cognitive function (250, 261), even when meat was consumed 4-6 times 
per week (280). In part support of these findings, we observed no added benefits of 
the lean red meat with exercise for any measure of cognitive function, despite 
participants in the Ex+Meat group consuming approximately 45 g of protein twice a 
day prior to and/or following each exercise session and achieving an average protein 
intake above 1.4 g/kg body weight on each of the three training days (and 1.2 g/kg on 
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the non-training days). In contrast, several previous RCTs which have reported 
improvements in cognitive function in healthy, pre-frail and frail older adults 
following ingestion of dietary protein alone (supplemental and animal protein), used 
doses ranging between 25 g of animal protein (pork and chicken) on four days a 
week for 12 weeks (54), 30 g of supplemental protein (milk protein concentrate) 
daily for six months (277), and a single dose of 50.5 g of whey protein (53). Further, 
one 24-week RCT which used a 30 g daily dose of milk protein concentrate 
combined with twice-weekly PRT, reported improvements in reaction time and 
processing speed in pre-frail and frail older adults (327). Although these findings do 
not provide any definitive evidence regarding whether there is an optimal dose of 
protein needed to maintain (or improve) cognitive function, the level of protein used 
in these studies (and the duration of the interventions) were comparable to our trial. 
Further, a number of previous RCTs which used protein doses similar to or below 
these levels (24 g of milk protein (270) and 20 g soy protein (269)) failed to detect 
any cognitive benefits in older adults. A possible explanation for the contrasting 
findings may relate to the participants’ habitual protein intake prior to the 
commencement of the study. In several of these trials, habitual protein intake was 
~76 to 81 g/day (54, 277), which is close to current recommended levels for older 
adults (501).  
 
As previously mentioned, participants in our study had a relatively high basal 
habitual intake (mean ~1.25 g/kg/d), which is comparable to current international 
consensus guidelines for dietary protein for older adults undertaking exercise 
(resistance) training (501). Although the mean change in total protein intake in the 
Ex+Meat group was ~0.16 g/kg/d on the three training days, any potential benefit for 
cognitive function may have been attenuated by the fact that habitual protein intake 
was already adequate. In part support of this notion, van de Rest and colleagues 
reported an added benefit of a protein enriched milk drink (2 x 15 g milk protein 
concentrate daily) on information processing speed, when combined with twice-
weekly PRT (327) in participants with a baseline protein intake of ~1.0 g/kg/d (70). 
In this study, mean habitual protein intake increased to ~1.3 g/kg/d with 
supplementation, which was double the mean change (0.30 vs 0.16 g/kg) observed in 
our trial. Another study in healthy older adults also reported that an inadequate 
protein intake (dose not reported) was associated with lower memory scores (46). In 
contrast, several other studies which included participants with intakes ranging from 
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1.1 to 1.5 g/kg/d at baseline (55, 277) have found beneficial effects of increased 
dietary protein on cognitive function. One of these studies was a 3-week RCT 
conducted in 23 healthy young men aged 19-31 years (55), and despite participants 
being young adults with a high habitual protein intake (~1.5 g/kg/d), they observed a 
much larger increase in protein intake following supplementation (mean change ~1.5 
g/kg/d). This suggests that the spread or magnitude of change in protein intake may 
also be an important factor. Another possible explanation for the contrasting findings 
may be that participants in these previous studies consumed additional protein daily 
(55, 277), whereas in our study, participants only consumed the protein on the three 
training days each week. Collectively, these findings suggest that when basal protein 
intakes are equivalent to or above current international consensus guidelines (~1.2 
g/kg/d), a larger and/or more frequent dose of protein than that used in our study, 
may be required to increase protein intake to a level which results in cognitive 
benefits. 
 
Previous research has shown that zinc is essential for the maintenance of homeostasis 
and also has the ability to act as a neurotransmitter for intercellular functioning 
(296), indicating that it is an important nutrient for cognitive function. In our study, 
mean dietary zinc intake at baseline (~11 mg/d) was within the Australian RDI (8-14 
mg/d). Despite this, the lean red meat resulted in a ~6.0 mg/d mean increase in 
dietary zinc intake in the Ex+Meat group on the training days, but serum zinc 
concentrations did not change over time or differ between the groups. Further, 
changes in serum bioavailable zinc were not associated with changes in cognitive 
function in the exploratory analysis. The lack of change in serum zinc levels may 
therefore be a contributing factor to the lack of added benefit observed for cognitive 
function in the Ex+Meat group. In support of this notion, a six month RCT in healthy 
adults aged 57 to 87 years which reported increased serum zinc levels following 
supplementation with 15 mg/d or 30 mg/d of zinc, found an interaction between zinc 
supplementation and improvements in the number of errors on a cognitive task after 
three months (298). Thus, the results of our study suggest that the intake of zinc 
obtained from lean red meat appears to be insufficient alone to increase serum zinc 
concentrations in healthy older adults.  
 
Previous research has shown that an increase in levels of circulating growth factors, 
particularly IGF-1, has been associated with benefits for cognitive function (109, 
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110). For instance, there is some evidence that IGF-1 levels are important for 
stimulating a number of different neuronal cells and for resistance to amyloid 
toxicity, preventing the onset of AD in adults (111). Additionally, a meta-analysis of 
13 studies examining the effects of IGF-1 on cognitive function in healthy older 
adults found a significant positive correlation between IGF-1 and MMSE scores 
(effect size of 0.81) and a positive correlation between serum IGF-1 and all measures 
of cognitive function (effect size of 0.57) (109). Although there is some evidence that 
protein intake or protein supplementation alone or with PRT can increase levels of 
IGF-1 (72, 308, 309), there are no studies which have investigated whether protein-
induced changes in IGF-1 are directly associated with changes in cognitive function. 
In our study, both groups experienced similar significant increases in serum IGF-1 
levels, with no additional benefits in the Ex+Meat group. Furthermore, exploratory 
analyses revealed that these increases were not associated with the changes in 
cognitive function. In part support of our findings, one 3-week RCT in 23 healthy 
young men found that a high animal protein (low fat pork, beef, chicken, milk and 
cheese) diet that increased protein intake to 3.0 g/kg/d was not associated with any 
changes in IGF-1, despite improvements in reaction time, a decrease in errors and an 
improvement in global cognitive function (55). The potential reason(s) for the lack of 
an added benefit of the protein on IGF-1 in our study may be related to the high 
habitual protein intake of our participants, the modest increase in dietary protein 
intake (~0.16 g/kg on training days) and the fact that participants only consumed the 
red meat on each of the three training days. In part support of this notion, a previous 
4-month RCT conducted in 100 healthy older women aged between 60 and 90 years 
in which habitual protein intake at baseline was ~1.1 g/kg/d, reported an additional 
10% increase in serum IGF-1 in a group consuming lean red meat across two meals 
(~160 g in total) six days per week combined with twice-weekly PRT, compared to 
PRT alone (72).  
 
Serum concentrations of BDNF have been shown to be associated with memory and 
learning (77), and reduced serum levels of BDNF have been associated with 
decreased cognitive performance in individuals with MCI (116). Further, while brain 
levels of VEGF have been suggested to improve cognitive function through 
angiogenesis (78) the evidence for the effects of circulating levels of VEGF on 
cognitive function is mixed (112-114). In our study, we did not observe any changes 
in serum BDNF or VEGF in either group, indicating that not only did the protein (red 
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meat) not have any added benefit on these measures, but there were no benefits 
associated with the exercise training. To our knowledge, no previous protein-exercise 
intervention trials have evaluated changes in serum BDNF or VEGF levels. 
Furthermore, previous data on the effect of other dietary factors on these markers is 
limited, although there are some animal and human studies which have found that 
intermittent fasting and caloric restriction is beneficial for cognitive function through 
increases in BDNF levels (315-318) and a high saturated diet results in decreases in 
BDNF levels (319, 320). There is also some evidence that increasing dietary zinc 
intake may influence BDNF levels (321). While is difficult to speculate why there 
was no effect of our intervention on these markers, it could relate to the high habitual 
protein intake and/or the modest change in protein. The potential reason(s) for a lack 
of effect related to the exercise will be discussed later. 
 
Another key finding from our study that may have contributed to the lack of an effect 
on cognitive function was that there was no effect of our intervention on any pro- or 
anti-inflammatory marker after 12 or 24 weeks, despite a reduction in fat mass in 
both groups. Increased levels of pro-inflammatory markers (e.g. IL-6, hs-CRP and 
TNF-α) have been associated with cognitive decline in older adults (23, 44, 179, 198, 
310). While there is some evidence that exercise can reduce inflammation which 
contributes to the prevention cognitive decline (25, 26), whether exercise-induced 
changes in inflammation have direct effects on cognitive function remains unknown. 
With regard to the effects of protein and meat on markers of inflammation, the 
evidence is mixed (58, 324, 325). For instance, while an increased meat intake 
(including processed meats) associated with a Western style diet has been associated 
with increased inflammation (IL-6) in adults aged 45-79 years (325), others have 
reported that lean red meat (200 g/d for 8 weeks) does not increase markers of 
inflammation (hs-CRP, leukocytes, fibrinogen) in non-smoking healthy adults with a 
mean age of ~60 years (58). The finding that there were no changes in any 
inflammatory marker in our study may be explained by the fact that we only 
recruited healthy older adults. Although many of our participants reported having 
one or more chronic diseases, most were managing these conditions with medication 
(e.g. lipid lowering or anti-hypertensive medication). Furthermore, only 18% of 
participants had a hs-CRP level >3 mg/L, which is often used as a global marker of 
increased inflammation. Subgroup analysis of a 2015 meta-analysis reported that 
there was a small, but significant effect of protein (whey) on lowering serum hs-CRP 
 236 
 
levels in those with baseline values ≥3 mg/L (502). Further, one previous 4-month 
RCT conducted in 100 older women (mean CRP 3.6 mg/L) found that lean red meat 
(consumed across two meals, 2x80 g cooked consumed on six days a week) 
combined with PRT resulted in a 16% greater reduction in serum IL-6 compared to 
PRT alone (72). Given that the inclusion criteria and intervention were very similar 
across these two studies, with the main difference being the frequency at which the 
lean red meat was consumed (six vs three days per week), this suggests that the dose 
of protein may play an important role. However, to our knowledge, no studies have 
investigated the effects of different doses of protein on markers of inflammation. 
Despite this, an 8-week RCT conducted in 31 adults (mean age: ~58 years) reported 
a trend for a decrease in hs-CRP following ~200 g/d raw weight of lean red meat 
compared to a control group, despite hs-CRP levels being within the normal range at 
baseline (mean 1.65 mg/L) (58). While further studies are needed to evaluate the 
effects of different types (and doses) of protein on markers of inflammation and 
cognition, the findings from our study provide some evidence that additional serves 
of lean red meat have no negative effect on markers of inflammation in healthy older 
adults participating in an exercise program. 
 
Despite the lack of an exercise-protein interactive effect on cognitive function in our 
study, we did observe that our multi-component exercise program incorporating 
aerobic training, PRT and challenging balance and mobility exercise was effective 
for improving global cognitive function (mean change 0.17-0.26 SD) as well as 
executive function (GMLT) (mean change 0.33-0.39 SD) in both groups. Consistent 
with these findings, many previous intervention trials have shown that different 
modes of exercise training including aerobic training and PRT can improve various 
domains of cognitive function in older adults (22, 23, 35, 161, 276, 327). Although 
questions still remains with regard to the optimal type and dose of training needed to 
improve cognitive function in older adults, a 2017 meta-analysis of 39 exercise 
intervention trials in adults aged 50 years and over reported that aerobic, resistance 
and multi-component exercise interventions were all effective for improving 
cognition (estimate mean effect size 0.24 to 0.33) (369). It was also reported the 
interventions that were moderate and high in intensity with a duration of 45 to 60 
minutes were optimal, both of which were key features of our multi-component 
exercise intervention. However, an important question in our study is whether the 
changes we observed in global cognitive function and executive function are 
 237 
 
clinically meaningful. While the CogState brief battery is a relatively new tool 
available for assessing cognitive function, there is data showing that it can be used to 
screen for AD-related cognitive changes (122). For instance, it has been reported that 
there was a ~0.4 to ~0.8 SD difference in working memory tasks and a ~1.1 to 1.7 
SD difference for psychomotor/attention tasks for those with MCI compared to 
healthy older adults (122). Others have suggested that a 0.5 SD improvement in 
cognitive function is regarded as a meaningful change in cognitively healthy adults 
(48). This is supported in part by the findings from a 36-week prospective study 
which reported that there was up to a ~0.5 SD greater deterioration for performance 
in working memory tasks in those with MCI compared to healthy controls who had 
low levels of beta amyloid in the brain (121). Another study reported that a 0.05 SD 
change in cognitive function is equivalent to being 1-2 years younger (205). Based 
on these findings, the mean 0.17-0.26 SD improvements in global cognitive function 
and 0.33-0.39 SD gains in executive function over 24 weeks in our trial is likely to 
represent clinically meaningful improvements.  
 
Executive function is a higher-level function and changes in this domain have been 
suggested to be related to changes in other more basic cognitive processes (e.g. 
memory) (80). The evidence for the effect exercise on executive function, for the 
most part, is positive with several previous RCTs reporting improvements in both 
healthy adults and those with MCI following PRT and multi-component exercise 
training (347, 349, 362, 365, 366). The findings of our study add to these findings as 
executive function as measured by the Groton Maze Learning Task (GMLT), 
increased by 0.33-0.39 SD in both groups. The type and dose of the exercise program 
may be a contributing factor to the positive findings for executive function in our 
study and previous studies. For instance, the prescribed type and dose of exercise in 
our study was similar to several previous successful trials involving moderate-
intensity multi-component exercise (including aerobic, PRT, balance/ postural 
exercises) performed on three-four days a week for a duration ranging from nine to 
16 weeks in older adults which also reported improvements in executive function 
(362, 365, 366). While it is difficult to compare the magnitude of improvement in our 
study to that of previous studies due to the diverse tests used to assess executive 
function, a 9-week RCT conducted in 109 adults with dementia which randomised 
participants to either a combined training program (two walking and two strength 
sessions per week), aerobic group (four walking sessions a week) or a social group 
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(four social visits a week), found that the combined program resulted in a 0.3 SD 
improvement for executive function compared to the social group (362), which was 
similar to that of our study. The larger positive effect in our study following the 24-
week intervention may be related to the longer study duration.  
 
Age-related declines in attention have been proposed to be due to a phenomenon 
known as the speed-accuracy trade off where deficits in information processing 
speed cause older adults to perform tasks more slowly in order to maintain the same 
level of accuracy as a younger person (92). In our study, there were no significant 
differences in psychomotor/attention scores between the groups after 24 weeks, 
however, there was a significant 0.32 SD decline in psychomotor/ attention scores in 
the Ex+CHO group after 12 weeks. It is difficult to determine whether the speed-
accuracy trade off phenomenon may be a contributing factor to our findings as we 
did not assess information processing speed specifically. Previous studies also 
suggest that age-related changes in various vascular risk factors (e.g. blood pressure), 
which can lead to white matter lesions in the brain (88) and damage myelin or lead to 
disruptions in connectivity, which may be related to impaired information processing 
(99) and declines in cognitive function including memory and executive function 
(97). However, given that just over half of participants in our study were taking anti-
hypertensive medication at baseline (44% and 34% in the Ex+Meat and Ex+CHO 
groups respectively), and the fact that this was an exercise intervention which has 
been shown to improve cardiovascular risk factors, it is unlikely that this was a 
contributing factor to our findings.  
 
An interesting finding from our study was that there were no improvements for 
working memory in the Ex+Meat group, but there were significant improvements in 
the Ex+CHO group after 12 and 24 weeks. Previous research which has examined 
the effect of protein on working memory is mixed (48, 249, 270, 277) which may be 
related to the type and dose of protein used across studies. The lack of effect in the 
Ex+Meat group for working memory and learning in our study is also difficult to 
explain, especially given that compliance with the exercise program was similar in 
both groups (Ex+Meat: 77.9% and Ex+CHO: 78.6%). One possible explanation for 
the beneficial effect in the Ex+CHO group may be related to the larger proportion of 
APOE-4 carriers. There is evidence to suggest that APOE-4 carriers are more 
sensitive to cognitive change (116) and so the participants in this group may have 
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been more sensitive to the effects of the exercise compared to those in the Ex+Meat 
group for the working memory domain. However, after adjusting for APOE status in 
the analysis, our results remained unchanged. Further, in our study, there were 
additional decreases observed for serum vitamin B12 in the Ex+CHO group 
compared to the Ex+Meat group. Vitamin B12 has been implicated in cognitive 
function through the removal of homocysteine (207, 290, 291). This complicates our 
findings as homocysteine has been associated with an increased risk for cognitive 
decline and dementia due to its role in promoting β-amyloid-peptide neurotoxicity 
(503) and there was an increase in serum homocysteine levels in the Ex+CHO group 
after 24 weeks compared to baseline. 
 
One of the mechanisms proposed through which exercise might improve cognitive 
function is via an increase in various circulating growth and neurotrophic factors. 
Specifically, IGF-1 has been shown to play an important role in proliferation, anti-
apoptotic functions and neurogenesis, all of which are important for cognitive 
function (107). There is also evidence that IGF-1 may promote cognitive benefits 
through an interaction with other neurotrophic factors such as BDNF and VEGF 
(321). In our study, we observed similar, albeit modest (~6%) increases in serum 
IGF-1 levels in both groups after 24 weeks of training. This is consistent with a 
number of previous exercise trials which have reported increases in serum IGF-1 
levels following aerobic and/or resistance training in older adults (22, 23, 25, 30, 34, 
376). However, in several of these studies it was found that serum IGF-1 levels 
increased by 12 to 35% after six to 12 months of aerobic and/or resistance training 
(74, 375, 376). The finding that the changes in serum IGF-1 levels were lower in our 
trial, may relate to the health status of our participants, the timing of the blood 
collection and/or the moderate intensity of our training program. For instance, a 12-
week RCT conducted in 35 healthy older adults reported a ~25% increase in IGF-1 
levels following high intensity resistance training (75-80% of 1-RM) on three days a 
week (375). In contrast, a 6-month RCT conducted in older adults failed to observe 
any increase in serum IGF-1 levels following low-intensity (50% of 1-RM) or high-
intensity PRT (80% of 1-RM) on three days a week (383). In this study, the authors 
suggested that serum IGF-1 may be redistributed from circulation into muscle tissue 
during resistance training (244). While further research is needed to test this 
hypothesis, there is also some evidence that IGF-1 levels increase acutely after 
exercise and then decline rapidly post training (504). Given that the blood samples in 
 240 
 
our study were not taken immediately post-exercise, it is possible that this may 
explain in part, the modest changes observed in our study. 
 
Previous research has shown that BDNF is a key neurotrophic factor that can 
enhance cognitive function as it promotes and strengthens synaptic connections 
associated with memory and learning (77) and is important for preventing neuronal 
death during stress (75, 76). In our study, we observed no change in serum BDNF 
levels after 12 or 24-weeks of training. There are a number of factors which may 
explain this finding including the training intensity, dose or duration of the 
intervention and the health status of participants. In our study, we recruited healthy 
participants and this may have attenuated any potential exercise-induced increases in 
circulating BDNF levels. In part support of this notion, two previous studies which 
have reported exercise-induced increases in BDNF levels were conducted in frail 
adults (361) and those with MCI (365). However, increases in BDNF levels have 
been reported in older adults without MCI following multi-component training (365), 
suggesting that other factors such as the dose and/or intensity of the exercise may be 
important. In our study, participants were asked to train at a moderate to high 
intensity, that is, they were asked to complete 15-20 minutes of aerobic training at 5-
8 (‘hard’ to ‘very hard’) on the 10-point RPE scale and seven PRT exercises at 5-8 
on the RPE scale for each session. This dose/intensity is consistent with the findings 
from one review which found that moderate to high intensity aerobic training (up to 
20% above ventilatory threshold) was required to elicit an increase in serum BDNF 
levels (389). However, a recent meta-analysis of 29 studies reported that the intensity 
of aerobic and/or resistance training was not associated with changes in BDNF levels 
in adults (390). A limitation of our study was that the intensity was measured on a 
self-report scale, and so the intensity of the exercise performed may not be 
equivalent to that of previous studies using objective measures of training intensity. 
Another possible explanation for the lack of increase in BDNF levels may be related 
to the fact that we measured peripheral serum BDNF levels rather than brain levels. 
There is some evidence to suggest that BDNF levels assessed in the jugular vein or 
main arteries may more accurately reflect exercise-induced increases in BDNF as 
BDNF is released from the brain (505). Further, endurance training has been found to 
increase BDNF mRNA expression in rodents (506), and thus it is possible that 
BDNF mRNA may be a more accurate marker of exercise-related effects. 
Alternatively, the fact that blood samples were not collected immediately post-
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exercise in our study may explain the lack of increase in BDNF levels as there is 
evidence to suggest that BDNF levels increase acutely but then return to baseline 
levels within 10 minutes (385, 507).  
 
Previous evidence suggests that VEGF may also be important for cognitive function 
as it plays an important role in angiogenesis (78). In our study, serum VEGF levels 
did not change after 12 or 24 weeks in either group. It is difficult to speculate what 
may be contributing to our findings, although the health status of the participants 
may be a contributing factor. As already discussed, we recruited healthy older adults 
whereas four previous studies which reported increases in VEGF levels following 
aerobic and/or multi-component training, were conducted in older adults with various 
conditions (peripheral arterial occlusive disease and obese women) (398, 508-510); 
those studies which included healthy participants reported no exercise-related 
increases in VEGF levels for these participants (398, 399, 509, 511-514). Another 
potential explanation for the lack of effect in our study may be related to the fact that 
VEGF levels were not assessed acutely. Two of four previous studies which reported 
increases in VEGF levels only measured acute effects (immediately post exercise) 
(509, 510) with one reporting that there were significant increases in VEGF levels 
between two and six hours following a maximal exercise test in people with coronary 
artery disease, but not between six and 48 hours (509). Given that the blood samples 
in our study were not taken immediately post-exercise, it is possible that any 
exercise-related increase in serum VEGF levels had normalised when the samples 
were collected. Another potential reason for the lack of effect may be related to the 
type of exercise used in our study, as the major component of the multi-component 
training was moderate-intensity PRT (30-40 minutes of a 60 minute program) with 
aerobic exercise largely performed as the warm-up. This is important because there 
may be differential effects of exercise modality on serum VEGF levels. For instance, 
one previous study using multi-component training (aerobic, yoga and resistance 
band training), in which the major component of the training was moderate to high 
intensity (10-13 RPE) aerobic training (40 minutes of a 70 minute program with 15 
minutes of resistance training using a green Thera-band), observed increases in 
VEGF levels (398). However, due to the limited studies in this area, further research 
is needed to confirm this.  
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An important question that remains uncertain is whether exercise-induced changes in 
IGF-1, BDNF and/or VEGF correlate with improvements in cognition. In our study, 
exploratory analysis revealed that changes in serum IGF-1, BDNF and VEGF levels 
were not associated with changes in cognitive function in any domain. It is likely that 
the lack of any marked changes in BDNF and VEGF may be a contributing factor to 
this finding as both of these factors can cross the BBB (112-114) and interact with 
each other to promote angiogenesis. In part support of this notion, one previous 
three-month RCT in healthy older adults which found no exercise-related increase in 
BDNF or VEGF also reported no association between changes in VEGF levels and 
changes in hippocampal volume (378). Another contributing factor to our findings 
may be the modest changes in IGF-1 levels observed in our study. In part support of 
this notion, the findings from a 12-month exercise trial involving high-intensity PRT 
(75-80% of 1-RM) in healthy older men found that a ~12% increase in IGF-1 levels 
was inversely correlated (r = -0.47) with cognitive decline, specifically in the visual 
attention domain (74). Similarly, a 12-month RCT in 65 older adults with a mean age 
of 66 years found that modest exercise-induced increases in serum IGF-1 (as well as 
BDNF and VEGF) were positively correlated with increased temporal lobe 
connectivity between the bilateral parahippocampus and middle temporal gyrus in 
those allocated to an aerobic training group (supervised walking sessions beginning 
at 10 minutes and increased gradually to 40 minutes over seven weeks) compared to 
a flexibility, toning and balance training group (399). It may also be possible that 
acute changes in IGF-1, BDNF and VEGF levels are associated with changes in 
cognitive function (378, 504, 509, 510) however, our study did not collect blood 
samples immediately post-exercise. This is supported by the findings of a 3-month 
study by Maass and colleagues (378) who collected BDNF samples up to one week 
following the last session of moderate-intensity treadmill exercise and failed to 
observe any exercise-related changes in plasma BDNF levels, nor any associations 
with changes in perfusion levels and hippocampal volume in older adults aged >60-
77 years. Together, our findings suggest that changes in growth and neurotrophic 
factors following moderate-intensity multi-component exercise are not associated 
with changes in cognitive function in healthy older adults. 
 
The evidence for the effects of exercise on markers of inflammation is mixed, 
although there are some studies which suggest that multi-component exercise can 
reduce inflammation in both healthy adults and those with MCI (365, 404). A 
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potential reason for these mixed findings is that a change in body composition, 
particularly fat mass, is often a confounding factor in these studies as fat mass is a 
major source of inflammation (400). In our study, there were no exercise-related 
changes in any marker of inflammation, even after adjusting for BMI. Possible 
explanations for our lack of effect may be related to the health status of our 
participants and basal levels of inflammation. CRP is a common marker used to 
determine whether inflammation levels fall within a ‘normal range’ (>3 mg/L), and 
in our study ~81% of participants had a CRP level below this cut-point at baseline. 
Basal levels of inflammation which exceed the ‘normal range’ may provide more 
opportunity for an exercise program to influence markers of inflammation. However, 
previous studies with basal CRP levels similar to that of our participants (~1.25 
mg/L), have reported beneficial effects on CRP levels following a multi-component 
exercise intervention (365, 404). There is also evidence which suggests that increases 
in growth factors such as IGF-1 may be related to reductions in levels of IL-6 (515, 
516). Thus, the modest increase observed in IGF-1 in our study may, in part, explain 
the lack of any reduction in IL-6. In support of this, a previous 4-month RCT in 
healthy older women reported a ~17% increase in IGF-1 levels and a similar 
decrease in serum IL-6 levels following PRT on three days a week combined with 
lean red meat on six days a week (72). Given that the dose and intensity of training in 
our study was consistent with several previous RCTs which have reported reductions 
in various markers of inflammation following moderate intensity (60-80% of heart 
rate reserve and 1-RM) multi-component exercise (365, 404), this seems to be an 
unlikely factor which contributed to the lack of effect in our study. 
 
Despite evidence which supports an association between increased inflammation and 
an increased risk for cognitive decline (23, 44, 177, 198), which may be related to 
impaired growth factor signalling peripherally and in the brain (23), whether 
exercise-related decreases in inflammation are related to changes (improvements) in 
cognitive function remains uncertain. In our study, exploratory analysis revealed that 
changes in inflammatory markers were not associated with changes in cognitive 
function. This suggests that small changes in inflammation in healthy older adults 
may be insufficient to induce changes in cognitive function. However, whether 
exercise-induced changes in inflammation in older adults with elevated levels of 
inflammation or MCI can have a positive effect on cognitive function remains 
unknown. 
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Recent evidence suggests that baseline and exercise-induced increases in muscle 
mass (14), strength (3, 15, 16, 19, 20, 243) and gait speed (19) may be related to 
improvements in cognitive function and a decreased risk for cognitive decline and 
dementia. For instance, one prospective study reported that each one unit increase in 
muscle strength was associated with a 43% decrease in the risk of AD and a 34% 
decreased risk for MCI (15). Further, one cross-sectional study reported that 
sarcopenia independently increased the odds of having cognitive impairment three-
fold (OR=3.03) (14). The results of our exploratory analysis are somewhat consistent 
with these previous studies (3, 14-16, 19, 20, 243) as we found that baseline 
appendicular lean mass was negatively associated with changes in working memory 
and learning scores independent of sex, BMI, change in physical activity and group. 
However, baseline muscle strength was not associated with changes in any cognitive 
domain. Collectively, these findings suggest that greater muscle mass but not 
strength at baseline was associated with a slower decline in cognitive function over 
the 24-week intervention. The underlying reason(s) for this observation remains 
uncertain, but those with greater muscle mass (and strength) are likely to be at a 
lower risk of frailty and sarcopenia, which has previously been associated with a 
greater risk for cognitive decline (3, 14). This may be related in part to the role of 
exercise-induced increases in various circulating inflammatory markers (e.g. IL-6 
and TNF-α), oxidative stress markers, which have been associated with sarcopenia 
and cognitive decline (3, 14) as well as growth and neurotrophic factors (244, 245), 
which have the ability to pass through the blood-brain barrier and which may 
potentially benefit cognitive function.  
 
While we observed that our multi-component exercise program was effective for 
increasing muscle mass, strength and function in both groups, changes in these 
measures were not associated with changes in any cognitive domain. While this 
might be related to the fact that our study included healthy community-dwelling 
older adults, it is possible that the changes observed in muscle mass (0.58 to 0.76 kg 
mean increase in total body lean mass), muscle strength (26 to 27% mean increase in 
leg strength) and/or function (0.27 to 0.70 second improvement for the FSST and up 
to a 0.05 m/sec improvement in gait speed), may not have been large enough to 
induce changes in cognitive function. In part support of this notion, a 6-month RCT 
conducted in older adults with MCI which reported a greater mean increase in lower 
 245 
 
body strength (up to 52%) compared to our study, resulting from high-intensity PRT 
(80-92% of current strength), found that these increases were positively associated 
with changes in cognitive function and greater changes in lower body strength 
mediated the effect of PRT on improvements in global cognitive function (243). This 
suggests that higher intensity PRT which results in greater increases in muscle mass 
and strength compared to lower intensities may be required to induce cognitive 
changes in healthy older adults. However, given that this is an emerging area of 
interest and there are currently limited studies in this area, further research is needed 
to confirm whether there is a given threshold of gain in muscle mass or strength 
needed to elicit changes in cognition. 
 
4.6 Strengths and Limitations 
The strengths of this study include the randomised controlled design, the relatively 
long-term intervention, the use of a dietary approach rather than supplementation that 
reflects ‘real-world’ practice, the implementation of the exercise program within 
community leisure centres and the comprehensive assessment of cognitive function, 
body composition, muscle strength and physical function as well as the inclusion of 
various circulating growth, neurobiological and inflammatory markers. In particular, 
the use of CogState as the primary measure of cognitive function is a strength as this 
measure has been validated for use in older adults over a short time period and is not 
subject to practice effects. In addition, study retention was excellent (mean 94%) and 
there was high compliance with the exercise (mean 79%) and dietary interventions 
(meat 87%; carbohydrates 91%). Importantly, the delivery of raw lean red meat in 
contrast with prepared meals demonstrates the feasibility of increasing dietary 
protein in older adults, as they successfully prepared and stored the meat themselves.   
 
There are a number of limitations associated with this study. First, the participants 
were all relatively healthy volunteers who were generally well educated which may 
have limited the ability to detect greater exercise-protein changes in the various 
outcome measures. Lower levels of education have been associated with a greater 
age-related decline in spatial and verbal memory (270) whereas higher levels of 
education have been associated with cognitive reserve (142).  
 
Second, our study took a holistic approach with regard to providing the additional 
protein, in that the lean red meat was encouraged to be consumed as part of the 
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participants’ current diets rather than as additional servings of protein (e.g. 
supplement). This makes it difficult to determine whether there were other dietary 
changes which may have contributed to the various findings from this study. For 
instance, it is possible that the addition of the red meat may have displaced other 
nutrients and food intake. Future studies should endeavour to measure food intake to 
ascertain whether the intake of certain foods increases or decreases with the addition 
of lean red meat into the diet as this may have an effect on cognitive function 
outcomes.  
 
Third, blood samples were not collected immediately post exercise and thus any 
acute effect may have been missed. Fourth, with regard to the testing and outcome 
measures, blinding of the researchers and participants to the group allocation was not 
possible due to the study design and inability to employ staff to organise delivery and 
distribution of food as well as for testing, potentially allowing bias to interfere with 
results. Further, the study was limited to a duration of 24-weeks, which was 
sufficient for detecting exercise-protein induced changes in muscle outcomes, but 
may not have been long enough to detect changes in certain domains of cognitive 
function. Previous research has shown that cognitive decline due to ageing is a slow 
process and it has been suggested that a study duration of 18 months or more is 
needed in order to see any effects (517).  
 
Fifth, given the link between aerobic fitness and cognitive function (329-331, 333, 
334), it is unknown whether changes in aerobic fitness due to the multi-component 
exercise in our study influenced our results as aerobic fitness was not assessed. 
 
Lastly, another important limitation is that the meat was delivered to the participant’s 
homes at no cost to them. Although it does highlight the feasibility of older adults to 
cook and prepare lean red meat and successfully maintain the high consumption of 
protein, it does beg the question as to whether the meat would be affordable to 
everyone in the real world setting. 
 
4.7 Summary and Conclusion 
In summary, the main finding of this 24-week community-based RCT in healthy 
older adults aged 65 years and over was that a multi-component exercise program 
was associated with improvements in global cognitive function and executive 
function, but the provision of a protein-enriched diet achieved through the 
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consumption of lean red meat on each of the three training days that was consistent 
with the current Australian dietary guidelines, did not enhance these benefits. For 
working memory and learning, there was evidence for a greater improvement in the 
Ex+CHO group compared to Ex+Meat group. While both groups experienced similar 
significant increases in lower limb muscle strength and a reduction in total body fat 
mass, there was a greater improvement in arm lean mass in the Ex+Meat group, with 
a trend for a greater net gain in appendicular lean mass after 24 weeks. For muscle 
function, there was an improvement in gait speed in the Ex+CHO group after 24 
weeks, and both groups significantly improved their mobility after 24 weeks. 
However, there were no changes in any circulating growth, neurobiological or 
inflammatory markers throughout the intervention in either group, with the exception 
of IGF-1 which increased in both groups. 
 
In conclusion, the findings from this study indicate that a multi-component exercise 
program combined with an increased consumption of protein achieved via lean red 
meat in healthy older adults does not provide any additional cognitive benefits 
compared to exercise alone. However, a community-run multi-component exercise 
program including a combination of PRT, aerobic exercise and challenging balance 
and mobility training was safe and effective for improving various cognitive domains 
as well as muscle mass and strength in healthy men and women aged 65 years and 
over.  
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Chapter 5 
 
Effects of a protein-enriched diet with lean red meat combined with 
multi-component exercise on HR-QoL in community-dwelling older 
adults, compared to multi-component exercise alone. 
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5.1 Introduction  
Globally, life expectancy of older people continues to rise and this has been 
associated with increased levels of chronic disease and illness which can impact on 
well-being, levels of independence and quality of life (QoL) (444). The World 
Health Organisation (WHO) defines QoL as an individual’s perception of their 
position in life in the context of the culture and value systems in which they live and 
in relation to their goals, expectations, standards and concerns (416), with health-
related (HR)-QoL referring to areas of QoL which are most affected by physical and 
mental health or illness (417). There is emerging evidence that sarcopenia, an age-
related disease defined as a loss in muscle mass, strength and function, is associated 
with reduced HR-QoL (444). This is likely due to the fact that losses in muscle mass, 
strength and function have been associated with many common chronic diseases such 
as osteoporotic fractures, types 2 diabetes, metabolic syndrome and CVD (518, 519). 
Therefore, strategies which target the prevention of age-related losses in muscle in 
older adults may also play a key role in ameliorating age and/or disease-related 
deteriorations in HR-QoL. 
 
There is some evidence from RCTs which indicates that regular physical activity 
(e.g. walking) and structured exercise training can improve HR-QoL, including both 
physical and mental health domains, in both clinical populations (including cancer, 
CVD, pulmonary conditions, neurological and musculoskeletal conditions) (37, 446) 
and healthy older adults (445, 447, 448). However, questions still remain with regard 
to what type and dose of physical activity or exercise training might be optimal for 
improving HR-QoL in older adults. To date, a diverse range of benefits have been 
reported following aerobic, PRT and/or challenging balance and mobility training 
(30, 354, 449, 451, 452, 455, 456). It has been suggested that some of the 
improvements may be related in part, to exercise-induced improvements in physical 
function and muscle strength (418, 454). Given that there are independent benefits of 
different types of exercise on HR-QoL, it is possible that multi-component training 
may offer the greatest benefits for HR-QoL in older adults. Currently, research 
comparing the effects of single modality exercise to multi-component training on 
HR-QoL is limited, but there are some positive findings supporting the role of multi-
component exercise on HR-QoL (31, 456). For instance, a 12-week RCT in elderly 
men at risk of falls reported improvements for global health following a low to 
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moderate intensity multi-component exercise program (strength, endurance, mobility 
and balance exercises) on three days per week compared to controls (520).  
 
Previous research has suggested that various dietary factors may also play an 
important role in maintaining and/or improving HR-QoL in older adults (207, 208, 
220, 229, 302, 422-429). Evidence suggests that various dietary patterns or nutrients 
which can alter various circulating neurotransmitters and growth factors such as 
serotonin, dopamine, BDNF and IGF-1, may be associated with improvements in 
cognitive function and/or a reduction in depressive symptoms, which may lead to 
improved HR-QoL (422, 430). Low intakes of particular nutrients (e.g. protein, zinc, 
vitamin D) which may be indicative of malnutrition and increase the risk for 
sarcopenia, frailty and various chronic diseases (440), may negatively impact on HR-
QoL. There is emerging evidence that low intakes of dietary protein are negatively 
associated with physical and mental aspects of HR-QoL in some clinical populations 
including those with cancer, clinical malnutrition and heart failure (435, 436, 442). 
While there are limited intervention studies which have investigated the effects of 
increased dietary protein alone on HR-QoL in healthy older adults, there is some 
promising data from a 12-week RCT conducted in 104 malnourished home residents 
which found that those receiving oral nutrition supplements (containing protein) 
experienced an improvement in HR-QoL (as measured by the EuroQoL) compared to 
those receiving dietary advice (436). However, further research is needed to ascertain 
whether increasing dietary protein through food sources (e.g. animal or vegetable 
protein) may also lead to improvements in HR-QoL in older adults.  
 
Current international consensus guidelines recommend a combination of adequate 
dietary protein and PRT to optimise muscle mass, strength and function in older 
adults (521). There is also emerging evidence that greater muscle mass and strength 
are associated with higher HR-QoL (452, 453). Despite this, whether the 
combination of protein and exercise is more effective at improving HR-QoL than 
either intervention alone remains uncertain. However, there is some promising 
evidence from several RCTs in pre-frail and sarcopenic older adults to support an 
additive benefit (458, 459). For instance, one 12-week RCT conducted in 89 pre-frail 
women aged 70 years and over found that once a week strength and balance training 
combined with a cooking class and nutritional education with a focus on increasing 
dietary protein and vitamin D, improved HR-QoL outcomes for the physical 
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component score and role physical, bodily pain and role emotional domains, 
compared to the exercise alone and control group (458). Further, a 12-week RCT 
conducted in 130 sarcopenic older adults reported improvements in both the physical 
and mental component scores following a moderate intensity multi-component 
exercise program combined with an amino acid/whey-protein (22 g/d) and vitamin D 
(100 IU/d) enriched supplement, compared to exercise alone (459). While this 
suggests that an intervention which targets both muscle and nutritional status may 
have added beneficial effects for improving HR-QoL in older adults, there is also 
some evidence that the combination of PRT with protein supplementation in older 
adults has no beneficial effects for HR-QoL (70). Whether increasing dietary protein 
through high quality food sources (e.g. red meat) in combination with exercise can 
promote greater improvements in HR-QoL than exercise alone, is one area of 
research that requires further investigation. 
 
In Australia, the major source of dietary protein is red meat with 100 g of cooked red 
meat providing 28-36 g of protein (59). Despite some evidence indicating that high 
intakes of processed and fatty cuts of red meat consumed as part of a Western diet 
may have some detrimental effects on mental health (443), other studies have found 
no relationship between meat intake and HR-QoL or depression (64, 522). Further, 
there is some evidence for a beneficial effect of daily consumption of lean red meat 
on HR-QoL in healthy older women when combined with exercise (418). For 
instance, one 4-month RCT conducted in 100 healthy older Australian women aged 
60-90 years who participated in PRT and balance/agility training twice a week and 
were randomised to receive either 160 g/d (cooked) lean red meat consumed across 
two meals/day, six days/week or ≥1 serving/day carbohydrates (control), found that 
there was an added benefit for physical HR-QoL scores in the exercise plus lean red 
meat group compared to those receiving exercise alone, despite participants having 
little physical functional impairment at the beginning of the study (418). However, 
no benefit for the mental domain of HR-QoL was observed in either group, although 
this may have been related to the high baseline HR-QoL scores (418). It is also 
important to acknowledge that the intake of meat in this study was well above the 
current Australian recommended guidelines of no more than 455 g per week (3-4 
serves per week), and thus it may not be feasible (or cost-effective) to maintain this 
level of intake for an extended period.  
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The aim of this 24-week study was to examine the effects of a multi-component 
exercise program combined with a protein-enriched diet achieved through the 
consumption of lean red meat on each of the three training days that is equivalent to 
the current Australian dietary guidelines, on HR-QoL in community-dwelling older 
adults, compared to multi-component exercise alone. It was hypothesised that the 
protein-enriched diet combined with the multi-component exercise program will 
result in greater improvements in HR-QoL outcomes as well as depression/anxiety 
symptoms, compared to exercise alone in community-dwelling older adults. 
 
5.2 Methods 
The methods of this study have been described in detail in Chapter 3. However, an 
outline of the methods directly related to this study is provided below. 
 
5.2.1 Participants 
One hundred and fifty-four community-dwelling older adults (58 men and 96 
women) aged 70.7 ± 4.1 years (mean ± SD) from Melbourne and surrounding area 
were recruited to take part in this study. Recruitment was divided into two cohorts 
across two years to aid with the implementation of the program, with 68 participants 
recruited in the first year and 86 in the second year. As outlined in Chapter 3, 
screening consisted of a four step process and included those with no signs of 
depression and who were deemed to be cognitively healthy. GP consent was obtained 
from all participants prior to beginning the study to ensure that they did not have any 
contraindicating medical conditions to the exercise program (based on the ACSM 
guidelines) (472). 
 
5.2.2 Intervention 
The study was a 24-week community-based trial that comprised of a multi-
component exercise program including aerobic training, PRT and balance training, 
combined with a protein-enriched diet achieved by eating lean red meat on each of 
the three training days. The multi-component exercise training took place across 15 
local health and fitness centres across Melbourne and was implemented by qualified 
exercise trainers. Participants in the Ex+Meat group were advised to consume two 
serves (~80 g cooked each) of lean red meat (beef, lamb, veal) on each of their three 
training days (lunch and dinner) while those in the Ex+CHO group were advised to 
consume at least one serve of carbohydrates (one medium sized potato or ½ cup of 
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cooked rice or pasta). All participants were asked to take a 1000 IU/d vitamin D3 
supplement. 
 
5.2.3 Outcome Measures 
A detailed description of the outcome measures used in this RCT is provided in 
Chapter 3. For this study, HR-QoL measures were the primary outcome of interest.  
 
Anthropometry 
Height and weight were measured using standardised procedures with height being 
recorded to the nearest 0.1 cm and weight to the nearest 0.1 kg. BMI was calculated 
using the formula: BMI=weight (kg)/ height (m)
2
. 
 
Medical history and lifestyle 
A questionnaire was used to collect information about education, medical history, 
non-prescription and prescription medication use, smoking history and alcohol 
intake. 
 
Health- related quality of life 
The SF36-v2 was used to assess HR-QoL. This is a 36-item questionnaire which 
consists of eight subscales (physical functioning, bodily pain, general health, vitality, 
social functioning, mental health and role-emotional and role-physical) (481). The 
data was normalised to reported data from the 2004 South Australian Health 
Omnibus survey to allow for appropriate and meaningful comparisons for changes in 
scores across the eight subscales (484). These subscales were converted into two 
summary scores: physical component summary scale (PCS) and mental component 
summary scale (MCS). The PCS and MCS were calculated based on a factor analysis 
of the eight domains among participants in the 2004 South Australian Health 
Omnibus Survey (484). An overall HR-QoL score was calculated as the mean of all 
the eight health sub-domains. The results are reported using previously published 
Australian norm-based scores (484). The use of norm-based weights gives each 
domain score a mean of 50 and a standard deviation (SD) of 10, allowing change in 
scores to be assessed on a comparable scale. 
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Depression/Anxiety 
Depression and anxiety were assessed using the 14-item Hospital Anxiety and 
Depression Scale (HADS). The results are reported as the sum of all 14 items and the 
sum for each of the two 7-item subscales (anxiety subscale and depression subscale). 
Scores of 11 or more on either subscale are considered to be consistent with 
significant 'caseness' of psychological morbidity, while scores of 8–10 represents 
'borderline' and 0–7 'normal' (489). 
 
Memory Complaints 
The Memory Assessment Questionnaire (MAC-Q) comprises six questions related to 
memory functioning in everyday situations. Participants were asked to compare and 
rate their current memory ability to when they were aged 40. The total score ranges 
from seven to 35, where greater scores indicate subjective memory loss. Scores 
greater than or equal to 25 have been found to be suggestive of age-associated 
memory impairment (491).  
 
Blood markers 
All participants provided a fasted, morning (8–10am) venous blood sample at 
baseline, 12 and 24 weeks. All blood was sent to a central laboratory and serum 
aliquots were collected and stored at –80 °C so that the following parameters could 
be assessed in a single batch at the completion of the study: serum IGF-1, BDNF, 
VEGF, adiponectin, IL-6, IL-8, IL-10 and TNF-α. High sensitivity C-reactive protein 
(hs-CRP) was measured by an Immunoturbidimetric assay from Roche Diagnostics, 
Mannheim. 
 
5.2.4 Statistical analysis 
Statistical analysis was conducted on an ITT basis using STATA statistical software 
version 14 (STATA, College Station, TX, USA). Baseline characteristics between 
the groups were compared by using independent t tests for continuous variables and 
chi-square tests for categorical variables. All data was checked for normality prior to 
analysis and the following variables were log transformed prior to analysis: serum 
IGF-1, BDNF, VEGF, adiponectin, hs-CRP, TNF-α, IL-6, IL-8 and IL-10.  
 
Multiple linear regression was used to assess the relationship between overall HR-
QoL and its component scores with appendicular lean mass, leg muscle strength and 
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function outcomes (FSST and gait speed) at baseline. Data from both groups were 
pooled. The results were analysed adjusted for sex (model 1) and then age, sex, 
habitual physical activity, number of chronic diseases and depression (model 2). All 
values are reported as unadjusted beta coefficients with 95% CI. A Bonferroni 
adjusted p-value of 0.0125 was used to determine significance. 
 
As discussed in Chapter 4, General Linear Mixed Models with random effects were 
used to assess time, group and group-by-time interactions. The results were analysed 
unadjusted and adjusting for the following covariates: age, sex, number of chronic 
diseases, change in physical activity and depression. A per protocol analysis was also 
conducted based on ≥66% compliance with the exercise and ≥80% compliance with 
the lean red meat. Between-group differences were calculated by subtracting within-
group changes from baseline for the Ex+Meat group from within-group changes for 
the Ex+CHO group after 24 weeks. For the log transformed data, the percentage 
change in these variables represented the absolute difference from baseline in log 
transformed data multiplied by 100. All data is presented as means ± SD or 95% CI 
and the significance level was set at P<0.05. A secondary analysis was also 
conducted to assess whether there were any gender interactions for each outcome. 
 
An exploratory analysis was also conducted using multiple linear regression to 
determine whether there were any associations between the absolute changes in the 
HR-QoL summary scores (PCS and MCS) and global HR-QoL with baseline and 
absolute changes in appendicular lean mass, leg muscle strength and function as well 
as the various circulating growth, neurotrophic and inflammatory markers which 
were log transformed. All results were adjusted for sex and group (model 1) and then 
for age, sex, number of chronic diseases, change in physical activity, depression and 
group (model 2). All values reported are unadjusted beta coefficients with 95% CI. 
The significance level was set using the Bonferroni correction method by dividing 
0.05 by the number of comparisons. 
 
5.3 Results 
5.3.1 Baseline characteristics 
Table 5.1 provides an overview of the participant characteristics at baseline. Briefly, 
62% of the participants were female and the mean age and BMI was 70.7 years 
(range 65 to 84 years) and 27.9 kg/m
2 
respectively. A total of 35.1% of the 
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participants were classified as overweight and 31.8% as obese. Thirty-six percent 
were either ex or current smokers (current smokers n=3) and a higher proportion of 
participants in the Ex+Meat group had a history of CVD (presence of heart disease, 
stroke or heart attack) compared to those in the Ex+CHO group (Ex+Meat, n=17; 
Ex+CHO, n=6) (Chi-square P=0.013). The number of APOE-4 carriers also differed 
significantly between the groups (Ex+Meat n=11; Ex+CHO n=22, P=0.037). There 
were no differences between the groups with regard to any other baseline 
characteristic. 
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Table 5.1 Baseline characteristics of the multi-component exercise and lean red meat 
(Ex+Meat) and control (carbohydrate) multi-component exercise (Ex+CHO) group 
Characteristic Ex+Meat Ex+CHO 
N 77 77 
Women, n (%) 48 (57%) 48 (57%) 
Age (years) 71.2 ± 4.0 70.3 ± 4.3 
Height (cm) 165.0 ± 8.8 165.3 ± 9.9 
Weight (kg) 76.1 ± 17.2 76.9 ± 18.7 
BMI (kg/m
2
) 27.8 ± 5.1 27.9 ± 5.5 
   Overweight (BMI 25-29.9), n (%) 32 (42%) 22 (29%) 
   Obese (BMI ≥ 30), n (%) 22 (29%) 27 (35%) 
Ex-smoker/ current smoker, n (%) 30 (39%) 26 (34%) 
Ethnicity, n (%)   
   Caucasian 66 (86%) 63 (82%) 
   Non-Caucasian 11 (14%) 14 (18%) 
Education, n (%)   
   High school or lower 43 (56%) 39 (51%) 
   University or higher 34 (44%) 38 (49%) 
Moderate- vigorous PA kJ per week 7897 ± 7555 8017 ± 7547 
Consume alcohol, n (%) 44.2% 40.3% 
Alcohol intake, g/d 13.3 ± 13.1 14.1 ± 11.4 
Number of health conditions 2.05 ± 1.72 2.23 ± 1.84 
History of CVD, n (%) 17 (22%) 6 (8%)* 
MCI, n (%) 3 (3.9%) 5 (6.5%) 
APOE-4 carrier , n (%) 11 (14%) 22 (29%)* 
25-Hydroxyvitamin D (nmol/L) 83.6 ± 23.0 83.0 ± 28.0 
   Insufficient (<75 nmol/L), n (%) 20 (26%) 26 (34%) 
   Deficient (<50 nmol/L), n (%) 5 (7%) 4 (5%) 
Values represent number and percentage or mean ± standard deviations. *P<0.05 versus Ex+Meat. 
BMI, body mass index; APOE, apolipoprotein E; Caucasians included those born in Australia, 
Northern Europe, Canada, USA and New Zealand; Non-Caucasians included those born in Southern 
Europe, Asia, the Middle East,  India and Sri Lanka, Pacific Islands, Africa, South and Central 
America, Aboriginal Australians and Strait Torres Islanders; MCI, mild cognitive impairment; PA, 
physical activity; CVD, cardiovascular disease. 
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5.3.2 Association between muscle outcomes and HR-QoL at baseline 
A Bonferroni adjusted P-value of 0.0125 was used to determine significance. At 
baseline there were no significant associations between global HR-QoL or the 
summary component scores (PCS and MCS) or depression with appendicular lean 
mass and leg muscle strength (Table 5.2). However, there were positive associations 
between PCS scores and MCS scores with gait speed in model 1 (P=0.010 and 
P=0.007, respectively). Further, MCS scores were inversely associated with mobility 
but depression scores were positively associated with mobility in model 1 (P=0.011).  
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Table 5.2 Cross-sectional association between the physical component summary (PCS), mental component summary (MCS) and global scores 
for health-related quality of life (HR-QoL) and depression with appendicular lean mass, muscle strength, gait speed and mobility at baseline.   
 ALM Muscle Strength
1 
Gait speed
2 
Mobility
3 
 β (95% CI) P value β (95% CI) P value β (95% CI) P value β (95% CI) P value 
PCS 
  Model 1 -0.32 (-0.70, 0.05) 0.091 -0.00 (-0.03, 0.03) 0.904 8.42 (2.03, 14.81)* 0.010 -0.29 (-1.05, 0.48) 0.458 
  Model 2 -0.38 (-0.73, -0.04) 0.027 -0.02 (-0.05, 0.01) 0.130 4.38 (-1.57, 10.33) 0.148 0.36 (-0.34, 1.06) 0.313 
MCS 
  Model 1 0.11 (-0.29, 0.51) 0.575 0.02 (-0.01, 0.05) 0.313 9.35 (2.59, 16.11)*  0.007 -1.64 (-2.41, -0.88)*
 
0.000 
  Model 2 0.22 (-0.14, 0.57) 0.226 0.02 (-0.01, 0.05) 0.166 6.41 (0.44, 12.38) 0.036 -1.35 (-2.04, -0.66)*
 
0.000 
Global HR-QoL Score 
  Model 1 -0.21 (-0.49, 0.07) 0.139 -0.01 (-0.04, 0.01) 0.222 -1.34 (-6.17, 3.50)  0.586 -0.51 (-1.07, 0.05)
 
0.072 
  Model 2 -0.20 (-0.49, 0.09) 0.180 -0.02 (-0.04, 0.01) 0.187 -2.09 (-7.14, 2.97) 0.416 -0.43 (-1.02, 0.16)
 
0.149 
Depression 
Model 1 -0.01 (-0.11, 0.09) 0.800 -0.00 (-0.01, 0.00) 0.230 -1.92 (-3.62, -0.21) 0.028 0.26 (0.06, 0.46)* 0.011 
Model 2 -0.02 (-0.12, 0.09) 0.753 -0.00 (-0.01, 0.00) 0.379 -1.66 (-3.42, 0.09) 0.063 0.22 (0.01, 0.42) 0.040 
All values represent unadjusted beta-coefficients (β) with 95% confidence interval (CI). Model 1: adjusted for sex, Model 2: adjusted for age, sex, habitual physical activity, 
number of chronic diseases and depression. Calculated Bonferroni p-value of 0.0125 was used to assess significance. *P<0.013. ALM: Appendicular lean mass; Muscle 
strength is one-repetition maximum strength from the leg press; 
1 
Leg press 3-RM muscle strength;
 2 
Gait speed assessed from the 4-m walk test; 
3 
Mobility was assessed 
using the four square step test (FSST). HR-QoL: health-related quality of life, PCS: physical component score, MCS: mental component score. 
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5.3.3 Study Attrition, compliance and adverse events  
Study Attrition 
Nine participants (6%) withdrew from the study and did not complete the 24-week 
testing (Ex+Meat, n=4; Ex+CHO, n=5), leaving 145 (94%) for the final analysis. 
Reasons for withdrawal included medical (Ex+Meat, n=2; Ex+CHO, n=4), no longer 
having the time (Ex+Meat, n=0; Ex+CHO, n=1) and loss of interest in the study 
(Ex+Meat, n=2; Ex+CHO, n=0). Participants who withdrew from the study did not 
differ from the remaining participants at baseline, with the exception of memory 
complaints. Those who remained in the study reported a higher mean score for 
memory complaints than those who withdrew (24.9 versus 20.8, P<0.01). Please 
refer to Chapter 3 for the full study design flow chart. 
 
Compliance 
Compliance with the exercise program was no different between the Ex+Meat 
[77.9%, (95% CI: 73.5, 82.2)] and Ex+CHO [78.6% (95% CI: 73.9, 83.2)] group 
(P=0.82). Mean dietary compliance with the lean red meat was 87.0% (95% CI, 82.4, 
91.5) and 91.3% (95% CI: 86.1, 96.4) for the carbohydrates. Compliance with the 
vitamin D supplementation was no different in the Ex+Meat [94.6%, (95% CI: 92.2, 
97.0)] and Ex+CHO [92.6%, (95% CI: 89.9, 95.3)] group (P=0.26).  
 
Adverse Events 
Adverse events are discussed in Chapter 4.  
 
5.3.4 Intervention effect   
HR-QoL 
After 24-weeks, there were no within group changes or between group differences 
for the change (group-by-time interactions) for any measure of HR-QoL, with the 
exception of the physical function subscale which improved by 1.88 units in the 
Ex+Meat group relative to baseline (P=0.011) (Table 5.3).  
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Table 5.3 Mean baseline scores for health-related quality of life for the multi-component exercise and red meat (Ex+Meat) and control 
carbohydrate exercise (Ex+CHO) group and the mean within-group changes and mean net differences between the groups for the change after 24 
weeks. 
 Baseline Values and Within-Group Changes  
 Ex+Meat Ex+CHO Intervention Effects 
 
Mean ± SD or  
(95% CI) 
P-value 
Mean ± SD or  
(95% CI) 
P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  | Model 2 
Physical Function      
    Baseline 47.52 ± 7.41  48.23 ± 7.05    
    Δ 24-weeks 1.88 (0.37, 3.39)* 0.011 1.33 (-0.29, 2.96) 0.084 0.55 (-1.65, 2.75) 0.637 | 0.626 
Role Physical      
    Baseline 48.16 ± 8.42  50.45 ± 7.00    
    Δ 24-weeks 0.99 (-1.07, 3.04) 0.293 -0.48 (-2.59, 1.62) 0.578 1.47 (-1.45, 4.39) 0.257 | 0.329 
Bodily Pain      
   Baseline 48.28 ± 10.97  47.69 ± 10.27    
   Δ 24-weeks  -1.30 (-3.46, 0.85) 0.246 -0.38 (-2.53, 1.77) 0.848 -0.92 (-3.94, 2.09) 0.497 | 0.565 
General Health      
   Baseline 51.10 ± 7.96  51.35 ± 6.92    
   Δ 24-weeks  1.21 (-0.23, 2.64) 0.113 -0.02 (-1.26, 1.23) 0.983 1.22 (-0.66, 3.11) 0.235 | 0.200 
Vitality      
    Baseline 53.74 ± 8.61  53.35 ± 6.64    
    Δ 24-weeks -0.32 (-2.18, 1.55) 0.696 0.17 (-1.24, 1.58) 0.725 -0.48 (-2.80, 1.84) 0.599 | 0.691 
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Social Functioning      
    Baseline 50.73 ± 8.85  52.33 ± 6.63    
    Δ 24-weeks -0.31 (-2.29, 1.67) 0.781 -1.87 (-3.79, 0.06) 0.093 1.56 (-1.18, 4.30) 0.311 | 0.246 
Role-emotional      
    Baseline 48.38 ± 9.77  49.80 ± 8.81    
    Δ 24-weeks 1.70 (-0.63, 4.02) 0.129 -1.12 (-3.81, 1.56) 0.486 2.82 (-0.70, 6.34) 0.126 | 0.133 
Mental Health      
    Baseline 52.08 ± 8.30  50.74 ± 6.97    
    Δ 24-weeks -0.85 (-2.51, 0.82) 0.312 1.47 (-0.30, 3.24) 0.086 -2.32 (-4.73, 0.09) 0.053 | 0.063 
Physical Component Score (PCS)      
    Baseline 48.43 ± 8.28  49.34 ± 7.94    
    Δ 24-weeks 0.82 (-0.77, 2.41) 0.292 0.17 (-1.55, 1.89) 0.795 0.65 (-1.67, 2.97) 0.594 | 0.551 
Mental Component Score (MCS)      
    Baseline 51.94 ± 9.13  51.96 ± 7.77    
    Δ 24-weeks -0.15 (-2.04, 1.74) 0.876 -0.46 (-2.40, 1.49) 0.720 0.31 (-2.39, 3.00) 0.878 | 0.839 
Global HR-QoL Score      
    Baseline 49.99 ± 6.05  50.51 ± 5.86    
    Δ 24-weeks 0.31 (-0.96, 1.57) 0.741 -0.03 (-1.20, 1.13) 0.311 0.34 (-1.36, 2.04) 0.374 | 0.368 
All baseline values are unadjusted means ± SDs. All change values are unadjusted means (95% CI) and were calculated from the absolute difference from baseline. 
Mean net differences (95% CI) were calculated by subtracting the within-group changes for the Ex+Meat group from the within-group changes for the Ex+CHO group 
after 12 and 24 weeks. Model 2 included age, sex, number of chronic diseases, change in physical activity and depression. HR-QoL: health-related quality of life; PCS: 
physical component score; MCS: mental component score. 
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Depression, Anxiety and Memory 
As depression was an exclusion criteria, there was very little evidence of depressive 
symptoms amongst the participants at baseline and the scores did not change after 24 
weeks (Table 5.4). At baseline, just over 50% of participants in each group were 
categorized as having a memory complaint (score ≥25 on MAC-Q). While the 
proportion of participants with memory complaints did not change significantly in 
either group after 24 weeks, there was a modest but significant (P<0.05) decrease in 
the mean raw scores in the Ex+Meat group after 24 weeks, indicating an 
improvement in memory. 
 
Table 5.4 Number and proportion of participants (along with mean or median 
scores) with depression scores considered to normal, borderline and a significant 
'case' of psychological morbidity in the Ex+Meat and Ex+CHO group at baseline 
and 24 weeks. 
 
 
Ex+Meat  Ex+CHO 
 Baseline Week 24  Baseline Week 24 
Depression/ Anxiety        
 Normal (score 0-7), n (%)  75 (97.4%) 72 (96.0%)  76 (98.7%) 76 (98.7%) 
 Borderline (score 8-10), n 
(%) 
 1 (1.3%) 3 (4.0%)  0 (0.0%) 0 (0.0%) 
 Caseness (score 11-21), n (%)  1 (1.3%) 0 (0.0%)  1 (1.3%) 1 (1.3%) 
 Median (IQR)  2.0 (3.0) 2.0 (2.0)  2.0 (3.0) 1.0 (2.0) 
Memory Complaints       
 Yes, n (%)  44 (57.1%) 36 (49.3%)  40 (51.9%) 36 (50.0%) 
 No, n (%)  33 (42.9%) 37 (50.7%)  37 (48.1%) 36 (50.0%) 
 Mean ± SD  25.0 ± 4.0 24.1 ± 4.6*  24.3 ± 4.4 23.9 ± 4.6 
All values are n and percentage or mean ± SD or median and IQR, interquartile range. HADS, 
Hospital Anxiety and Depression Scale; MAC-Q, Memory Assessment Questionnaire (MAC-Q);      
* P<0.05 versus baseline. 
  
 
5.3.5 Per protocol analysis 
All per protocol results (n=122) were similar to the ITT with the exception of the 
following (Appendix AI): 1) for the role physical subscale, there was a significant 
improvement in the Ex+Meat group after 24 weeks (2.40 unit, P<0.05) with no 
marked changes in the Ex+CHO group, which lead to a significant group-by-time 
interaction after 24 weeks (P<0.05); 2) for the role emotional subscale, there was a 
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significant 3.12 unit increase in the Ex+Meat group after 24 weeks (P<0.05) and no 
change in the Ex+CHO group, which lead to a trend for a difference between groups 
for the change over time (group-by-time interaction, P=0.075), and 3) for the mental 
health subscale, the Ex+CHO group had a 1.73 unit increase relative to baseline 
(P=0.05). 
 
5.3.6 Exploratory analysis 
Exploratory analysis of the association between the changes in HR-QoL scores and 
lean mass, muscle strength and function in all participants combined at baseline 
revealed that there were no significant associations using the Bonferroni corrected P-
value of 0.0125 (Table 5.5). In contrast, analysis of the changes in HR-QoL with the 
changes in appendicular lean mass, muscle strength and function showed that there 
was a significant positive association between changes in the MCS score and 
changes in gait speed (Table 5.6; Figure 5.1). No other associations were observed. 
 
For the various circulating growth, neurobiological and inflammatory markers, an 
adjusted Bonferroni P-value of 0.017 was used to assess significance for the various 
growth and neurotrophic factors while a P-value of 0.007 was used to assess 
significance for inflammatory markers. There were no significant associations found 
between HR-QoL and baseline levels of IGF-1, BDNF or VEGF (Table 5.7). With 
regard to the inflammatory markers, changes in PCS scores were positively 
associated with baseline levels of IL-6 and IL-10 (P=0.003 and P=0.005 [model 2 
only] respectively) (Table 5.7). Further, changes in global HR-QoL scores was 
positively associated with changes in serum IGF-1 after 24-weeks (P=0.007) (Table 
5.8). This persisted after adjusting for covariates in model 2. No significant 
associations were observed between changes in HR-QoL and changes in 
inflammation. 
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Table 5.5 Association between change in health-related quality of life (HR-QoL) and muscle mass, strength and function at baseline.   
 ∆ PCS ∆ MCS ∆ Global HR-QoL 
 β (95% CI) P value β (95% CI) P value β (95% CI) P value 
ALM 
  Model 1 0.16 (-0.18, 0.51)  0.351 -0.08 (-0.49, 0.32) 0.688 0.00 (-0.26, 0.26) 0.977 
  Model 2 0.19 (-0.17, 0.55) 0.323  -0.07 (-0.48, 0.35) 0.756 0.04 (-0.23, 0.31) 0.787 
Muscle strength
1 
  Model 1 0.00 (-0.02, 0.03) 0.748 -0.00 (-0.04, 0.03) 0.781 0.01 (-0.02, 0.03) 0.612 
  Model 2 0.01 (-0.02, 0.04) 0.579 -0.01 (-0.04, 0.03) 0.698 0.01 (-0.01, 0.04) 0.244 
Gait speed
2 
  Model 1 -0.78 (-6.76, 5.19) 0.796 -0.10 (-7.07, 6.88) 0.978 -1.38 (-5.80, 3.03) 0.537 
  Model 2 -0.06 (-6.45, 6.33) 0.985 0.06 (-7.25, 7.37) 0.987 -1.03 (-5.79, 3.73) 0.670 
Mobility
3 
  Model 1 -0.02 (-0.75, 0.70) 0.950 -0.02 (-0.86, 0.82) 0.962 0.19 (-0.44, 0.82) 0.551 
  Model 2 -0.11 (-0.88, 0.66) 0.783 -0.04 (-0.92, 0.84) 0.925 0.22 (-0.46, 0.90) 0.530 
All values represent unadjusted beta coefficients (β) values and 95% confidence interval (CI). Model 1: adjusted for sex and group, Model 2: adjusted for age, 
sex, change in physical activity, number of chronic diseases, depression and group. Calculated Bonferroni p-value of 0.0125 was used to assess significance. 
*P<0.013. 
1 
Leg press 3-RM muscle strength;
 2 
Gait speed assessed from the 4-m walk test; 
3 
Mobility was assessed using the four square step test (FSST). ALM: 
Appendicular lean mass, HR-QoL: health-related quality of life, PCS: physical component score, MCS: mental component score. 
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Table 5.6 Association between change in health-related quality of life (HR-QoL) and changes in muscle mass, strength and function 
after 24-weeks.   
 ∆ PCS ∆ MCS ∆ Global HR-QoL 
 β (95% CI) P value β (95% CI) P value β (95% CI) P value 
∆ ALM 
  Model 1 1.07 (-1.10, 3.25)  0.330 2.67 (0.17, 5.18) 0.037 -0.17 (-1.87, 1.53) 0.843 
  Model 2 1.09 (-1.10, 3.29) 0.327 2.61 (0.12, 5.10)  0.040 -0.11 (-1.78, 1.56) 0.896 
∆ Muscle strength1 
  Model 1 0.03 (-0.01, 0.07) 0.161 -0.01 (-0.06, 0.05) 0.820 0.01 (-0.02, 0.04) 0.560 
  Model 2 0.03 (-0.01, 0.07) 0.134 -0.00 (-0.05, 0.05) 0.974 0.01 (-0.02, 0.05) 0.511 
∆ Gait speed2 
  Model 1 -1.71 (-8.58, 5.16) 0.623 12.75 (5.01, 20.49)* 0.001 -2.48 (-7.59, 2.63) 0.339 
  Model 2 -1.57 (-8.56, 5.43) 0.659 11.92 (4.15, 19.68)* 0.003 -3.41 (-8.48, 1.66) 0.185 
∆ Mobility3 
  Model 1 0.06 (-0.86, 0.97) 0.904 -0.21 (-1.30, 0.87) 0.698 -0.29 (-0.97, 0.39) 0.400 
  Model 2 0.07 (-0.86, 0.99) 0.888 -0.20 (-1.29, 0.88) 0.709 -0.33 (-1.00, 0.35) 0.337 
All values represent unadjusted beta coefficients (β) values and 95% confidence interval (CI). Model 1: adjusted for sex and group, Model 2: adjusted for age, 
sex, change in physical activity, number of chronic diseases, depression and group. Calculated Bonferroni p-value of 0.0125 was used to assess significance. * 
P<0.013 
1 
Leg press 3-RM muscle strength;
 2 
Gait speed assessed from the 4-m walk test; 
3 
Mobility was assessed using the four square step test (FSST). ALM: 
Appendicular lean mass, HR-QoL: health-related quality of life, PCS: physical component score, MCS: mental component score. 
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Figure 5.1 Scatterplots of the associations between the change in the physical 
component summary (PCS) (panel A and C) scores and the mental component 
summary (MCS) scores with the changes in appendicular lean mass and gait speed. 
 
 
d b 
r=0.08, P=0.330 
a 
r=-0.04, P=0.623 
c 
r=0.18, P=0.037 r=0.27, P=0.001 
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Table 5.7 Association between change in health-related quality of life (HR-QoL) with the various serum growth, neurotrophic and 
inflammatory markers at baseline.   
 ∆ PCS ∆ MCS ∆ Global HR-QoL 
 β (95% CI) P value β (95% CI) P value β (95% CI) P value 
Growth and Neurotrophic Factors 
IGF-1 
  Model 1 -4.32 (-8.66, 0.03)  0.051 3.18 (-1.92, 8.28) 0.220 -1.65 (-4.90, 1.61) 0.319 
  Model 2 -4.08 (-8.50, 0.34) 0.070 2.75 (-2.34, 7.85) 0.287 -1.63 (-4.96, 1.71) 0.336 
BDNF 
  Model 1 0.96 (-2.19, 4.10) 0.549 2.03 (-1.63, 5.69) 0.274 1.73 (-0.58, 4.05) 0.141 
  Model 2 1.48 (-1.85, 4.82) 0.381 2.02 (-1.79, 5.83) 0.297 1.92 (-0.52, 4.35) 0.121 
VEGF 
  Model 1 0.87 (-0.39, 2.14) 0.176 0.42 (-1.07, 1.90) 0.580 -0.78 (-1.71, 0.14) 0.097 
  Model 2 0.83 (-0.47, 2.13) 0.210 0.61 (-0.88, 2.11) 0.420 -0.89 (-1.85, 0.06) 0.066 
Inflammatory markers 
Adiponectin 
  Model 1 1.27 (-0.60, 3.13) 0.183 -0.10 (-2.29, 2.09) 0.928 -0.48 (-1.86, 0.89) 0.490 
  Model 2 1.34 (-0.57, 3.25) 0.166 0.02 (-2.18, 2.22) 0.987 -0.20 (-1.61, 1.21) 0.780 
CRP 
Model 1 0.39 (-0.84, 1.62) 0.534 0.39 (-1.05, 1.83) 0.591 0.06 (-0.84, 0.96) 0.890 
Model 2 0.40 (-0.85, 1.65) 0.528 0.38 (-1.05, 1.81) 0.597 0.00 (-0.91, 0.92) 0.993 
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Homocysteine 
Model 1 -0.03 (-5.05, 4.98) 0.990 1.50 (-4.34, 7.34) 0.613 -0.76 (-4.49, 2.97) 0.689 
Model 2 -0.24 (-5.46, 4.98) 0.928 3.03 (-2.92, 8.98) 0.316 -0.33 (-4.22, 3.57) 0.869 
TNF-α 
Model 1 0.74 (-2.43, 3.91) 0.645 0.11 (-3.59, 3.81) 0.953 1.48 (-0.93, 3.89) 0.227 
Model 2 0.79 (-2.44, 4.02) 0.629 0.31 (-3.39, 4.00) 0.870 1.32 (-1.15, 3.79) 0.293 
IL-6 
Model 1 1.63 (0.55, 2.71)† 0.003 0.69 (-0.61, 1.98) 0.294 -0.11 (-0.92, 0.71) 0.798 
Model 2 1.76 (0.64, 2.87)† 0.002 0.54 (-0.77, 1.86) 0.415 -0.15 (-0.99, 0.70) 0.734 
IL-8 
Model 1 1.05 (-1.14, 3.24) 0.344 -2.11 (-4.65, 0.42) 0.102 1.03 (-0.56, 2.62) 0.203 
Model 2 1.02 (-1.21, 3.26) 0.367 -1.90 (-4.44, 0.65) 0.143 0.91 (-0.76, 2.57) 0.283 
IL-10 
Model 1 1.04 (0.25, 1.83) 0.011 -0.19 (-1.14, 0.76) 0.692 -0.08 (-0.68, 0.52) 0.792 
Model 2 1.19 (0.37, 2.02)† 0.005 -0.41 (-1.38, 0.56) 0.403 -0.12 (-0.75, 0.51) 0.703 
All values represent unadjusted beta coefficients (β) values and 95% confidence interval (CI). All growth, neurotrophic and inflammatory markers were log 
transformed prior to analysis. Model 1: adjusted for sex and group, Model 2: adjusted for age, sex, change in physical activity, number of chronic diseases, 
depression and group. Significance determined using a Bonferroni adjusted p-value of 0.0125 for growth and neurotrophic factors and 0.007 for inflammatory 
markers. * P<0.013; 
†
 P<0.007. ALM: Appendicular lean mass, FSST: four square step test, HR-QoL: health-related quality of life, PCS: physical component 
score, MCS: mental component score, IGF-1: insulin-like growth factor-1, BDNF: brain derived neurotrophic factor, VEGF: vascular endothelial factor, CRP: 
C-reactive protein, TNF-α: tumor necrosis factor-α, IL: interleukin. 
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Table 5.8 Association between change in health-related quality of life (HR-QoL) and changes in growth, neurotrophic and 
inflammatory markers after 24-weeks.   
 ∆ PCS ∆ MCS ∆ Global HR-QoL 
 β (95% CI) P value β (95% CI) P value β (95% CI) P value 
Growth and Neurotrophic Factors 
∆ IGF-1 
  Model 1  0.12 (-7.41, 7.65) 0.974 -3.71 (-12.48, 5.05) 0.404 7.76 (2.19, 13.34)* 0.007 
  Model 2 -0.42 (-8.12, 7.27) 0.913 -3.50 (-12.30, 5.30) 0.432 8.18 (2.63, 13.74)*  0.004 
∆ BDNF 
  Model 1 4.05 (-0.71, 8.82) 0.095 -4.81 (-10.37, 0.75) 0.090 0.41 (-3.31, 4.13) 0.828 
  Model 2 4.56 (-0.49, 9.62) 0.077 -5.03 (-10.83, 0.77) 0.089 2.00 (-1.83, 5.84) 0.303 
∆ VEGF 
  Model 1 0.88 (-1.68, 3.44) 0.498 -0.67 (-3.66, 2.32) 0.659 1.33 (-0.65, 3.31) 0.187 
  Model 2 1.04 (-1.62, 3.71) 0.440 -0.77 (-3.83, 2.29) 0.620 2.15 (0.14, 4.17) 0.037 
Inflammatory markers 
∆ Adiponectin 
  Model 1 -4.35 (-10.16, 1.46) 0.141 0.08 (-6.75, 6.91) 0.982 2.14 (-2.22, 6.51) 0.333 
  Model 2 -4.49 (-10.54, 1.55) 0.144 0.18 (-6.79, 7.16) 0.959 3.29 (-1.16, 7.73) 0.146 
∆ CRP 
Model 1 -0.66 (-2.11, 0.80) 0.373 -1.11 (-2.80, 0.58) 0.198 0.21 (-0.89, 1.30) 0.712 
Model 2 -0.66 (-2.13, 0.82) 0.380 -1.06 (-2.74, 0.62) 0.214 0.17 (-0.91, 1.25) 0.756 
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∆ Homocysteine 
Model 1 1.76 (-7.31, 10.82) 0.702 5.74 (-4.80, 16.28) 0.284 -0.38 (-7.18, 6.42) 0.912 
Model 2 2.19 (-7.06, 11.44) 0.640 4.59 (-5.97, 15.16) 0.392 -1.05 (-7.80, 5.69) 0.758 
∆ TNF-α 
Model 1 -3.31 (-7.57, 0.95) 0.127 0.45 (-4.56, 5.46) 0.859 1.65 (-1.76, 5.05) 0.340 
Model 2 -3.31 (-7.69, 1.06) 0.136 0.27 (-4.78, 5.33) 0.914 1.31 (-2.08, 4.71) 0.446 
∆ IL-6 
Model 1 -0.96 (-2.69, 0.77) 0.274 -1.25 (-3.27, 0.77) 0.222 -0.33 (-1.70, 1.05) 0.640 
Model 2 -0.95 (-2.71, 0.82) 0.291 -1.23 (-3.25, 0.79) 0.231 -0.25 (-1.61, 1.10) 0.711 
∆ IL-8 
Model 1 -2.72 (-5.96, 0.52) 0.099 1.63 (-2.18, 5.44) 0.399 0.84 (-1.66, 3.34) 0.509 
Model 2 -2.47 (-5.88, 0.94) 0.154 0.80 (-3.13, 4.74) 0.687 0.64 (-1.92, 3.20) 0.624 
∆ IL-10 
Model 1 -0.37 (-1.82, 1.07) 0.609 0.24 (-1.44, 1.93) 0.775 -0.32 (-1.37, 0.74) 0.554 
Model 2 -0.34 (-1.81, 1.13) 0.648 0.33 (-1.36, 2.01) 0.701 -0.35 (-1.42, 0.71) 0.511 
All growth, neurotrophic and inflammatory variables were log transformed prior to analysis. Values represent unadjusted beta coefficients (β) values (95% CI). 
Change data was calculated from the absolute difference from baseline in log-transformed data multiplied by 100. 
 
Model 1: adjusted for sex and group, Model 
2: adjusted for age, sex, change in physical activity, number of chronic diseases, depression and group. Significance determined using a Bonferroni adjusted p-
value of 0.0125 for growth and neurotrophic factors and 0.007 for inflammatory markers. * P<0.013; 
†
 P<0.007. ALM: Appendicular lean mass, FSST: four 
square step test, HR-QoL: health-related quality of life, PCS: physical component score, MCS: mental component score, IGF-1: insulin-like growth factor-1, 
BDNF: brain derived neurotrophic factor, VEGF: vascular endothelial factor, CRP: C-reactive protein, TNF-α: tumor necrosis factor-α, IL: interleukin. 
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5.4 Discussion  
The main finding from this 24-week RCT in community dwelling older adults was 
that a multi-component exercise program alone or in combination with a protein-
enriched diet achieved through the consumption of lean red meat (2 x ~80 g cooked) 
on each of the three training days, did not result in any significant improvements in 
HR-QoL, symptoms of anxiety and depression or memory complaints, with the 
exception of a modest but significant within-group improvement for the physical 
function subscale and memory complaints in the Ex+Meat group. However, the 
findings from the per-protocol analysis which included participants with at least 66% 
compliance with the exercise and 80% compliance with the lean red meat revealed 
that there was a significant net benefit in the Ex+Meat group for the role-physical 
subscale compared to Ex+CHO group, with a trend for a net benefit in the role-
emotional subscale. 
 
Several previous studies and meta-analyses have reported that the level of physical 
activity and/or exercise training can have a positive effect on HR-QoL in middle 
aged and older adults (446, 523, 524). There is some evidence that aerobic training, 
resistance training or the combination of different modalities can improve measures 
of HR-QoL, including both the physical and mental health domains (451, 454, 525). 
While there was some evidence for a modest improvement in the physical function 
subdomain of HR-QoL in the Ex+Meat (P<0.05) and Ex+CHO (P=0.08) groups in 
our study, overall our multi-component exercise program was largely ineffective for 
improving overall HR-QoL or any of its subdomains. Given that HR-QoL has been 
shown to be influenced by aspects of life related to illness, chronic conditions, 
disability and socioeconomic status (415, 446, 526, 527), the lack of any marked 
improvements in our study may be related to the fact the participants recruited into 
the study were relatively healthy older adults, and thus there could have been a 
ceiling effect. On average, the mean baseline HR-QoL scores for our cohort were 
close to 50, which is within the healthy range relative to the Australian population. 
Participants were excluded if they had any major chronic conditions or functional 
limitations that would limit participation with the exercise training or if they 
displayed evidence of depression or were not cognitively intact. Further, the vast 
majority of participants which reported one or more chronic conditions (e.g. 
hypertension), were taking medication to control their condition. In support of this 
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notion, there is some evidence that exercise may be particularly effective for 
improving measures of HR-QoL in older adults with various chronic conditions. For 
instance, a meta-analysis of 56 RCTs conducted in healthy and clinical populations 
(rehabilitation or disease management) including those with musculoskeletal, 
neurological and pulmonary conditions as well as cancer, CVD, rheumatoid arthritis, 
renal disease and fibromyalgia, found that exercise interventions typically had a 
positive effect on overall QoL after three to six months of training in rehabilitation 
patients but not in healthy or disease management groups (446). Together, this 
suggests that those who are most unwell may experience the greatest exercise-related 
benefit for HR-QoL, which explains the lack of any marked benefits following our 
intervention in healthy community-dwelling older adults. 
 
Previous research has indicated that the dose or intensity of aerobic and/or resistance 
training may be an important factor influencing whether exercise has a beneficial 
effect on measures of HR-QoL. While the optimal dose/intensity of training to 
improve HR-QoL remains unknown, there is some evidence that moderate-intensity 
aerobic exercise is beneficial for behavioural, affective and mood aspects of HR-QoL 
(30) as well as physical domains (446). Others have also reported that 24-weeks of 
moderate and high intensity PRT (60 minutes three times a week) (73) and 12 weeks 
of high-intensity power training (50-70 minutes at 75% 1-RM, performed either 
twice or three times per week) (528) can improve various measures of HR-QoL. 
Although compliance with the exercise program was not reported in the study by 
Ramirez-Campillo and colleagues, the exercise compliance in the former study was 
above 75%, equivalent to approximately two sessions per week (73), which suggests 
that this dose/frequency may be needed to improve measures of HR-QoL in older 
adults. In part support of this notion, an 8-week RCT which prescribed supervised 
PRT one day per week reported no benefits for HR-QoL in healthy older adults 
(529). In our study, participants were asked to train at a moderate intensity for both 
the aerobic and resistance training three times per week, but there was no evidence 
for a significant improvement in HR-QoL despite a mean ~79% compliance to the 
24-week training program. Thus, it is unlikely that the lack of any beneficial effects 
in our study was due to an inadequate training dose. Consistent with our findings, an 
8-week RCT conducted in 109 older people aged 55 years and over with 
osteoarthritis in the hip found no improvements in HR-QoL following moderate 
intensity PRT once a week, despite improvements in pain and hip function (530). 
  
274 
 
However, the results of this study should be interpreted with caution as it was 
underpowered which may have affected the ability to detect subtle changes in HR-
QoL (530). Another possible reason for the lack of any beneficial effects in our study 
may relate to the study duration. There is some evidence that acute training leads to 
improvements in HR-QoL and these benefits are not sustained over the long-term 
(31, 531). That is, it has been proposed that participants may experience greater 
initial improvements in their physical abilities (e.g. amount of weight they can lift) 
after a short period of time thereby increasing their HR-QoL, but as these benefits 
begin to plateau over time, the changes may become less noticeable thereby 
attenuating any perceived improvements in HR-QoL (31). Since there was no 
measure of HR-QoL after 12-weeks in our study, it may be possible that any 
improvements in HR-QoL associated with our multi-component exercise training 
were missed. 
 
For mental health components of HR-QoL, there is some evidence that exercise-
related improvements in healthy adults may be related to the social interaction from 
group-based training and the positive feelings associated with exercising with others 
(354, 455). Despite the participants in our study undertaking a supervised, group-
based training program to promote social interaction, there was no evidence for any 
positive effects on the MCS score (or its subdomains). It is possible that this may 
also be explained by the inclusion of relatively healthy older adults in our study, and 
the exclusion of participants with evidence of depression and cognitive impairment, 
as previous research has shown that depression and cognitive impairment are related 
to lower mental HR-QoL (449, 532). In our study, 98% of the participants had 
normal scores for depression and anxiety at baseline based on the HADS 
questionnaire. Further, the average baseline MCS scores were approximately 52 for 
both groups which is above average for a similar population sample of older 
Australians aged 65 years and older (484). This suggests that a ceiling effect may 
have occurred which may have limited the capacity for any marked improvement in 
MCS scores (or its subdomains) over the 24-week period. In part support of this, a 
12-week study in older adults with normal baseline HR-QoL scores found that there 
were no improvements in MCS scores (or subscales) following twice-weekly 
moderate-intensity (60% of 1-RM) PRT (455). Thus, those with HR-QoL ratings 
below the average and/or those who may be experiencing social isolation or 
loneliness may be more likely to experience a greater benefit from group-based 
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moderate-intensity exercise training in terms of mental health outcomes, but further 
research is needed to test this assumption. 
 
Previous research has suggested that exercise-related improvements in HR-QoL may 
also be related to improvements in physical function measures, including muscle 
strength (418, 453, 533). In our study, we found that our multi-component exercise 
program led to a significant 26-27% improvement in muscle strength and up to a 
0.05 m/sec improvement in gait speed, but we failed to observe any improvement in 
PCS scores. However, baseline measures indicated that there was little evidence of 
impaired function in our cohort which may have contributed to the lack of effect for 
HR-QoL, particularly PCS scores. Again, this may be related to our key inclusion 
criterion in that participants had to be healthy community-dwelling older adults with 
no major physical limitations which would interfere with completion of the exercise 
program. For instance, our participants had a mean gait speed of 1.39 m/sec with 
only one participant having a gait speed below 0.8 m/sec
 
and three participants 
having a gait speed below 1.0 m/sec. This is important as gait speeds below 0.8 to 
1.0 m/sec
 
have previously been shown to be indicative of physical impairment (534, 
535). Further, as previously mentioned, our participants had baseline HR-QoL scores 
equivalent to the Australian norms, which may also reflect a lack of any physical 
limitation. Previous research in older adults has shown that physical functioning 
plays an important role in HR-QoL, with energy, freedom from pain, ability to 
undertake activities of daily living and ability to move around being found to be an 
important predictor of physical function in those with sarcopenia (536). Thus it is 
possible that there may have been a ceiling effect of the intervention on physical 
function for our participants. In support of this notion, a 12-week RCT conducted in 
89 pre-frail women aged 70 years and over with baseline PCS scores as well as 
physical function and role physical subscale scores ~7 to 11 points lower than the 
baseline scores in our study, reported improvements in HR-QoL outcomes for the 
PCS and role physical, bodily pain and role emotional domains following once a 
week strength and balance exercises (intensity not reported) (458). This highlights 
that participants with a higher level of physical impairment prior to an exercise 
intervention may experience greater health benefits, which is consistent with the 
exercise training principle of diminished returns.  
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Given that there is some evidence indicating that protein can augment the effects of 
exercise (particularly PRT) on muscle mass and strength (68, 69) which may 
improve physical functional outcomes, it was hypothesised that the provision of 
additional protein (lean red meat) to the multi-component exercise would enhance 
the effects on HR-QoL. In the per protocol analysis which included participants with 
at least 66% compliance with the exercise (mean compliance 85%) and at least 80% 
compliance to the red meat (mean compliance 93%), there was evidence for a greater 
benefits on the role physical and the role emotional subscales in the Ex+Meat group 
compared to the Ex+CHO group. However, there was no evidence that the additional 
protein (red meat) had any beneficial effects on HR-QoL or its subdomains in the 
ITT analysis. This suggests that compliance may be an important factor for 
improving HR-QoL. In support of these findings, two previous RCTs reported some 
added benefits of protein when combined with multi-component exercise on certain 
measures of HR-QoL; compliance with the protein (red meat consumed on six days 
per week) was 81% in one study (418) while in another study 63% of participants 
had above 80% compliance (nutritional supplement containing 20 g of protein) 
(457); compliance with the exercise interventions in these trials ranged from 74% to 
80% (418, 457). In contrast, several previous RCTs have reported no benefits of 
protein supplementation (doses ranging from 15 to 22 g/d) combined with moderate-
intensity multi-component exercise or PRT on HR-QoL in healthy older adults after 
12 to 24 weeks, even when compliance with the protein was 98-100% (70, 459). 
There are a number of factors which may explain the lack of any additive or 
interactive effects of protein combined with exercise on HR-QoL in our trial and 
these previous studies, including the health status of participants (e.g. most previous 
studies have been conducted in healthy older adults), the similar exercise-protein 
related improvements in muscle mass, strength and/or function and potentially the 
dose of protein prescribed and habitual protein intake of participants.  
 
There is emerging evidence that greater exercise-induced gains in muscle mass and 
strength are associated with improved HR-QoL (452, 453). In our study, the finding 
that there was no added benefit of the lean red meat with exercise on lean mass 
(except for arm lean mass) or muscle strength may have therefore contributed to the 
lack of any interactive effects on HR-QoL. Further, subsequent exploratory analysis 
revealed that changes in appendicular lean mass and muscle strength in both groups 
combined was not associated with changes in overall HR-QoL, or the physical 
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subdomains. While this may be due in part to the fact that there was a modest 0.58 to 
0.76 kg increase in total body lean mass, there was a significant 26 to 27% gain in 
muscle strength in both groups after 24-weeks. Nevertheless, consistent with our 
findings a previous 4-month RCT in healthy older women conducted by our group 
showed that exercise plus lean red meat induced changes in leg lean tissue mass 
(mean 0.11-0.33 kg) were not associated with changes in PCS scores (418). 
However, in contrast to the current trial this previous study found that changes in leg 
muscle strength (mean increase 10-28%) were significantly associated with changes 
in overall HR-QoL and the mental health subdomain (418). It is difficult to explain 
these contrasting findings given that the inclusion/exclusion criteria and exercise 
interventions were similar between these two studies, and the intervention-related 
gains in lean mass and strength were also comparable. The main differences between 
these two trials was that the initial study by our group was conducted in women only 
and over 16 weeks, and the dose of protein (red meat) was double (six versus three 
days per week).  
 
Despite the lack of any association changes in lean mass or strength with the physical 
domains of HR-QoL, an interesting finding from the present study was that changes 
in gait speed were positively associated with changes in the MCS scores in all 
participants combined. A previous 8-month exercise intervention in 50 community-
dwelling older adults also found that exercise-induced changes in functional 
performance (stair ascent time) were associated with changes in MCS scores as well 
as bodily pain and mental health (451). Similar to our findings, they also found that 
changes in muscle strength or function were not associated with changes in PCS 
scores. While a number of previous exercise intervention trials in older adults have 
reported that changes in muscle strength and/or function have been more strongly 
related to changes in the PCS scores (533), these above findings suggest that 
improvements in functional performance may provide a global indicator of health 
and functioning by which improvements in general well-being and mental health can 
be perceived (451). 
 
Current Australian dietary guidelines recommend that red meat be consumed 3-4 
times per week, but whether such a dose in combination with exercise can improve 
HR-QoL has not been investigated. The dose of protein consumed in our study was 
~45 g/d on each of the three training days, which resulted in the mean dietary protein 
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intake increasing from approximately 1.2 to 1.4 g/kg per day on each of the three 
training days in the Ex+Meat group. This magnitude of change in protein intake is 
consistent with the previous 4-month RCT conducted by our group which reported 
an increase in mean daily protein intake from approximately 1.1 to 1.3 g/kg per day 
following lean red meat (~45 g/d) on six days a week plus exercise (418) and 
observed some beneficial effects on HR-QoL. However, this study also reported 
significantly greater gains in total body and leg lean mass and muscle strength in the 
exercise plus meat group compared to the exercise alone group (418). Key 
differences between this study and our study which may explain the lack of any 
added benefit on HR-QoL in the current study include a difference of approximately 
0.15 g/kg in habitual protein intake at baseline, and the frequency of the consumption 
of the lean red meat. In our study, participants consumed the red meat only on the 
three training days over 24-weeks, whereas in the study by Torres and colleagues 
(418), it was consumed on six days per week over 16 weeks. This suggests that a 
more frequent dose of protein on most days of the week may be required to improve 
HR-QoL in older adults. In part support of this notion, a previous 12-week 
prospective study conducted in 91 institutionalised adults aged 70 years and over 
reported improvements in HR-QoL following the ingestion of a 200 ml oral 
nutritional supplement containing 20 g of protein twice daily on five days a week, in 
combination with balance, flexibility and PRT (457). Although it is difficult to 
compare these studies given that this latter trial was conducted in institutionalised 
elderly who were likely to have poorer basal HR-QoL scores, taken together, it is 
possible that a more frequent dose of protein may be required to improve HR-QoL 
measures, although further studies are required to investigate this assumption.  
 
Another potential reason that may have contributed the lack of any additive effects of 
the protein with exercise on HR-QoL is the adequate basal habitual protein intake of 
the participants in our study. The mean habitual protein intake for all participants at 
baseline was ~1.2 g/kg, which is in line with current consensus guidelines for older 
adults undertaking resistance training (e.g. >1.2 g/kg) (537). Previous research has 
shown that lower habitual intakes of protein are associated with various chronic 
conditions and a poorer health status in older adults (440, 501). Thus, it is possible 
that older adults not meeting current dietary protein requirements may be more likely 
to experience greater exercise-protein related gains in muscle mass and strength 
which may subsequently benefit HR-QoL. In support of this notion, a 12-week RCT 
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conducted in 130 sarcopenic older adults with a baseline protein intake much lower 
than that of our study (54 to 59 g/d versus ~90 g/d) reported improvements in MCS 
scores, and a greater benefit in PCS scores following a moderate intensity multi-
component exercise program combined with an amino acid/whey-protein (22 g/d) 
and vitamin D (100 IU/d) enriched supplement, compared to exercise alone (459). 
Conversely, another study failed to observe improvements in HR-QoL when habitual 
protein intakes were equivalent to or above current requirements (55). A 3-week 
RCT in young healthy males (aged 19-31 years) with a habitual protein intake of 1.5 
g/kg/d failed to report any improvements in HR-QoL, when comparing a high protein 
diet (3.0 g protein/kg of bodyweight) to a usual protein diet (1.5 g protein/kg of 
bodyweight) (55). However, the lack of effect in this study may also be related to the 
fact that the participants were healthy young men and the study duration was only 
three weeks. Thus, it is possible that the higher basal protein intake in our study may 
have limited the ability to detect any additive or synergistic benefits of the additional 
protein on HR-QoL.  
 
There is also some evidence which suggests that lower levels of circulating growth 
factors and neurobiological markers such as IGF-1 and BDNF, and higher levels of 
inflammation are associated with lower HR-QoL as well as depression (23, 376, 460, 
462, 463, 465-467). However, cross-sectional analyses in our study revealed that 
baseline levels of growth and neurotrophic factors as well as inflammatory markers 
were not associated with any HR-QoL domain. A potential explanation for this 
finding may be related to the above average HR-QoL scores of our participants and 
their good health status which was reflected in part by their normal levels of 
inflammation. As described in chapter 4, this may have also contributed to our 
finding that there were no significant changes for any of the neurobiological or 
inflammatory markers in either group with the exception that serum IGF-1 levels 
increased in both groups. However, an interesting finding from our exploratory 
analyses was that changes in global HR-QoL were positively associated with changes 
in IGF-1 in all participants combined. Previous evidence suggests that IGF-1 is a 
primary regulator of depressive symptoms and it has been used in the treatment of 
depression, along with BDNF (23). Further, there is some evidence indicating that 
IGF-1 can reduce circulating pro-inflammatory cytokines which could impair BDNF 
signalling in the brain (23). This suggests that exercise-induced increases in IGF-1 
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may be associated with improvements in HR-QoL although no study has established 
a clear link between circulating IGF-1 levels and HR-QoL in older adults. 
 
Given that increased levels of inflammation have been associated with chronic 
conditions which may limit physical function (e.g. osteoarthritis) (403, 538), a 
decrease in inflammation may subsequently result in an improvement in physical 
function and PCS scores. In support of this notion, in the previously discussed study 
by Torres and colleagues which reported an added benefit of red meat with exercise 
on physical HR-QoL scores (418), they also reported a greater reduction in the pro-
inflammatory marker IL-6 in the exercise plus lean red meat group compared to 
those receiving exercise alone (72). In the current study, there were no improvements 
(changes) in any inflammatory markers in either group, but we did find that baseline 
levels of IL-6 and IL-10 were positively associated with changes in PCS scores. We 
are unable to explain this finding as it suggests that those with higher levels of 
inflammation at baseline were likely to experience a larger change in PCS scores, 
although for IL-10, it suggests that those with higher levels of this anti-inflammatory 
marker experience larger improvements in PCS scores. 
 
While there is evidence from some cross-sectional studies which suggest that 
increased levels of inflammation are associated with lower MCS scores and feelings 
of happiness and wellbeing (465, 466), in our study, exploratory analyses revealed 
that there was no association between baseline levels or changes in IGF-1, BDNF, 
VEGF or inflammation with changes in MCS scores. A possible explanation for our 
findings may be related to the high baseline MCS scores and the small number of 
participants with depressive symptoms at baseline, which indicates that our 
participants were likely to have good mental health at the beginning of the study, 
thereby creating a ceiling effect for any improvement in MCS scores. However, 
previous studies which have reported a beneficial effect for MCS scores in healthy 
older adults have not assessed baseline levels of growth factors, neurobiological 
markers or inflammation (354, 455). 
 
5.5 Limitations 
Several strengths of this study include the relatively long-term follow-up, adequate 
sample size and the multi-component nature of the exercise program which was 
designed to target multiple aspects of health including muscle mass, strength, 
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function as well as aerobic capacity. Furthermore, compliance with the exercise 
training which was implemented within local community health and leisure centres 
was excellent (mean ~78%), as was compliance with the lean red meat (mean 87%). 
This demonstrates the feasibility of such an approach in the ‘real world’. The fact 
that this study was a food-based intervention rather than a supplementation trial is 
also a strength, as the consumption of the lean red meat increased the likelihood that 
participants benefited from additional components of the lean red meat (e.g. omega 3 
and zinc). 
 
There are also a number of limitations associated with this study. First, this study 
was conducted in relatively healthy community-dwelling older adults who had HR-
QoL scores close to normative values relative to the Australian population. Although 
only inactive participants were recruited into the study, it is possible that this may 
have limited the scope for any marked improvements following the intervention. 
Second, there was no non-exercising control group included in our study, and thus it 
cannot be determined whether either intervention was more effective than usual care. 
Third, as this was a food-based intervention, the consistency of the protein dose 
consumed by each participant may have varied due to differences in preparation and 
cooking of the red meat. Fourth, given the increasing cost of red meat in Australia it 
remains uncertain whether older adults would typically purchase and consume red 
meat twice a day, three times per week. Thus, the implications of our findings for a 
real world setting given that the lean red meat was delivered to the participants’ 
homes free of cost, may be somewhat limited. Fifth, HR-QoL was only assessed at 
baseline and 24 weeks and thus it is possible that shorter-term (e.g. after 8-12 weeks) 
benefits may have been missed. Sixth, this study was not specifically designed to 
detect between group differences in HR-QoL as this was a secondary outcome; 
muscle mass, strength and cognitive function were the primary outcomes. However, 
as discussed in Chapter three (section 3.11) post-hoc power calculations indicated 
that the study was adequately powered to detect differences in HR-QoL. Finally, 
there is evidence which suggests that the self-report nature of the SF-36v2 
questionnaire may result in reporting bias and there may be a ceiling effect which 
may limit the ability to detect subtle changes in healthy older adults (539).  
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5.6 Conclusion 
In conclusion, this study indicates that 24-weeks of moderate-intensity multi-
component exercise on three days a week is largely ineffective for improving HR-
QoL, symptoms of depression and anxiety or memory complaints in healthy 
community-dwelling older adults. Further, the addition of lean red meat in line with 
current Australian dietary guidelines to a multi-component exercise program does 
not enhance the effects of exercise on HR-QoL, symptoms of depression and anxiety 
or memory complaints. Future studies should investigate the effects of this exercise 
and nutritional approaches in clinical populations (e.g. those with sarcopenia or 
depression) or those with malnutrition who are more likely to exhibit a poorer 
baseline HR-QoL.  
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Summary, Implications and Future Directions 
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6.1 Summary 
Globally it is estimated that 33% of the population will be aged 60 years or over by 
the year 2050 (1). This is problematic as ageing is associated with a myriad of 
physiological changes, particularly losses of muscle mass, strength and function, 
which are associated with a higher risk for many chronic diseases as well as an 
increased risk of falls and fracture (2). While this has been shown to impose a 
significant burden on the healthcare system as well as the individual (3), such 
conditions can also lead to a decline in HR-QoL which has been associated with an 
increased risk for depression and related disorders as well as pathological 
progressions of age-related cognitive decline leading to an increased risk for MCI 
and dementia (4-6). Similarly, dementia and cognitive decline have also been 
associated with declines in HR-QoL (7, 8). Thus, there is a need to identify safe and 
effective strategies to maintain muscle and cognitive function in healthy older adults, 
and to ensure that HR-QoL is maintained into old age.  
 
Previous research suggests that a number of lifestyle factors, particularly diet and 
exercise, can have a beneficial effect on optimising muscle health and function and 
reducing the risk of falls, as well as slowing cognitive decline and improving HR-
QoL (4-6, 188, 445, 446). With regard to muscle health and function, both PRT and 
dietary protein are widely recognised as important factors for older adults and the 
elderly, but there is emerging evidence that both factors may also influence brain 
health and cognitive function (15, 16, 19, 20, 46, 247). This may occur via direct 
and/or indirect pathways, as there is other evidence that exercise and protein can alter 
the regulation of various growth and neurotrophic factors (e.g. IGF-1 and BDNF) 
and/or the modulation of various systemic inflammatory markers. This suggests that 
the combination of dietary protein and exercise may have synergistic effects on 
various growth and neurotrophic markers which may promote greater gains for 
muscle and cognitive function, compared to protein or exercise alone. 
 
Therefore, the aim of this thesis was to investigate whether a multi-component 
exercise program combined with increased dietary protein achieved through the 
consumption of lean red meat in line with the current Australian dietary guidelines, 
could lead to greater improvements in muscle and cognitive function as well as 
various neurobiological, growth and inflammatory markers and HR-QoL, compared 
to the multi-component training alone. Specifically, this thesis aimed to: 
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(1) Investigate the effects of a multi-component exercise program in combination 
with a protein-enriched diet achieved by consuming lean red meat on each of the 
three training days, on cognitive function and HR-QoL in community-dwelling older 
adults, compared to multi-component exercise alone (Chapter 4 and 5).  
 
(2) Investigate the effects of a multi-component exercise program in combination 
with a protein-enriched diet achieved by consuming lean red meat on each of the 
three training days on circulating neurobiological and inflammatory markers, IGF-1 
and bioavailable zinc, compared to multi-component exercise alone (Chapter 4).  
 
(3) Investigate the cross-sectional association between muscle mass, size, strength 
and function with measures of cognitive function and HR-QoL (Chapter 4 and 5). 
 
(4) Investigate whether baseline and changes in muscle mass, size, strength and 
function as well as various growth, neurobiological and inflammatory markers, and 
bioavailable zinc, are associated with changes in cognitive function and HR-QoL 
(Chapter 4 and 5). 
 
This chapter will summarise the key findings from this thesis and will provide 
direction for future research with consideration for the limitations discussed in 
previous chapters, and will discuss the implications of this research for the broader 
population. 
 
6.2 Key research findings, limitations and directions for future research 
1. The main finding from this study was that the provision of additional protein 
(lean red meat) did not enhance the effects of exercise on any domain of 
cognitive function after 24 weeks in healthy older adults aged 65 years and over. 
 
2. The multi-component exercise program performed three times per week was 
effective for improving a number of cognitive domains, including global 
cognitive function and executive function, but not psychomotor /attention or 
working memory and learning 
 
3. There were no effects of the multi-component exercise program alone or in 
combination with the protein-enriched diet on any circulating neurobiological or 
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inflammatory markers or bioavailable zinc after 12 and 24 weeks in this study of 
healthy adults, with the exception that serum IGF-1 levels increased in both 
groups. For vitamin B12, there was a significant 5.1% reduction in the Ex+CHO 
group and no change in the Ex+Meat group after 12 weeks although after 24 
weeks, there was a non-significant 6.5% increase in the Ex+Meat group and a 
4.2% decrease in the Ex+CHO group. After 24 weeks, there was a significant 
3.0% increase in homocysteine in the Ex+CHO group with no change in the 
Ex+Meat group which lead to a trend for a significant group-by-time interaction.  
 
4. The addition of protein (lean red meat) to the thrice weekly multi-component 
exercise program did result in some added benefits to muscle mass and mobility 
compared to multi-component training alone, but there were no added benefits to 
muscle strength which increased similarly in both groups.  
 
5. The multi-component exercise training alone or in combination with the 
additional lean red meat was largely ineffective for improving HR-QoL in this 
group of community-dwelling healthy older adults. However, per protocol 
analysis revealed that there were greater improvements for the role physical 
subscale and role emotional subscale, with no change in the Ex+CHO group. 
 
6. Exploratory analysis of the baseline data revealed that appendicular lean mass 
and lower leg muscle strength were positively associated with global cognitive 
function and executive function. Further, mobility was negatively associated with 
global cognitive function and executive function. In contrast, there were no 
significant associations between appendicular lean mass and muscle strength with 
HR-QoL scores indicating that baseline measures of muscle mass and strength 
may not be important predictors for exercise-related changes in HR-QoL in 
healthy older adults. However, gait speed was positively associated with PCS and 
MCS scores while mobility was positively associated with depression scores but 
inversely associated with MCS scores, suggesting that measures of function may 
be important for HR-QoL.  
 
7. Exploratory analysis of the intervention data revealed that there was a significant 
negative association between ALM at baseline and changes in working 
memory/learning composite scores after 24 weeks, indicating that greater 
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appendicular lean mass is associated with smaller changes in cognitive function. 
However, there were no significant associations found between the changes in 
appendicular lean mass, strength or function and the changes in cognitive 
function. For HR-QoL, only the changes in gait speed were positively associated 
with changes in MCS scores after 24-weeks.  
 
8. Baseline levels of BDNF were positively associated with changes in executive 
function and negatively associated with changed in the behavioural regulation 
index. However, there were no associations between changes in growth, 
neurotrophic and inflammatory markers with changes in cognitive function. With 
regard to HR-QoL, baseline levels of IL-6 and IL-10 were positively associated 
with changes in PCS scores while changes in serum IGF-1 were positively 
associated with changes in global HR-QoL scores after 24-weeks. 
 
The following section will briefly discuss these key findings, including their 
implications, strengths and limitations, and the corresponding future research 
directions.  
 
6.2.1 Additional protein (lean red meat) does not enhance the effects of a 
structured and supervised multi-component exercise program on cognitive 
function or growth factors, neurobiological markers or inflammation in healthy 
older adults or improve HR-QoL. 
Evidence suggests that aerobic and PRT can have independent benefits on cognitive 
function in healthy older adults (22, 23, 35, 161, 276, 327), but there is also limited 
evidence suggesting beneficial effects following multi-component exercise (361, 
363, 367, 369). The aim of Chapter 4 of this thesis was to investigate the effect of 
additional protein (lean red meat) combined with a multi-component exercise 
program on cognitive function, growth factors and various neurobiological and 
inflammatory markers in relatively healthy community-dwelling older adults. It was 
found that the provision of protein (lean red meat) did not enhance the effects of the 
multi-component exercise training on any of these outcomes. Despite this, the 
intervention did show that the consumption of lean red meat in accordance with the 
current dietary guidelines had no negative health consequences for older adults, and 
was effective for increasing dietary protein intake. Further, there was a non-
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significant 6.5% increase in the Ex+Meat group and a 4.2% decrease in the Ex+CHO 
group after 24 weeks indicating that the lean red meat may have been effective in 
increasing vitamin B12 levels. However, changes in vitamin B12 levels were not 
associated with changes in cognitive function in any domain. The finding that there 
were no additive effects in our study is likely due to a number of factors, including 
the recruitment of relatively healthy community-dwelling older adults, the baseline 
habitual protein intake of the participants which was ~1.2 g/kg (a level equivalent to 
current guidelines for older adults undertaking resistance training), and the lack of 
any marked changes in other outcome measures associated with cognitive function 
including circulating growth factors, neurobiological and inflammatory markers.   
 
The hypothesis that the additional protein might enhance the effects of exercise on 
cognitive function was based in part, on the premise that previous research has 
shown that muscle mass (14), strength (3, 15, 16, 19, 20, 243) and gait speed (19) has 
been associated with cognitive function, and that changes in these muscle measures 
have been related to a decreased risk for cognitive decline and dementia. While our 
multi-component exercise program was effective for improving total body and 
regional lean mass and muscle strength, the finding that there were no marked 
additive benefits with the additional protein (except for arm lean mass) (Chapter 4) 
could also help to explain why both groups experienced similar improvements in 
various cognitive domains.  
 
Evidence suggests that a combination of increased dietary protein (>1.2 g/kg/d) and 
PRT is required to optimise muscle mass, strength and function in older adults (68, 
69, 521) and given that previous research in older adults has shown that physical 
functioning plays an important role in HR-QoL (536), it was hypothesised that 
protein combined with exercise would results in greater benefits for HR-QoL 
compared to exercise alone. However, we found no added benefits of the protein on 
any domain of HR-QoL. While this may be related to the fact that our participants 
were healthy adults with no physical limitations and above average HR-QoL scores 
at baseline, it may also be related to the similar increases in muscle mass and 
strength observed for both groups. This may also be related in part to the dose of 
protein and the high habitual protein intake as previously mentioned. However, the 
per protocol analysis revealed greater improvements for the role physical subscale 
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and the role emotional subscale in the Ex+Meat group with no change in the 
Ex+CHO group, which suggests that compliance with the protein is an important 
factor for improving HR-QoL. 
 
Future Directions 
Future studies should endeavour to encourage a diverse range of participants with 
variations in health status to participate as this may provide a greater insight to the 
effects of the intervention across different health conditions as well as those with 
inadequate protein intake. In particular, those with MCI, who are malnourished and 
are at risk of frailty/sarcopenia should be included in future studies to provide insight 
into whether this intervention may be useful for slowing cognitive decline in groups 
at increased risk for dementia, as this population may experience greater cognitive 
gains due to the intervention. As such, HR-QoL may also improve in these groups. 
 
Further work is also needed to determine whether exercise and/or nutrition related 
gains in muscle mass, strength or function (and the magnitude of change in these 
measures) may be critical for inducing improvements in cognitive function and HR-
QoL. Moreover, given that there is evidence suggesting that changes in muscle 
strength mediate exercise-related improvements in cognitive function (243), future 
studies should investigate the role of muscle mass, strength and function to determine 
which muscle gains (i.e. mass, strength, power or function) may be most important 
for improving cognitive function. 
 
Lastly, there is little research which has investigated the effects of the type of protein 
on cognitive function when combined with exercise. As highlighted by previous 
research, there is some evidence that the type of protein may be important with 
regard to the effects on cognitive function. Future research should investigate and 
compare the effects of different types and doses of protein on cognitive function to 
determine whether there is an optimal dose and source. Results from such studies 
would be useful for developing more precise nutrition guidelines regarding protein, 
to optimise muscle and cognitive gains in older adults. 
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6.2.2 Structured and supervised multi-component exercise improves cognitive 
function, muscle mass, strength and IGF-1 levels in healthy older adults, but has 
no effects on various neurobiological or inflammatory markers. 
In Chapter 4, it was found that there were exercise-related improvements in total 
body and regional lean mass, muscle strength, global cognitive function and 
executive function in our cohort of relatively healthy community-dwelling older 
adults. In contrast, there was no effect on psychomotor/attention scores, the 
behavioural regulation index (a measure of inhibition, emotional control, and self-
monitoring) and metacognition index (a measure of initiative, working memory, 
planning, task monitoring and organization). These contrasting findings in terms of 
the different cognitive domains are consistent with previous research showing that 
exercise is effective for improving some, but not all, cognitive domains in older 
adults (22, 23, 35, 161, 276, 327). Nevertheless, given the relatively healthy nature of 
the participants in our study, the mean 0.17 to 0.26 SD and 0.33 to 0.39 SD exercise-
related improvements detected over 24 weeks for global cognitive function and 
executive function respectively, likely represent important and clinically relevant 
gains. For instance, it has been previously reported that a difference of 0.05 SD is the 
equivalent of being 1-2 years younger in age with regard to cognitive performance 
(205), however other studies have used 0.5 SD to gauge a meaningful change in 
cognitive function in older adults (48).  
 
Consistent with previous studies, our multi-component exercise increased muscle 
mass and strength and the magnitude of improvements were similar to that of many 
previous RCTs. This added to the growing body of evidence that moderate-intensity 
multi-component exercise performed on three days a week represents an effective 
approach to optimise muscle health and function and reduces the risk for sarcopenia 
in relatively sedentary healthy older adults. 
 
In contrast to our hypothesis and the findings of several previous studies, the exercise 
alone failed to improve any of the growth, neurotrophic or inflammatory markers. 
However, consistent with previous research, we observed a significant increase in 
serum IGF-1 levels in both groups due to the exercise. However, these exercise-
related changes in IGF-1 were not associated with changes in cognitive function and 
this suggests that modest exercise-related increases in IGF-1 in healthy older people 
may be insufficient to induce a change in cognitive function.  
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An important strength of this study is that the intervention was conducted within 
community-based leisure centres using best practice exercise and retention rates and 
compliance with the exercise training were excellent. Thus, from a translational 
perspective the intervention used in this study could be directly implemented within 
the community. 
 
Future directions 
Despite observing some cognitive benefits for various cognitive domains over 24 
weeks, changes in other cognitive domains may require a longer period before 
exercise-related changes occur. Thus, future studies with longer durations (18 
months or more) may provide greater insight into the effects of multi-component 
exercise on various cognitive domains. The inclusion of those with MCI and/or 
dementia would also be an important next step to see whether the multi-component 
exercise is effective in slowing the progression of further cognitive decline. Further, 
current research which compares the effects of different combinations of multi-
component exercise with single modalities on cognitive function is mixed. This may 
be related in part to the dose of the exercise prescribed across studies. Therefore, 
further studies are needed in order to determine the optimal combination and dose of 
exercise modalities, as beneficial results may help to inform recommendations 
regarding exercise for prevention and treatment plans for cognitive decline and 
dementia.  
 
Lastly, as the program was not self-funded, the sustainability of this intervention 
with regard to gym membership costs and affordability of lean red meat needs to be 
considered to determine whether this intervention may be sustainable or feasible in a 
financial regard for older adults in a real-life setting. This is particularly important 
when considering the foreseeable cost of implementing such a program into the 
community through government and non-profit organisations. Other factors which 
may also contribute to sustainability and feasibility with regard to the consumption 
of red meat in older adults such as possible dentition issues and an increased feeling 
of satiety associated with meat intake which may decrease the intake of other 
nutrients through a decreased consumption of other foods, also needs to be 
investigated. 
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6.2.3 Compliance with structured and supervised multi-component exercise 
combined with lean red meat may be an important factor for improving HR-
QoL in healthy older adults. 
In Chapter 5 of this thesis, the effect of protein combined with multi-component 
exercise on HR-QoL was investigated. It was shown that neither the multi-
component exercise nor the addition of the protein was effective for improving any 
aspect of HR-QoL in healthy older adults. The lack of effect with regard to the multi-
component exercise is inconsistent with a number of previous trials (446, 523, 524), 
although as discussed in Chapter 5, this may be related to the above average baseline 
HR-QoL scores for our participants. Nevertheless, in the per protocol analysis, there 
were additional improvements in the Ex+Meat group for the role physical subscale 
and the role emotional subscale, which suggests that compliance with the protein and 
exercise are important contributing factors for improving HR-QoL in healthy older 
adults. This is consistent with limited evidence which suggests that a high exercise 
compliance results in HR-QoL benefits (73).  
 
Future directions 
Future studies should investigate the effect of protein combined with multi-
component exercise in those with chronic conditions which are likely to impact on 
muscle mass and physical function, as it has been suggested that improvements in 
muscle mass (418, 453, 533) and physical function (536) play an important role in 
HR-QoL. Further, the effect of the group-based multi-component exercise on those 
who are experiencing depression or loneliness should be investigated due to evidence 
indicating improvements in mental HR-QoL due to an increase in social interaction 
(354, 455). 
 
6.2.4 Baseline appendicular muscle mass, strength and function are associated 
with cognitive function while only muscle function is associated with HR-QoL in 
healthy older adults. 
As previously indicated, recent evidence suggests that baseline and exercise-induced 
increases in muscle mass (14) and strength (3, 15, 16, 19, 20, 243) may be related to 
a decreased risk for cognitive decline. In Chapter 4 and 5, the cross-sectional 
association between cognitive function and HR-QoL with muscle mass, strength and 
function were assessed. For both global cognitive function and executive function, 
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there was a significant positive association with appendicular muscle mass and 
muscle strength at baseline, which supports emerging evidence that greater muscle 
mass and strength is related to better cognitive function. In contrast, there were no 
significant associations between global HR-QoL, the HR-QoL summary scores (PCS 
and MCS) or depression with muscle mass or strength which is inconsistent with 
some studies which have reported an association between HR-QoL and muscle mass 
and strength (418, 452, 453, 533). These findings may be explained by a tendency 
for those who do less physical activity to be at an increased risk for cognitive decline 
and a loss in muscle mass (3, 14), whereas poor physical function which may be 
related to pain, may be more important for perceived HR-QoL. In part support of this 
notion, there were significant positive associations found between gait speed and 
PCS and MCS scores and between mobility and depression scores. However, 
interestingly, these findings suggest that those with a slower gait speed have higher 
HR-QoL scores which contrasts previous evidence (536). However, we also observed 
a negative association between mobility and MCS scores which is line with previous 
evidence (451). Together, these findings suggest that measures of muscle function 
may be an important factor for HR-QoL rather than muscle mass and strength in 
older adults.  
 
Future directions 
The cross-sectional evidence for muscle and cognitive function is an emerging area 
and the results of our study add to this limited research supporting an association 
between muscle mass and strength with cognitive function. The lack of association 
observed between muscle mass and strength with HR-QoL should continue to be 
investigated in healthy people as our findings contrasted several previous studies. 
Thus, future studies should endeavour to include both healthy adults and those with 
MCI and sarcopenia to gain a broader understanding of this relationship and 
underlying mechanisms. 
 
6.2.5 Baseline appendicular muscle mass and baseline levels of serum BDNF are 
associated with changes in cognitive function. 
Our finding that ALM at baseline was negatively associated with changes in the 
working memory/learning composite scores suggests that those with the greatest 
muscle mass experienced little change in working memory/learning. This finding 
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adds to emerging research that muscle mass is related to cognitive function, but most 
previous studies have examined the association between muscle mass and cognitive 
function cross-sectionally (3, 14, 19). Given that our participants were healthy older 
adults this may suggest that those with higher muscle mass at baseline were at a 
lower risk for sarcopenia which has been associated with cognitive decline. The 
finding that there were no significant associations found between changes in muscle 
mass, strength or function and changes in cognitive function however, suggests that 
modest changes in muscle in healthy older people are insufficient to induce changes 
in cognitive function.  
 
Previous research indicates that growth factors, neurotrophic and inflammatory 
markers may influence cognitive function through protein and/or exercise-related 
improvements in these markers (61, 73, 74, 308, 349, 385). In Chapter 4, we 
investigated the relationship between baseline levels and changes in various growth 
and neurotrophic factors as well as inflammation with changes in cognitive function. 
It was found that those with higher baseline levels of BDNF were more likely to 
experience greater changes in executive function but smaller changes in the 
behavioural regulation index. These findings may be related to the fact that these 
markers can cross the BBB and thus higher levels of these markers may lead to 
higher bioavailability and improvements in cognitive function due to reuptake into 
the brain. However, given the negative association found for the BRI and the fact 
that BRI assesses several specific components of executive function, our findings 
suggest that BDNF may only be beneficial for aspects of executive function not 
relating to inhibition, emotional control and self-monitoring.  
 
Neither baseline levels nor changes in inflammation were found to be associated with 
changes in cognitive function. This suggests that in older adults who do not have 
elevated levels of inflammation, inflammation is not a key factor for predicting 
exercise-related cognitive improvements. However, these findings may also reflect 
the good health of our participants which offers partial support for previous research 
which suggests that higher levels of inflammation are associated with a greater risk 
for cognitive decline (23, 179).  
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Future directions 
Our results show some promise for a relationship between muscle and changes in 
cognitive function. Given that our study was conducted in healthy older adults, future 
studies should investigate the use of multi-component exercise and the addition of 
protein as a preventative measure for cognitive decline in those with MCI. Further, 
our findings provide some support for previous research with regard to the role of 
inflammation for cognitive function, however further studies are needed to 
investigate the role of different markers of inflammation in the prevention of 
cognitive decline. 
 
6.2.6 Baseline levels of inflammation and changes in IGF-1 and muscle function 
are associated with changes in HR-QoL in healthy older adults. 
There is evidence to suggest that dietary patterns or nutrients which can alter various 
circulating neurotransmitters and growth factors associated with a reduction in 
depressive symptoms and improvement in cognitive function, may lead to improved 
HR-QoL (422, 430). In Chapter 5, it was found that baseline levels of IL-6 and IL-10 
were positively associated with changes in PCS scores. This suggests that higher 
basal levels of inflammation are associated with greater change in the physical aspect 
of HR-QoL. It is possible that higher levels of inflammation (IL-6) offer more 
opportunity for a reduction in inflammation (via exercise) which may improve HR-
QoL, especially given that increased levels of inflammation have been associated 
with chronic conditions which may limit physical function (e.g. osteoarthritis) (403, 
538) and thus HR-QoL. Alternatively, our findings may suggest that higher levels of 
anti-inflammatory markers such as IL-10 may improve levels of pain and physical 
functioning. Further, larger changes in global HR-QoL scores were associated with 
larger changes in IGF-1 after 24-weeks. This supports previous research which has 
reported that increases in IGF-1 may lead to improvements in cognitive function and 
thus HR-QoL. 
 
In Chapter 5, larger changes in gait speed were associated with greater changes in 
MCS scores after 24-weeks. This is consistent with previous research which suggests 
that physical function is an important contributing factor to HR-QoL in older adults. 
A possible explanation for this finding may be related to the good compliance with 
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the group-based exercise program. Although regular gym attendance is likely to 
result in greater improvements in physical function, given that this study used a 
group-based exercise program and previous evidence has reported improvements in 
mental health due to increased social interaction following group-based exercise, it is 
possible that those with greater improvements in gait speed experienced 
improvements in MCS scores due to their regular attendance at the gym. However, 
our per-protocol analysis revealed that there were no significant improvements in 
gait speed or MCS scores. Despite this, our findings may have important 
implications for the design of exercise programs for older adults who have low levels 
of physical function and who may be limited in their social interaction. 
 
Future directions 
Our findings indicate that basal levels of growth and neurotrophic factors may be 
implicated in HR-QoL and this relationship requires further investigation. 
Specifically, research into the relationship between markers of inflammation and 
specific domains of HR-QoL is needed to provide insight into the role of anti-
inflammatory markers on subjective physical function and mental health. 
Additionally, the effect of group-based exercise on HR-QoL in frail older adults or 
those at risk of falls, should also be investigated to determine whether group-based 
exercise facilitates improvements in physical function and MCS scores through 
increased social interaction.  
 
6.2.7 Limitations 
Despite the strengths of this trial, such as the well-designed and independently 
tailored multi-component program, the relatively high level of compliance with the 
exercise and protein, the high retention rate and low number of adverse events 
related to the exercise, there were a number of limitations associated with this study 
which need to be considered when interpreting the above findings.  
 
A key limitation with regard to all findings was that the participants were healthy, 
generally well-educated older adults with adequate habitual protein intakes, normal 
levels of inflammation and little or no evidence of cognitive impairment or 
depression. This may have resulted in a ceiling effect for a number of measures 
including muscle, blood markers, cognitive function and HR-QoL, thus limiting the 
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amount of improvement which could be achieved in these measures. Further, our 
participants displayed little evidence of physical limitations which resulted in 
baseline HR-QoL scores above that of Australian normative data. This also resulted 
in minimal variability in the level of impairment for muscle at baseline and thus our 
results may not reflect a true representation of the relationship between HR-QoL and 
different levels of physical impairment in the broader Australian population. Another 
key inclusion criterion was that participants had to have no contraindications or 
physical limitations which would interfere with completion of the exercise program. 
This is important as those with chronic conditions such as sarcopenia or frailty may 
experience greater increases in muscle mass and function following exercise.  
 
Although the main component of the multi-component training was moderate-
intensity PRT, which is consistent with the current PRT guidelines required to 
enhance muscle mass and strength, the combination of the PRT with an aerobic 
training element and balance/mobility exercises may have limited the potential to 
induce exercise-related gain in muscle alone and when combined with the additional 
protein. Given previous evidence which suggests that muscle mass and function may 
be related to cognitive function and HR-QoL, this may have attenuated any changes 
in cognitive function and HR-QoL. Further, little is known about what type of multi-
component exercise program is the best to induce cognitive benefits. For instance, a 
recent meta-analysis reported that aerobic, PRT and multi-component exercise may 
have similar effects (369). Thus, it is unclear whether the combination of aerobic, 
PRT and balance/mobility exercises is the optimal combination for promoting 
cognitive benefits in healthy older people as this study did not compare multi-
component exercise to single modality exercise or other combinations of multi-
component exercise. It is also unclear whether high-intensity PRT alone or a longer 
session duration combined with protein is needed to enhance muscle gains and 
changes in cognitive function, in healthy older adults. Further, we did not include 
any measure of aerobic fitness in this study, and given previous research which 
suggests that this may be associated with cognitive function (329-331, 333, 334) this 
is a limitation of our study. Moreover, blood samples were not collected immediately 
post-exercise and thus acute effects of the exercise may have been missed. This may 
have attenuated relationships between various blood markers and cognitive function 
or HR-QoL. 
  
298 
 
Another key limitation is that there was no control group in this study and thus it is 
difficult to speculate whether the multi-component exercise attenuated age-related 
cognitive decline or had added benefits for other outcomes compared to a non-
intervention group. Although this study was consistent with the length of previous 
trials which have investigated the effect of exercise on cognitive function, it has been 
suggested that durations of 18 months or longer are needed in order to observe 
changes in cognitive function (517). Our study was only 24-weeks in duration, and 
thus it is possible that this was not long enough to observe changes in cognitive 
function. Further, due to the use of CogState, it was difficult to compare the findings 
of our study to previous trials as many of these studies commonly employed the use 
of traditional pen and paper questionnaires/ assessments.  
 
6.3 Conclusions  
In this thesis, additional dietary protein achieved through the consumption of lean red 
meat combined with multi-component exercise was prescribed with the aim of 
improving muscle mass and strength, cognitive function and various circulating 
growth factors and neurobiological markers as well as HR-QoL in healthy 
community-dwelling older adults. This 24-week RCT demonstrated that the 
combination of a multi-component training program combined with a protein-
enriched diet achieved through the consumption of lean red meat on each of the three 
training days, had no added benefits for cognitive function, neurobiological markers, 
inflammation or HR-QoL compared to multi-component training alone. However, 
the multi-component exercise intervention was effective for improving muscle mass 
and strength and cognitive function, specifically global cognitive function and 
executive function. Thus, funding at both local government and national level should 
prioritise the implementation of sustainable and accessible group-based exercise 
programs tailored to middle aged and older adults with a focus on maintaining 
cognitive function and reducing the risk for falls, sarcopenia, MCI and other chronic 
lifestyle-based conditions (e.g. diabetes and CVD) which may contribute to the onset 
of MCI and dementia. 
 
Overall, it can be concluded that the consumption of lean red meat in accordance 
with the current recommended dietary guidelines is a safe dose of dietary protein for 
healthy older adults and does not have negative effects on these aspects of health. 
Although it appears that there may be a limited role for the combination of exercise 
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and protein intake for cognitive function in healthy older people, future studies which 
address the limitations highlighted would be beneficial to determine whether the 
combination of protein and multi-component exercise is beneficial for improving or 
slowing the progression of cognitive decline in other populations. 
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Appendix E: Example Exercise Program 
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Appendix F: 24-hour Diet History Recall Recording sheets 
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Appendix G: Lifestyle Questionnaire 
 
  
In this questionnaire, we will ask you questions about your general 
background, health status and smoking history. Please allow 45 
minutes to complete this questionnaire. All responses will remain 
confidential. 
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Section 1 – Personal Details 
 
 
 
1. ID: _____________  Initials: ______________      Gender (Tick):      Male        
Female        
2. Date of Birth: ____ / ____ / _____        Present Age:    Years: _______     
Months: ______ 
3. Where were you born?                                             Tick one ( ) 
     Australia  1 
     UK  2 
     Italy  3 
     Greece  4 
     New Zealand  5 
     Vietnam  6 
     Other (specify below)  7 
 
If other, please specify: 
__________________________________________________ 
4. We are also interested in your parents’ ethnic origin (that is, the place 
where most of their ancestors came from) and the country they were born 
in.  
 Country of Birth Ethnic Origin (Tick one) 
Mother _________________ 
North European           Asian               African   
South European           Other (specify) __________ 
Father _________________ 
North European           Asian               African   
South European           Other (specify) __________ 
 
       
5. What is your highest level of schooling?                        (Tick one box) 
 Never attended school     1 
 Primary school      2 
 Some high school      3 
 Completed high school     4 
 Technical/Trade certificate     5 
 University or Tertiary level     6 
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6. Do you currently work?  (Tick one box)   YES    (go to Q. 7)  
NO     (go to Q. 9) 
 
7. What is your current employment status? (Tick one box) 
 Full time employment      1 
 Part time employment      2 
 Home duties (e.g. gardening)     3 
_________________________ 
 Retired         4 
_________________________ 
 Other (please specify)       5 
_________________________ 
8.  What type of work are you currently involved with? (Tick one box) 
   Don’t work  
 Predominately physical (e.g. heavy lifting, packing shelves, exercise  teacher, 
heavy gardening, cleaner & heavy housework, maintenance worker, factory worker 
with heavy physical work, nurse)    
   Standing and some walking (e.g. office workers, bank workers, light house 
work, factory work with some walking and some lifting, light gardening, teachers)  
   Predominately sitting (e.g. desk work, factory but mostly sitting, cashier, 
student, academic, computer work)   
    Other (please specify): _________________________________-
______________________ 
_________________________________________________________________
_________ 
 
9. Which one of the following best describes your current living arrangement?   
(Tick one box) 
 Living alone       1 
 Living with adults without children    2 
 Living with adults with children     3 
 Living in a retirement village / hostel   4 
 Other (please specify, e.g. home help, support) 
_________________________________      
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10.  Are you: (Please tick one only) 
 Married  1 
 De Facto  2 
 Separated  3 
 Divorced    4 
 Widowed  5 
 Never Married  6 
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2 - Musculoskeletal Questionnaire 
 
 
1. Do you have a family history of osteoporosis or low trauma fracture?    
YES   NO    DON’T KNOW                                
      If YES, which relative (Tick one or more responses):  
Mother               Grandfather  
Father              Sister(s)  
Grandmother                Brother(s)   
 
2. Have you broken any bones since the age of 45?   (Tick one box)   
NO      (Go to Q. 3)  
YES      If YES, please specify which bones below 
    Site  How old were you? How did the fracture happen? 
E.g. Wrist  Left 
 Right 
       53 years 
 
Slipped on wet floor and fell on an 
outstretched arm 
Toe(s)  Left 
 Right 
_________________ 
_________________ 
______________________________ 
______________________________ 
Ankle  Left 
 Right 
_________________ 
_________________ 
______________________________ 
______________________________ 
Leg  Left 
 Right 
_________________ 
_________________ 
______________________________ 
______________________________ 
Hip  Left 
 Right 
_________________ 
_________________ 
______________________________ 
______________________________ 
Finger(s)  Left 
 Right 
_________________ 
_________________ 
______________________________ 
______________________________ 
Hand  Left 
 Right 
_________________ 
_________________ 
______________________________ 
______________________________ 
Wrist  Left 
 Right 
_________________ 
_________________ 
______________________________ 
______________________________ 
Forearm  Left 
 Right 
_________________ 
_________________ 
______________________________ 
______________________________ 
Back  _________________ 
_________________ 
______________________________ 
______________________________ 
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Other  
  
 
3. Have you ever been treated for or been told that you have arthritis?   
      NO   YES   DON’T KNOW            
 
      If yes, please specify:  Rheumatoid Arthritis   
    Osteoarthritis    
    Other (please specify)   
______________________________ 
       
      Please indicate the body site(s) affected: 
______________________________________________ 
 
 
 
 
 
 
Please proceed to section 3 
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3 – Health Questionnaire 
 
 
1. Are you a: (Tick one box)    Current smoker?  
Ex-smoker?       
Non-smoker               (If no, go to Q.2)                                                                                             
 • If you are a current smoker, how many cigarettes do you smoke per day? 
___________ 
     • How long have you been smoking? 
 ____________________________________________ 
     • If you are an ex-smoker, how many cigarettes did you smoke per day? 
 _____________ 
     • At what age did you start smoking?  
___________________________________________ 
     • At what age did you stop smoking? 
 ___________________________________________ 
2. Vision 
a. Do you wear glasses to correct your vision?  YES       NO  
  If so, are your glasses used to: 
i. Assist you to see things clearly at a distance? YES       NO  
ii. Assist you to see things located close to you? YES       NO  
b. Do you wear bifocal (or multifocal) lenses?  YES       NO  
c. Do you suffer from: 
i. Glaucoma      YES       NO  
ii. Cataracts      YES       NO  
   If so, have you already or do you plan to have surgery?  YES      NO  
  Please describe________________________________________________ 
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iii. Any other eye condition that affects your vision   YES       NO  
 Please describe 
_________________________________________________________ 
3. Have you ever had or has your Doctor ever told you that you have                                                    
(Only tick if appropriate): 
High blood pressure   Angina      
Stroke/hemiplegia   Heart attack    
Alzheimer’s disease   Impaired memory   
 Parkinson’s disease   Epilepsy     
 Asthma   Neurological/brain damage  
 Chronic kidney failure    Kidney disease or stones  
 Hyperthyroidism   Liver disease    
 Hypothyroidism   Osteomalacia/Rickets  
 Hypogonadism (too little)   Vitamin D abnormality   
 Hypercortisolism   Spinal surgery   
  Heart Disease   Diabetes, Type 1  
  
 Cancer   Diabetes, Type 2    
 Cushing’s Syndrome    Lactose intolerance    
 Gastrectomy     Hypercholesterolemia  
 Celiac disease    Primary hyperparathyroidism  
Malabsorption syndrome (chronic bowel disease, Crohn's disease, ulcerative colitis)
 Please specify: _________________________ 
 Other (Please specify): 
_________________________________________________________________ 
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4 – Medications Questionnaire 
 
This section is about the medication you take. If you are unsure how to fill this in, 
please bring the form and all your medication (or a list) with you to the testing 
site.  
Non-Prescription Medications 
 
1. If you are CURRENTLY taking any NON-PRESCRIPTION medications or 
supplements please specify the NAME of the medication/supplement, the 
DOSE, the DURATION OF USE and the REASON for using the NON-
PRESCRIPTION medication(s). Supplements included vitamin, mineral and 
herbal types/remedies. 
 
  Tick if not currently taking any NON-PRESCRIPTION medications or 
supplements and go to Q2. 
 
Name of 
medication  
 
Dose 
 
Frequency 
(per day)       
 
Duration                                                                                                        
 
Reason for 
taking 
medication  
 
eg1. Caltrate 500mg once a day 6 months 
 
low bone density 
 
eg2. Glucosamine 1.5g twice a day 2 years arthritis 
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Prescription Medications 
2.  This next section refers to medications prescribed to you by your doctor. If you 
are CURRENTLY taking any PRESCRIPTION medications, including medication 
for your diabetes, please specify the NAME of the medication, the DOSE, the 
DURATION OF USE and the REASON for using the PRESCRIPTION medication(s) 
you are currently taking. 
 
       Tick if not currently taking any PRESCRIPTION medications 
 
Name of 
medication  
 
Dose 
 
 
Frequency 
(per day)       
 
Duration                                                                                                        
 
Reason for taking 
medication  
 
eg1. Avapro 
 
150mg 
 
once a day 
 
6 weeks 
 
high blood pressure 
 
eg2. Lipitor 20mg twice a day 2 years high cholesterol 
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5 - Alcohol Questionnaire  
 
1. Does this statement best describe your alcohol consumption? 
“I only drink on special occasions (e.g. Christmas, Easter, birthdays, weddings 
etc.)”  
   NO   YES  
  If you ticked NO, please go to the next question (Q.2)  
2. Please write the details of TYPE and AMOUNT of alcohol consumed LAST 
WEEK and on an AVERAGE WEEK in the table below.  
 Please indicate as accurately as possible, the type and amount of beverage 
consumed last week and for an average week.  
 Please provide alcohol content (percentage alcohol), if known or brand 
name. 
 Start by filling out yesterday’s intake then work backwards 1 day at a time. 
 
Day Date Last Week Average Week 
 
E.g. 
Monday 
 
05/04/13 
 
 
 
 
 
2 cans of VB (375 ml) 
3 glasses of Brown Bros. 
Moselle (200 ml each) 
 
 
   
2 cans of VB 
(375 ml); 1 Nip 
of Jim Beam 
Bourbon (30 ml); 
3 glasses of red 
wine (300 ml) 
Monday 
 
 
 
    
Tuesday 
 
     
Wednesday 
 
     
Thursday 
 
     
Friday 
 
     
Saturday 
 
     
Sunday 
 
     
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Appendix H: Compliance diaries 
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Appendix I: Adverse event recording sheet 
 
Adverse Events Checklist  
ID No: _________________           Date: __________________ 
In the past 4 weeks, have you experienced any adverse events (AE) or 
side effects related to the study? 
An Adverse Event (AE) is any adverse change in your state of health. This includes 
conditions such as a sprained ankle or muscle sprain or injury resulting from the study, as 
well as more serious injuries or illnesses. If you have experienced an adverse event in the 
past 4 week, briefly describe the AE in a few short words, or where appropriate, provide 
the doctor’s diagnosis. Record the onset date and any treatment, include any 
medications, therapy or procedures that they may have received specifically for the AE 
concerned. 
 
      NO I have not had an adverse event in the last 4 weeks.  
  
      YES I have had an adverse event(s) in the last 4 weeks. 
           If yes, please provide further details 
 
1. Describe the adverse event in detail. Is it painful when performing exercise 
only or at other times? 
 
 
2. Event date:  _____________________________________________ 
3. Did you see a health professional for this problem?   Yes     No   
GP     Specialist    Physio    Other  (Please indicate)_______________ 
What was the diagnosis? 
 
 
4. Did this problem limit your participation in the study? For how long? Please 
explain.  
 
 
5. How long did the pain last/is it ongoing? Any additional details. 
_________________________________________________________
_________________________________________________________ 
 
6.  Was this a pre-existing or new injury? When did the original injury occur? 
Had you completely recovered from the original injury? 
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Appendix J: Cross-sectional association between global cognitive function and composite scores with appendicular lean mass, muscle strength, gait 
speed and mobility at baseline for model 3. 
 ALM Muscle strength
1
 Gait speed
2 
Mobility
3 
 β (95% CI) P value β (95% CI) P value β (95% CI) P value β (95% CI) P value 
Global Cognitive Function 
  Model 3 0.04 (0.01, 0.07)* 0.005 0.00 (0.00, 0.01)* 0.006 0.32 (-0.16, 0.80) 0.194 -0.05 (-0.11, 0.01) 0.077 
Executive Function (GMLT) 
  Model 3 0.04 (-0.01, 0.08) 0.134 0.00 (-0.00, 0.01) 0.056 0.28 (-0.56, 1.12) 0.511 -0.12 (-0.21, -0.02) 0.019 
Executive Function (GEC) 
  Model 3 0.12 (-0.29, 0.53) 0.572 0.01 (-0.03, 0.04) 0.675 -1.56 (-8.81, 5.70) 0.672 -0.33 (-1.19, 0.52) 0.440 
Working Memory/ Learning 
  Model 3 0.04 (0.01, 0.08) 0.020 0.00 (-0.00, 0.01) 0.073 0.15 (-0.51, 0.81) 0.651 -0.02 (-0.09, 0.06) 0.679 
Psychomotor/Attention 
  Model 3 0.03 (-0.01, 0.07)
 
 0.139 0.00 (-0.00, 0.01) 0.418 0.24 (-0.51, 0.99) 0.522 -0.06 (-0.15, 0.03) 0.191 
All values represent unadjusted beta-coefficients (β) with 95% confidence interval (CI). Model 3: adjusted for education, age, sex, smoking status, depression, habitual physical 
activity, APOE genotype and history of CVD. Calculated Bonferroni p-value of 0.0125 was used to assess significance. *P<0.013. ALM: Appendicular lean mass, GEC: global 
executive composite, 
1 
Leg press 3-RM muscle strength;
 2 
Gait speed assessed from the 4-m walk test; 
3 
Mobility was assessed using the four square step test (FSST). 
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Appendix K: Mean baseline CogState cognitive function Z-scores for the exercise and lean red meat (Ex+Meat) and control carbohydrate (Ex+CHO) group, 
and the mean within-group changes and net differences between the groups for the change after 12 and 24 weeks, for model 3. 
 Baseline Values and Within-Group Changes  
 Ex+Meat Ex+CHO Intervention Effects 
 
Mean ± SD or  
(95% CI) 
P-value 
Mean ± SD or  
(95% CI) 
P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  | Model 3 
GMLT (Z scores total errors)      
  Baseline -0.02 ± 0.97  0.02 ± 1.04    
  Absolute  Δ 12-weeks 0.16 (-0.05, 0.37) 0.123 0.15 (-0.04, 0.34) 0.127 0.01 (-0.27, 0.29) 0.920 | 0.902 
  Absolute  Δ 24-weeks 0.39 (0.19, 0.60) 0.000 0.33 (0.13, 0.52) 0.001 0.07 (-0.21, 0.35) 0.613 | 0.611 
Psychomotor/ attention (DET Task Z scores for speed) 
  Baseline -0.14 ± 1.01  0.14 ± 0.98    
  Absolute  Δ 12-weeks -0.00 (-0.33, 0.32) 0.989 -0.39 (-0.66, -0.12) 0.001 0.39 (-0.03, 0.80) 0.035 | 0.138 
  Absolute  Δ 24-weeks 0.15 (-0.12, 0.42) 0.326 0.05 (-0.18, 0.28) 0.951 0.09 (-0.26, 0.44) 0.477 | 0.706 
Attention/processing speed (IDN Task Z scores for speed) 
  Baseline -0.13 ± 0.99  0.13 ± 1.00    
  Absolute  Δ 12-weeks -0.05 (-0.25, 0.16) 0.629 -0.25 (-0.44, -0.05) 0.006 0.21 (-0.08, 0.49) 0.123 | 0.224 
  Absolute  Δ 24-weeks 0.15 (-0.03, 0.32) 0.095 0.06 (-0.13, 0.25) 0.616 0.09 (-0.16, 0.34) 0.387 | 0.473 
Working memory/ learning (OCL Task Z score for accuracy)  
  Baseline 0.09 ± 1.01  -0.09 ± 0.99    
  Absolute  Δ 12-weeks -0.06 (-0.28, 0.15) 0.634 0.23 (0.00, 0.45) 0.017 -0.29 (-0.60, 0.19) 0.047 | 0.073 
  Absolute  Δ 24-weeks 0.11 (-0.16, 0.38) 0.285 0.38 (0.16, 0.61) 0.000 -0.27 (-0.62, 0.08) 0.085 | 0.138 
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Working memory/ learning (ONB Task Z score for speed)  
  Baseline 0.03 ± 1.01  -0.03 ± 1.00    
  Absolute  Δ 12-weeks 0.04 (-0.13, 0.20) 0.626 0.23 (0.06, 0.39) 0.004 -0.19 (-0.42, 0.04)
 
0.077 | 0.076 
  Absolute  Δ 24-weeks 0.06 (-0.09, 0.21) 0.316 0.34 (0.17, 0.50) 0.000 -0.28 (-0.50, -0.05) 0.017 | 0.012 
Working Memory/ Learning Composite      
  Baseline 0.06 ± 0.75  -0.06 ± 0.76    
  Absolute  Δ 12-weeks -0.01 (-0.15, 0.12) 0.867 0.23 (0.09, 0.36) 0.000 -0.24 (-0.43, -0.05) 0.023 | 0.015 
  Absolute  Δ 24-weeks 0.09 (-0.08, 0.25) 0.181 0.36 (0.22, 0.50) 0.000 -0.27 (-0.49, -0.06) 0.008 | 0.010 
Psychomotor/Attention Composite      
  Baseline -0.14 ± 0.85  0.14 ± 0.87    
  Absolute  Δ 12-weeks -0.02 (-0.24, 0.19) 0.785 -0.32 (-0.51, -0.13) 0.000 0.30 (0.01, 0.58)
 
0.018 | 0.083 
  Absolute  Δ 24-weeks 0.15 (-0.02, 0.32) 0.097 0.06 (-0.12, 0.23) 0.762 0.09 (-0.15, 0.33) 0.314 | 0.511 
Cognitive Brief Battery Composite      
  Baseline -0.04 ± 0.65  0.04 ± 0.66    
  Absolute  Δ 12-weeks -0.02 (-0.15, 0.11) 0.749 -0.05 (-0.17, 0.08) 0.446 0.03 (-0.15, 0.21)
 
0.753 | 0.919 
  Absolute  Δ 24-weeks 0.12 (0.00, 0.23) 0.033 0.21 (0.09, 0.33) 0.001 0.09 (-0.26, 0.07) 0.419 | 0.314 
Global Cognitive Score      
  Baseline 0.00 ± 0.57  -0.00 ± 057    
  Absolute  Δ 12-weeks 0.01 (-0.10, 0.12) 0.899 0.05 (-0.05, 0.16) 0.291 -0.05 (-0.20, 0.10) 0.508 | 0.357 
  Absolute  Δ 24-weeks 0.17 (0.08, 0.26) 0.001 0.26 (0.15, 0.38) 0.000 -0.09 (-0.24, 0.05) 0.288 | 0.237 
All baseline values are unadjusted means ± SDs. All change values are unadjusted means (95% CI) and were calculated from the absolute difference from baseline. Mean net differences (95% CI) were calculated 
by subtracting the within-group changes for the Ex+Meat group from the within-group changes for the Ex+CHO group after 12 and 24 weeks. Model 3 adjusted for age, sex, education, smoking status, depression 
at baseline, history of CVD, change in physical activity and APOE genotype. GMLT, Groton Maze learning; DET, detection task; IDN, identification task; OCL, one card learning task; ONB, one back working 
memory task. 
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Appendix L: Mean baseline T-scores for the BRIEF-A cognitive scores in the exercise and lean red meat (Ex+Meat) and exercise and 
control carbohydrate (Ex+CHO) group, and mean within-group changes and net differences between the groups for the change after 24 
weeks, for model 3. 
 Baseline Values and Within-Group Changes  
 Ex+Meat Ex+CHO Intervention Effects 
 
Mean ± SD or  
(95% CI) 
P-value 
Mean ± SD or  
(95% CI) 
P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  | Model 3 
BRI      
  Baseline, T-score 51.34 ± 10.22  49.53 ± 9.17    
  Absolute Δ 24-weeks -1.16 (-2.90, 0.57) 0.161 0.00 (-1.65, 1.65) 0.972 -1.16 (-3.54, 1.21) 0.298 | 0.359 
MI      
  Baseline, T-score 52.40 ± 9.25  51.30 ± 11.06    
  Absolute Δ 24-weeks -0.08 (-1.89, 1.73)
 
0.930 -0.35 (-2.18, 1.49)
 
0.775 0.27 (-2.29, 2.82) 0.894 | 0.825 
GEC      
  Baseline, T-score 52.01 ± 9.14  50.57 ± 9.91    
  Absolute  Δ 24-weeks -0.52 (-2.26, 1.22)
 
0.534 -0.14 (-1.83, 1.55) 0.930 -0.38 (-2.79, 2.03) 0.698 | 0.786 
All baseline values are unadjusted means ± SDs. All change values are unadjusted means (95% CI) and were calculated from the absolute difference from 
baseline. Mean net differences (95% CI) were calculated by subtracting the within-group changes for the Ex+Meat group from the within-group changes for the 
Ex+CHO group after 12 and 24 weeks. Model 3 adjusted for age, sex, education, smoking status, depression at baseline, history of CVD, change in physical 
activity and APOE genotype. BRI, behavioural regulation index; MI, metacognition index; GEC, global executive composite. 
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Appendix M: Mean baseline serum IGF-1, BDNF and VEGF values in the exercise and lean red meat (Ex+Meat) and exercise and control carbohydrate 
(Ex+CHO) group, and mean within-group changes and net differences between the groups for the change after 12 and 24 weeks, for model 3. 
 Baseline Values and Within-Group Changes  
 Ex+Meat Ex+CHO Intervention Effects 
 
Mean ± SD or  
(95% CI) 
P-value 
Mean ± SD or  
(95% CI) 
P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  | Model 3 
IGF-1      
  Baseline, nmol/L 17.70 ± 4.83  16.66 ± 4.60    
  %∆ 12-weeks 9.1 (6.0, 12.3) 0.000 6.9 (2.4, 11.3) 0.001 -2.3 (-7.8, 3.3) 0.397 | 0.749 
  %∆ 24-weeks 6.4 (2.2, 10.6) 0.000 5.3 (1.5, 9.1) 0.011 -1.1 (-6.7, 4.4) 0.636 | 0.616 
BDNF      
  Baseline, ng/mL 21.59 ± 7.01  21.34 ± 7.94    
  %∆ 12-weeks -3.0 (-10.6, 4.5) 0.388 -1.6 (-7.2, 4.1) 0.571 1.4 (-7.8, 10.7) 0.733 | 0.339 
  %∆ 24-weeks -4.1 (-10.4, 2.3)
 
0.260 0.00 (-5.4, 5.4)
 
0.988 4.1 (-4.1, 12.3) 0.364 | 0.102 
VEGF      
  Baseline, pg/mL 372.35 ± 265.35  463.04 ± 625.41    
  %∆ 12-weeks 3.2 (-6.9, 13.2) 0.602 -3.0 (-10.8, 4.7) 0.412 -6.2 (-18.6, 6.2) 0.384 | 0.604 
  %∆ 24-weeks -7.1 (-23.5, 9.4)
 
0.348 1.5 (-5.2, 8.3) 0.661 8.6 (-8.4, 25.6) 0.285 | 0.236 
All variables were log transformed prior to analysis. All baseline values are unadjusted means ± SDs. All change values are unadjusted means (95% CI) and were calculated from the absolute 
difference from baseline in log-transformed data multiplied by 100. Mean net differences (95% CI) were calculated by subtracting the within-group changes for the Ex+Meat group from the 
within-group changes for the Ex+CHO group after 12 and 24 weeks. P values for all measures were based on log-transformed data. Model 3 adjusted for age, sex, change in physical activity, 
BMI and APOE genotype. IGF-1, insulin like growth factor-1; BDNF, brain-derived neurotrophic factor; VEGF, vascular endothelial growth factor. 
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Appendix N: Mean baseline values for adiponectin and the various inflammatory markers in the exercise and lean red meat (Ex+Meat) and exercise 
and control carbohydrate (Ex+CHO) group, and mean within-group changes and net differences between the groups for the percent change after 12 
and 24 weeks, for model 3. 
 Baseline Values and Within-Group Changes  
 Ex+Meat Ex+CHO Intervention Effects 
 
Mean ± SD or  
(95% CI) 
P-value 
Mean ± SD or  
(95% CI) 
P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  | Model 3 
Adiponectin      
  Baseline, µg/ml 4.79 ± 3.48  5.11 ± 3.15    
  %∆ 12-weeks 1.3 (-2.6, 5.3) 0.545 -3.8 (-8.9, 1.4) 0.142 -5.1 (-11.6, 1.4) 0.132 | 0.103 
  %∆ 24-weeks 1.9 (-2.5, 6.2) 0.334 -2.7 (-8.5, 3.2) 0.299 -4.6 (-11.9, 2.8) 0.164 | 0.438 
hs-CRP      
  Baseline, mg/L 2.00 ± 2.33  1.98 ± 2.28    
  %∆ 12-weeks 11.1 (-15.8, 38.0) 0.361 5.0 (-13.5, 23.6) 0.614 -6.1 (-37.8, 25.7) 0.701 | 0.844 
  %∆ 24-weeks 8.7 (-12.5, 30.0)
 
0.464 13.8 (-4.0, 31.5)
 
0.169 5.0 (-22.2, 32.2) 0.746 | 0.822 
IL-10      
  Baseline, pg/mL 13.06 ± 24.38  9.51 ± 11.35    
  %∆ 12-weeks -6.1 (-26.7, 14.5) 0.500 -2.4 (-20.0, 15.1) 0.791 3.6 (-23.0, 30.2) 0.794 | 0.504 
  %∆ 24-weeks -3.6 (-23.7, 16.6)
 
0.676 -0.6 (-22.2, 21.0) 0.946 2.9 (-26.5, 32.4) 0.817 | 0.597 
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IL-8      
  Baseline, pg/mL 16.34 ± 11.09  14.60 ± 11.4    
  %∆ 12-weeks -4.8 (-17.6, 8.1) 0.465 3.2 (-4.0, 10.3) 0.437 8.0 (-6.2, 22.1) 0.286 | 0.344 
  %∆ 24-weeks -0.8 (-10.8, 9.3)
 
0.890 6.4 (-2.5, 15.2) 0.121 7.2 (-6.0, 20.4) 0.302 | 0.460 
IL-6      
  Baseline, pg/mL 4.86 ± 8.90  4.02 ± 5.76    
  %∆ 12-weeks -5.4 (-19.9, 9.2) 0.518 -1.1 (-17.5, 15.4) 0.893 4.3 (-17.7, 26.3) 0.751 | 0.522 
  %∆ 24-weeks -5.0 (-19.4, 9.3)
 
0.461 -1.2 (-19.0, 16.6) 0.881 3.9 (-19.1, 26.8) 0.714 | 0.630 
TNF-α      
  Baseline, pg/mL 10.36 ± 3.85  10.52 ± 4.51    
  %∆ 12-weeks -2.6 (-7.5, 2.3) 0.621 3.7 (-1.7, 9.0) 0.199 6.3 (-1.0, 13.5) 0.218 | 0.308 
  %∆ 24-weeks -0.4 (-7.6, 6.9)
 
0.909 1.9 (-4.4, 8.2) 0.505 2.3 (-7.2, 11.7) 0.593 | 0.456 
All variables were log transformed prior to analysis. All baseline values are unadjusted means ± SDs. All change values are unadjusted means (95% CI) and were 
calculated from the absolute difference from baseline in log-transformed data multiplied by 100. Mean net differences (95% CI) were calculated by subtracting the within-
group changes for the Ex+Meat group from the within-group changes for the Ex+CHO group after 12 and 24 weeks. P values for all measures were based on log-
transformed data. Adjusted model included age, sex, BMI and change in physical activity as covariates. Model 3 adjusted for age, sex, change in habitual physical activity, 
BMI and APOE genotype. CRP, C-reactive protein; IL, interleukin; TNF-α, tumor necrosis factor. 
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Appendix O: Mean baseline values for serum homocysteine, zinc, vitamin B12 and 25-hydroyxvitamin D in the exercise and lean red meat (Ex+Meat) and 
exercise and control carbohydrate (Ex+CHO) group, and the mean within-group change and net between group difference for change after 12 and 24 weeks 
for model 3. 
 Baseline Values and Within-Group Changes  
 Ex+Meat Ex+CHO Intervention Effects 
 
Mean ± SD or  
(95% CI) 
P-value 
Mean ± SD or  
(95% CI) 
P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  | Model 3 
Homocysteine      
  Baseline, umol/L 11.1 ± 2.6  11.0 ± 2.6    
  %∆ 12-weeks 0.7 (-2.0, 3.5) 0.621 1.8 (-0.7, 4.4) 0.189 -1.1 (-4.8, 2.6) 0.604 | 0.438 
  %∆ 24-weeks -1.1 (-4.3, 2.2) 0.571 3.0 (0.1, 5.9) 0.036 -4.1 (-8.4, 0.2) 0.066 | 0.052 
Zinc      
  Baseline, ug/dL 77.6 ± 10.3  78.6 ± 10.2    
  %∆ 12-weeks 2.7 (-0.2, 5.5) 0.160 0.3 (-2.6, 3.2) 0.688 2.4 (-1.6, 6.4) 0.199 | 0.255 
  %∆ 24-weeks 2.41 (-0.8, 5.6) 0.163 -0.74 (-3.5, 2.0) 0.334 3.2 (-1.0, 7.3) 0.098 | 0.161 
Vitamin B12      
  Baseline, pmol/L 318.8 ± 148.3  335.13 ± 182.46    
  %∆ 12-weeks 0.8 (-3.6, 5.2) 0.487 -5.1 (-10.3, 0.0) 0.042 6.0 (-0.8, 12.7) 0.050 | 0.052 
  %∆ 24-weeks 6.5 (-2.0, 15.1) 0.258 -4.2 (-9.8, 1.4) 0.111 10.7 (0.6, 20.8) 0.053 | 0.080 
25-hydroyxvitamin D      
  Baseline, nmol/L 83.6 ± 23.0  83.0 ± 28.0    
  Absolute ∆ 24-weeks 10.8 (6.9, 14.6) 0.000 8.8 (4.6, 12.9) 0.000 2.0 (-3.7, 7.6) 0.462 | 0.648 
All variables were log transformed prior to analysis. All baseline values are unadjusted means ± SDs. All change values are unadjusted means (95% CI) and were calculated from the absolute difference 
from baseline in log-transformed data multiplied by 100. Mean net differences (95% CI) were calculated by subtracting the within-group changes for the Ex+Meat group from the within-group changes 
for the Ex+CHO group after 12 and 24 weeks. P values for all measures were based on log-transformed data. Adjusted model included age, sex, BMI and change in physical activity as covariates. Model 
3 adjusted for age, sex, BMI, change in physical activity and APOE genotype.  
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Appendix P: Mean baseline weight, total body and regional (arms and legs) lean mass and fat mass and appendicular lean mass for the multi-
component exercise and red meat (Ex+Meat) and control (carbohydrate) multi-component exercise (Ex+CHO) group and the within-group changes 
and net differences between the groups for the change after 24 weeks, for the per protocol analysis. 
 Baseline Values and Within-Group Changes  
 Ex+Meat Ex+CHO Intervention Effects 
 
Mean ± SD or  
(95% CI) 
P-value 
Mean ± SD or  
(95% CI) 
P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  | Model 2 
Total Body      
Weight      
  Baseline, kg 75.6 ± 14.8  76.9 ± 19.0    
  Absolute  Δ 24-weeks -0.02 (-0.55, 0.51) 0.954 -0.14 (-0.54, 0.27) 0.899 -0.12 (-0.77, 0.53) 0.715 | 0.801 
Total body lean mass      
  Baseline, kg 44.34 ± 10.10  45.28 ± 11.36    
  Absolute  Δ 24-weeks 0.86 (0.52, 1.19)
 
0.000  0.57 (0.32, 0.82)
 
0.000 -0.29 (-0.70, 0.12) 0.159 | 0.169 
Total body fat mass      
  Baseline, kg 27.79 ± 9.63  28.05 ± 11.25    
  Absolute  Δ 24-weeks -0.87 (-1.38, -0.37)
 
0.000 -0.71 (-1.05, -0.37)
 
0.000 0.17 (-0.42, 0.76) 0.578 | 0.528 
Regional      
Appendicular lean mass      
  Baseline, kg 19.46 ± 5.04  20.10 ± 5.92    
  Absolute  Δ 24-weeks 0.40 (0.26, 0.55)
 
0.000 0.19 (0.06, 0.32) 0.003 -0.21 (-0.40, -0.02) 0.030 | 0.026 
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Arm lean mass      
  Baseline, kg 4.83 ± 1.50  5.01 ± 1.68    
  Absolute  Δ 24-weeks 0.18 (0.13, 0.23)
 
0.000 0.11 (0.06, 0.17) 0.000 -0.07 (-0.14, 0.00) 0.060 | 0.031 
Leg lean mass      
  Baseline, kg 14.63 ± 3.60  15.09 ± 4.28    
  Absolute  Δ 24-weeks 0.22 (0.10, 0.34)
 
0.000 0.08 (-0.03, 0.19)  0.144 -0.14 (-0.30, 0.02) 0.082 | 0.090 
Arm fat mass      
  Baseline, kg 2.90 ± 1.23  2.85 ± 1.34    
  Absolute  Δ 24-weeks -0.03 (-0.09, 0.02) 0.264 -0.05 (-0.11, 0.01) 0.074 -0.02 (-0.10, 0.06) 0.585 | 0.687 
Leg fat mass      
  Baseline, kg 9.04 ± 3.96  8.86 ± 4.42    
  Absolute  Δ 24-weeks -0.14 (-0.30, 0.02) 0.071 -0.13 (-0.24, -0.02) 0.021 0.01 (-0.18, 0.20) 0.912 | 0.807 
All baseline values are unadjusted means ± SDs. All change values are unadjusted means (95% CI) and were calculated from the absolute difference from baseline. Mean net 
differences (95% CI) were calculated by subtracting the within-group changes for the Ex+Meat group from the within-group changes for the Ex+CHO group after 12 and 24 weeks. 
Adjusted model included age, change in physical activity and sex. 
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Appendix Q: Mean baseline muscle strength and function for the multi-component exercise with lean red meat (Ex+Meat) and control (carbohydrate) multi-
component exercise (Ex+CHO) group, and the mean within-group changes and net differences between the groups for the change after 24 weeks, for the per 
protocol analysis. 
 Baseline Values and Within-Group Changes  
 Ex+Meat Ex+CHO Intervention Effects 
 
Mean ± SD or  
(95% CI) 
P-value 
Mean ± SD or  
(95% CI) 
P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  | Model 2 
Muscle Strength      
1-RM (Leg Press)      
  Baseline, kg 126.8 ± 48.5  135.9 ± 52.6    
  % Δ 24-weeks 26.2 (17.8, 34.6) 0.000 25.6 (17.4, 33.8)
 
0.000 -0.6 (-12.2, 11.1) 0.776 | 0.751 
Knee extensor strength      
  Baseline, kg 26.8 ± 10.4  26.5 ± 11.9    
  % Δ 24-weeks 39.7 (18.3, 61.0) 0.000 34.5 (20.7, 48.3) 0.000 -5.2 (-29.9, 19.6) 0.775 | 0.682 
Muscle Function      
4 metre walk (gait speed)      
  Baseline, m/sec 1.37 ± 0.19  1.41 ± 0.22    
  Absolute  Δ 24-weeks 0.01 (-0.03, 0.06) 0.569 -0.05 (-0.09, -0.00) 0.039 -0.06 (-0.12, 0.00) 0.061 | 0.074 
Four square step test      
  Baseline, sec 8.91 ± 2.01  8.34 ± 1.33    
  Absolute  Δ 24-weeks -0.66 (-0.97, -0.34) 0.000 -0.23 (-0.55, 0.08) 0.140 0.42 (-0.02, 0.87) 0.066 | 0.058 
All baseline values are unadjusted means ± SDs. All change values are unadjusted means (95% CI) and were calculated from the absolute difference from baseline. Mean net differences (95% CI) were 
calculated by subtracting the within-group changes for the Ex+Meat group from the within-group changes for the Ex+CHO group after 12 and 24 weeks. Adjusted model included age, sex, body mass 
index and change in physical activity as covariates. 
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Appendix R: Mean baseline CogState cognitive function Z-scores for the multi-component exercise and lean red meat (Ex+Meat) and control (carbohydrate) 
multi-component exercise (Ex+CHO) group, and the mean within-group changes and net differences between the groups for the change after 12 and 24 
weeks, for the per protocol analysis. 
 Baseline Values and Within-Group Changes  
 Ex+Meat Ex+CHO Intervention Effects 
 
Mean ± SD or  
(95% CI) 
P-value 
Mean ± SD or  
(95% CI) 
P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  | Model 2 
GMLT (Z scores total errors)      
  Baseline 0.08 ± 0.77  -0.01 ± 1.10    
  Absolute  Δ 12-weeks 0.17 (-0.01, 0.35) 0.078 0.24 (0.05, 0.43) 0.009 0.08 (-0.18, 0.33) 0.598 | 0.598 
  Absolute  Δ 24-weeks 0.32 (0.12, 0.53) 0.001 0.34 (0.14, 0.55) 0.000 0.02 (-0.26, 0.31) 0.885 | 0.872 
Psychomotor/ attention (DET Task Z scores for speed) 
  Baseline -0.16 ± 0.97  0.15 ± 0.99    
  Absolute  Δ 12-weeks 0.00 (-0.36, 0.37) 0.977 -0.31 (-0.56, -0.05) 0.013 -0.31 (-0.75, 0.13) 0.119 | 0.149 
  Absolute  Δ 24-weeks 0.19 (-0.08, 0.46) 0.230 0.08 (-0.16, 0.32) 0.492 -0.11 (-0.47, 0.25) 0.590 | 0.700 
Psychomotor/ attention (IDN Task Z scores for speed) 
  Baseline -0.16 ± 0.84  0.11 ± 1.00    
  Absolute  Δ 12-weeks -0.03 (-0.26, 0.21) 0.813 -0.22 (-0.43, -0.01) 0.034 -0.19 (-0.51, 0.12) 0.203 | 0.241 
  Absolute  Δ 24-weeks 0.13 (-0.07, 0.32) 0.232 0.10 (-0.11, 0.30) 0.366 -0.03 (-0.31, 0.25) 0.795 | 0.773 
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Working memory/ learning (OCL Task Z score for accuracy) 
  Baseline 0.06 ± 1.01  -0.00 ± 0.90    
  Absolute  Δ 12-weeks 0.04 (-0.21, 0.29) 0.783 0.27 (0.02, 0.52) 0.020 0.24 (-0.11, 0.59) 0.188 | 0.217 
  Absolute  Δ 24-weeks 0.15 (-0.16, 0.46) 0.262 0.40 (0.16, 0.63) 0.001 0.24 (-0.14, 0.63) 0.197 | 0.271 
Working memory/ learning (ONB Task Z score for speed) 
  Baseline 0.07 ± 0.87  -0.05 ± 0.99    
  Absolute  Δ 12-weeks -0.01 (-0.19, 0.17) 0.928 0.25 (0.08, 0.41) 0.003 0.25 (0.01, 0.50)
 
0.025 | 0.025 
  Absolute  Δ 24-weeks 0.00 (-0.16, 0.16) 0.885 0.35 (0.18, 0.53) 0.000 0.35 (0.12, 0.59) 0.003 | 0.000 
Working Memory/ Learning Composite      
  Baseline 0.06 ± 0.69  -0.03 ± 0.73    
  Absolute  Δ 12-weeks 0.02 (-0.14, 0.17) 0.853 0.26 (0.12, 0.40) 0.000 0.24 (0.04, 0.45) 0.023 | 0.028 
  Absolute  Δ 24-weeks 0.08 (-0.12, 0.27) 0.325 0.37 (0.22, 0.52) 0.000 0.30 (0.06, 0.54) 0.008 | 0.011 
Psychomotor/Attention Composite      
  Baseline -0.16 ± 0.79  0.13 ± 0.85    
  Absolute  Δ 12-weeks -0.01 (-0.25, 0.23) 0.919 -0.26 (-0.46, -0.06) 0.004 -0.25 (-0.56, 0.56)
 
0.072 | 0.097 
  Absolute  Δ 24-weeks 0.16 (-0.02, 0.33) 0.127 0.09 (-0.10, 0.27) 0.334 -0.07 (-0.32, 0.18) 0.599 | 0.669 
Cognitive Brief Battery      
  Baseline -0.05 ± 0.58  0.05 ± 0.64    
  Absolute  Δ 12-weeks 0.00 (-0.15, 0.15) 0.973 -0.00 (-0.13, 0.13) 0.985 -0.00 (-0.20, 0.19)
 
0.971 | 0.981 
  Absolute  Δ 24-weeks 0.12 (-0.01, 0.24) 0.064 0.23 (0.10, 0.36) 0.000 0.11 (-0.06, 0.29) 0.247 | 0.241 
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Global Cognitive Score      
  Baseline 0.01 ± 0.50  -0.01 ± 0.56    
  Absolute  Δ 12-weeks 0.03 (-0.09, 0.14) 0.630 0.11 (0.00, 0.22) 0.047 0.08 (-0.08, 0.24) 0.298 | 0.295 
  Absolute  Δ 24-weeks 0.15 (0.05, 0.26) 0.006 0.30 (0.18, 0.41) 0.000 0.14 (-0.01, 0.30) 0.074 | 0.074 
All baseline values are unadjusted means ± SDs. All change values are unadjusted means (95% CI) and were calculated from the absolute difference from baseline. Mean net 
differences (95% CI) were calculated by subtracting the within-group changes for the Ex+Meat group from the within-group changes for the Ex+CHO group after 12 and 24 
weeks. Adjusted model included age, sex, education, smoking status, change in physical activity, depression at baseline and history of CVD as covariates. GMLT, Groton 
Maze learning; DET, detection task; IDN, identification task; OCL, one card learning task; ONB, one back working memory task. 
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Appendix S: Mean baseline T-scores for the BRIEF-A cognitive scores for multi-component exercise and lean red meat (Ex+Meat) and control 
(carbohydrate) multi-component exercise (Ex+CHO) group, and mean within-group changes and net differences between the groups for the change 
after 24 weeks, for the per protocol analysis. 
 Baseline Values and Within-Group Changes  
 Ex+Meat Ex+CHO Intervention Effects 
 
Mean ± SD or  
(95% CI) 
P-value 
Mean ± SD or  
(95% CI) 
P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  | Model 2 
BRI      
  Baseline, T-score 51.41 ± 10.14  49.64 ± 9.17    
  Absolute Δ 24-weeks -1 (-3.07, 1.07) 0.333 0 (-1.80, 1.80) 0.973 1.0 (-1.70, 3.70) 0.449 | 0.469 
MI      
  Baseline, T-score 52.83 ± 9.29  51.86 ± 11.42    
  Absolute Δ 24-weeks -0.33 (-2.43, 1.78)
 
0.755 -0.38 (-2.34, 1.58)
 
0.690 -0.05 (-2.89, 2.79) 0.965 | 0.987 
GEC      
  Baseline, T-score 52.29 ± 9.22  50.95 ± 10.15    
  Absolute  Δ 24-weeks -0.55 (-2.62, 1.52)
 
0.593 -0.16 (-1.98, 1.66) 0.867 0.39 (-2.32, 3.11) 0.769 | 0.765 
All baseline values are unadjusted means ± SDs. All change values are unadjusted means (95% CI) and were calculated from the absolute difference from baseline. Mean net 
differences (95% CI) were calculated by subtracting the within-group changes for the Ex+Meat group from the within-group changes for the Ex+CHO group after 12 and 24 
weeks. Adjusted model included age, sex, education, smoking status, change in physical activity, depression at baseline and history of CVD as covariates. BRI, behavioural 
regulation index; MI, metacognition index; GEC, global executive composite. 
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Appendix T: Mean baseline IGF-1, BDNF and VEGF values for the multi-component exercise and lean red meat (Ex+Meat) and control (carbohydrate) 
multi-component exercise (Ex+CHO) group, and mean within-group changes and net differences between the groups for the change after 12 and 24 weeks, 
for the per protocol analysis. 
 Baseline Values and Within-Group Changes  
 Ex+Meat Ex+CHO Intervention Effects 
 
Mean ± SD or  
(95% CI) 
P-value 
Mean ± SD or  
(95% CI) 
P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  | Model 2 
IGF-1      
  Baseline, nmol/L 17.70 ± 4.83  16.66 ± 4.60    
  %∆ 12-weeks 9.1 (6.0, 12.3) 0.000 6.9 (2.4, 11.3) 0.001 -2.3 (-7.8, 3.3) 0.397 | 0.383 
  %∆ 24-weeks 6.4 (2.2, 10.6) 0.000 5.3 (1.5, 9.1) 0.011 -1.1 (-6.7, 4.4) 0.636 | 0.678 
BDNF      
  Baseline, ng/mL 21.59 ± 7.01  21.34 ± 7.94    
  %∆ 12-weeks -3.0 (-10.6, 4.5) 0.388 -1.6 (-7.2, 4.1) 0.571 1.4 (-7.8, 10.7) 0.733 | 0.655 
  %∆ 24-weeks -4.1 (-10.4, 2.3)
 
0.260 0.00 (-5.4, 5.4)
 
0.988 4.1 (-4.1, 12.3) 0.364 | 0.353 
VEGF      
  Baseline, pg/mL 372.35 ± 265.35  463.04 ± 625.41    
  %∆ 12-weeks 3.2 (-6.9, 13.2) 0.602 -3.0 (-10.8, 4.7) 0.412 -6.2 (-18.6, 6.2) 0.384 | 0.462 
  %∆ 24-weeks -7.1 (-23.5, 9.4)
 
0.348 1.5 (-5.2, 8.3) 0.661 8.6 (-8.4, 25.6) 0.285 | 0.283 
All variables were log transformed prior to analysis. All baseline values are unadjusted means ± SDs. All change values are unadjusted means (95% CI) and were calculated from the absolute 
difference from baseline in log-transformed data multiplied by 100. Mean net differences (95% CI) were calculated by subtracting the within-group changes for the Ex+Meat group from the 
within-group changes for the Ex+CHO group after 12 and 24 weeks. P values for all measures were based on log-transformed data. Adjusted model included age, sex, BMI and change in 
physical activity as covariates. IGF-1, insulin like growth factor-1; BDNF, brain-derived neurotrophic factor; VEGF, vascular endothelial growth factor. 
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Appendix U: Mean baseline values for adiponectin and the various inflammatory markers for the multi-component exercise and lean red meat 
(Ex+Meat) and control (carbohydrate) multi-component exercise (Ex+CHO) group, and mean within-group changes and net differences between the 
groups for the percent change after 12 and 24 weeks, for the per protocol analysis. 
 Baseline Values and Within-Group Changes  
 Ex+Meat Ex+CHO Intervention Effects 
 
Mean ± SD or  
(95% CI) 
P-value 
Mean ± SD or  
(95% CI) 
P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  | Model 2 
Adiponectin      
  Baseline, µg/ml 4.79 ± 3.48  5.11 ± 3.15    
  %∆ 12-weeks 1.3 (-2.6, 5.3) 0.545 -3.8 (-8.9, 1.4) 0.142 -5.1 (-11.6, 1.4) 0.132 | 0.129 
  %∆ 24-weeks 1.9 (-2.5, 6.2) 0.334 -2.7 (-8.5, 3.2) 0.299 -4.6 (-11.9, 2.8) 0.164 | 0.216 
hs-CRP      
  Baseline, mg/L 2.00 ± 2.33  1.98 ± 2.28    
  %∆ 12-weeks 11.1 (-15.8, 38.0) 0.361 5.0 (-13.5, 23.6) 0.614 -6.1 (-37.8, 25.7) 0.701 | 0.609 
  %∆ 24-weeks 8.7 (-12.5, 30.0)
 
0.464 13.8 (-4.0, 31.5)
 
0.169 5.0 (-22.2, 32.2) 0.746 | 0.813 
IL-10      
  Baseline, pg/mL 13.06 ± 24.38  9.51 ± 11.35    
  %∆ 12-weeks -6.1 (-26.7, 14.5) 0.500 -2.4 (-20.0, 15.1) 0.791 3.6 (-23.0, 30.2) 0.794 | 0.585 
  %∆ 24-weeks -3.6 (-23.7, 16.6)
 
0.676 -0.6 (-22.2, 21.0) 0.946 2.9 (-26.5, 32.4) 0.817 | 0.613 
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IL-8      
  Baseline, pg/mL 16.34 ± 11.09  14.60 ± 11.4    
  %∆ 12-weeks -4.8 (-17.6, 8.1) 0.465 3.2 (-4.0, 10.3) 0.437 8.0 (-6.2, 22.1) 0.286 | 0.265 
  %∆ 24-weeks -0.8 (-10.8, 9.3)
 
0.890 6.4 (-2.5, 15.2) 0.121 7.2 (-6.0, 20.4) 0.302 | 0.299 
IL-6      
  Baseline, pg/mL 4.86 ± 8.90  4.02 ± 5.76    
  %∆ 12-weeks -5.4 (-19.9, 9.2) 0.518 -1.1 (-17.5, 15.4) 0.893 4.3 (-17.7, 26.3) 0.751 | 0.661 
  %∆ 24-weeks -5.0 (-19.4, 9.3)
 
0.461 -1.2 (-19.0, 16.6) 0.881 3.9 (-19.1, 26.8) 0.714 | 0.682 
TNF-α      
  Baseline, pg/mL 10.36 ± 3.85  10.52 ± 4.51    
  %∆ 12-weeks -2.6 (-7.5, 2.3) 0.621 3.7 (-1.7, 9.0) 0.199 6.3 (-1.0, 13.5) 0.218 | 0.120 
  %∆ 24-weeks -0.4 (-7.6, 6.9)
 
0.909 1.9 (-4.4, 8.2) 0.505 2.3 (-7.2, 11.7) 0.593 | 0.607 
All variables were log transformed prior to analysis. All baseline values are unadjusted means ± SDs. All change values are unadjusted means (95% CI) and were calculated 
from the absolute difference from baseline in log-transformed data multiplied by 100. Mean net differences (95% CI) were calculated by subtracting the within-group changes 
for the Ex+Meat group from the within-group changes for the Ex+CHO group after 12 and 24 weeks. P values for all measures were based on log-transformed data. Adjusted 
model included age, sex, BMI and change in physical activity as covariates. CRP, C-reactive protein; IL, interleukin; TNF-α, tumor necrosis factor; IL: interleukin. 
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Appendix V: Mean baseline values for serum homocysteine, zinc, vitamin B12 and 25-hydroyxvitamin D in the multi-component exercise and lean red 
meat (Ex+Meat) and control (carbohydrate) multi-component exercise (Ex+CHO) group, and the mean within-group change and net between group 
difference for change after 12 and 24 weeks, for the per protocol analysis. 
 Baseline Values and Within-Group Changes  
 Ex+Meat Ex+CHO Intervention Effects 
 
Mean ± SD or  
(95% CI) 
P-value 
Mean ± SD or  
(95% CI) 
P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  | Model 2 
Homocysteine      
  Baseline, umol/L 11.15 ± 3.09  11.00 ± 2.73    
  %∆ 12-weeks -0.7 (-3.8, 2.3) 0.649 2.6 (-0.2, 5.4) 0.068 3.4 (-0.7, 7.4) 0.124 | 0.124 
  %∆ 24-weeks -0.8 (-4.8, 3.1) 0.705 3.3 (0.2, 6.5) 0.020 4.2 (-0.8, 9.1) 0.070 | 0.072 
Zinc      
  Baseline, ug/dL 78.22 ± 9.64  78.27 ± 10.55    
  %∆ 12-weeks 3.5 (0.2, 6.8) 0.134 0.5 (-2.7, 3.6) 0.845 -3.0 (-7.5, 1.5) 0.210 | 0.213 
  %∆ 24-weeks 3.6 (-0.1, 7.3)
 
0.111 -0.5 (-3.5, 2.5)
 
0.510 -4.1 (-8.8, 0.6) 0.103 | 0.128 
Vitamin B12      
  Baseline, pmol/L 329.45 ± 139.18  321.69 ± 171.84    
  %∆ 12-weeks 4.0 (-0.7, 8.7) 0.055 -5.7 (-11.3, -0.2) 0.029 -9.7 (-17.0, -2.4) 0.004 | 0.008 
  %∆ 24-weeks 3.3 (-1.8, 8.5)
 
0.181 -4.2 (-10.2, 1.7) 0.106 -7.6 (-15.4, 0.00) 0.037 | 0.028 
25-hydroyxvitamin D      
  Baseline, nmol/L 83.7 ± 21.4  83.9 ± 28.8    
  Absolute ∆ 24-weeks 11.7 (7.5, 16.0) 0.000 9.5 (5.0, 14.1) 0.000 -2.2 (-8.4, 4.0) 0.491 | 0.545 
All variables were log transformed prior to analysis. All baseline values are unadjusted means ± SDs. All change values are unadjusted means (95% CI) and were calculated from the absolute difference 
from baseline in log-transformed data multiplied by 100. Mean net differences (95% CI) were calculated by subtracting the within-group changes for the Ex+Meat group from the within-group changes 
for the Ex+CHO group after 12 and 24 weeks. P values for all measures were based on log-transformed data. Adjusted model included age, sex, BMI and change in physical activity as covariates. 
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Appendix W: Association between change in global cognitive function, executive function and composite scores and baseline muscle mass, 
strength and function.   
 ALM Muscle Strength
1 
Gait speed
2 
Mobility
3 
 β (95% CI) P values β (95% CI) P values β (95% CI) P values β (95% CI) P values 
∆ Global cognitive function 
  Model 1 -0.02 (-0.04, -0.00)  0.048 -0.00 (-0.00, -0.00) 0.048 0.08 (-0.29, 0.45) 0.672 0.03 (-0.02, 0.07) 0.269 
  Model 2 -0.02 (-0.05, -0.00) 0.034 -0.00 (-0.00, -0.00)  0.032 0.01 (-0.39, 0.42) 0.945 0.04 (-0.01, 0.09) 0.404 
∆ Executive function (GMLT) 
  Model 1 -0.01 (-0.05, 0.03)  0.603 -0.00 (-0.01, -0.00) 0.046 -0.15 (-0.86, 0.56) 0.669 0.10 (0.01, 0.18) 0.026 
  Model 2 -0.00 (-0.05, 0.04) 0.938 -0.00 (-0.01, 0.00)  0.154 -0.02 (-0.79, 0.75) 0.960 0.10 (0.01, 0.19) 0.030 
∆ Working memory/learning composite 
  Model 1 -0.04 (-0.07, -0.01)* 0.010 -0.00 (-0.00, 0.00) 0.148 0.11 (-0.44, 0.66) 0.700 -0.00 (-0.07, 0.07) 0.983 
  Model 2 -0.05 (-0.08, -0.02)* 0.003 -0.00 (-0.01, 0.00) 0.071 0.09 (-0.51, 0.70) 0.760 0.00 (-0.07, 0.08) 0.927 
∆ Psychomotor/Attention composite 
  Model 1 -0.01 (-0.04, 0.03) 0.709 -0.00 (-0.00, 0.00) 0.631 0.42 (-0.19, 1.02) 0.176 -0.00 (-0.07, 0.07) 0.987 
  Model 2 -0.00 (-0.04, 0.03) 0.791 -0.00 (-0.00, 0.00) 0.648 0.29 (-0.37, 0.95) 0.386 0.02 (-0.06, 0.10) 0.595 
∆ Executive function (GEC) 
  Model 1 0.09 (-0.25, 0.44) 0.597 0.00 (-0.02, 0.03) 0.761 -1.98 (-7.78, 3.82) 0.502 0.33 (-0.37, 1.03) 0.358 
  Model 2 0.18 (-0.17, 0.53) 0.316 0.01 (-0.02, 0.04) 0.393 -1.12 (-7.22, 4.99) 0.719 0.23 (-0.51, 0.97) 0.542 
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∆ Behavioural regulation index 
  Model 1 -0.03 (-0.38, 0.31) 0.847 0.00 (-0.03, 0.03) 0.989 -3.97 (-9.86, 1.91) 0.184 0.34 (-0.38, 1.05) 0.355 
  Model 2 0.03 (-0.33, 0.38) 0.889 0.01 (-0.02, 0.04) 0.640 -3.31 (-9.53, 2.92) 0.295 0.22 (-0.53, 0.97) 0.565 
∆ Metacognition index 
  Model 1 0.21 (-0.16, 0.57) 0.270 0.01 (-0.02, 0.04) 0.603 -0.39 (-6.54, 5.76) 0.900 0.23 (-0.51, 0.98) 0.533 
  Model 2 0.30 (-0.07, 0.68) 0.115 0.02 (-0.02, 0.05) 0.305 0.48 (-6.07, 7.02) 0.885 0.16 (-0.63, 0.95) 0.693 
All values represent unstandardized β values and 95% confidence interval (CI). Model 1: adjusted for sex and group, Model 2: adjusted for age, sex, ethnicity, BMI, education, 
smoking status, history of CVD, depression, change in physical activity and group. Reported P values are unadjusted. Significance was determined based on a Bonferroni p-
value of 0.0125. * P<0.013. 
1 
Leg press 3-RM muscle strength;
 2 
Gait speed assessed from the 4-m walk test; 
3 
Mobility was assessed using the four square step test (FSST). 
ALM: Appendicular lean mass, GEC: global executive composite, GMLT: Groton Maze Learning task. 
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Appendix X: Association between change in global cognitive function, executive function and composite scores and changes in muscle mass, 
strength and function after 24-weeks.   
 ∆ ALM ∆ Muscle Strength1 ∆ Gait speed2 ∆ Mobility3 
 β (95% CI) P values β (95% CI) P values β (95% CI) P values β (95% CI) P values 
∆ Global cognitive function 
  Model 1  0.08 (-0.06, 0.21) 0.276 -0.00 (-0.00, 0.00) 0.652 0.16 (-0.26, 0.59) 0.444 -0.04 (-0.10, 0.02) 0.177 
  Model 2 0.07 (-0.07, 0.21) 0.293 -0.00 (-0.00, 0.00) 0.454 0.13 (-0.31, 0.57) 0.565 -0.05 (-0.11, 0.01) 0.121 
∆ Executive function (GMLT) 
  Model 1 0.10 (-0.16, 0.36)  0.460 0.00 (-0.01, 0.01) 0.937 0.11 (-0.70, 0.93) 0.785 -0.10 (-0.21, 0.00) 0.059 
  Model 2 0.09 (-0.18, 0.35) 0.519 0.00 (-0.01, 0.01) 0.971 -0.01 (-0.85, 0.83) 0.973 -0.11 (-0.22, 0.00) 0.056 
∆ Working memory/learning composite 
  Model 1 0.07 (0.13, 0.27) 0.502 -0.00 (-0.01, 0.00) 0.071 0.06 (-0.57, 0.70) 0.839 -0.02 (-0.10, 0.07) 0.688 
  Model 2 0.07 (-0.14, 0.28) 0.498 -0.00 (-0.01, -0.00) 0.046 0.12 (-0.54, 0.77) 0.726 -0.03 (-0.12, 0.07) 0.578 
∆ Psychomotor/Attention composite 
  Model 1 0.02 (-0.20, 0.25) 0.835 0.00 (-0.00, 0.00) 0.930 0.21 (-0.49, 0.91) 0.560 0.00 (-0.09, 0.10) 0.921 
  Model 2 0.02 (-0.21, 0.25) 0.839 -0.00 (-0.01, 0.00) 0.784 0.11 (-0.61, 0.82) 0.768 -0.00 (-0.10, 0.10) 0.935 
∆ Executive function (GEC) 
  Model 1 -0.48 (-2.66, 1.70) 0.665 0.01 (-0.03, 0.06) 0.594 0.29 (-6.43, 7.00) 0.933 -0.41 (-1.31, 0.49) 0.372 
  Model 2 -0.70 (-2.86, 1.45) 0.519 0.02 (-0.02, 0.07) 0.347 0.31 (-6.39, 7.00) 0.928 -0.32 (-1.23, 0.58) 0.483 
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∆ Behavioural regulation index 
  Model 1 -0.63 (-2.82, 1.56) 0.571 -0.01 (-0.05, 0.04) 0.803 -1.69 (-8.52, 5.14) 0.626 -0.60 (-1.51, 0.32) 0.200 
  Model 2 -0.81 (-2.98, 1.36) 0.460 0.00 (-0.04, 0.05) 0.943 -1.66 (-8.50, 5.18) 0.632 -0.53 (-1.45, 0.40) 0.265 
∆ Metacognition index 
  Model 1 -0.30 (-2.61, 2.02) 0.801 0.02 (-0.02, 0.07) 0.314 2.40 (-4.69, 9.49) 0.505 -0.26 (-1.21, 0.69) 0.596 
  Model 2 -0.51 (-2.83, 1.80) 0.661 0.04 (-0.01, 0.09) 0.161 2.47 (-4.69, 9.62) 0.497 -0.17 (-1.14, 0.80) 0.729 
All values represent unstandardized β values and 95% confidence interval (CI). Model 1: adjusted for sex and group, Model 2: adjusted for age, sex, ethnicity, BMI, 
education, smoking status, history of CVD, depression, change in physical activity and group. Reported P values are unadjusted. Significance was determined based on a 
Bonferroni p-value of 0.0125. * P<0.013. 
1 
Leg press 3-RM muscle strength;
 2 
Gait speed assessed from the 4-m walk test; 
3 
Mobility was assessed using the four square step 
test (FSST). ALM: Appendicular lean mass, GEC: global executive composite, GMLT: Groton Maze Learning task. 
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Appendix Y: Association between change in global cognitive function and composite scores and baseline growth and neurotrophic factors, inflammatory 
markers, bioavailable zinc and vitamin B12.  
 ∆ Global cognitive function ∆ Working memory/learning ∆ Psychomotor/attention ∆ Executive function (GMLT) 
 β (95% CI) P values β (95% CI) P values β (95% CI) P values β (95% CI) P values 
Growth and Neurotrophic Factors 
IGF-1 
  Model 1 0.05 (-0.22, 0.33)  0.693 -0.08 (-0.49, 0.32) 0.689 0.23 (-0.22, 0.68) 0.318 0.17 (-0.35, 0.69) 0.518 
  Model 2 0.02 (-0.26, 0.31) 0.869 -0.03 (-0.46, 0.39) 0.875 0.14 (-0.32, 0.61) 0.548 0.12 (-0.43, 0.66) 0.671 
BDNF 
  Model 1 0.20 (0.01, 0.39) 0.044 0.06 (-0.23, 0.36) 0.660 0.09 (-0.23, 0.41) 0.580 0.41 (0.04, 0.78) 0.030 
  Model 2 0.22 (0.01, 0.43) 0.043 0.06 (-0.26, 0.38) 0.698 0.08 (-0.27, 0.43) 0.659 0.56 (0.17, 0.96)* 0.005 
VEGF 
  Model 1 0.08 (0.00, 0.16) 0.047 0.07 (-0.05, 0.19) 0.248 0.12 (-0.01, 0.25) 0.072 0.11 (-0.04, 0.26) 0.151 
  Model 2 0.08 (-0.01, 0.16) 0.071 0.06 (-0.06, 0.19) 0.299 0.13 (-0.00, 0.26) 0.056 0.10 (-0.06, 0.26) 0.215 
Inflammatory markers 
Adiponectin 
  Model 1 0.09 (-0.03, 0.20) 0.145 0.12 (-0.06, 0.29) 0.185 -0.15 (-0.34, 0.04) 0.126 0.05 (-0.17, 0.28) 0.650 
  Model 2 0.08 (-0.04, 0.21) 0.174 0.13 (-0.05, 0.32) 0.153 -0.18 (-0.38, 0.02) 0.071 0.04 (-0.19, 0.28) 0.705 
CRP 
Model 1 0.05 (-0.02, 0.13) 0.172 -0.03 (-0.15, 0.08) 0.554 0.11 (-0.01, 0.24) 0.076 0.16 (0.01, 0.30) 0.035 
Model 2 0.05 (-0.03, 0.14) 0.191 -0.04 (-0.17, 0.08) 0.481 0.13 (0.00, 0.27) 0.047 0.17 (0.02, 0.32) 0.031 
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TNF-α 
Model 1 -0.02 (-0.23, 0.18) 0.830 0.03 (-0.27, 0.33) 0.859 0.07 (-0.26, 0.41) 0.667 0.04 (-0.35, 0.42) 0.856 
Model 2 0.01 (-0.20, 0.23) 0.904 0.00 (-0.31, 0.32) 0.976 0.14 (-0.20, 0.49) 0.413 0.13 (-0.27, 0.54) 0.516 
IL-6 
Model 1 0.06 (-0.01, 0.13) 0.117 0.06 (-0.04, 0.17) 0.247 0.14 (0.02, 0.25) 0.023 -0.06 (-0.20, 0.08) 0.410 
Model 2 0.05 (-0.02, 0.13) 0.143 0.07 (-0.04, 0.18) 0.202 0.13 (0.01, 0.25) 0.033 -0.08 (-0.22, 0.06) 0.283 
IL-8 
Model 1 -0.10 (-0.24, 0.04) 0.150 -0.06 (-0.27, 0.15) 0.557 -0.12 (-0.35, 0.11) 0.320 -0.11 (-0.38, 0.15) 0.410 
Model 2 -0.09 (-0.23, 0.06) 0.232 -0.08 (-0.30, 0.14) 0.460 -0.09 (-0.33, 0.15) 0.465 -0.06 (-0.34, 0.22) 0.670 
IL-10 
Model 1 0.01 (-0.04, 0.06) 0.742 -0.02 (-0.10, 0.05) 0.528 0.10 (0.01, 0.18) 0.022 -0.03 (-0.13, 0.07) 0.533 
Model 2 0.01 (-0.04, 0.06) 0.778 -0.02 (-0.10, 0.06) 0.624 0.09 (0.01, 0.18) 0.028 -0.04 (-0.14, 0.06) 0.457 
 
Homocysteine 
Model 1 -0.12 (-0.44, 0.20) 0.459 -0.27 (-0.74, 0.20) 0.251 -0.10 (-0.62, 0.42) 0.705 0.11 (-0.50, 0.71) 0.731 
Model 2 -0.14 (-0.47, 0.19) 0.392 -0.25 (-0.74, 0.24) 0.310 -0.17 (-0.71, 0.36) 0.521 0.08 (-0.54, 0.71) 0.790 
Bioavailable zinc 
Model 1 -0.00 (-0.01, 0.01) 0.605 -0.00 (-0.02, 0.01) 0.374 -0.00 (-0.01, 0.01) 0.997 0.01 (-0.01, 0.02) 0.374 
Model 2 -0.00 (-0.01, 0.01) 0.523 -0.01 (-0.02, 0.01) 0.334 -0.00 (-0.01, 0.01) 0.846 0.01 (-0.01, 0.02) 0.217 
Vitamin B12   
Model 1 -0.03 (-0.18, 0.12) 0.674 -0.02 (-0.25, 0.20) 0.833 -0.00 (-0.25, 0.25) 0.989 -0.07 (-0.36, 0.22) 0.619 
Model 2 -0.02 (-0.18, 0.13) 0.768 -0.02 (-0.26, 0.21) 0.857 0.01 (-0.25, 0.27) 0.945 -0.05 (-0.35, 0.25) 0.746 
All values represent β values and 95% confidence interval (CI). All growth, neurotrophic, inflammatory markers, bioavailable zinc and vitamin B12 were log transformed prior to analysis. Model 1: adjusted for sex and group, Model 
2: adjusted for age, sex, ethnicity, BMI, education, smoking status, history of CVD, depression, change in physical activity and group. Reported P values are unadjusted. Significance was determined based on a Bonferroni p-value of 
0.0167 for growth and neurotrophic factors as well as homocysteine, vitamin B12 and bioavailable zinc. A Bonferroni p-value of 0.0083 was used for inflammation. * P<0.017; † P<0.008.  GMLT: Groton Maze Learning Task; IGF-
1: insulin-like growth factor; BDNF: brain derived neurotrophic factor; VEGF: vascular endothelial factor; CRP: C-reactive protein; TNF: tumor necrosis factor; IL: interleukin. 
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Appendix Z: Association between change in executive function, the behavioural regulation index and metacognition index and baseline growth, 
neurotrophic, inflammatory markers, bioavailable zinc and vitamin B12.   
 ∆ Executive function (GEC) ∆ Behavioural regulation index ∆ Metacognition index 
 β (95% CI) P values β (95% CI) P values β (95% CI) P values 
Growth and Neurotrophic Factors 
IGF-1 
  Model 1 0.48 (-3.91, 4.86)  0.830 -0.21 (-4.61, 4.19) 0.924 1.10 (-3.55, 5.75) 0.641 
  Model 2 0.07 (-4.34, 4.48) 0.976 -0.58 (-5.02, 3.86) 0.797 0.73 (-4.01, 5.46) 0.762 
BDNF 
  Model 1 -3.50 (-6.58, -0.41) 0.026 -4.02 (-7.10, -0.94)* 0.011 -2.78 (-6.08, 0.52) 0.098 
  Model 2 -3.28 (-6.52, -0.04) 0.047 -4.12 (-7.35, -0.88)* 0.013 -2.38 (-5.89, 1.12) 0.181 
VEGF 
  Model 1 0.09 (-1.18, 1.36) 0.884 0.36 (-0.92, 1.63) 0.581 -0.17 (-1.52, 1.18) 0.801 
  Model 2 0.21 (-1.07, 1.48) 0.748 0.40 (-0.88, 1.68) 0.537 -0.04 (-1.40, 1.33) 0.960 
Inflammatory markers 
Adiponectin 
  Model 1 -1.98 (-3.82, -0.14) 0.036 -1.55 (-3.41, 0.31) 0.103 -2.09 (-4.05, -0.13) 0.037 
  Model 2 -1.88 (-3.76, -0.00) 0.050 -1.52 (-3.43, 0.38) 0.116 -1.98 (-4.00, 0.04) 0.055 
CRP 
Model 1 0.36 (-0.86, 1.59) 0.559 -0.18 (-1.41, 1.06) 0.776 0.75 (-0.55, 2.05) 0.256 
Model 2 0.54 (-0.73, 1.81) 0.401 -0.20 (-1.48, 1.08) 0.758 1.04 (-0.31, 2.40) 0.131 
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TNF-α 
Model 1 1.45 (-1.70, 4.60) 0.365 1.96 (-1.20, 5.12) 0.222 0.67 (-2.69, 4.02) 0.695 
Model 2 1.02 (-2.18, 4.21) 0.530 1.67 (-1.54, 4.89) 0.305 0.20 (-3.23, 3.64) 0.907 
IL-6 
Model 1 -0.91 (-2.01, 0.19) 0.106 -0.93 (-2.04, 0.17) 0.097 -0.80 (-1.97, 0.37) 0.179 
Model 2 -1.00 (-2.08, 0.09) 0.072 -1.03 (-2.12, 0.06) 0.064 -0.88 (-2.05, 0.29) 0.139 
IL-8 
Model 1 0.81 (-1.38, 2.99) 0.466 -0.46 (-2.65, 1.74) 0.681 1.63 (-0.68, 3.94) 0.164 
Model 2 1.15 (-1.03, 3.34) 0.299 -0.24 (-2.45, 1.97) 0.830 2.02 (-0.31, 4.35) 0.089 
IL-10 
Model 1 0.21 (-0.60, 1.02) 0.609 0.48 (-0.32, 1.29) 0.238 -0.04 (-0.90, 0.82) 0.929 
Model 2 0.16 (-0.64, 0.97) 0.688 0.42 (-0.39, 1.22) 0.310 -0.07 (-0.93, 0.80) 0.880 
 
Homocysteine 
Model 1 1.46 (-3.53, 6.45) 0.565 0.45 (-4.57, 5.46) 0.860 2.06 (-3.24, 7.35) 0.444 
Model 2 1.54 (-3.43, 6.51) 0.542 0.39 (-4.62, 5.40) 0.879 2.20 (-3.13, 7.52) 0.416 
Bioavailable zinc 
Model 1 -0.10 (-0.22, 0.01) 0.235 -0.08 (-0.20, 0.03) 0.404 -0.10 (-0.22, 0.02) 0.243 
Model 2 -0.07 (-0.19, 0.05) 0.075 -0.05 (-0.17, 0.07) 0.161 -0.07 (-0.20, 0.05) 0.093 
Vitamin B12   
Model 1 -0.09 (-2.50, 2.32) 0.941 -0.37 (-2.79, 2.04) 0.760 0.19 (-2.36, 2.75) 0.881 
Model 2 0.27 (-2.16, 2.70) 0.827 0.02 (-2.43, 2.46) 0.989 0.47 (-2.14, 3.07) 0.724 
All values represent β values and 95% confidence interval (CI). All growth, neurotrophic, inflammatory markers, bioavailable zinc and vitamin B12 were log transformed prior to analysis. Model 1: adjusted for sex and 
group, Model 2: adjusted for age, sex, ethnicity, BMI, education, smoking status, history of CVD, depression, change in physical activity and group. Reported P values are unadjusted. Significance was determined 
based on a Bonferroni p-value of 0.0167 for growth and neurotrophic factors as well as homocysteine, vitamin B12 and bioavailable zinc. A Bonferroni p-value of 0.0083 was used for inflammation. * P<0.017; † 
P<0.008. GEC: global executive composite; IGF-1: insulin-like growth factor; BDNF: brain derived neurotrophic factor; VEGF: vascular endothelial factor; CRP: C-reactive protein; TNF: tumor necrosis factor; IL: 
interleukin. 
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Appendix AA: Association between change in global cognitive function and composite scores and changes in growth and 
neurotrophic factors, inflammatory markers, bioavailable zinc and vitamin B12 after 24 weeks.   
 ∆ Global cognitive function ∆ Working memory/learning ∆ Psychomotor/attention ∆ Executive function (GMLT) 
 β (95% CI) P values β (95% CI) P values β (95% CI) P values β (95% CI) P values 
Growth and Neurotrophic Factors 
∆ IGF-1   
  Model 1 -0.28 (-0.75, 0.18)  0.232 -0.30 (-0.99, 0.40) 0.400 -0.22 (-0.98, 0.55) 0.575 -0.28 (-1.17, 0.61) 0.539 
  Model 2 -0.30 (-0.78, 0.18) 0.225 -0.27 (-0.99, 0.45) 0.466 -0.24 (-1.02, 0.54) 0.543 -0.39 (-1.31, 0.52) 0.396 
∆ BDNF   
  Model 1 -0.12 (-0.44, 0.20) 0.468 -0.07 (-0.55, 0.40) 0.758 -0.22 (-0.74, 0.30) 0.404 -0.14 (-0.75, 0.47) 0.640 
  Model 2 -0.19 (-0.54, 0.16) 0.281 -0.04 (-0.57, 0.49) 0.880 -0.36 (-0.93, 0.20) 0.207 -0.28 (-0.95, 0.39) 0.410 
∆ VEGF   
  Model 1 0.08 (-0.09, 0.24) 0.362 -0.08 (-0.33, 0.16) 0.499 -0.01 (-0.28, 0.26) 0.955 0.13 (-0.19, 0.44) 0.422 
  Model 2 0.05 (-0.13, 0.22) 0.587 -0.08 (-0.34, 0.18) 0.531 -0.07 (-0.35, 0.22) 0.638 0.10 (-0.24, 0.43) 0.565 
Inflammatory markers 
∆ Adiponectin   
  Model 1 -0.03 (-0.40, 0.33) 0.859 0.06 (-0.48, 0.60) 0.829 0.08 (-0.52, 0.67) 0.802 -0.43 (-1.12, 0.26) 0.224 
  Model 2 -0.05 (-0.43, 0.34) 0.814 0.09 (-0.49, 0.67) 0.751 0.02 (-0.60, 0.65) 0.944 -0.42 (-1.16, 0.31) 0.256 
∆ CRP   
Model 1 -0.04 (-0.14, 0.05) 0.375 -0.14 (-0.28, 0.00) 0.051 0.06 (-0.09, 0.22) 0.429 -0.07 (-0.25, 0.12) 0.463 
Model 2 -0.04 (-0.14, 0.06) 0.445 -0.15 (-0.30, -0.01) 0.040 0.07 (-0.09, 0.23) 0.400 -0.04 (-0.23, 0.15) 0.695 
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∆ TNF-α   
Model 1 0.06 (-0.23, 0.35) 0.673 -0.23 (-0.65, 0.20) 0.293 0.06 (-0.41, 0.53) 0.795 0.14 (-0.41, 0.69) 0.625 
Model 2 0.04 (-0.26, 0.34) 0.801 -0.24 (-0.68, 0.20) 0.288 0.01 (-0.48, 0.49) 0.976 0.12 (-0.45, 0.68) 0.689 
∆ IL-6   
Model 1 -0.04 (-0.16, 0.07) 0.437 -0.19 (-0.35, -0.02) 0.026 0.07 (-0.11, 0.26) 0.431 -0.01 (-0.23, 0.20) 0.900 
Model 2 -0.05 (-0.16, 0.07) 0.425 -0.20 (-0.37, -0.03) 0.023 0.06 (-0.13, 0.25) 0.506 0.02 (-0.20, 0.24) 0.852 
∆ IL-8   
Model 1 0.26 (0.06, 0.46) 0.012 0.11 (-0.19, 0.41) 0.473 0.26 (-0.07, 0.59) 0.125 0.37 (-0.01, 0.76) 0.058 
Model 2 0.23 (0.02, 0.44) 0.031 0.13 (-0.19, 0.45) 0.437 0.19 (-0.16, 0.54) 0.277 0.34 (-0.06, 0.75) 0.097 
∆ IL-10   
Model 1 -0.04 (-0.13, 0.05) 0.337 -0.11 (-0.24, 0.02) 0.094 -0.06 (-0.20, 0.09) 0.433 0.04 (-0.13, 0.21) 0.659 
Model 2 -0.05 (-0.14, 0.05) 0.332 -0.11 (-0.25, 0.03) 0.119 -0.08 (-0.24, 0.07) 0.276 0.06 (-0.12, 0.24) 0.511 
 
∆ Homocysteine 
Model 1 0.24 (-0.32, 0.80) 0.402 0.22 (-0.62, 1.05) 0.608 0.28 (-0.63, 1.19) 0.540 -0.15 (-1.22, 0.93) 0.789 
Model 2 0.23 (-0.35, 0.80) 0.437 0.19 (-0.68, 1.05) 0.669 0.30 (-0.63, 1.22) 0.526 -0.10 (-1.19, 1.00) 0.860 
∆ Bioavailable zinc   
Model 1 -0.04 (-0.01, 0.01) 0.905 0.03 (-0.01, 0.01) 0.564 -0.00 (-0.01, 0.01) 0.838 -0.01 (-0.02, 0.01) 0.347 
Model 2 0.00 (-0.01, 0.01) 0.767 0.01 (-0.01, 0.02) 0.388 0.00 (-0.01, 0.01) 0.987 -0.01 (-0.02, 0.01) 0.387 
∆ Vitamin B12   
Model 1 -0.03 (-0.18, 0.12) 0.674 -0.02 (-0.25, 0.20) 0.833 -0.00 (-0.25, 0.25) 0.989 -0.07 (-0.36, 0.22) 0.619 
Model 2 -0.02 (-0.18, 0.13) 0.768 -0.02 (-0.26, 0.21) 0.857 0.01 (-0.25, 0.27) 0.945 -0.05 (-0.35, 0.25) 0.746 
All values represent β values and 95% confidence interval (CI). All change values are unadjusted means (95% CI) and were calculated from the absolute difference from baseline in log-transformed data multiplied 
by 100. 
 
Model 1: adjusted for sex and group, Model 2: adjusted for age, sex, ethnicity, BMI, education, smoking status, history of CVD, depression, change in physical activity and group. Reported P values are 
unadjusted. Significance was determined based on a Bonferroni p-value of 0.0167 for growth and neurotrophic factors as well as homocysteine, vitamin B12 and bioavailable zinc. A Bonferroni p-value of 0.0083 
was used for inflammation. * P<0.017; † P<0.008. GMLT: Groton Maze Learning task; IGF-1: insulin-like growth factor; BDNF: brain derived neurotrophic factor; VEGF: vascular endothelial factor; CRP: C-
reactive protein; TNF: tumor necrosis factor; IL: interleukin. 
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Appendix AB: Association between change in executive function, the behavioural regulation index and metacognition index and changes in growth, 
neurotrophic, inflammatory markers, bioavailable zinc and vitamin B12 after 24 weeks.   
 ∆ Executive function (GEC) ∆ Behavioural regulation index ∆ Metacognition index 
 β (95% CI) P values β (95% CI) P values β (95% CI) P values 
Growth and Neurotrophic Factors 
∆ IGF-1 
  Model 1 0.90 (-6.60, 8.41)  0.812 -0.11 (-7.64, 7.43) 0.978 1.61 (-6.36, 9.58) 0.690 
  Model 2 0.85 (-6.66, 8.36) 0.822 0.04 (-7.52, 7.61) 0.991 1.39 (-6.67, 9.45) 0.733 
∆ BDNF 
  Model 1 4.09 (-0.67, 8.84) 0.091 4.24 (-0.52, 9.01) 0.080 3.49 (-1.57, 8.56) 0.175 
  Model 2 3.27 (-1.76, 8.31) 0.201 4.00 (-1.05, 9.06) 0.120 2.36 (-3.06, 7.78) 0.391 
∆ VEGF 
  Model 1 -2.04 (-4.58, 0.49) 0.113 -1.19 (-3.75, 1.37) 0.360 -2.18 (-4.87, 0.51) 0.112 
  Model 2 -2.17 (-4.74, 0.40) 0.098 -1.19 (-3.80, 1.41) 0.367 -2.37 (-5.13, 0.38) 0.091 
Inflammatory markers 
∆ Adiponectin 
  Model 1 -0.82 (-6.66, 5.02) 0.782 -1.40 (-7.25, 4.46) 0.638 -0.43 (-6.63, 5.76) 0.890 
  Model 2 -1.15 (-7.12, 4.81) 0.703 -1.29 (-7.30, 4.72) 0.671 -1.04 (-7.45, 5.36) 0.748 
∆ CRP 
Model 1 -1.16 (-2.61, 0.28) 0.113 -0.63 (-2.09, 0.83) 0.394 -1.41 (-2.94, -0.12) 0.070 
Model 2 -0.97 (-2.41, 0.48) 0.187 -0.43 (-1.89, 1.03) 0.562 -1.25 (-2.79, 0.30) 0.113 
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∆ TNF-α 
Model 1 -2.79 (-7.05, 1.47) 0.197 -2.74 (-7.02, 1.53) 0.207 -2.01 (-6.56, 2.52) 0.381 
Model 2 -1.97 (-6.29, 2.35) 0.369 -2.17 (-6.52, 2.17) 0.324 -1.09 (-5.74, 3.56) 0.643 
∆ IL-6 
Model 1 0.09 (-1.65, 1.82) 0.920 -0.21 (-1.95, 1.53) 0.813 0.34 (-1.50, 2.18) 0.719 
Model 2 0.49 (-1.23, 2.21) 0.575 0.17 (-1.57, 1.90) 0.847 0.70 (-1.15, 2.55) 0.455 
∆ IL-8 
Model 1 -3.66 (-6.86, -0.46) 0.025 -3.01 (-6.24, 0.22) 0.068 -3.53 (-6.94, -0.11) 0.043 
Model 2 -3.94 (-7.17, -0.70) 0.017 -3.29 (-6.57, -0.01) 0.049 -3.72 (-7.21, -0.24) 0.036 
∆ IL-10 
Model 1 -0.35 (-1.79, 1.09) 0.630 -0.65 (-2.09, 0.79) 0.375 0.03 (-1.50, 1.56) 0.968 
Model 2 -0.14 (-1.57, 1.29) 0.846 -0.46 (-1.90, 0.97) 0.525 0.23 (-1.30, 1.77) 0.764 
 
∆ Homocysteine 
Model 1 1.02 (-7.97, 10.02) 0.822 -1.93 (-10.94, 7.07) 0.672 3.31 (-6.26, 12.88) 0.495 
Model 2 1.55 (-7.38, 10.48) 0.732 -1.52 (-10.51, 7.47) 0.738 3.89 (-5.71, 13.49) 0.425 
∆ Bioavailable zinc 
Model 1 0.04 (-0.08, 0.16) 0.996 0.01 (-0.11, 0.13) 0.705 0.04 (-0.08, 0.17) 0.911 
Model 2 -0.00 (-0.12, 0.12) 0.542 -0.02 (-0.15, 0.10) 0.868 0.01 (-0.13, 0.14) 0.506 
∆ Vitamin B12   
Model 1 -0.09 (-2.50, 2.32) 0.941 -0.37 (-2.79, 2.04) 0.760 0.19 (-2.36, 2.75) 0.881 
Model 2 0.27 (-2.16, 2.70) 0.827 0.02 (-2.43, 2.46) 0.989 0.47 (-2.14, 3.07) 0.724 
All values represent β values and 95% confidence interval (CI). Model 1: adjusted for sex and group, Model 2: adjusted for age, sex, ethnicity, BMI, education, smoking status, history of CVD, depression, change in 
physical activity and group. . Reported P values are unadjusted. Significance was determined based on a Bonferroni p-value of 0.0167 for growth and neurotrophic factors as well as homocysteine, vitamin B12 and 
bioavailable zinc. A Bonferroni p-value of 0.0083 was used for inflammation. * P<0.017; † P<0.008. GEC: global executive composite; IGF-1: insulin-like growth factor; BDNF: brain derived neurotrophic factor; 
VEGF: vascular endothelial factor; CRP: C-reactive protein; TNF: tumor necrosis factor; IL: interleukin. 
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Appendix AC: Association between change in global cognitive function, executive function and composite scores and baseline muscle 
mass, strength and function for model 3.   
 ALM Muscle Strength
1 
Gait speed
2 
Mobility
3 
 β (95% CI) P value β (95% CI) P value β (95% CI) P value β (95% CI) P value 
∆ Global cognitive function 
  Model 3 -0.02 (-0.05, -0.00)  0.038 -0.00 (-0.00, -0.00) 0.028 0.03 (-0.38, 0.43) 0.901 0.04 (-0.01, 0.09) 0.110 
∆ Executive function (GMLT) 
  Model 3 -0.00 (-0.05, 0.04)  0.940 -0.00 (-0.01, 0.00) 0.154 -0.02 (-0.80, 0.76) 0.961 0.10 (0.01, 0.19) 0.031 
∆ Working memory/learning composite 
  Model 3 -0.05 (-0.08, -0.02)* 0.004 -0.00 (-0.01, 0.00) 0.057 0.11 (-0.49, 0.72) 0.709 0.00 (-0.07, 0.08) 0.942 
∆ Psychomotor/Attention composite 
  Model 3 -0.00 (-0.04, 0.03) 0.814 -0.00 (-0.00, 0.00) 0.609 0.31 (-0.36, 0.97) 0.362 0.02 (-0.06, 0.10) 0.604 
∆ Executive function (GEC) 
  Model 3 0.18 (-0.18, 0.53) 0.325 0.01 (-0.02, 0.04) 0.449 -0.99 (-7.14, 5.16) 0.752 0.22 (-0.52, 0.96) 0.554 
∆ Behavioural regulation index 
  Model 3 0.02 (-0.34, 0.38) 0.901 0.01 (-0.03, 0.04) 0.707 -3.21 (-9.49, 3.06) 0.313 0.22 (-0.54, 0.97) 0.575 
∆ Metacognition index 
  Model 3 0.30 (-0.08, 0.68) 0.117 0.02 (-0.02, 0.05) 0.329 0.60 (-6.00, 7.19) 0.858 0.15 (-0.64, 0.95) 0.703 
All values represent unstandardized β values and 95% confidence interval (CI). Model 3: adjusted for age, sex, ethnicity, BMI, education, smoking status, history of 
CVD, depression, change in physical activity, APOE genotype and group. Reported P values are unadjusted. Significance was determined based on a Bonferroni p-
value of 0.0125. * P<0.013. 
1 
Leg press 3-RM muscle strength;
 2 
Gait speed assessed from the 4-m walk test; 
3 
Mobility was assessed using the four square step test 
(FSST). ALM: Appendicular lean mass, GEC: global executive composite, GMLT: Groton Maze Learning task. 
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Appendix AD: Association between change in global cognitive function, executive function and composite scores and changes in 
muscle mass, strength and function after 24-weeks for model 3.   
 ∆ ALM ∆ Muscle Strength1 ∆ Gait speed2 ∆ Mobility3 
 β (95% CI) P value β (95% CI) P value β (95% CI) P value β (95% CI) P value 
∆ Global cognitive function 
  Model 3  0.07 (-0.07, 0.21) 0.314 -0.00 (-0.00, 0.00) 0.367 0.15 (-0.29, 0.59) 0.514 -0.05 (-0.11, 0.01) 0.109 
∆ Executive function (GMLT) 
  Model 3 0.09 (-0.18, 0.35)  0.521 4.65 (-0.01, 0.01) 1.00 -0.01 (-0.86, 0.83) 0.975 -0.11 (-0.22, 0.00) 0.058 
∆ Working memory/learning composite 
  Model 3 0.07 (-0.14, 0.28) 0.534 -0.00 (-0.01, -0.00) 0.034 0.15 (-0.51, 0.81) 0.658 -0.03 (-0.12, 0.06) 0.523 
∆ Psychomotor/Attention composite 
  Model 3 0.02 (-0.21, 0.25) 0.869 -0.00 (-0.01, 0.00) 0.660 0.13 (-0.59, 0.85) 0.721 -0.01 (-0.11, 0.09) 0.896 
∆ Executive function (GEC) 
  Model 3 -0.77 (-2.94, 1.40) 0.484 0.02 (-0.03, 0.07) 0.415 0.71 (-6.07, 7.49) 0.836 -0.38 (-1.30, 0.53) 0.409 
∆ Behavioural regulation index 
  Model 3 -0.87 (-3.06, 1.32) 0.434 -0.00 (-0.05, 0.04) 0.907 -1.38 (-8.32, 5.56) 0.696 -0.58 (-1.52, 0.36) 0.225 
∆ Metacognition index 
  Model 3 -0.56 (-2.90, 1.78) 0.636 0.03 (-0.02, 0.09) 0.182 2.81 (-4.45, 10.07) 0.445 -0.22 (-1.20, 0.77) 0.665 
All values represent unstandardized β values and 95% confidence interval (CI). Model 3: adjusted for age, sex, ethnicity, BMI, education, smoking status, history of 
CVD, depression, change in physical activity, APOE genotype and group. Reported P values are unadjusted. Significance was determined based on a Bonferroni p-
value of 0.0125. * P<0.013. 
1 
Leg press 3-RM muscle strength;
 2 
Gait speed assessed from the 4-m walk test; 
3 
Mobility was assessed using the four square step test 
(FSST). ALM: Appendicular lean mass, GEC: global executive composite, GMLT: Groton Maze Learning task. 
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Appendix AE: Association between change in global cognitive function and composite scores and baseline growth and neurotrophic 
factors, inflammatory markers, bioavailable zinc and vitamin B12 for model 3.  
 ∆ Global cognitive function ∆ Working memory/learning ∆ Psychomotor/attention 
∆ Executive function 
(GMLT) 
 β (95% CI) P value β (95% CI) P value β (95% CI) P value β (95% CI) P value 
Growth and Neurotrophic Factors 
IGF-1 
  Model 3 0.03 (-0.26, 0.31) 0.857 -0.03 (-0.46, 0.40) 0.890 0.14 (-0.32, 0.61) 0.541 0.12 (-0.43, 0.66) 0.672 
BDNF 
  Model 3 0.24 (0.03, 0.45) 0.028 0.09 (-0.23, 0.42) 0.557 0.10 (-0.25, 0.46) 0.577 0.59 (0.18, 0.99)* 0.005 
VEGF 
  Model 3 0.08 (-0.01, 0.16) 0.070 0.07 (-0.06, 0.19) 0.293 0.13 (-0.00, 0.26) 0.055 0.10 (-0.06, 0.26) 0.217 
Inflammatory markers 
Adiponectin 
  Model 3 0.08 (-0.04, 0.21) 0.176 0.13 (-0.05, 0.31) 0.155 -0.18 (-0.38, 0.02) 0.071 0.04 (-0.19, 0.28) 0.706 
CRP 
Model 3 0.06 (-0.02, 0.14) 0.168 -0.04 (-0.16, 0.08) 0.533 0.14 (0.01, 0.27) 0.040 0.17 (0.02, 0.33) 0.031 
TNF-α 
Model 3 0.02 (-0.20, 0.23) 0.884 0.01 (-0.31, 0.33) 0.951 0.15 (-0.20, 0.50) 0.402 0.13 (-0.27, 0.54) 0.517 
IL-6 
Model 3 0.05 (-0.02, 0.13) 0.148 0.07 (-0.04, 0.18) 0.209 0.13 (0.01, 0.25) 0.035 -0.08 (-0.22, 0.06) 0.284 
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IL-8 
Model 3 -0.09 (-0.23, 0.06) 0.251 -0.08 (-0.29, 0.14) 0.497 -0.08 (-0.32, 0.16) 0.490 -0.06 (-0.34, 0.22) 0.672 
IL-10 
Model 3 0.01 (-0.05, 0.06) 0.825 -0.02 (-0.10, 0.06) 0.568 0.09 (0.01, 0.18) 0.032 -0.04 (-0.14, 0.06) 0.455 
 
Homocysteine 
Model 3 -0.15 (-0.49, 0.17) 0.353 -0.28 (-0.77, 0.21) 0.267 -0.19 (-0.73, 0.35) 0.482 0.08 (-0.54, 0.71) 0.792 
Bioavailable zinc 
Model 3 -0.00 (-0.01, 0.00) 0.486 -0.01 (-0.02, 0.01) 0.297 -0.00 (-0.01, 0.01) 0.808 0.01 (-0.01, 0.02) 0.218 
Vitamin B12 
Model 3 -0.02 (-0.18, 0.14) 0.824 -0.01 (-0.25, 0.23) 0.930 0.02 (-0.24, 0.28) 0.896 -0.05 (-0.35, 0.25) 0.748 
All values represent β values and 95% confidence interval (CI). All growth, neurotrophic, inflammatory markers, bioavailable zinc and vitamin B12 were log 
transformed prior to analysis.
 
Model 3: adjusted for age, sex, ethnicity, BMI, education, smoking status, history of CVD, depression, change in physical activity, 
APOE genotype and group. Reported P values are unadjusted. Significance was determined based on a Bonferroni p-value of 0.0167 for growth and neurotrophic 
factors as well as homocysteine, vitamin B12 and bioavailable zinc. A Bonferroni p-value of 0.0083 was used for inflammation.* P<0.017; † P<0.008. GMLT: 
Groton Maze Learning Task; IGF-1: insulin-like growth factor; BDNF: brain derived neurotrophic factor; VEGF: vascular endothelial factor; CRP: C-reactive 
protein; TNF: tumor necrosis factor; IL: interleukin. 
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Appendix AF: Association between change in executive function, the behavioural regulation index and metacognition index and 
baseline growth, neurotrophic, inflammatory markers, bioavailable zinc and vitamin B12 for model 3.   
 ∆ Executive function (GEC) ∆ Behavioural regulation index ∆ Metacognition index 
 β (95% CI) P value β (95% CI) P value β (95% CI) P value 
Growth and Neurotrophic Factors 
IGF-1 
  Model 3 0.19 (-4.26, 4.64)  0.934 -0.48 (-4.97, 4.01) 0.832 0.81 (-3.97, 5.59) 0.739 
BDNF 
  Model 3 -3.25 (-6.57, 0.07) 0.055 -4.14 (-7.45, -0.82)
*
 0.015 -2.34 (-5.94, 1.25) 0.199 
VEGF 
  Model 3 0.24 (-1.05, 1.52) 0.715 0.43 (-0.87, 1.72) 0.514 -0.02 (-1.40, 1.36) 0.979 
Inflammatory markers 
Adiponectin 
  Model 3 -1.90 (-3.79, -0.01) 0.049 -1.54 (-3.45, 0.38) 0.115 -1.99 (-4.02, 0.04) 0.055 
CRP 
  Model 3 0.59 (-0.69, 1.87) 0.365 -0.17 (-1.47, 1.13) 0.799 1.09 (-0.28, 2.46) 0.119 
TNF-α 
  Model 3 0.93 (-2.37, 4.23) 0.579 1.64 (-1.68, 4.96) 0.330 0.14 (-3.41, 3.69) 0.937 
IL-6 
  Model 3 -1.04 (-2.14, 0.06) 0.063 -1.07 (-2.17, 0.04) 0.058 -0.91 (-2.09, 0.27) 0.131 
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IL-8 
  Model 3 1.17 (-1.06, 3.39) 0.302 -0.26 (-2.51, 1.99) 0.819 2.07 (-0.30, 4.45) 0.086 
IL-10 
  Model 3 0.15 (-0.66, 0.96) 0.720 0.40 (-0.41, 1.22) 0.328 -0.08 (-0.95, 0.79) 0.855 
 
Homocysteine 
  Model 3 1.25 (-3.83, 6.33) 0.627 0.12 (-5.01, 5.24) 0.963 2.04 (-3.41, 7.49) 0.460 
Bioavailable zinc 
  Model 3 -0.07 (-0.19, 0.04) 0.22 -0.05 (-0.17, 0.07) 0.387 -0.08 (-0.20, 0.05) 0.232 
Vitamin B12 
  Model 3 0.35 (-2.11, 2.81) 0.781 0.08 (-2.40, 2.56) 0.951 0.53 (-2.11, 3.17) 0.691 
All values represent β values and 95% confidence interval (CI). Model 3: adjusted for age, sex, ethnicity, BMI, education, smoking status, history of CVD, 
depression, change in physical activity, APOE genotype and group. Reported P values are unadjusted. Significance was determined based on a Bonferroni p-value 
of 0.0167 for growth and neurotrophic factors as well as homocysteine, vitamin B12 and bioavailable zinc. A Bonferroni p-value of 0.0083 was used for 
inflammation. * P<0.017; † P<0.008. GEC: global executive composite; IGF-1: insulin-like growth factor; BDNF: brain derived neurotrophic factor; VEGF: 
vascular endothelial factor; CRP: C-reactive protein; TNF: tumor necrosis factor; IL: interleukin. 
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Appendix AG: Association between change in global cognitive function and composite scores and changes in growth and neurotrophic 
factors, inflammatory markers, bioavailable zinc and vitamin B12 after 24 weeks for model 3.   
 ∆ Global cognitive function ∆ Working memory/learning ∆ Psychomotor/attention ∆ Executive function (GMLT) 
 β (95% CI) P value β (95% CI) P value β (95% CI) P value β (95% CI) P value 
Growth and Neurotrophic Factors 
∆ IGF-1   
  Model 3 -0.30 (-0.78, 0.18)  0.215 -0.28 (-1.00, 0.44) 0.443 -0.25 (-1.03, 0.53) 0.528 -0.40 (-1.32, 0.53) 0.397 
∆ BDNF   
  Model 3 -0.23 (-0.59, 0.13) 0.212 -0.09 (-0.64, 0.45) 0.730 -0.42 (-1.00, 0.16) 0.158 -0.30 (-0.98, 0.39) 0.397 
∆ VEGF   
  Model 1 0.04 (-0.14, 0.22) 0.651 -0.10 (-0.37, 0.16) 0.448 -0.08 (-0.37, 0.21) 0.580 0.10 (-0.24, 0.44) 0.565 
Inflammatory markers 
∆ Adiponectin   
  Model 3 -0.04 (-0.43, 0.35) 0.837 0.10 (-0.48, 0.68) 0.722 0.03 (-0.60, 0.66) 0.926 -0.42 (-1.16, 0.31) 0.258 
∆ CRP   
Model 3 -0.04 (-0.14, 0.06) 0.464 -0.15 (-0.30, -0.00) 0.044 0.07 (-0.09, 0.23) 0.386 -0.04 (-0.23, 0.15) 0.697 
∆ TNF-α   
Model 3 0.03 (-0.27, 0.33) 0.858 -0.27 (-0.71, 0.18) 0.243 -0.01 (-0.50, 0.48) 0.975 0.12 (-0.46, 0.69) 0.690 
∆ IL-6   
Model 3 -0.05 (-0.17, 0.06) 0.367 -0.21 (-0.38, -0.04) 0.015 0.06 (-0.13, 0.25) 0.554 0.02 (-0.20, 0.25) 0.854 
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∆ IL-8   
Model 3 0.23 (0.02, 0.44) 0.034 0.12 (-0.20, 0.44) 0.456 0.19 (-0.16, 0.54) 0.287 0.34 (-0.06, 0.75) 0.098 
∆ IL-10   
Model 3 -0.05 (-0.14, 0.05) 0.336 -0.11 (-0.25, 0.03) 0.122 -0.08 (-0.24, 0.07) 0.280 0.06 (-0.12, 0.24) 0.513 
 
∆ Homocysteine 
Model 3 0.23 (-0.35, 0.81) 0.433 0.19 (-0.67, 1.06) 0.662 0.30 (-0.63, 1.23) 0.523 -0.10 (-1.20, 1.00) 0.860 
∆ Bioavailable zinc   
Model 3 0.00 (-0.01, 0.01) 0.818 0.00 (-0.01, 0.02) 0.436 -0.00 (-0.01, 0.01) 0.969 -0.01 (-0.02, 0.01) 0.385 
∆ Vitamin B12   
Model 3 -0.02 (-0.18, 0.14) 0.824 -0.01 (-0.25, 0.23) 0.930 0.01 (-0.24, 0.28) 0.896 -0.05 (-0.35, 0.25) 0.748 
All values represent β values and 95% confidence interval (CI). Growth, neurotrophic, inflammatory markers, bioavailable zinc and vitamin B12 were log 
transformed prior to analysis. All baseline values are unadjusted means ± SDs. Change values for growth, neurotrophic, inflammatory markers, bioavailable zinc and 
vitamin B12 are unadjusted means (95% CI) and were calculated from the absolute difference from baseline in log-transformed data multiplied by 100. Mean net 
differences (95% CI) were calculated by subtracting the within-group changes for the Ex+Meat group from the within-group changes for the Ex+CHO group after 12 
and 24 weeks. P values for all measures were based on log-transformed data. Model 3: adjusted for age, sex, ethnicity, BMI, education, smoking status, history of 
CVD, depression, change in physical activity, APOE genotype and group. Reported P values are unadjusted. Significance was determined based on a Bonferroni p-
value of 0.0167 for growth and neurotrophic factors as well as homocysteine, vitamin B12 and bioavailable zinc. A Bonferroni p-value of 0.0083 was used for 
inflammation. * P<0.017; † P<0.008. GMLT: Groton Maze Learning task; IGF-1: insulin-like growth factor; BDNF: brain derived neurotrophic factor; VEGF: 
vascular endothelial factor; CRP: C-reactive protein; TNF: tumor necrosis factor; IL: interleukin. 
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Appendix AH: Association between change in executive function, the behavioural regulation index and metacognition index and changes 
in growth, neurotrophic, inflammatory markers, bioavailable zinc and vitamin B12 after 24 weeks for model 3.   
 ∆ Executive function (GEC) ∆ Behavioural regulation index ∆ Metacognition index 
 β (95% CI) P value β (95% CI) P value β (95% CI) P value 
Growth and Neurotrophic Factors 
∆ IGF-1 
  Model 3 0.84 (-6.73, 8.40)  0.827 0.03 (-7.60, 7.65) 0.995 1.36 (-6.76, 9.49) 0.740 
∆ BDNF 
  Model 3 3.18 (-2.02, 8.37) 0.229 3.99 (-1.23, 9.21) 0.133 2.26 (-3.34, 7.86) 0.426 
∆ VEGF 
  Model 3 -2.31 (-5.03, 0.41) 0.095 -1.25 (-4.01, 1.51) 0.373 -2.60 (-5.51, 0.32) 0.080 
Inflammatory markers 
∆ Adiponectin 
  Model 3 -1.15 (-7.15, 4.86) 0.706 -1.29 (-7.34, 4.76) 0.674 -1.03 (-7.49, 5.42) 0.752 
∆ CRP 
Model 3 -0.96 (-2.42, 0.49) 0.191 -0.43 (-1.90, 1.05) 0.568 -1.24 (-2.80, 0.31) 0.117 
∆ TNF-α 
Model 3 -1.98 (-6.55, 2.59) 0.394 -2.24 (-6.84, 2.37) 0.339 -1.12 (-6.04, 3.80) 0.653 
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∆ IL-6 
Model 3 0.47 (-1.29, 2.22) 0.599 0.14 (-1.63, 1.91) 0.873 0.68 (-1.20, 2.57) 0.474 
∆ IL-8 
Model 3 -3.95 (-7.25, -0.64) 0.020 -3.30 (-6.65, 0.05) 0.054 -3.78 (-7.35, -0.22) 0.038 
∆ IL-10 
Model 3 -0.14 (-1.58, 1.30) 0.850 -0.46 (-1.91, 0.99) 0.529 0.24 (-1.31, 1.78) 0.764 
 
∆ Homocysteine 
Model 3 1.48 (-7.52, 10.47) 0.746 -1.59 (-10.65, 7.47) 0.729 3.86 (-5.82, 13.54) 0.431 
∆ Bioavailable zinc 
Model 3 -0.00 (-0.13, 0.12) 0.966 -0.03 (-0.15, 0.10) 0.682 0.01 (-0.13, 0.14) 0.936 
∆ Vitamin B12 
Model 3 0.35 (-2.11, 2.81) 0.781 0.08 (-2.40, 2.56) 0.951 0.53 (-2.11, 3.17) 0.691 
All values represent β values and 95% confidence interval (CI). Growth, neurotrophic, inflammatory markers, bioavailable zinc and vitamin B12 were log transformed prior to analysis. 
All baseline values are unadjusted means ± SDs. Change values for growth, neurotrophic, inflammatory markers, bioavailable zinc and vitamin B12 are unadjusted means (95% CI) 
and were calculated from the absolute difference from baseline in log-transformed data multiplied by 100. Mean net differences (95% CI) were calculated by subtracting the within-
group changes for the Ex+Meat group from the within-group changes for the Ex+CHO group after 12 and 24 weeks. P values for all measures were based on log-transformed data. 
Model 3: adjusted for age, sex, ethnicity, BMI, education, smoking status, history of CVD, depression, change in physical activity, APOE genotype and group. Reported P values are 
unadjusted. Significance was determined based on a Bonferroni p-value of 0.0167 for growth and neurotrophic factors as well as homocysteine, vitamin B12 and bioavailable zinc. A 
Bonferroni p-value of 0.0083 was used for inflammation. * P<0.017; † P<0.008. ALM: Appendicular lean mass, FSST: four square step test, GEC: global executive composite, IGF-1: 
insulin-like growth factor; BDNF: brain derived neurotrophic factor; VEGF: vascular endothelial factor; CRP: C-reactive protein; TNF: tumor necrosis factor; IL: interleukin. 
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Appendix AI: Mean baseline scores for health-related quality of life for the multi-component exercise and red meat (Ex+Meat) and control 
(carbohydrate) exercise (Ex+CHO) group and the mean within-group changes and mean net differences between the groups for the change after 24 
weeks, for the per protocol analysis. 
 Baseline Values and Within-Group Changes  
 Ex+Meat Ex+CHO Intervention Effects 
 Mean ± SD (95% CI) P-value Mean ± SD (95% CI) P-value Net Difference (95% CI) 
P-values 
Model 1  | Model 2 
Physical Function      
    Baseline 47.83 ± 7.00  49.20 ± 6.47    
    Δ 24-weeks 2.37 (0.90, 3.84) 0.001 1.16 (-0.57, 2.89) 0.194 -1.21 (-3.47, 1.05) 0.276 | 0.290 
Role Physical      
    Baseline 48.31 ± 8.51  50.96 ± 6.74    
    Δ 24-weeks 2.40 (0.33, 4.47) 0.020 -0.40 (-2.67, 1.88) 0.693 -2.80 (-5.86, 0.27) 0.066 | 0.071 
Bodily Pain      
   Baseline 49.03 ± 10.56  48.95 ± 9.63    
   Δ 24-weeks  -0.71 (-3.12, 1.70) 0.553 0.18 (-2.06, 2.42) 0.807 0.89 (-2.36, 4.15) 0.549 | 0.587 
General Health      
   Baseline 51.66 ± 8.29  51.25 ± 7.06    
   Δ 24-weeks  0.81 (-0.71, 2.34) 0.286 0.33 (-0.92, 1.58) 0.562 -0.48 (-2.42, 1.46) 0.648 | 0.625 
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Vitality      
    Baseline 53.25 ± 9.19  53.43 ± 7.03    
    Δ 24-weeks 0.83 (-1.18, 2.84) 0.408 0.33 (-1.23, 1.90) 0.626 -0.49 (-2.99, 2.00) 0.723 | 0.696 
Social Functioning      
    Baseline 51.07 ± 8.97  52.77 ± 6.51    
    Δ 24-weeks 0.29 (-1.82, 2.40) 0.784 -1.78 (-3.81, 0.26) 0.129 -2.06 (-4.97, 0.84) 0.194 | 0.160 
Role-emotional      
    Baseline 47.25 ± 10.71  49.67 ± 9.07    
    Δ 24-weeks 3.12 (0.60, 5.64) 0.013 -0.68 (-3.71, 2.35) 0.788 -3.80 (-7.74, 0.14) 0.075 | 0.057 
Mental Health      
    Baseline 51.76 ± 8.75  50.37 ± 7.07    
    Δ 24-weeks -0.61 (-2.66, 1.44) 0.552 1.73 (-0.17, 3.62) 0.050 2.33 (-0.42, 5.09) 0.080 | 0.092 
Physical Component Score      
    Baseline 49.17 ± 7.96  50.36 ± 7.30    
    Δ 24-weeks 1.38 (-0.29, 3.04) 0.098 0.26 (-1.57, 2.08) 0.798 -1.12 (-3.58, 1.34) 0.356 | 0.368 
Mental Component Score      
    Baseline 51.13 ± 9.91  51.45 ± 7.66    
    Δ 24-weeks 0.63 (-1.53, 2.78) 0.561 -0.11 (2.23, 2.00) 0.915 -0.74 (-3.73, 2.25) 0.714 | 0.625 
Global Score      
    Baseline 50.17 ± 5.08  50.70 ± 5.52    
    Δ 24-weeks 0.72 (-0.64, 2.09) 0.633 0.18 (-1.13, 1.49) 0.414 -0.54 (-2.42, 1.33) 0.393 | 0.403 
All baseline values are unadjusted means ± SDs. All change values are unadjusted means (95% CI) and were calculated from the absolute difference from baseline. Mean net differences (95% CI) were calculated by subtracting 
the within-group changes for the Ex+Meat group from the within-group changes for the Ex+CHO group after 12 and 24 weeks. Model 2 included age, sex, number of chronic diseases, change in physical activity and 
depression. Bolded p-values indicate significance at P<0.05. 
 
